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ABSTRACT 
 
P53 is a tetrameric transcription factor which exhibits DNA binding activity through its 
core domain which encompasses the conserved domains (known as Box II, III, IV and 
V).  The N-terminal domain of p53 provides a scaffold for binding of components of the 
transcriptional machinery.  Phosphorylation at residues within the N-terminal 
transactivation domain of p53 such as Serine 20 is a crucial event in the activation of 
p53.  It stabilises the binding of the co-activator p300, reduces the binding of the 
inhibitory partner Mdm2 and enhances activation of p53 target genes. The identification 
of enzymes that phosphorylate p53 transactivation domain is an important development 
in the ongoing mapping of signaling pathways that control p53-dependent transcription 
and resultant tumour suppression.  Environmental and physiological stresses activate 
p53 which has led to the creation of several hypothetical models in which tumour 
suppressor kinases mediate p53 activation by phosphorylation at Serine 20.  Although 
much researched the identity of the main Serine 20 kinase in cells remains undefined.  In 
this study we have identified Calcium Calmodulin kinase superfamily (CAMK) 
members as potent Serine 20 kinases in cells and show that the co-transfection of p53 
peptides derived from the conserved domains can modify this response.  Moreover, we 
show that the multi-protein docking site, p53 Box V domain, is required for Serine 20 
phosphorylation and ubiquitination of p53.  To further define the domains required for 
the interaction of p53 with CAMK superfamily members, mutagenesis of p53 was 
performed.  Using transcriptional and binding based assays we were able to establish 
that p53 does indeed form an interaction with Chk1 and DAPK1.  Development of cell 
models and gene expression studies demonstrated that depletion of Chk1 and DAPK1 
results in activation of the p53 signalling pathway.  There may therefore be a role for 
kinases as negative regulators of p53 and a potential for the development of kinases as 




 - iv - 
ABBREVIATIONS 
 
aa Amino acid 
Ab Antibody 
AMP Adenosine monophosphate 
AMPK  5’AMP-activated protein kinase 
ARF ADP ribosylation factor 
ASPP Apoptosis-stimulatory protein of p53  
A-T Ataxia-telangiectasia 
ATM Ataxia-telangiectasia Mutated 
ATP Adenosine triphosphate 
ATR ATM and Rad-3 related 
BER Base excision repair 
βGP Beta Glycerol Phosphate 
BAX Bcl-2 associated protein X 
Bcl-2 B-cell lymphoma-2 
BSA Bovine serum albumin 
CAMK Calcium Calmodulin kinase superfamily 
C-terminus Carboxy terminus of protein  
CBP CREB binding protein 
Cdc Cell division cycle 
CDK Cyclin dependent kinase 
CHIP Chaperone-associated ubiquitin ligase 
Chk1 Checkpoint kinase 1 
Chk2 Checkpoint kinase 2 
CIP1 CDK interacting protein 1 
CK  Casein kinase 
DAPK1 Death-associated protein kinase 1 
DBD DNA binding domain 
 
 - v - 
DMEM Dulbecco’s modified eagle’s medium 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
DRP-1 DAPK related protein 1 
DSB Double strand break 
dsRNA Double stranded RNA 
DTT Dithiolthretiol 
E2F-1 E2F transcription factor 1 
E.Coli Escherichia Coli 
ECL Enhanced chemiluminescence 
EDTA Ethylene diamine tetra-acetic acid 
ERK  Extracellular single related kinase 
FBS Foetal bovine serum 
FL  Full-length 
G1 Gap phase 1 
G2 Gap phase 2 
GADD Growth arrest and DNA damage gene 
GST Glutathione S-transferase 
Gy Gray 
HAT Histone acetyltransferase 
HAUSP Herpes virus-associated ubiquitin-specific protein 
HDAC Histone deacetylase 
HEPES N-(2-Hydroxethyl)piperazine-N’-(2-ethanesulfonic acid) 
HIF-1 Hypoxia-inducible factor 1 
HR Homologous recombination 





 - vi - 
IR Ionising radiation 
JNK Jun NH2-terminal kinase 
kb Kilo-base 
kDa Kilodalton 
LB Luria Bertani 
LF 2000 Lipofectamine 2000 
LFS Li-Fraumeni syndrome 
M Mitosis 
mA Milli-amperes  
MAPK Mitogen-activated protein kinase 
Mdm2 Mouse double minute 2 
MEF Mouse Embryonic Fibroblast 
MMR Mismatch repair 
MRN Mre11/Nbs1/Rad50 
mTOR Mammalian target of rapamycin 
MTT Methylthiazolylphenyl-tetrazolium bromide 
NE Nuclear extract 
NER  Nucleotide excision repair 
NES Nuclear export signal 
NFκB Nuclear factor-kappa B 
NHEJ Non-homologous end joining 
NHF Normal Human Fibroblast  
NLS Nuclear localization signal 
NO Nitric oxide 
NP40 Nonidet P40 
N-terminus Amino terminus of a protein 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
 
 - vii - 
PBST PBS-Tween 20 (0.01% v/v) 
PCNA Proliferating cell nuclear antigen 
PI3-K Phosphoinositide 3-kinase 
PIKK Phosphoinositide 3-kinase related kinase 
PLB Passive lysis buffer 
PML Promyelocytic leukaemia 
PMSF Phenylmethanesulphonyl fluoride 
Pu Purine 
PUMA p53 upregulated modulator of apoptosis 
Py Pyrimidine 
REG  Regulatory domain 
RLU Relative light unit 
RNA Ribonucleic acid 
RNAi RNA interference 
ROS Reactive oxygen species 
RT-PCR Reverse transcriptase polymerase chain reaction 
SDS Sodium dodecyl sulfate 
Ser Serine 
SH-3 Src homology domain 3 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SMG Suppressor with morphogenetic effect on genitalia 
SSB Single strand break 
SUMO Small ubiquitin-like modifier 
TA Transactivation domains 
TAF TBP-associated factors 
TBP TATA box-binding protein 
TET Tetramerisation domain 
Thr Threonine 
 
 - viii - 
TK Tyrosine kinase 
TNF-α Tumour necrosis factor alpha 
Tris Tris(hydroxymethyl)methylamine 
TRRAP Transformation/translation domain associated protein 
TSC Tuberous sclerosis 
Tween 20 Polyoxyethylene sorbitan monolaurate 
Ub Ubiquitin 
UV Ultra violet light 
v/v Volume per volume 
w/v Weight per volume 
WAF1 Wild-type p53 activated fragment 
WT Wild Type 
 
 
 - ix - 





LIST OF CONTENTS ..............................................................................................................................IX 
LIST OF FIGURES ................................................................................................................................ XV 
LIST OF TABLES ............................................................................................................................... XVII 
1 INTRODUCTION ............................................................................................................................. 1 
1.1 THE P53 TUMOUR SUPPRESSOR ................................................................................................... 1 
1.1.1 Discovery and Classification................................................................................................. 1 
1.1.2 Structure of p53..................................................................................................................... 2 
1.1.2.1 The amino terminus ....................................................................................................................4 
1.1.2.2 The Central domain ....................................................................................................................5 
1.1.2.3 The Carboxy terminal .................................................................................................................6 
1.1.3 Isoforms and family members of p53..................................................................................... 6 
1.1.4 Activation of p53 ................................................................................................................... 8 
1.1.4.1 Genotoxic Stresses......................................................................................................................8 
1.1.4.2 Non Genotoxic Stresses ............................................................................................................10 
1.1.5 Function of p53 ................................................................................................................... 12 
1.1.5.1 Cell cycle arrest and Senescence ..............................................................................................12 
1.1.5.2 Apoptosis ..................................................................................................................................14 
1.1.5.3 DNA Repair and Recombination ..............................................................................................15 
1.1.5.4 Cell survival and autophagy......................................................................................................16 
1.2 REGULATION OF P53 TRANSCRIPTIONAL ACTIVITY ................................................................... 19 
1.2.1 Protein stabilization ............................................................................................................ 19 
1.2.2 Post-translational modification........................................................................................... 20 
1.2.2.1 Phosphorylation ........................................................................................................................21 
1.2.2.2 Acetylation................................................................................................................................23 
1.2.2.3 Ubiquitination...........................................................................................................................25 
1.2.2.4 Other modifications ..................................................................................................................27 
1.3 REGULATORS OF P53 FUNCTION................................................................................................ 28 
1.3.1 P300 .................................................................................................................................... 28 
 
 - x - 
1.3.2 Mdm2................................................................................................................................... 31 
1.3.3 The Calcium Calmodulin Kinase Superfamily .................................................................... 36 
1.3.3.1 Chk1 .........................................................................................................................................37 
1.3.3.2 Chk2 .........................................................................................................................................41 
1.3.3.3 DAPK1 .....................................................................................................................................46 
1.3.3.4 AMPK.......................................................................................................................................52 
1.4 PROJECT AIMS .......................................................................................................................... 55 
2 MATERIALS AND METHODS .................................................................................................... 56 
2.1 GENERAL .................................................................................................................................. 56 
2.1.1 Reagents and Materials....................................................................................................... 56 
2.1.2 Buffers and Stock Solutions ................................................................................................. 56 
2.1.3 Plasmid DNA....................................................................................................................... 56 
2.2 CELL CULTURE ......................................................................................................................... 57 
2.2.1 Cell lines.............................................................................................................................. 57 
2.2.2 Media and Sub-culturing of Cells........................................................................................ 57 
2.2.3 Storage and Recovery of Cells ............................................................................................ 57 
2.2.4 Transient transfection of plasmid DNA............................................................................... 58 
2.2.5 Transient transfection of siRNA .......................................................................................... 58 
2.2.6 Cell treatments .................................................................................................................... 60 
2.2.7 MTT: Cell viability assay .................................................................................................... 60 
2.2.7.1 Transient Transfection and Damage Treatment of Cells...........................................................61 
2.2.7.2 MTT treatment and measurement .............................................................................................61 
2.2.8 Gene reporter assay ............................................................................................................ 61 
2.2.8.1 Transient Transfection ..............................................................................................................61 
2.2.8.2 Luciferase/ β-Gal assay system.................................................................................................62 
2.2.8.3 Dual-Luciferase Reporter Assay System ..................................................................................63 
2.3 SDS-PAGE............................................................................................................................... 64 
2.3.1 Preparation of Cell lysates.................................................................................................. 64 
2.3.2 Protein Quantification......................................................................................................... 64 
2.3.3 Preparation of gels and separation of proteins by SDS-PAGE........................................... 65 
2.3.4 Detection of fractionated proteins....................................................................................... 65 
2.3.4.1 Coomassie brilliant blue staining..............................................................................................65 
2.3.4.2 Immunoblotting ........................................................................................................................65 
2.3.4.3 Stripping Nitrocellulose membranes.........................................................................................66 
2.4 MICROBIOLOGICAL TECHNIQUES.............................................................................................. 67 
2.4.1 Preparation of competent cells............................................................................................ 68 
 
 - xi - 
2.4.2 Agar bacterial culture dishes .............................................................................................. 68 
2.4.3 Transformation of plasmid DNA by heat shock................................................................... 68 
2.4.4 Amplification of plasmid DNA............................................................................................. 69 
2.4.5 Glycerol stocks .................................................................................................................... 69 
2.4.6 Purification of plasmid DNA............................................................................................... 69 
2.4.7 Quantification...................................................................................................................... 69 
2.4.8 Agarose Gel Electrophoresis............................................................................................... 70 
2.5 SITE DIRECTED MUTAGENESIS ................................................................................................. 70 
2.5.1 Primer Design ..................................................................................................................... 70 
2.5.2 Site directed mutagenesis and PCR..................................................................................... 73 
2.5.3 Sequence Analysis ............................................................................................................... 74 
2.6 IN VIVO CO-IMMUNOPRECIPITATION......................................................................................... 75 
2.6.1 Transient transfection of plasmid DNA............................................................................... 75 
2.6.2 Cell lysis and Pre-clearing.................................................................................................. 75 
2.6.3 Co-immunoprecipitation of FLAG-tagged proteins ............................................................ 75 
2.6.4 Coimmunoprecipitation using antibody coupled NHS beads .............................................. 76 
2.6.4.1 Coupling of antibodies to NHS (N-hydroxysuccinimide) activated beads................................76 
2.6.4.2 Co-immunoprecipitation of antibody bound beads ...................................................................76 
2.6.5 Western Blot analysis .......................................................................................................... 77 
2.7 MICROARRAY ANALYSIS .......................................................................................................... 77 
2.7.1 Isolation of total RNA.......................................................................................................... 77 
2.7.2 cRNA Target Labeling for Oligo GEarray® Hybridisation ................................................ 77 
2.7.3 Oligo GEArray® Hybridization .......................................................................................... 78 
2.7.4 Data analysis....................................................................................................................... 78 
2.8 BUFFERS AND SOLUTIONS ......................................................................................................... 79 
2.8.1 SDS PAGE........................................................................................................................... 79 
2.8.1.1 Lysis Buffers: ...........................................................................................................................79 
2.8.1.2 Protein quantification................................................................................................................79 
2.8.1.3 Preparation of gels and separation of proteins by SDS-PAGE .................................................79 
2.8.1.4 Detection of fractionated protein by Coomassie Brilliant Blue ................................................80 
2.8.1.5 Immunoblotting ........................................................................................................................80 
2.8.2 Microbiological Techniques................................................................................................ 81 
2.8.2.1 Bacterial Cultures .....................................................................................................................81 
2.8.2.2 Preparation of competent cells..................................................................................................81 
2.8.2.3 Agarose Gel Electrophoresis.....................................................................................................81 
3 THE ROLE OF THE P53 SER 20 SITE IN MODULATION OF P53 TRANSCRIPTIONAL 
ACTIVITY................................................................................................................................................. 82 
 
 - xii - 
3.1 INTRODUCTION ......................................................................................................................... 82 
3.1.1 A role for p53 Ser 20 phosphorylation in assembly of the p53 transcription complex........ 82 
3.1.2 Signaling pathways target p53 ............................................................................................ 84 
3.1.3 The modulation of p53 Ser 20 phosphorylation by Calcium Calmodulin kinase superfamily 
members has been demonstrated in vitro........................................................................................... 86 
3.1.4 Evaluation of DAPK1, Chk1 and Chk2 as p53 activating kinases in vivo........................... 87 
3.1.5 Identification of a novel p53 isoform................................................................................... 88 
3.1.6 Objectives of this chapter .................................................................................................... 89 
3.2 RESULTS ................................................................................................................................... 90 
3.2.1 Development of an in vivo p53 Ser 20 phosphorylation assay ............................................ 90 
3.2.2 Specific Calcium Calmodulin Superfamily members stimulate p53 Ser 20 phosphorylation
 92 
3.2.3 Chk1 induces a dose-dependent increase in p53-dependent transcription.......................... 93 
3.2.4 Identification of distinct Calcium Calmodulin Kinases as the major endogenous mediators 
of Ser 20 phosphorylation in human tumour cells ............................................................................. 96 
3.2.5 The conserved Box-V domain of p53 is required for Ser 20 site phosphorylation of p53 by 
Calcium Calmodulin kinases. ............................................................................................................ 98 
3.2.6 The p53 ΔV spliced isoform is transcriptionally active ..................................................... 101 
3.2.7 The Box-V peptide attenuates p53 Ser 20 phosphorylation............................................... 103 
3.2.8 The Box-V peptide cannot restore p53 ΔV Ser 20 phosphorylation by endogenous Calcium 
Calmodulin Kinases......................................................................................................................... 105 
3.2.9 Chk1 stimulation of p53-dependent transcriptional activity is docking-dependent and not 
phosphorylation-dependent ............................................................................................................. 105 
3.3 DISCUSSION ............................................................................................................................ 108 
3.3.1 Chk1 is an endogenous modifier of p53 ............................................................................ 108 
3.3.2 The Calcium Calmodulin kinase interaction with p53 requires the Box-V domain of p53111 
4 THE CONSERVED P53 BOX V DOMAIN IS A CALCIUM CALMODULIN KINASE 
BINDING SITE ....................................................................................................................................... 117 
4.1 INTRODUCTION ....................................................................................................................... 117 
4.1.1 Defining key domains required for p53 interactions......................................................... 117 
4.1.2 Examining the role of ‘Gain of function’ mutation on kinase modulation of p53 activity. 119 
4.1.3 Objectives of chapter......................................................................................................... 124 
4.2 RESULTS ................................................................................................................................. 125 
4.2.1 Examination of kinase and Mdm2 binding to p53 core domain ........................................ 125 
4.2.1.1 The Calcium Calmodulin Kinases bind stably to the EGFP-Box-V fusion peptide in cells....125 
 
 - xiii - 
4.2.1.2 Binding of Mdm2 stabilizes the EGFP Box-V fusion peptide ................................................132 
4.2.2 Creation of p53 ‘Gain of function’ mutants to examine kinase - p53 interaction ............. 133 
4.2.2.1 The p53 His175 mutant is transcriptionally activated by Chk1 ..............................................135 
4.2.2.2 Transfected of Calcium Calmodulin kinases have little effect on Ser 20 phosphorylation of 
ectopically expressed p53 mutants...............................................................................................................137 
4.2.2.3 Basal transcriptional activity of the p53 mutants is promoter dependent................................139 
4.2.2.4 P53 Mutants are not stimulated transcriptionally by addition of kinases or Mdm2 ................146 
4.2.3 Examination of specific sites of interation of kinases on p53 Box-V domain .................... 151 
4.2.3.1 DAPK1 and Chk1 have distinct but overlapping binding requirements on p53 Box-V..........152 
4.2.3.2 The EGFP-Box-V fusion peptide binds preferentially to Mdm2 ............................................155 
4.3 DISCUSSION ............................................................................................................................ 158 
4.3.1 Chk1 and Mdm2 have overlapping binding requirements on p53 Box-V.......................... 158 
4.3.2 The role of p53 ‘Gain of Function’ mutants...................................................................... 162 
5 IDENTIFICATION OF KINASE DRUG TARGETS FOR REACTIVATION OF THE P53 
RESPONSE.............................................................................................................................................. 166 
5.1 INTRODUCTION ....................................................................................................................... 166 
5.1.1 siRNA technology .............................................................................................................. 166 
5.1.2 Microarray technology...................................................................................................... 167 
5.1.3 Objectives and Experimental Approach ............................................................................ 172 
5.2 RESULTS ................................................................................................................................. 173 
5.2.1 Development of cell models to study the effect of loss of kinases on p53 signaling .......... 173 
5.2.1.1 Optimisation of siRNA technology.........................................................................................173 
5.2.1.2 P53 is stabilized following damage ........................................................................................177 
5.2.1.3 Comparison of lysis buffers ....................................................................................................180 
5.2.2 A cell viability assay demonstrates that depletion of kinases and subsequent damage does 
not result in any additional cell death ............................................................................................. 185 
5.2.3 A microarray study demonstrates that silencing of kinases leads to increased activation of 
p53 target genes............................................................................................................................... 188 
5.2.3.1 Microarray analysis of Chk1 or DAPK1 depleted (undamaged) cells ....................................188 
5.2.3.2 Microarray analysis of kinase depleted, X-Ray treated cells ..................................................202 
5.2.3.3 Microarray analysis following the combined depletion of p53 and DAPK1...........................214 
5.3 DISCUSSION ............................................................................................................................ 229 
5.3.1 A role for kinases a negative regulators of p53................................................................. 229 
5.3.2 Kinase drug targets for reactivation of the p53 response ................................................. 235 
6 SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS................................................ 238 
6.1 DEFINING THE ROLE OF CALCIUM CALMODULIN KINASES IN MODULATION OF P53 ACTIVITY 238 
 
 - xiv - 
6.2 CALCIUM CALMODULIN KINASES & MDM2 HAVE OVERLAPPING BINDING REQUIREMENTS ON 
P53 BOX-V............................................................................................................................................ 240 
6.3 THE ROLE OF ‘GAIN OF FUNCTION’ MUTATION ON KINASE MODULATION OF P53 ACTIVITY .... 241 
6.4 THE IDENTIFICATION OF KINASE DRUG TARGETS FOR REACTIVATION OF THE P53 RESPONSE .. 244 
6.4.1 A role for kinases as negative regulators of p53 ............................................................... 244 
6.4.2 Development of drug targets ............................................................................................. 246 
6.5 CONCLUSION .......................................................................................................................... 247 
7 REFERENCES .............................................................................................................................. 248 
 
 
 - xv - 
LIST OF FIGURES 
FIGURE 1.1 THE PROTEIN STRUCTURE OF P53................................................................................................. 3 
FIGURE 1.2 THE P53-MDM2 AUTOREGULATORY FEEDBACK LOOP. .............................................................. 32 
FIGURE 1.3 THE DOMAIN REGIONS OF THE MDM2 PROTEIN.......................................................................... 33 
FIGURE 1.4  A SCHEMATIC DIAGRAM OF THE PROTEIN STRUCTURES OF CHK1 AND CHK2............................ 36 
FIGURE 1.5 A SCHEMATIC DIAGRAM OF THE DAPK FAMILY........................................................................ 46 
FIGURE 3.1 P53 IS A TETRAMERIC TRANSCRIPTION FACTOR. ........................................................................ 82 
FIGURE 3.2 THE HUMAN KINOME. ............................................................................................................... 84 
FIGURE 3.3  COMPARISON OF WT P53 AND THE P53 ΔV ISOFORM. .............................................................. 88 
FIGURE 3.4 IN VIVO INDUCTION OF SER 20 PHOSPHORYLATION OF P53 BY THE CALCIUM CALMODULIN 
KINASE SUPERFAMILY MEMBERS. ....................................................................................................... 91 
FIGURE 3.5  DETERMINATION OF THE OPTIMAL P53 DOSE IN P53-DEPENDENT TRANSCRIPTIONAL ASSAYS. . 94 
FIGURE 3.6 EFFECT OF THE CALCIUM CALMODULIN SUPERFAMILY GENE TRANSFECTION ON P53-DEPENDENT 
REPORTER ACTIVITY. .......................................................................................................................... 95 
FIGURE 3.7  DETERMINATION OF THE MAJOR ENDOGENOUS MEDIATOR OF SER 20 PHOSPHORYLATION OF 
ECTOPICALLY EXPRESSED P53 IN H1299 CELLS. ................................................................................. 97 
FIGURE 3.8 DELETION OF THE CENTRAL REGION OF P53 CONTAINING THE BOX-V DOMAIN BLOCKS BOTH SER 
20 SITE PHOSPHORYLATION AND UBIQUITINATION OF P53. ................................................................. 99 
FIGURE 3.9  P53 ΔV-DEPENDENT TRANSCRIPTIONAL ACTIVITY IS NOT STIMULATED BY TRANSFECTION OF 
CHK1................................................................................................................................................ 102 
FIGURE 3.10 THE EGFP-BOX-V FUSION PEPTIDE ATTENUATES SER 20 SITE PHOSPHORYLATION OF P53 IN 
VIVO. ................................................................................................................................................ 104 
FIGURE 3.11  KINASE STIMULATION OF P53-DEPENDENT TRANSCRIPTIONAL ACTIVITY IS DOCKING 
DEPENDENT AND NOT SER 20 PHOSPHORYLATION DEPENDENT......................................................... 107 
FIGURE 3.12 THE MULTI-PROTEIN BINDING SITES IN THE BOX-I AND BOX-V DOMAINS OF P53.................. 115 
FIGURE 4.1 THE BOX PEPTIDES ARE ADJACENT IN THE TERTIARY STRUCTURE OF P53................................ 117 
FIGURE 4.2  RELATIVE MUTATION FREQUENCY IN HUMAN CANCER. .......................................................... 119 
FIGURE 4.3 CHK1 BINDS STABLY TO THE EGFP-BOX-V FUSION PEPTIDE IN CELLS.................................... 126 
FIGURE 4.4 DAPK1 BINDS STABLY TO EGFP-BOX-V FUSION PEPTIDE IN CELLS. ...................................... 129 
FIGURE 4.5 THE BINDING OF MDM2 STABILIZES THE BOX-V FUSION PEPTIDE. .......................................... 131 
FIGURE 4.6 A DIAGRAM OF P53 SHOWING THE LOCATION OF THE MUTATIONS (CRAIG ET AL. 2003).......... 135 
FIGURE 4.7 THE P53HIS 175 ISOFORM IS TRANSCRIPTIONALLY ACTIVATED BY CHK1. .............................. 136 
FIGURE 4.8 P53 MUTANTS ARE NOT PHOSPHORYLATED AT SER 20............................................................. 138 
 
 - xvi - 
FIGURE 4.9  P53 MUTANTS DISPLAY SOME KINASE STIMULATED P53-DEPENDENT TRANSCRIPTIONAL 
ACTIVITY. ......................................................................................................................................... 140 
FIGURE 4.10 BASAL TRANSCRIPTIONAL ACTIVITY OF P53 MUTANTS IS PROMOTER DEPENDENT................. 142 
FIGURE 4.11  BASAL TRANSACTIVATION ACTIVITY OF P53 MUTANTS IS PROMOTER DEPENDENT. .............. 144 
FIGURE 4.12 KINASES DO NOT STIMULATE TRANSACTIVATION ACTIVITY OF THE P53 MUTANTS................ 148 
FIGURE 4.13 MDM2 DOES NOT STIMULATE TRANSACTIVATION ACTIVITY OF THE P53 MUTANTS ON P21 
PROMOTER........................................................................................................................................ 150 
FIGURE 4.14  CREATION OF DOUBLE ALANINE MUTANTS TO EXAMINE KINASE-P53 INTERACTION. ............ 151 
FIGURE 4.15 EXAMINATION OF KINASE BINDING TO BOX-V MUTANTS DEMONSTRATES THAT BINDING 
OCCURS AT SPECIFIC SITES................................................................................................................ 153 
FIGURE 4.16 THE EGFP-BOX-V PEPTIDE BINDS PREFERENTIALLY TO MDM2............................................ 156 
FIGURE 5.1 COMPARISON OF DHARMAFECT AND LIPOFECTAMINE TRANSFECTION DELIVERY REAGENTS.174 
FIGURE 5.2  OPTIMISATION OF SIRNA TO DETERMINE THE OPTIMAL SIRNA INCUBATION TIME. ............... 176 
FIGURE 5.3  COMPARISON OF EFFECT DAMAGE TREATMENTS FOLLOWING KINASE DEPLETION ON P53 
STABILISATION IN A375 CELLS. ........................................................................................................ 178 
FIGURE 5.4 EFFECT OF LYSIS BUFFER ON P53 STABILISATION. ................................................................... 181 
FIGURE 5.5  AN MTT ASSAY DEMONSTRATES THAT DEPLETION OF KINASES AND DAMAGE HAS NO EFFECT 
ON CELL VIABILITY........................................................................................................................... 186 
FIGURE 5.6 A MICROARRAY ANALYSIS OF EFFECT OF KINASE DEPLETION ON P53 SIGNALLING PATHWAY. 189 
FIGURE 5.7  COMPARISON OF BASAL AND KINASE STIMULATED TRANSCRIPT LEVELS OF GENES. ............... 196 
FIGURE 5.8  COMPARISON OF FOLD INDUCTION LEVELS FOLLOWING KINASE DEPLETION........................... 198 
FIGURE 5.9 GENE EXPRESSION PROFILE FOLLOWING DEPLETION OF KINASES DEMONSTRATES THAT CHK1 
AND DAPK1 DEPLETION LEADS TO UPREGULATION OF P53 TARGET GENE EXPRESSION. .................. 201 
FIGURE 5.10 A MICROARRAY ANALYSIS OF EFFECT OF X-RAY DAMAGE ON KINASE DEPLETED CELLS. ...... 203 
FIGURE 5.11 GENES UPREGULATED FOLLOWING DAMAGE. ........................................................................ 210 
FIGURE 5.12 GENE EXPRESSION PROFILE DEMONSTRATES THAT IR DAMAGE LEADS TO UPREGULATION OF 
P53 TARGET GENE EXPRESSION IN CONTROL GROUP ONLY................................................................ 213 
FIGURE 5.13 IMMUNOBLOTS CONFIRM DEPLETION OF PROTEIN LEVELS FOLLOWING THE COMINED 
DEPLETION OF P53 AND KINASES. ..................................................................................................... 215 
FIGURE 5.14  MICROARRAY ANALYSIS OF COMBINED DEPLETION OF P53 AND DAPK1 IN A375 CELLS. .... 216 
FIGURE 5.15  COMPARISON OF TRANSCRIPT LEVELS OF GENES UPREGULATED FOLLOWING EITHER SINGLE 
GENE OR COMBINED GENE DEPLETION. ............................................................................................. 225 
FIGURE 5.16 THE COMBINED DEPLETION OF DAPK1 AND P53 LEADS TO DOWNREGULATION OF P53 TARGET 
GENE EXPRESSION............................................................................................................................. 228 
FIGURE 6.1 A PROPOSED MECHANISM FOR THE ACTIVATION OF P53 FOLLOWING CHK1 DEPLETION. ......... 245 
 
 
 - xvii - 
LIST OF TABLES 
TABLE 2.1 CELL LINES................................................................................................................................. 57 
TABLE 2.2 DHARMACON SIRNA PRODUCTS ................................................................................................ 59 
TABLE 2.3 CELL TREATMENTS ..................................................................................................................... 60 
TABLE 2.4 ANTIBODIES................................................................................................................................ 67 
TABLE 2.5 SITE DIRECTED MUTAGENESIS PRIMERS FOR P53......................................................................... 71 
TABLE 2.6 SITE DIRECTED MUTAGENESIS PRIMERS TO EGFP BOX V ........................................................... 72 
TABLE 2.7 SEQUENCING PRIMERS................................................................................................................ 74 
TABLE 4.1 A SUMMARY OF THE SELECTED P53 MUTANTS: TRANSCRIPTIONAL AND APOPTOTIC ACTIVITY . 134 
TABLE 4.2 LEVELS OF STABILIZATION OF DOUBLE ALANINE BOX-V MUTANTS COMPARED TO BOX-V-WT
......................................................................................................................................................... 157 
TABLE 5.1 GENES EXPRESSED IN A375 CELLS FOLLOWING DEPLETION OF KINASES................................... 190 
TABLE 5.2 RATIO OF GENE EXPRESSION BETWEEN SAMPLES (REPRESENTED AS FOLD CHANGES)............... 193 
TABLE 5.3 GENES EXPRESSION IN A375 CELLS FOLLOWING KINASE DEPLETION AND IR DAMAGE............. 204 
TABLE 5.4 RATIO OF GENE EXPRESSION BETWEEN SAMPLES (REPRESENTED AS FOLD CHANGES)............... 208 
TABLE 5.5 GENES EXPRESSED FOLLOWING THE COMBINED DEPLETION OF DAPK1 AND P53..................... 218 
TABLE 5.6 RATIO OF GENES EXPRESSED BETWEEN SAMPLES (REPRESENTED AS FOLD CHANGES) .............. 221 
 
 
Chapter 1 Introduction 
 - 1 - 
1 INTRODUCTION 
1.1 The p53 tumour suppressor  
The tumour suppressor gene p53 is a key gene involved in the control of cancer 
progression.  It has been described as the ‘guardian of the genome’ (Lane 1992) and in 
this report we will describe the function and activity of p53 as a tumour suppressor. 
1.1.1 Discovery and Classification 
The clarification of the role of p53 in carcinogenesis has been and continues to be a 
complex process.  A protein, which was subsequently named p53, was initially identified 
in 1979 following the observation that antibodies against a SV40 large T antigen from 
tumours produced by SV-40 transformed cells coimmunoprecipitated a protein of 
molecular mass of 53kDa.   It was concluded that p53 interacted with this SV40 large T 
antigen (Lane and Crawford 1979; Linzer and Levine 1979) and due to its high 
expression levels in transformed cells, p53 was termed a transformation-associated 
protein (Lane and Crawford 1979; Linzer et al. 1979; Rotter et al. 1980).  Supporting 
this classification were the findings that transformed cells as well as cells from patients 
with various types of tumours contained elevated p53 levels, whereas in non-
transformed cells p53 levels were negligible (Oren et al. 1982).  Several studies then 
went on to examine the role of p53 as a cell-cycle dependent protein, and the results 
suggested that p53 was a regulator of growth (Milner 1984; Reich and Levine 1984).  
p53 was subsequently classified as a proto-oncogene due to its apparent upregulation of 
expression in proliferating cells (Milner and Milner 1981; Milner 1984; Reich and 
Levine 1984).   It was also demonstrated following exposure of non-transformed cells to 
UV irradiation, that there was accumulation of p53 due to post-translational stabilization 
suggesting that p53 may be involved in DNA synthesis (Maltzman and Czyzyk 1984).   
 
The molecular cloning of the TP53 gene (Zakut-Houri et al. 1983; Zakut-Houri et al. 
1985) and discovery of the sequence of the mouse wild-type TP53 gene led to the 
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revelation that previous experiments had employed mutant p53 variants (Eliyahu et al. 
1988; Finlay et al. 1988) and that wild-type p53 actually suppressed oncogene-mediated 
transformation (Eliyahu et al. 1989; Finlay et al. 1989).  This development clearly 
established p53 as a bona fide tumour suppressor instead of the previous classification as 
an oncogene.  Since then there has been significant development in the clarification of 
the role of p53 in carcinogenesis.  P53 protein was shown to be lost or inactivated due to 
the presence of mutations in p53 in about half of human cancers from a wide variety of 
tissues and it is now known to be the most commonly mutated gene in human cancer 
(Baker et al. 1989; Baker et al. 1990; Hollstein et al. 1994).  These developments have 
provided a basis for elucidation of the various roles of p53 in carcinogenesis and have 
established distinct roles in which one of three events can occur; firstly, p53 loss of 
function, where the p53 gene is mutated or there is complete loss of the gene; secondly, 
mutant p53 dominant-negative function, where there is promotion of tumourigenesis due 
to the mutant p53 inactivating WT p53 in cells by oligomerisation; and finally, mutant 
p53 gain of function, where expression of mutant p53 in cells lacking WT p53 enhances 
their tumourigenic potential (Weisz et al. 2007).  p53 has been identified as a key 
regulator in a wide variety of cellular processes such as cell-cycle control, DNA repair, 
genome stability, senescence and programmed cell death, most of which will be 
discussed in this report (see below). 
 
1.1.2 Structure of p53 
The human p53 gene was shown to be localized to the short arm of chromosome 17 
(17q13), spanning approximately 20kb of DNA and composed of 11 exons the first of 
which is non-coding, localized 8 -10 kb away from exons 2 through 11 (Benchimol et al. 
1985).  An extensive phylogenetic study revealed that p53 has been conserved 
throughout evolution and by cross-species comparison of amino-acid sequences, the 
existence of five highly conserved domains (within amino acid residues 13 – 23, 117 – 
142, 171 – 181, 234 – 250 and 270 – 286) was revealed (Soussi et al. 1990; Soussi and 
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May 1996).  These domains were subsequently termed domains I to V or Box I to V (see 




Figure 1.1 The protein structure of p53.   
The amino terminus (1 to 42) contains the transactivation domain and the highly conserved 
region I (Box I).  The proline rich region is adjacent to the transactivation domain and forms part 
of the N-terminal region.  The central region contains the DNA-binding domain (101 to 300).  The 
C-terminal negative regulatory region (301 to 392) contains the oligomerisation domain and a 
nuclear export signal.  
 
The human p53 protein (as shown in Figure 1.1) consists of 393 amino-acids and 
consists of four major functional domains.  The N-terminal region contains a 
transcriptional activation domain (amino-acids 1 - 42) and a proline rich domain (amino-
acids 62 -92) , the central region contains the DNA-binding domain (amino-acids 102 – 
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292) and the C-terminal region contains both the oligomerisation domain (amino-acids 
323 – 356) and a regulatory domain (amino-acids 360 – 393) (May and May 1999).  
These four domains modulate the activity of p53 as a stress-induced sequence-specific 
DNA-binding protein and transcription factor.  The detail of each structure and the 
relation to function will be discussed in the following sections. 
 
1.1.2.1 The amino terminus 
The amino terminal region of p53 (amino-acids 1 - 42) contains the transactivation 
domain through which p53 interacts with components of the transcriptional machinery 
and a smaller highly conserved domain known as Box-I.  This Box-I domain directs the 
binding of p53 to proteins such as p300 (a positive regulator of p53 required to drive 
p53-dependent gene expression) and the components of the basal transcription complex 
TFIID, TATA box binding protein (TBP) and TBP-associated factors (TAF) (Lu and 
Levine 1995).   The regulation of protein-protein interactions can be modulated by 
phosphorylation within the Box-I domain or by protein-protein interactions which 
compete with p300 docking.  Phosphorylation within the Box-I region at sites Ser 15, 
Thr 18 and Ser 20 stabilizes the binding of the co-activator p300 (Lambert et al. 1998; 
Dornan and Hupp 2001; Dornan et al. 2003).   
 
In contrast to these positive regulatory binding factors, negative regulation of p53 occurs 
following the binding of Mdm2 or adenovirus E1B-55kDa which bind to amino acid 
residues 19, 22 and 23 within the transactivation domain  (Momand et al. 1992; Lin et al. 
1994; Levine 1997).  The binding of Mdm2 inhibits the transcriptional function of p53 
by competing with p300 and by promoting ubiquitination of p53 in the nucleus and the 
subsequent export of p53 to the cytoplasm for degradation by the 26S proteasome 
(Honda et al. 1997; Kubbutat et al. 1997; Michael and Oren 2003). 
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The N-terminal region also contains a proline rich region (also known as the Src 
homology 3-like or SH3 domain) which is characterized by the recurrence of proline 
residues in the form of PXXP (where X is any amino acid).  This region, which includes 
five repeats of the PXXP motif, has similarity to the SH3-binding proteins.  In addition, 
this motif is often required for p53-mediated apoptosis in conjunction with proteins such 
as ASPP (Trigiante and Lu 2006).  It has also been shown that this domain may be 
important for p300 binding and furthermore it can allosterically control DNA-dependent 
acetylation of p53, thus controlling p53 activity (Dornan et al. 2003).    
 
1.1.2.2 The Central domain  
The central region from amino-acids 102 – 292 contains the sequence specific DNA-
binding domain which consists of the four highly conserved regions Box II – V.  The 
consensus DNA-binding site contains two copies of the 10bp motif 5’ – 
PuPuPuCWWGPyPyPy – 3’ (Pu is a purine base, Py is a pyrimidine base and W means 
A or T) which p53 recognizes and binds to (el-Deiry et al. 1992).  The central region 
also functions as a protein binding domain, interacting with proteins such as ASPP2 
(Gorina and Pavletich 1996).   Elucidation of the crystal structure of the core domain 
allowed the identification of a large β sandwich that forms a scaffold for a loop-sheet-
helix and two loops that coordinate a zinc ion (Cho et al. 1994).  The scaffold anchors 
the loops and participates in head-to-tail dimerisation, loop L1 binds to DNA within the 
major groove, loop L2 binds to DNA within the minor groove and loop L3 packs against 
L1, stabilizing it.  The zinc atom stabilizes the structure of the loops and the loop-sheet-
helix motif form the DNA binding surface of p53 (Cho et al. 1994) (also see Figure 4.6 
for details of this structure).  The central region contains 80 - 90% of the mutations 
within p53 found in human cancers, the majority of mutations residing within the three 
loops.  These mutations result in either prevention of DNA binding or destabilisation of 
the protein (May and May 1999).   
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1.1.2.3 The Carboxy terminal  
The C-terminal region (residues 300 – 393) includes a flexible linker region connecting 
the central core domain and the C-terminal region, and a tetramerisation domain from 
amino-acids 323 – 356, which is also known as the oligomerisation domain responsible 
for tetramerisation of the p53 structure (Johnson et al. 1995).  The tetramerisation 
domain forms a highly symmetrical tetramer composing of 4 monomers each of which 
contains a turn, a β-strand, a second turn and an α-helix.  Two monomers form a dimer 
and two dimers interact through their α-helices to form a four-helix bundle (May and 
May 1999).  Tetramerisation is important for modulation of p53’s tumour suppressor 
activity and efficient transactivation (May and May 1999).  The C-terminal region is 
also thought to be important for nuclear localization and is known to contain three 
nuclear localization signals, which when altered leads to cytoplasmic localization of p53, 
thus affecting the tumourigenesis activity of p53 (Shaulsky et al. 1990; Shaulsky et al. 
1991).   
 
The C-terminal region also contains a basic region (amino-acids 363 – 393), known as 
the regulatory domain which is adjacent to the oligomerisation domain.  This region acts 
as a negative regulator of specific binding by p53, which due to the allosteric regulation 
of the DNA-binding domain, maintains the p53 tetramer in an inactive state (Hupp et al. 
1992).  Post-translational modification alters the specific activity of p53.   
Phosphorylation of Ser 392 within this domain is thought to regulate the stabilization of 
the tetramerisation domain and it has been shown that mutation of a site adjacent to Ser 
392 (Lys 386) can increase p53’s activity, most likely due to the neutralization of the 
negative-regulatory motif (Hupp et al. 2000).   
 
1.1.3 Isoforms and family members of p53 
Although originally p53 was thought to possess just one active promoter that transcribed 
three mRNA splice variants (FLp53, p53i9 and Δ40p53), the recent discovery that p53 
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actually possesses two promoters has led to the identification of several new 
alternatively spliced isoforms of p53 (Bourdon et al. 2005).  This group used a technique 
that ensured only full-length, capped p53 mRNA molecules were analysed, which 
allowed the identification of mRNA species initiated from different start sites in exon 1 
(P1 and P1’), and one mRNA species from derived from the novel promoter 2 (P2) 
within intron 4.   Further cloning and sequencing of RT-PCR products led to the 
identification of three different splice variants involving intron 9: an α form terminating 
at amino-acid 393 and two variants lacking amino acids 323 – 392 (p53 β and p53 γ).   
This group therefore concluded that this and previously reported data suggested that p53 
was capable of producing nine different transcripts.  They also went on to demonstrate 
that these nine isoforms show different patterns of expression within tissues and cell 
lines and that the alternative promoter (P2) is conserved through evolution from 
Drosophila to mammalian species (Bourdon et al. 2005).   
 
A recent study by Dornreiter and colleagues described another novel p53 variant which 
originated in primates and is derived from alternative splicing (Rohaly et al. 2005).  This 
isoform (named Δp53 or as in this report p53 ΔV) lacks 66 internal amino-acids 
(residues 257 -322) which removes a significant C-terminal portion of the DNA-binding 
domain, including the conserved Box-V region.  This study demonstrated that p53 ΔV 
can induce the transcription of a subset of p53 targets such as p21 and was shown to 
associate with p21 in S phase after UV irradiation (Rohaly et al. 2005).   
 
Family members of p53 include p63 and p73.  The three family members share 
significant homology at the amino-acid level within the three domains (the 
transcriptional activation domain, the sequence-specific DNA binding domain and the 
tetramerisation domain) (Yang et al. 2002).  As homologues of p53, p63 and p73 have 
similar structural and functional characteristics, enabling them to bind p53 DNA-binding 
sites, to transactivate p53 target genes, and to induce cell cycle arrest and apoptosis.    
There are, however slight differences in structure, regulation and activity of p63 and p73 
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compared to p53, which means that these isoforms perform biological tasks which are 
not performed by p53 and vice versa (Blandino and Dobbelstein 2004).  Whereas p53 is 
mutated in approximately 50% of all human cancers, mutation of its family members, 
p63 and p73 is rare.  Disruption of p73 expression is thought to lead to defects in 
neuronal development and homeostasis, and loss of p63 in mice leads to the loss of 
squamous epithelia (Blandino and Dobbelstein 2004).   
 
1.1.4 Activation of p53 
The activation of different stress-induced signaling pathways leads to posttranslational 
modifications or groups of modifications on the p53 protein that modulate p53 activity, 
and ultimately regulate cell fate (see section 1.1.5).  Activation of p53 can occur 
following genotoxic stresses such as ionizing radiation, UV light and cancer drugs 
(including Adriamycin and etoposide) which lead to DNA damage normally in the form 
of double strand breaks or bulky lesions.  Alternatively, p53 can also be activated 
following non-genotoxic stresses such as hypoxia, oncogene activation and nutrient 
deprivation.  
 
1.1.4.1 Genotoxic Stresses 
The activation of p53 following DNA damage such as double strand breaks has led to 
p53 being regarded as the ‘guardian of the genome’ (Lane 1992).  Damage insults such 
as ionizing radiation result in the formation of DNA backbone changes such as single 
strand breaks (SSB) or double strand breaks (DSB) and activate a signaling cascade 
which involves major molecular sensors such as ATM, ATR and DNA-PK (DNA 
protein kinase) (Efeyan and Serrano 2007).  These sensor proteins are recruited to sites 
of damage, forming nuclear ‘foci’.  Signaling molecules such as Chk1 and Chk2 are then 
recruited and activated, and they inturn activate p53 by phosphorylation at various sites 
(Sancar et al. 2004; Efeyan and Serrano 2007).  Phosphorylation of p53 following DNA 
damage ultimately leads to stabilization and accumulation of the protein in the nucleus 
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through inhibition of the binding of the negative regulator Mdm2.  In addition, 
phosphorylation leads to the activation of p53 by stabilisation of the binding of co-
activators such as p300 (Meek 2004) (see section 1.1.2.1).  The sensor protein ATM, 
which is mutated in the cancer-prone disease ataxia telangectasia (AT) (Kastan et al. 
1992), directly phosphorylates p53 at Ser 15 as well as activating other protein kinases 
such as Chk1 and Chk2, which can phosphorylate the N-terminal domain of p53 at sites 
such as Ser 15, Thr 18, Ser 20 and Ser 46 (Shieh et al. 1997; Chehab et al. 1999; Craig et 
al. 1999; Unger et al. 1999; Appella and Anderson 2001; Saito et al. 2002).  It has been 
shown that cells lacking ATM and Chk2 are defective in their ability to stabilize p53 
following ionizing radiation, thus highlighting the role of ATM and Chk2 in p53 
stabilisation following damage (Vousden 2002).  It is also thought that phosphorylation 
of p53-binding pocket on Mdm2 at residue Ser 17 by DNA-PK may inhibit Mdm2 
binding, and therefore contribute to the activation of p53 following damage (Vousden 
2002).   
 
A second DNA damage response pathway is activated following UV-C radiation, which 
causes bulky lesions such as pyrimidine dimers and photoproducts that crosslink DNA 
bases. This pathway is thought to involve sensing a block to transcriptional elongation, 
thereby leading to the activation of ATR (Appella and Anderson 2001; Latonen and 
Laiho 2005).   This damage-response pathway is also thought to be less rapid and more 
long-lived than that following ionising radiation (Appella and Anderson 2001; Latonen 
and Laiho 2005).  In general a UV damage signal sensed by ATR is transduced by Chk1 
to p53, but there can be some cross-talk between the pathways that lead to p53 
activation.  UV damage is thought to lead to the activation of kinases such as Chk1, p38, 
MAPK (mitogen-activated protein kinase), CK2 and HIPK2 (homeodomain-interacting 
protein kinase 2) which phosphorylate multiple sites across p53 including N-terminal 
sites (Ser 20, Ser 33, Ser 37 and Ser 46) and C-terminal sites (Ser 315 and Ser 392) 
(Appella and Anderson 2001).   
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Many other environmental, physiological and therapeutic agents also cause genotoxic 
stress leading to the activation of p53 through different signaling pathways.  These 
agents include cancer drugs such as Adriamycin, topoisomerase inhibitors such as 
etoposide, DNA synthesis and transcription inhibitors such as aphidicoline, and DNA 
cross-linking agents such as cisplatinin.  It is thought that most of these agents cause 
accumulation of p53 and its phosphorylation on Ser 15 (Appella and Anderson 2001).  A 
recent report described a critical role for ATR, and not ATM or DNA-PK in mediating 
damage response to cisplatin treatment of renal cells and tissues (Pabla et al. 2008).  
They showed that ATR activated Chk2, which in turn induced p53 activation and 
apoptosis (Pabla et al. 2008).   
 
1.1.4.2 Non Genotoxic Stresses 
Activation of p53 can also occur following physiological processes such as hypoxia, 
oncogene activation, microtubule disruption and nutrient deprivation that are not 
associated with DNA damage.  Hypoxia can be a feature of both solid tumours and 
ischemic disorders.  Hypoxia also activates hypoxia-inducible factor-1 (HIF-1) which is 
a master regulator of cellular responses to hypoxia.  The accumulation and dimerisation 
of HIF-1 results in the activation of target genes (Wang and Semenza 1995).  It has been 
shown that hypoxia can induce p53 accumulation as a result of downregulation of Mdm2 
(Alarcon et al. 1999; Koumenis et al. 2001; Wang et al. 2002).  Moreover, in contrast to 
genotoxic insults such as IR, hypoxia does not induce the transcription of target genes 
such as GADD45, Bax and p21WAF1, suggesting that p53-dependent transactivation 
requires a DNA damage signal that is lacking following hypoxia treatment (Koumenis et 
al. 2001).  Hypoxia primarily caused p53 to associate with the corepressor mSin3A 
rather than the co-activator p300 leading to p53-mediated transrepression (Koumenis et 
al. 2001).  Although most data supports a role for p53 in the inhibition of the HIF system 
thereby inhibiting tumourigenesis, it has been demonstrated recently that Mdm2 can 
positively activate HIF-1α in hypoxic tumour cells in a p53-independent manner that 
Chapter 1 Introduction 
 - 11 - 
promotes tumour development (Nieminen et al. 2005).  This recent data would suggest 
the existence of a negative feedback loop, whereby Mdm2 activates HIF-1, and HIF-1 
downregulates Mdm2.   
 
Stabilisation of p53 can occur following the activation of the p53-p14-Mdm2 pathway 
whereby p14 is activated by oncogenic stress signals (such as E2F), which inhibits 
Mdm2, and thereby stabilises p53.  The presence of oncogenes such as c-myc and E2F-1 
in cells can promote malignant transformation under certain conditions.  However, 
oncogenes such as c-myc also activate p53.  Raveh and colleagues investigated whether 
death-associated protein kinase (DAPK), a tumour suppressor which sensitises cells to 
apoptotic signals, could affect the initial steps of oncogenesis (Raveh et al. 2001).  They 
found that DAPK suppresses oncogene-induced transformation of primary embryonic 
fibroblasts by activating p53 in a p19ARF (the murine equivelent of p14) – dependent 
manner.  This led to induction of apoptosis in order to eliminate the pre-malignant cells.  
More recently it has been demonstrated that ATM plays a critical role in inhibiting the 
development of cancer by responding to oncogenic stress and inducing the accumulation 
and phosphorylation of p53 in response to deregulated Myc expression (Hong et al. 
2006).  In support of this, the group demonstrated that inactivation of ATM led to 
reduced apoptosis and increased tumourigenesis in Myc transgenic mice, suggesting that 
ATM is critical for the activation of p53 to allow apoptosis to proceed (Hong et al. 
2006).   
 
Activation of p53 can also occur in response to anti-cancer agents such as colcemid, 
nocodazole and taxol that deregulate cell adhesion, microtubule architecture or 
dynamics.   Taxol, the first identified microtubule stabilizing drug has been used to treat 
solid tumours of the breast, ovary, head and neck (Bergstralh and Ting 2006).  Taxol, 
but not nocodazole, was found to induce multi-site phosphorylation of p53 in several 
tumour cell lines. However, the pattern of phosphorylation was distinct from that 
observed after DNA damage induced by IR (Stewart et al. 2001).  P53 activation after 
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colcemid treatment was accompanied by an increase in Ser 15 phosphorylation, which 
correlated with the activation of ERK1/2 MAP kinases and the development of focal 
adhesions, rather than the disruption of the microtubule system (Sablina et al. 2001).  
 
Nutrient deprivation can also lead to the activation of p53 which will be discussed in 
more detail in the following section (see 1.1.5.4).  
 
1.1.5 Function of p53 
As a stress-induced sequence-specific DNA-binding protein and transcription factor, p53 
plays a crucial role in the cellular response to genotoxic and non-genotoxic stresses.  In 
unstressed cells, p53 is maintained at very low levels.  However, following stresses such 
as double strand breaks induced by genotoxic agents, hypoxia or oncogene expression, 
the p53 protein becomes activated and accumulates rapidly (Lu and Lane 1993; Vousden 
2002).   In response to such stress signals, p53 becomes activated in a specific manner 
by post-translational mechanisms leading to either cell cycle arrest or cellular apoptosis 
(Jin and Levine 2001).  This is achieved by p53’s ability to regulate target genes, thereby 
allowing the cell to arrest temporarily to repair the damage or to activate apoptosis to 
eliminate the damaged cell.  The decision to activate either cell cycle arrest of apoptosis 
depends on the type or degree of damage and the subsequent differential 
phosphorylation.  The specific roles of p53 in the cellular responses to damage will be 
discussed below. 
 
1.1.5.1 Cell cycle arrest and Senescence 
Cell cycle checkpoints are activated following damage to delay progression from G1 to 
S phase, to inhibit DNA synthesis as part of the intra-S phase checkpoint, and to prevent 
passage of cells from G2 into mitosis (Lavin and Gueven 2006).  Following stress 
signals p53 induces cell cycle arrest which can occur in either the G1, G2 or S phases of 
the cell cycle (Agarwal et al. 1998).  p53-induced G1 arrest is mediated by 
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phosphorylation at multiple sites, which involves ATM, Chk1 or Chk2 (see section 
1.1.4.1).  This stabilises the binding of the co-activator p300 (Dornan and Hupp 2001), 
reduces the binding of the inhibitory partner Mdm2 (Unger et al. 1999), and thereby 
enhances activation of p53 target genes such as p21WAF1/CIP1 (Jabbur et al. 2000).  p21 
inhibits the phosphorylation of Rb by the cyclin E-Cdk2 or cyclin D-Cdk4/6 complexes 
ultimately leading to hypophosphorylation of Rb which sequesters E2F family members.  
This prevents E2F from activating the transcription of genes necessary for S phase entry, 
and thereby causes G1 arrest.   p21 can therefore prevent progression into S phase and 
allow sufficient time for any damage to be repaired (Nyberg et al. 2002; Jackson et al. 
2004).   
 
p53-induced G2 arrest is mediated in part by the synthesis of 14-3-3 sigma which binds 
to Cdc25C and keeps it in the cell cytoplasm, thus preventing Cdc25C from activating 
cyclin B-Cdc2 (a complex essential for G2 to M phase transition) (Iliakis et al. 2003).  
14-3-3 sigma, like p21WAF1, is a p53 target gene.  It has been shown that in colorectal 
cancer cells exposure to ionizing radiation leads to significant upregulation of 14-3-3 
sigma in a p53-dependent manner resulting in G2 arrest (Hermeking et al. 1997).    
 
Cellular senescence appears to be an irreversible form of cell cycle arrest that is a potent 
barrier to tumourigenesis (Chen et al. 2005; Collado and Serrano 2005).  It can be 
triggered by the oncogene Ras or excessive P13K signaling (Collado and Serrano 2005).  
The activation of cellular senescence is thought to occur in a p53-dependent manner.  A 
recent report has examined the effect of loss of p53 in aggressive carcinomas (Xue et al. 
2007).  They showed that following reactivation of p53 in vivo, hepatocarcinomas 
expressing either Ras or Akt showed clear signs of senescence, including the 
accumulation of senescence-associated-β-galactosidase activity and the senescence 
markers p16INK4a, DrR2 and p15INK4b (Xue et al. 2007).   Cellular senescence has also 
been shown to trigger the upregulation of inflammatory cytokines and other immune 
modulators (Shelton et al. 1999).  Xue and colleagues reported the upregulation of 
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inflammatory cytokines following p53 reactivation which led to targeting of the tumour 
cells and therefore contributed to tumour clearance (Xue et al. 2007). p53 can therefore 
play a crucial role in the control of tumour development by activating a program of 
cellular senescence. 
 
1.1.5.2 Apoptosis  
In contrast to cell cycle arrest that prevents cell cycle progression to allow the repair of 
damage, apoptosis (or programmed cell death) allows the complete elimination of the 
damaged cell, which promotes tissue homeostasis and tumour prevention.  p53 can 
induce apoptosis through an extrinsic or receptor-mediated pathway, or through an 
intrinsic or mitochondrial-mediated pathway.  The latter shifts the balance in the Bcl-2 
family towards pro-apoptotic members, thus promoting the formation of the apoptosome 
and consequently caspase-mediated apoptosis via caspase 9 (Haupt et al. 2003).  The 
receptor mediated apoptotic pathway also triggers the activation of a caspase cascade, 
but via caspase 8.  External signaling molecules such as tumour-necrosis factor-α 
(TNFα) and CD95 ligand (also known as Fas ligand) bind to their receptors TNFR and 
CD95 (also known as Fas or Apo-1), respectively and convey signals to the cell causing 
the activation of caspase 8 which results in apoptosis (Haupt et al. 2003).  The intrinsic 
pathway is considered to be the main cellular protection mechanism against damage of 
various types.  Cell fate is determined by a balance between pro-apoptotic (BAX, Bid, 
Bim and BAK) and anti-apoptotic (BCL2 and BCL-XL) members of the BCL-2 family 
at the mitochondrial membrane.  A dominance of pro-apoptotic members leads to the 
release of cytochrome c from the mitochondria, which together with apoptosis 
peptidase-activating factor 1 (APAF1) and caspase 9 form a complex known as the 
apoptosome.  The apoptosome activates downstream caspases ultimately leading to 
apoptosis (Haupt et al. 2003).    
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Many members of the BCL-2 family including both pro-apoptotic (e.g. Bax, Bak, Bok 
and BAD) and anti-apoptotic (e.g. Bcl-2 and BCL-XL) representatives are all 
transcriptional targets of p53.  In addition, it has been shown that p53 can localize to the 
mitochondria and bind to pro-apoptotic genes such as Bak, leading to the release of 
cytochrome c from the mitochondria.  P53 can therefore have a direct effect on apoptosis 
as well as transcription-dependent effects (Leu et al. 2004).  In addition, a role for p53 in 
formation has been suggested whereby p53 induces APAF-1 expression (Haupt et al. 
2003).  Uniquely, the pro-apoptotic gene, Bid, seems to be capable of connecting the 
extrinsic and intrinsic pathways by firstly being activated by caspase-8 in the cytoplasm 
and translocating to the mitochondria to activate BAX and BAK (Haupt et al. 2003).   
 
Manipulation of the apoptotic functions of p53 could provide an attractive target for 
cancer therapy, whereby directly activating p53 pro-apoptotic targets in tumours could 
provide an effective anti-tumourigenic therapy.   
 
1.1.5.3 DNA Repair and Recombination  
A role for p53 in DNA repair and recombination has been suggested.  The five main 
DNA repair processes are nucleotide-excision repair (NER), base-excision repair (BER), 
mismatch repair (MMR), non-homologous end joining (NHEJ) and homologous 
recombination (HR). Although the transactivation-independent function of p53 is 
involved in HR regulation, the other DNA repair processes involve both the 
transactivation-dependent and independent activities of p53 (Sengupta and Harris 2005).  
The transcription-independent roles of p53 contribute to the control and efficiency of 
DNA repair and recombination which cooperate with its function in transcription.   P53 
is thought to be involved in the multi-step process of HR by binding to HR specific 
proteins such as RAD51 and RAD54 or by directly checking the fidelity of HR events 
(Sengupta and Harris 2005).  p53 may also have a role to play in the regulation of the 
proteins that are involved in the NER process (Sengupta and Harris 2005).   
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Transcription-dependent effects of p53 can occur following exposure to nitric oxide 
(NO), which causes the p53-dependent transcriptional repression of the 3-methyladenine 
DNA-glycosylase (MPG) gene that functions in the BER pathway (Sengupta and Harris 
2005).   
 
P53 and MMR positively affect each other’s activity, whereby the stabilization of a 
mismatch repair protein heterodimer augments p53 activation during DNA damage 
(Sengupta and Harris 2005). It is also thought that p53 functions as a sequence-
dependent transactivator by binding to response elements in the promoter region of 
MMR proteins such as MutS homologue-2 (MSH2). It is thought that MMR proteins 
and p53 may cooperate in the repair process (Sengupta and Harris 2005).  A role for p53 
in NHEJ has been suggested whereby p53 may interact with NHEJ proteins such as 
DNA-PK which leads to stabilization of p53 and ultimately apoptosis (Sengupta and 
Harris 2005).  P53 may also have a direct transactivation-independent role in NHEJ 
whereby it is capable of rejoining DNA after DSBs or can facilitate precise ligation 
(Sengupta and Harris 2005). 
 
The role of p53 in modulation of several DNA repair processes by both transactivation-
dependent and transactivation-independent pathways has led to the idea that p53 may 
function as a ‘molecular node’ whereby it operates at the intersection of upstream 
signaling cascades and downstream DNA-repair and -recombination pathways 
(Sengupta and Harris 2005).   
 
1.1.5.4 Cell survival and autophagy  
A novel role for p53 function in metabolism has recently been reported in several studies 
whereby p53 either drives cells to undergo apoptosis or controls how cells use nutrients 
to preserve their survival (Jones et al. 2005; Bensaad et al. 2006; Crighton et al. 2006; 
Matoba et al. 2006).  A report demonstrated that glucose (a direct energy source for 
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mammalian cells) availability directly regulates cell proliferation (Jones et al. 2005).  
They showed that cells arrest in the G1 phase of the cell cycle under low glucose 
conditions and this arrest is p53-dependent. When the cell is glucose deprived, AMPK is 
activated leading phosphorylation of p53 at Ser15 and activation of p53.  Thus, 
implicating both AMPK and p53 as proteins required to promote cell cycle arrest and 
allow the cell to survive the unfavourable glucose deprived conditions (Jones et al. 
2005) 
 
P53 has also been reported to play a direct role in metabolism.  In a study by Bensaad 
and colleagues, a product of a p53 target gene, TIGAR (TP53-induced glycolysis and 
apoptosis regulator) was identified, which functions to regulate glycolysis and protect 
cells against oxidative stress (Bensaad et al. 2006).  TIGAR is thought to inhibit 
glycolysis by causing a decline in fructose-2,6-biphosphate which leads to the formation 
of fructose-6-phosphate and NADPH.   This increased NADPH generation is thought to 
increase glutathione levels which promotes the scavenging of reactive oxygen species 
(ROS) thereby protecting cells from ROS and DNA damage-induced apoptosis (Bensaad 
et al. 2006).   
 
In addition, p53 may modulate the balance between the utilization of respiratory and 
glycolytic pathways (Matoba et al. 2006).  Cancer cells often use energy derived from 
glycolysis to sustain their growth and therefore their survival advantage (known as the 
Warburg effect) (Vousden and Lane 2007).  The report by Matoba and colleagues 
suggested that p53 modulates the balance between the utilization of respiratory and 
glycolytic pathways and identified SCO2 (synthesis of cytochrome c oxidase 2) as a 
downstream mediator of this effect.  They showed that disruption of SCO2 in cells wild-
type for p53 caused a similar metabolic switch to glycolysis as that observed in p53 
deficient cells.  SCO2 therefore couples p53 to mitochondrial respiration (Matoba et al. 
2006). 
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P53 is also thought to play a role in the autophagy pathway.  Autophagy is an 
evolutionary conserved membrane-trafficking process that operates at basal levels to 
degrade cytosolic proteins and organelles by engulfing them in autophagosomes.  It is 
thought to contribute to cell survival when nutrients are limiting (Crighton et al. 2006).   
This recent report demonstrated that the p53 target DRAM (damage regulated autophagy 
modulator) engages autophagy by the accumulation of autophagosomes in a p53-
dependent manner.  In addition, DRAM is required for p53-induced apoptosis as 
DRAM-dependent autophagy operates upstream of cytochrome c release from the 
mitochondria and is required for apoptosis to proceed (Crighton et al. 2006).   
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1.2 Regulation of p53 transcriptional activity 
The activity of p53 is controlled by cellular levels of p53, its DNA-binding ability, its 
subcellular localization and the recruitment of transcriptional activators and repressors. 
1.2.1 Protein stabilization 
The regulation of cellular levels of p53 can be controlled by several proteins which by 
interacting with p53 can either positively or negatively control its level of expression.  
Mdm2, an E3 ubiquitin ligase, is thought to be one of the main proteins involved in 
control of p53 stability.  It has been shown to bind to the transactivation domain of p53, 
repressing transcription but also promoting its ubiquitination and export to the cytoplasm 
for degradation by the 26S proteasome (Momand et al. 1992; Lu and Levine 1995; Thut 
et al. 1995; Chen et al. 1996; Haupt et al. 1996; Honda et al. 1997; Kubbutat et al. 1997; 
Thut et al. 1997; Michael and Oren 2003).  p300 forms part of a positive regulatory 
pathway which facilitates induction of p53 dependent gene expression (Goodman and 
Smolik 2000). The interaction of p53 with CBP/p300 results in acetylation and 
transcriptional activation of p53 (Goodman and Smolik 2000).  The roles of both Mdm2 
and p300 in regulation of p53 transcriptional activity will be discussed in detail in 
section 1.3, and the role of ubiquitination and acetylation will be discussed in sections 
1.2.2.2 and 1.2.2.3. 
 
Although Mdm2 was thought to be the major p53 E3 ubiquitin ligase, several other E3 
ligases that mediate p53 ubiquitination and degradation have recently been identified.  
These include Pirh2, constitutively photomorphogenic 1 (COP1), chaperone-associated 
ubiquitin ligase (CHIP), human topoisomerase I- and p53-binding protein (topors) and 
ARF-binding protein (ARF-BP1) (Liu and Chen 2006).  In addition to its role as a 
ubiquitin ligase, inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 
stabilisation (Chen et al. 2005).  COP1 has been shown to inhibit p53-dependent 
transcription and apoptosis as well as target p53 for degradation by the proteasome 
(Dornan et al. 2004).  CHIP was also described to induce proteasomal degradation of 
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p53 (Esser et al. 2005).  Finally, Pirh1, a gene that encodes a RING-H2 domain-
containing protein with intrinsic ubiquitin ligase activity, interacts with p53 and 
promotes p53 ubiquitination and represses p53 functions (Leng et al. 2003).   
 
Stabilisation of p53 can also occur by removal of the ubiquitin modification.  Recently a 
novel p53-interacting protein was identified, herpes virus-associated ubiquitin-specific 
protease (HAUSP), which has intrinsic enzymatic activity that specifically 
deubiquitinates p53, therefore stabilizing p53 and promoting p53-dependent growth 
suppression (Li et al. 2002).  HAUSP has also been shown to deubiquitinate and 
stabilise Mdm2, suggesting that Mdm2 is directly regulated by the deubiquitinase 
function of HAUSP (Li et al. 2004).  Therefore HAUSP may play a crucial in the 
regulation of the p53-Mdm2 pathway.  However, other proteins such as NAD(P)H 
quinone oxidoredectase (NQO1) can influence the degradation of p53 in an Mdm2- and 
ubiquitin-independent manner (Asher and Shaul 2005).  The interaction of p53 with 
NQO1 leads to the degradation of p53 by the 20S proteasome (Asher and Shaul 2005).   
 
A number of protein kinases influence the stabilization of the p53 protein by 
phosphorylation.  The CAMK superfamily plays an important role in this process and is 
discussed in section 1.3.3.  The role of phosphorylation is discussed in section 1.2.2.1.  
Other examples of kinases include homodomain-interacting protein kinase 2 (HIPK2), 
which is thought to increase p53 stability by phosphorylation of p53 on Ser 46, leading 
to the dissociation of p53 from Mdm2 and decreased shuttling of p53 from the nucleus 
(Di Stefano et al. 2004); and Jun NH2-terminal kinase (JNK), which has been suggested 
to be an Mdm2-independent regulator of p53 in unstressed cells (Fuchs et al. 1995).    
 
1.2.2 Post-translational modification 
Control of p53 function can also be exerted via post-translational modifications such as 
phosphorylation of Serine and Threonine residues and acetylation, ubiquitination and 
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sumoylation of lysine residues.   These post-translational modifications influence the 
interaction between Mdm2 and p53, the major mechanism for controlling p53 stability, 
as well as the interaction with p300, the major mechanism for controlling p53’s activity 
as a transcription factor.    
 
1.2.2.1 Phosphorylation  
Phosphorylation is a reversible mechanism which is crucial for the regulation of the 
biological activity of protein.  Protein kinases phosphorylate target proteins leading to 
their activation or inactivation (Bode and Dong 2004).  Phosphorylation of p53 is one of 
the major mechanisms of post-translational modification that influences the stability of 
p53.   Phosphorylation of p53 can occur at multiple sites across the protein although the 
majority of sites are located within 100 amino acids of the N-terminus or within the C-
terminus.  Following DNA damage, phosphorylation of p53 is thought to change the 
conformation of p53, preventing the binding of Mdm2 and therefore leading to the 
accumulation of p53 (Xu 2003; Bode and Dong 2004).  The activation of various protein 
kinases such as ATM, ATR, Chk1, Chk2 and CK2 upon stress leads to the 
phosphorylation of multiple residues such as Ser 6, 9, 15, 20, 33, 37, 46, 149, 315 and 
392, and Thr 18, 81, 150 and 155.  Moreover, residues Thr 55, Ser 376 and Ser 378 are 
phosphorylated in unstressed cells (Xu 2003; Bode and Dong 2004). There is often 
overlap between sites of phosphorylation by the various different kinases and this can 
often be attributed to the type of stress signal which the cell is exposed to (Lavin and 
Gueven 2006).  The most frequently described residue is the Ser 15 site which is 
phosphorylated by ATM as a result of DNA damage such as double-strand breaks 
(Banin et al. 1998; Khanna et al. 1998).  Phosphorylation of Ser 15 results in reduced 
binding of Mdm2 and the subsequent stabilization of p53 (Shieh et al. 1997).  ATM can 
phosphorylate multiple sites such as Ser 6, 9, 15, 20 and 46 as well as Thr 18 following 
ionizing radiation (Saito et al. 2002).   
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Other commonly described N-terminal sites of phosphorylation include Thr 18, Ser 20, 
Ser 33 and Ser 46.   Phosphorylation at residues Thr 18 and Ser 20, which are within the 
Mdm2 binding region, stabilises the binding of the co-activator p300 (Dornan and Hupp 
2001), reduces the binding of the inhibitory partner Mdm2 (Unger et al. 1999) and 
enhances activation of p53 target genes (Jabbur et al. 2000).  This is supported by 
studies which demonstrated that Asp substitution (mimics phosphorylation due to the 
introduction of a negative charge within the functional group) at the two 
phosphoacceptor sites reduces the interaction of p53 with Mdm2 and increases the 
transactivation of the p53 target genes, p21WAF1/CIP1 and Fas (Jabbur and Zhang 2002).  
In addition, mutation of the Ser 20 site in mice (Ser 23) leads to the formation of 
spontaneous B-cell lymphoma (MacPherson et al. 2004).  Phosphorylation of Ser 20 in 
stressed cells was thought to be predominantly mediated by Chk1 and by ATM-activated 
Chk2, resulting in the alleviation of the inhibition mediated by Mdm2 (Shieh et al. 1997; 
Khanna et al. 1998; Chehab et al. 1999; Unger et al. 1999; Shieh et al. 2000).  However, 
it has been shown that disruption of Chk2 did not affect p53 stabilization, 
phosphorylation or transcriptional activation of downstream targets (Ahn et al. 2003; 
Jallepalli et al. 2003), suggesting that Chk2 may play a less important role in p53 
activation.  Phosphorylation at Ser 33, Ser 46 and Thr 81 have also been suggested to 
lead to p53 stabilisation (Bode and Dong 2004).   
 
The C-terminal region of p53 is a target for phosphorylation by casein kinase 2 (CK2)  
and protein kinase C which stimulate the binding of p53 to DNA (Hupp et al. 1993).  
The C-terminal region is thought to be key in regulating p53’s DNA binding ability.  In 
support of this, the phosphorylation of Ser 392 is thought to regulate the stability of the 
tetramerisation domain.  It has been shown that mutation of a site adjacent to Ser 392 
(Lys 386) can increase p53’s activity, likely due to the neutralization of the negative-
regulatory motif (Hupp et al. 2000).  It has also been shown that phosphorylation of p53 
at this CK2 site (Ser 392) leads to sequence-specific DNA binding stimulated by 
allosteric mechanisms that converts p53 protein from a low affinity to a high affinity 
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DNA-binding form by a conformational change (Lane and Hupp 2003).  More recently, 
both Chk1 and Chk2 have been shown to phosphorylate p53 at multiple sites in both the 
N- and C-termini of p53 leading to its stabilization (Ou et al. 2005).  This group 
identified several sites in the C-terminus including Ser 366, Ser 378 and Thr 387, which 
were damage inducible.  Abrogation of either Chk1 or Chk2 prevented phosphorylation 
of two of these sites, which led to reduced induction of p53 downstream target genes 
(Ou et al. 2005).   
 
Therefore the phosphorylation of several residues across the p53 protein plays a role in 
the modulation of its activity.  The most extensively studied damage response pathways 
being the IR-ATM-Chk2-Ser20 and the UV-ATR-Ser15/Ser20 axes.  The role of Ser 20 
phosphorylation in assembly of the transcription complex and therefore the control of 
p53 activity will be discussed in more detail in section 3.1.1.  
 
1.2.2.2 Acetylation 
Phosphorylation stabilizes not only the p53:DNA complex but also the protein-protein 
interactions with the co-activator and acetyltransferase, p300.  Acetylation is thought to 
be important for p53 stability and transcriptional activation (Bode and Dong 2004).  
Both p300 and CREB-binding protein (CBP) are histone acetyltransferases (HAT)-
containing proteins that can coactivate transcription factors such as p53 (Chan and La 
Thangue 2001).  It has been shown that p300/CBP interact with and acetylate p53 in the 
C-terminal domain, a region critical for the regulation of p53:DNA binding, thus 
suggesting that acetylation of p53 can stimulate DNA binding activity (Gu and Roeder 
1997).  Following the report by Gu and Roeder, the ability of p53 to be acetylated by 
p300 in vivo was confirmed using acetylation specific antibodies (Sakaguchi et al. 
1998).   PCAF and p300 can acetylate p53 at Lys 320 and Lys 372, 373, 381 and 382, 
respectively, and these lysine residues can be phosphorylated in response to DNA 
damage (Gu and Roeder 1997; Lill et al. 1997; Sakaguchi et al. 1998).  Studies have 
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supported a role for DNA-damage induced phosphorylation of p53 as a modification 
which regulates the interaction between PCAF/p300 and p53 (Moll and Petrenko 2003; 
Xu 2003).  These reports have shown that phosphorylation of p53 at Ser 15 or Ser 33/37 
promotes the interaction with p300/CBP (Xu 2003).  Acetylation of p53 may also 
regulate p53 stability.  Studies have shown that the C-terminal lysine residues acetylated 
after DNA-damage are also residues ubiquitinated by Mdm2 (Moll and Petrenko 2003; 
Xu 2003).   This would suggest that acetylation of these lysine residues after DNA 
damage could prevent ubiquitination by Mdm2, thereby promoting p53 stabilisation.   
 
A recent report has shown that the native conformation of the p53 tetramer is critical to 
restrain acetylation in the absence of consensus site DNA (Ceskova et al. 2006).  They 
developed a model whereby DNA binding in the core domain of p53 simultaneously 
stabilizes p300 docking to N-terminal p53 and exposes an acetylation motif within the 
C-terminal and thereby removes any conformational restraints to acetylation (Ceskova et 
al. 2006).  The identification a novel site of acetylation within the DNA-binding domain 
of p53 (K120) that proteins of the MYST family of acetyltransferases directly acetylate 
has been described in a recent report (Sykes et al. 2006).   Mutation of this site (to 
arginine) occurs in human cancer and leads to inhibition of acetylation, which prevents 
p53-mediated apoptosis by blocking transcription of pro-apoptotic genes BAX and 
PUMA (Sykes et al. 2006).   Therefore acetylation has several functions in regulating 
the DNA-binding activity and stabilization of p53, as well as its ability to regulate the 
induction of apoptosis.   
 
Histone acetylation by p300/CBP can be reversed by histone deacetylases (HDACs) 
which act as p53 corepressors (Liu and Chen 2006).  P53 can transcriptionally repress 
target genes such as Myc, Nanog and HSP90 beta by recruitment of HDACs to 
promoters through interaction with mSin3a and other DNA-binding proteins (Liu and 
Chen 2006).   A balance between p53 acetylation and deacetylation may allow the 
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activation and stabilization of p53 upon damage and once the damage is repaired the 
acetylated p53 may be inactivated by deacetylation (Liu and Chen 2006).   
 
1.2.2.3 Ubiquitination 
Ubiquitination of proteins is controlled by a series of enzymatic reactions catalysed by 
enzymes known as E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) 
and E3 (ubiquitin protein ligase) (Bode and Dong 2004).   Ubiquitination can either 
occur in the form of monoubiquitination, whereby the ubiquitin monomer conjugates 
with one or more lysines within the target protein, or alternatively polyubiquitination, 
whereby a polymeric ubiquitin chain conjugates with one or more lysines within the 
target protein (Bode and Dong 2004).  Monoubiquitination is thought to regulate the 
function of target promoters, whereas polyubiquitination marks the protein for 
degradation by the 26S proteasome.  Mdm2 was one of the first E3 ubiquitin ligases 
identified to mediate p53 degradation (Momand et al. 1992; Lu and Levine 1995; Thut et 
al. 1995; Chen et al. 1996; Haupt et al. 1996; Thut et al. 1997) (see section 1.2.1 for 
details on other E3 ligases).  Upon binding to the Box-I region of p53, Mdm2 transfers 
ubiquitin tags onto lysine residues in the C-terminus of p53.  It is thought that different 
levels of Mdm2 can induce either mono- or polyubiquitination of p53 in a dose-
dependent manner, thereby controlling the fate of p53 (Li et al. 2003).  Indeed, mono-
ubiquitination is thought to act as a nuclear export signal for p53 whereas 
polyubiquitination marks p53 for degradation.   
 
In unstressed cells, p53 is maintained at low levels by continuous ubiquitination and 
subsequent degradation by the 26S proteasome, which is primarily due to the interaction 
of p53 with the ubiquitin E3 ligase, Mdm2.   It is only upon stress that this negative 
repression of p53 is released, allowing stabilization of p53 which accumulates in the 
nucleus (Shieh et al. 1997; Chehab et al. 1999; Craig et al. 1999; Unger et al. 1999).  
These reports demonstrate that DNA damage such as IR and UV lead to phosphorylation 
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of the N-terminal domain of p53 at sites such as Ser 15, Thr 18 and Ser 20, reducing the 
binding of Mdm2 and leading to the stabilization of p53.  Mdm2 seems to play a role in 
controlling both the localization and degradation of p53.  Overexpression of Mdm2 has 
been observed in many tumour types and can lead to complete deactivation of p53 (Bode 
and Dong 2004).  The specific role of Mdm2 in control of ubiquitination of p53 will be 
discussed in more detail in section 1.3.2.   
 
Histone ubiquitination is also able to regulate the transcription of p53 target genes and 
this ubiquitination mainly occurs on histones H2A and H2B.   Although little is known 
about the regulation of p53-mediated transcription by histone ubiquitination, Mdm2 has 
been shown to bind histones H2A and H2B (Minsky and Oren 2004).  This group 
showed that Mdm2 overexpression enhanced histone ubiquitination close to the p53 
binding site within the p21WAF1 promoter, suggesting that ubiquitination of H2A and 
H2B by Mdm2 may represent another mechanism by which Mdm2 negatively regulates 
p53 activity. This work also suggests that Mdm2 may drive gene silencing via chromatin 
modification (Minsky and Oren 2004).   
 
A recent report described the analysis of enzymes required for the ubiquitination of p53 
and identified UbcH5B/C as an E2-like protein involved in controlling levels of p53 and 
Mdm2 (Saville et al. 2004).  This group showed that depletion of UbcH5B/C inhibited 
p53 ubiquitination and degradation, but that this p53 was transcriptionally inactive as it 
remained bound to Mdm2 (that was not ubiquitinated either).  Activation of the 
stabilized p53 therefore required complete removal of the bound Mdm2 (Saville et al. 
2004).   It has also been reported that both p53 and Mdm2 can be modified by the 
ubiquitin-like proteins NEDD8, a well characterized regulator of p27kip1, IκBα and 
SUMO (Watson and Irwin 2006).  There are therefore several pathways involved in the 
ubiquitination and inactivation of p53.   
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1.2.2.4 Other modifications  
Other post-translational modifications involved in the control of p53 transcriptional 
activity include sumoylation, glycosylation and ribosylation (although little is known 
about the role of the latter two in carcinogenesis) (Bode and Dong 2004).  Sumolytion is 
similar to ubiquitination in that an iso-peptide bond is formed between the C-terminal 
group of a the small ubiquitin-like molecule, SUMO1 and the ε-amino group of lysine 
residues within transcription factors (Bode and Dong 2004).  The sumoylation-specific 
E2 conjugating enzyme for p53 is Ubc9 and the sumoylation specific E3 ligase for p53 
is protein inhibitor of activated STAT1 (PIAS-1) (Liu and Chen 2006).  The target site 
for sumoylation in p53 is K386 and it was shown that sumoylation stimulates p53 
transcriptional activity, but does not affect p53 ubiquitination (Liu and Chen 2006).  
Sumoylation of p53 appears to be regulated by Mdm2- and p14 ARF- mediated nuclear 
targeting and sumoylation may also have a repressive effect (Chen and Chen 2003).  The 
debate over whether sumoylation of p53 results in the activation or the repression of p53 
is still to be settled.  The regulation of p53 activity therefore occurs as the result of 
several modifications and by the intervention of several proteins.  The following section 
will examine in detail the regulators of p53 function.  
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1.3 Regulators of p53 function 
Modulation of p53 activity depends on docking of several regulators, most of which 
have already been mentioned in previous sections.  Two regulators, Mdm2 and p300 
play crucial roles in regulating p53.  Mdm2 is a negative regulator which facilitates p53 
degradation via the proteasome (Oren 1999), whereas P300 is a positive regulator that 
facilitates p53-dependent gene expression (Goodman and Smolik 2000). These two 
components compete for binding to the N-terminal Box-I domain of p53 resulting in the 
modulation of the specific activity of p53 as a tumour suppressor (Dornan and Hupp 
2001).   Members of the Calcium Calmodulin kinase superfamily such as Chk1, Chk2 
and DAPK1, also play an important role in the control of p53 activity by altering p53’s 
interactions with p300 and Mdm2.  This is achieved by phosphorylation in the Box-I 
domain.  P300, Mdm2 and CAM kinases will therefore be discussed in this section. 
 
1.3.1 P300 
P300 forms part of a positive regulatory pathway which facilitates induction of p53 
dependent gene expression (Goodman and Smolik 2000).  P300 as well as CREB 
binding protein (CBP) were initially identified in protein-interaction studies.  CBP was 
found to associate with CREB and p300 was shown to interact with the adenoviral-
transforming protein E1A (Stein et al. 1990; Eckner et al. 1994).  Eckner and colleagues 
cloned and analysed the 300 kDa protein, p300, and mapped the gene encoding p300 to 
chromosome 22q13.  p300 contains 3 cysteine and histidine rich regions and a carboxy-
terminal region which interacts specifically with E1A (Eckner et al. 1994).  They also 
described how p300 may function as a transcriptional adaptor protein for transcriptional 
regulatory elements. 
 
The link between p53 function and p300 was described in a report by Lill et al 1997.  
They showed that p300 and p53 colocalise in the nucleus in a stable DNA binding 
complex.  Furthermore, p53’s ability to mediate functions such as G1 checkpoint 
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activation was shown to be p300/CBP dependent  (Lill et al. 1997).  The discovery that 
p53 can be acetylated by p300 (Gu and Roeder 1997) provided an insight into the 
aspects of p300/CBP function.  They showed that p53 was acetylated by p300 in the C-
terminal domain, a region critical for the regulation of binding of the p53 to DNA.  This 
acetylation was shown in both in vitro and in vivo assays and was shown to be 
evolutionary conserved (Gu and Roeder 1997; Sakaguchi et al. 1998).    It is now known 
that p53 interacts with the carboxy-terminal region of CBP/p300 resulting in 
transcriptional activation of p53 responsive promoters such as p21 and Bax (Goodman 
and Smolik 2000). 
 
Phosphorylation of p53 at Thr 18 and Ser 20 stabilises the binding of the co-activator 
p300 (Dornan and Hupp 2001).  Further studies defined the interaction of p53 with p300 
In particular, comparison of p53 Box I phosphorylation sites revealed that Chk2 
mediated phosphorylation at Ser 20 had the most stabilizing effect on p53:p300 complex 
formation compared to other phosphorylation sites (Dornan et al. 2003).  This study 
mapped two consensus p53 binding sites within p300; the C-terminal Interferon-binding 
domain (IBiD) and the N-terminal domain which has homology to IBiD, IHD.  
Consensus site binding of p300 to p53 is essential for sequence specific DNA 
acetylation of p53, which results in stabilization of the p53:p300 acetyl-complex 
(Dornan et al, 2003).  Dornan and collaegues identified three stages in the assembly of 
the p53:p300 complex: firstly, as a result of phosphorylation at Ser20 or Thr18 by Chk2, 
p300 docks stably to the phosphorylated – Box-I transactivation domain of p53 via the 
IBiD and IHD domains of p300; secondly, p300 docking leads to DNA dependent 
acetylation of p53; and finally leading to the acetyl-co-A dependent stabilization of the 
p300:p53 complex is achieved. Therefore, the complementary role of phosphorylation 
and acetylation is essential in assembly the p53-p300 transcription complex.  
 
Dornan and colleagues also identified a further p300-binding motif which exists within 
the proline repeat region within the N-terminal domain of p53 (Dornan et al. 2003). 
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Using a technique which can define novel protein-protein interfaces, p300 was subjected 
to a peptide selection from a phage-peptide display library.  PXXP-containing peptides 
derived from the p53 transactivation domain were identified and p300 was shown to 
bind to the PXXP containing peptides.  In addition, deletion of the proline rich region 
destabilised the p53-p300 complex and prevented acetylation of p53.  Furthermore, 
PXXP containing peptides inhibited sequence-specific DNA-dependent acetylation of 
p53, suggesting that p300 docking to both the Box-I (LXXLL) and the PXXP motifs of 
p53 is essential for p53 acetylation (Dornan et al. 2003).   
 
Other reports have examined how p53 acetylation by p300 may be controlled in trans by 
other regulatory factors.  A report by Dornan and colleagues focused on interferon 
regulatory factor 1 (IRF-1) binding to p300.  They describe a crosstalk mechanism 
between the two transcription factors, p53 and IRF-1, in which IRF-1 binding to p300 
results in stabilization of p300 binding to the LXXLL domain of p53.  This in turn, leads 
to DNA-dependent acetylation of p53 and therefore stimulation p53 activity (Dornan et 
al. 2004).   
 
The role of p300 as a scaffold for binding of components of the transcriptional 
machinery can be partly attributed to the presence of three broad functional domains: an 
acetyltransferase domain that mediates substrate acetylation; a bromodomian which is 
implicated in binding to acetylated amino acids; and transactivation peptide-binding 
domains such as LXXLL and PXXP.  Further definition of the nature of the p300:p53 
complex was described in a report by Finlan and collaegues.  They characterized the 
IBiD homology domain (IHD) and defined the minimal IHD scaffold as a 75 amino acid 
fragment.  This fragment displayed similar characteristics to full-length p300 including 
affinity for LXXLL-containing peptides.  The minimal IHD scaffold was shown to 
interact with the LXXLL activation domain of p53 and stimulated the binding to Ser 20 
phosphorylated tetramers to DNA (Finlan and Hupp 2004).  These results therefore 
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demonstrate that the minimal IHD scaffold forms a transcriptionally active complex with 
p53.    
 
1.3.2 Mdm2 
Mdm2 (mouse double minute 2) is a key player in the negative regulation of p53 tumour 
suppressor protein (Oren 1999).  Mdm2 is an oncogene product which was found to be 
amplified in mouse tumour cell lines in the form of ‘double minutes’, small 
acentromeric, extrachromosomal nuclear bodies  (Fakharzadeh et al. 1991).  It was later 
found to be amplified in human sarcomas (Oliner et al. 1992). A 90kDa protein was 
shown to form complexes with mutant and wild-type p53 and was subsequently 
identified as Mdm2 (Momand et al. 1992).  Furthermore, this group showed that Mdm2 
inhibited p53 mediated transactivation (Momand et al. 1992).   
  
The relationship between Mdm2 and p53 was subsequently described in several reports 
Mdm2 was shown to bind to p53’s transactivation domain, repressing transcription, and 
thereby inactivating p53. The reports also described how Mdm2 binding led to the 
subsequent degradation of p53 (Momand et al. 1992; Lu and Levine 1995; Thut et al. 
1995; Chen et al. 1996; Haupt et al. 1996; Thut et al. 1997).  Chen and colleagues 
described how Mdm2 binding could reverse p53 mediated cell cycle arrest and apoptotic 
functions (Chen et al. 1996).  Mdm2 was also shown to contain an autoinhibitory 
domain which directly represses basal transcription in the absence of p53 (Thut et al. 
1997). Using in vitro binding assays, a direct interaction between Mdm2 and two 
components of the transcriptional machinery, TFIIE and TBP was identified.  p53 and 
Mdm2 therefore have a unique relationship, whereby binding of Mdm2 to p53 leads to 
inhibition of transcription functions and therefore inactivation of p53. 
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Figure 1.2 The p53-Mdm2 autoregulatory feedback loop.   
This regulates the activity of the p53 protein and the expression of the Mdm2 gene (Oren 1999).  
 
The relationship between Mdm2 and p53 is even more unique given that p53 can bind to 
the Mdm2 gene and stimulates its transcription (Barak et al. 1993; Wu et al. 1993).  
Barek and colleagues initially described how Mdm2 expression is induced by wild type 
p53 activity (Barak et al. 1993).  A report by Wu and colleagues then examined the p53-
Mdm2 interaction and demonstrated that the p53 protein regulates the Mdm2 gene at the 
transcription level, suggesting that the Mdm2 gene is autoregulated.  A feedback loop (as 
shown in Figure 1.2) therefore regulates both the activity of the p53 protein and the 
expression of the Mdm2 gene (Wu et al. 1993).     
 
Mdm2 consists of an N-terminal domain which contains the p53 binding region; a 
central acidic domain which is capable of interacting with p14 ARF tumour suppressor 
and ribosomal protein L5; a zinc finger motif which is located downstream of the acidic 
domain; a RING finger domain at the C-terminus; and finally a nuclear localization 
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Figure 1.3 The domain regions of the Mdm2 protein.   
This includes the p53 binding domain, acidic domain, Zinc finger and RING finger domains (Ma 
et al. 2006). 
 
The ability of Mdm2 to inactivate p53 requires direct binding of the two proteins.  One 
of the key mechanisms for the regulation of p53 activity by Mdm2 indeed occurs when 
Mdm2 competes with p300 for binding to the N-terminal transactivation domain of p53. 
This results in the repression of p53-dependent transcription.  The Mdm2-mediated 
negative regulation of p53 is also the result of the E3-ligase function of Mdm2, which 
can catalyse ubiquitination and the subsequent export of p53 to the cytoplasm for 
degradation by the 26S proteasome (Honda et al. 1997; Kubbutat et al. 1997; Michael 
and Oren 2003).   The negative effect of Mdm2 is dependent on the relative amount of 
Mdm2, whereby when Mdm2 is abundant it promotes p53 polyubiquitination and 
degradation.  However, lower levels of Mdm2 lead to p53 monoubiquitination and 
export to the cytoplasm (Li et al. 2003).   
 
For the ubiquitination (and degradation) of p53 by Mdm2 to occur, a highly conserved 
region within the N-terminal activation domain (Box-I) of p53 interacts with a 
hydrophobic pocket in the N-terminal domain of Mdm2 (Bottger et al. 1997).   Studies 
have shown that small peptide ligands designed to mimic the activation domain of p53 
disrupt the p53-Mdm2 complex and stimulate p53-dependent gene expression (Bottger 
et al. 1997).  Moreover, small-molecule antagonists of Mdm2 that mimic the p53 
activation domain contact with Mdm2 can also activate p53 in cells (Vassilev et al. 
2004).  Together these results suggested that the activation domain of p53 was required 
for Mdm2-mediated inhibition of p53.  However, it has since been demonstrated that the 
oligomerisation domain in the C-terminal region of p53 also contributes to efficient 
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Mdm2 binding and degradation (Kubbutat et al. 1998).  In addition, the DNA-binding 
domain of p53 has been identified as a secondary binding site for Mdm2 (Shimizu et al. 
2002; Wallace et al. 2006).   
 
The regulation of ubiquitination of p53 by Mdm2 can occur by a variety of mechanisms 
such as phosphorylation and acetylation (see sections 1.2.2.1 and 1.2.2.2), but also by 
protein-protein interactions.  These ultimately result in the inhibition of complex 
formation between Mdm2 and p53 thus preventing ubiquitination (Michael and Oren 
2003).  Abrogation of Mdm2 expression can also inhibit p53 ubiquitination.  One such 
study demonstrated that treatment of cells with nitric oxide led to the accumulation of 
transcriptionally active p53, which was preceded by a downregulation of Mdm2 protein 
and a reduction in levels of ubiquitination.  This therefore allowed p53 to avoid the 
inhibitory effects of Mdm2 (Wang et al. 2002).  Phosphorylation of Mdm2 also controls 
the negative interaction with p53.  For example, damage induced phosphorylation of 
Mdm2 at Ser 395 by ATM leads to accumulation of p53 (Maya et al. 2001).  In addition, 
Mdm2 can itself be regulated by ubiquitination (see section 1.2.2.3). Protein-protein 
interactions also control the activity of Mdm2.  The tumour suppressor p14 ARF has 
been shown to bind tightly to Mdm2, preventing Mdm2-mediated degradation of p53 
(Kamijo et al. 1998).  In addition p14 ARF is able to prevent Mdm2 from shuttling 
between the nucleus and the cytoplasm where it targets p53 for degradation (Tao and 
Levine 1999).  TSG101 has also been shown to interact with p53 and Mdm2, leading to 
an increased half-life of Mdm2, elevated Mdm2 levels and decreased levels of p53 (Li et 
al. 2001) 
 
Family members such as MdmX (Mdm4), a protein with structural homology to Mdm2, 
have been shown to increase the levels of both p53 and Mdm2, which is partly due to it 
forming a complex with p53 (Wang et al. 2001).  Although Mdmx appears to compete 
with Mdm2 for binding to p53, it has no E3 ligase activity, and therefore cannot target 
p53 for degradation (Wang et al. 2001).  This in turn, leads to the upregulation of Mdm2 
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levels via the feedback loop.  MdmX has been shown to be overexpressed in tumours 
and tumour-derived cell lines where it coexists with wild-type p53 (Michael and Oren 
2002).   
 
Although Mdm2 gene amplifications occur at relatively low frequencies in human cancer 
(Momand et al. 2000), Mdm2 is a potent oncogene product whose excess activity can 
lead to the development of cancer.  Indeed, Mdm2 is frequently overexpressed at the 
protein level in human cancer.  Strategies which can inhibit Mdm2 activity have 
therefore been investigated.  Anti-Mdm2 therapy could allow reactivation of p53 activity 
in tumours with overexpressed Mdm2, but could also promote p53 activity in tumour 
which express wild-type p53 and normal levels of Mdm2 (Momand et al. 2000).  More 
recently, the development of small molecules which interfere with the p53-Mdm2 
complex has proved an interesting development.  In particular, Nutlin-3 was identified in 
a screen for small-molecule antagonists of Mdm2 (Vassilev et al. 2004).  This study 
demonstrated that Nutlin-3 binds to Mdm2 in the p53-binding pocket, therefore 
competing with p53 for binding to Mdm2.  Nutlin-3 was therefore able to activate the 
p53 pathway to eliminate the cancer cell (Vassilev et al. 2004).   
 
Thus, Mdm2 may inhibit transcription from p53 responsive promoters by four distinct 
mechanisms: (i) direct competition for binding to the activation domain of p53 with 
p300; (ii) direct inhibition of basal transcriptional machinery (Thut et al. 1997); (iii) 
indirectly affecting p53’s activity by affecting p53’s stability (see section 1.2.1); and (iv) 
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1.3.3 The Calcium Calmodulin Kinase Superfamily 
The Calcium Calmodulin Kinase (CAMK) superfamily form part of the human kinome, 
and are a complete family of protein kinases which are related based on their catalytic 
domains.  The categorization of protein kinases demonstrated that there are seven major 
family groups, which include CAMK as well as families such as casein kinase-1 (CK-1), 
tyrosine kinases (TK) and tyrosine-like kinase (TLK) (Manning et al. 2002).  For the 
purpose of this report we will focus on four members of the CAMK superfamily; Chk1, 
Chk2, DAPK1 and AMPK.   Figure 1.4 shows the protein structure of Chk1 and Chk2.  
  
 
Figure 1.4  A schematic diagram of the protein structures of Chk1 and Chk2.  
A. Chk1 is comprised of a kinase domain (shown in yellow) at the N-terminus and a regulatory 
domain at the C-terminus which contains the SQ/TQ domain (blue), the site of phosphorylation 
by ATM/ATR.  B. In contrast to Chk1, the kinase domain (yellow) of Chk2 is located at the C-
terminus of the protein.  The N-terminal regulatory domain contains a fork-head associated 
domain (FHA) and an SQ/TQ domain (blue) at which phosphorylation by ATM occurs at Thr 68.   
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1.3.3.1 Chk1 
Checkpoint kinase 1 (Chk1), a member of the CAMK superfamily, is a classical 
serine/threonine kinase that plays a major role in cell cycle checkpoint control.  It is an 
evolutionary conserved protein kinase which was first identified in fission yeast as a 
gene product which functioned as a DNA damage checkpoint (Walworth et al. 1993).  
Chk1 homologues have since been identified in mammals, Drosophila, Xenopus and 
chicken, and the checkpoint function is thought to be largely conserved (Chen and 
Sanchez 2004).   Chk1 is essential for embryonic development and studies in mammals 
have shown early embryonic lethality in Chk1-deficient mice and acute lethality of 
Chk1-deficient embryonic cells (Liu et al. 2000; Takai et al. 2000).  However, Chk1 is 
dispensable in chicken DT40 B-lymphoma cells (Zachos et al. 2003).  Zachos and 
colleagues showed that although Chk1 was not universally essential for vertebrate cell 
survival, Chk1 deficient cells failed to arrest in G2/M in response to ionizing radiation 
(IR) and failed to maintain viable replication forks.  This led to decreased cell survival 
(Zachos et al. 2003).   
 
Chk1 has a well conserved primary structure (Figure 1.4 A).  Chk1 is composed of an N-
terminal kinase domain and a C-terminal regulatory domain that contains the 
serine/glutamine rich SQ/TQ domain, which itself contains multiple phosphorylation 
sites (Bartek and Lukas 2003).  Chk1 is activated through phosphorylation by both ATR 
and ATM at Serine/Threonine residues that are followed by glutamine (SQ/TQ) (Chen 
and Sanchez 2004).  There are several SQ/TQ motifs found in the C-terminal regulatory 
domain, including two conserved sites: S345/Q346 and S317/Q318 which are important 
in the damage response (Chen and Sanchez 2004).  Human Chk1 has been shown to be 
phosphorylated at S345 in response to IR, UV and hydroxyurea (HU) (Liu et al. 2000) 
and at S317 in response to UV and HU (Zhao and Piwnica-Worms 2001).  Mutation of 
the conserved S345 motif in yeast results in a defective checkpoint response and renders 
the cell sensitive to IR, UV and other DNA damaging agents (Lopez-Girona et al. 2001).   
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The clarification of the crystal structure of recombinant human Chk1 revealed an open-
kinase conformation, suggesting that the kinase domain itself is catalytically active 
without any modification (Chen et al. 2000).  The role of the C-terminus of Chk1 in the 
regulation of Chk1 activity is beginning to be defined.  It is thought to play an inhibitory 
role, and phosphorylation at the conserved sites (S317 and S345) within the SQ/TQ 
domain is thought to be required to release this inhibition (Chen and Sanchez 2004).  For 
example, reports have shown that human and Xenopus truncated C-termini demonstrate 
much higher kinase activity than the full-length proteins (Chen et al. 2000; Oe et al. 
2001), suggesting that the C-terminal region may have an autoinhibitory sequence that 
may interact with and inhibit the kinase domain.  To address this issue, a group 
investigated the effects of mutation and phosphorylation of the SQ/TQ motifs on the 
domain-domain interaction and the kinase activity of Chk1 (Katsuragi and Sagata 2004).  
They showed that the C-terminal region does indeed contain an autoinhibitory region 
(AIR) that can bind to and inhibit the kinase domain of Chk1. Mutation or 
phosphorylation of the SQ/TQ motifs prevented this AIR-kinase domain interaction and 
inhibition (Katsuragi and Sagata 2004).  Moreover, a report demonstrated that disruption 
of the C-terminal regulatory domain in truncation mutants of Chk1 activated Chk1 even 
in the absence of stress, and that full-length Chk1 had comparitivity low basal activity 
(Ng et al. 2004).   
 
The phosphorylation of SQ/TQ motifs is therefore essential for the activation of Chk1 at 
the DNA damage/replication checkpoints.  However, several other proteins are required 
for the activation of Chk1 by ATR/ATM.  These ‘adaptor proteins’ function to either 
recruit Chk1 to ATR/ATM or to provide a platform on which phosphorylation can take 
place (Chen and Sanchez 2004).  In yeast (Saccaromyces cerevisae), Rad9 (scRad9) has 
been shown to interact with scChk1 and scChk2 (Rad53) (Schwartz et al. 2002).  
Claspin also associates with Chk1, regulating Chk1 activation in response to replication 
stress.  This study in mammalian cells found that Claspin coimmunoprecipitated with 
Chk1 after UV and HU treatment and that Claspin was hyperphosphorylated (Chini and 
Chapter 1 Introduction 
 - 39 - 
Chen 2003).   Proteins such as replication protein A (RPA) which interacts with single 
stranded DNA are also required for Chk1 activation.  RPA is recruited by ATR and the 
ATR interacting protein, ATRIP, to sites of DNA damage, and depletion of RPA results 
in reduced Chk1 activation (Zou and Elledge 2003).     
 
Chk1 is a key regulator of the G2/M checkpoint of the cell cycle, and when activated 
Chk1 targets key cell cycle factors.  Chk1 is one of several regulators (along with ATR, 
ATM, Chk2 and Pik1) involved in the blocking of activity of Cdc25C, a phosphatase 
which promotes mitosis by removing phosphates from cyclin B-Cdc2 complexes (see 
section 1.1.5.1).  Activated Chk1 negatively regulates Cdc25C by phosphorylation at 
Ser216, which creates a binding site for 14-3-3 proteins, rendering Cdc25C catalytically 
inactive (Nyberg et al. 2002).  It has been shown using a Chk1-deficient ES cell line that 
Chk1 is regulated by ATR and that Chk1 deficient cells are defective for the G2/M DNA 
damage checkpoint (Liu et al. 2000).    
 
The intra-S phase checkpoint protects the integrity of replication forks, facilitates the 
recovery of DNA replication, and ensures that cells do not divide before the entire 
genome is duplicated (Bartek et al. 2004).  The role of Chk1 at the intra-S phase 
checkpoint was investigated by the Carl Smythe group.  They showed that treatment 
with HU led to significant phosphorylation and activation of Chk1, suggesting that Chk1 
was necessary for the intra-S phase checkpoint (Feijoo et al. 2001).   The role of Chk1 
during replication arrest has been investigated by Zachos and colleagues.  They showed 
that DT40 cells in which the Chk1 gene has been disrupted (but remain viable) entered 
mitosis with incompletely replicated DNA when DNA synthesis was blocked, but only 
after an initial delay (Zachos et al. 2005).  They proposed a role for Chk1 at the 
replication checkpoint in the maintenance of viable replication structures, and it is the 
continued presence of these structures which delays mitosis until DNA replication is 
complete (Zachos et al. 2005).  A report also described Chk1’s involvement in normal S 
phase to prevent increased initiation of DNA replication.  They demonstrated that Chk1 
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inhibition led to increased initiation of DNA replication and DNA breakage (Syljuasen 
et al. 2005).  More recently it has been shown that Chk1 is required for spindle 
checkpoint function, which delays the onset of anaphase in cells with mitotic spindle 
defects (Zachos et al. 2007).  In addition, Chk1 catalytic activity is involved in DNA 
damage induced centrosome amplification (Bourke et al. 2007).   
 
These studies combined demonstrate that Chk1 plays a crucial to promote cell survival 
during DNA damage by inhibiting of DNA replication and cell cycle progression.   
Many tumour cells suffer defects in p53 pathways and are therefore defective in G1 
arrest.  Indeed they rely on the p53-independent components of the S and G2 
checkpoints to repair DNA damage and maintain a degree of genome integrity.  By 
targeting components of the G2 pathway such as Chk1, it has been proposed that normal 
cells will arrest in G1, whereas tumour cells will undergo mitotic catastrophe and 
apoptosis (Zhou and Bartek 2004).  Therefore reports have examined the targeting of 
Chk1 to improve the effectiveness of anti-cancer treatments in p53-deficient tumours.   
A report has described the development Chk1 inhibitors which abrogate cell cycle 
checkpoints and enhance the cytotoxicity of DNA-damaging agents in p53-deficient 
cells, but not p53 wild type cells (Chen et al. 2006).  It has also been shown that when 
Chk1 is depleted in p53 and p21 null cells, there is abrogation of the G2 checkpoint and 
increased sensitization to DNA damaging agents.  This suggests that G2 checkpoint 
abrogation in a G1 checkpoint deficient situation would favour cell death, and that 
targeting Chk1 may be a strategy to increase selectivity of anti-cancer treatment 
(Carrassa et al. 2004).  Moreover, a cooperation between Chk1 and p21 has been 
proposed, whereby depletion of Chk1 and p21 following replication fork arrest 
eliminates the protection of G1 phase cells and leads to significant apoptosis in the cell 
population (Rodriguez and Meuth 2006).  They propose that Chk1 inhibitor based 
therapies may be enhanced by inhibition of p21 function in the treatment of p53 
deficient tumours (Rodriguez and Meuth 2006).  Therefore Chk1 is a putative target for 
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pharmacological manipulation of checkpoint pathways, which could enhance the 
efficiency of anti-cancer therapies. 
1.3.3.2 Chk2 
Checkpoint 2 (Chk2), also a member the CAM kinase superfamily, is a nuclear serine 
threonine kinase that plays a key role in cell cycle arrest, activation of DNA repair 
pathways, maintenance of telomeres, as well as the induction of cell death by apoptosis 
(Zhou and Elledge, 2000).  The first homologue of the Chk2 family, Rad 53, was 
identified in 1994 and was shown to be involved in checkpoint responses in budding 
yeast (Allen et al. 1994).  In the following years several groups identified the 
mammalian homologue of Chk2 (Matsuoka et al. 1998; Blasina et al. 1999; Brown et al. 
1999; Tominaga et al. 1999), and when the human homologue was identified by the 
Elledge group, it was named Chk2 (Matsuoka et al, 1998).  Along with yeast 
homologues Saccaromyces cerevisae Rad 53 and Schizosaccharomyces pombe Cds1, 
homologues have also been identified in nematode Caenorhabdatis elegans and fruit fly 
Drosophila melanogaster (Bartek et al. 2001).  The overall structure of Chk2 proteins is 
similar in all eukaryotes.  Human Chk2 has ~82% homology with rat and mouse kinases 
and shares 34% homology with zebrafish.  There are however functional differences 
between homologues: mammalian kinases seem to mainly respond to lethal DNA 
damage breaks, whereas yeast respond to various types of DNA damage (Bartek et al. 
2001). 
 
Although both Chk1 and Chk2 share functional similarities, there is no sequence 
homology outside the kinase domain. Chk2 consists of three functional domains (as 
shown in Figure 1.4 B): an amino terminal domain, rich in Serine or Threonine residues 
followed by glutamine (SQ/TQ; a consensus site for regulators such as ATM and ATR); 
the fork head associated (FHA) domain, which modulates protein-protein interactions as 
well as interactions with other domains within the protein itself (Ahn et al. 2004); and 
the kinase domain, which shares homology with other Ser/Thr kinases and occupies 
Chapter 1 Introduction 
 - 42 - 
almost the entire carboxyl terminal half of Chk2 (Bartek et al. 2001).  A recent report 
compared the functions of the regulatory kinase domains of Chk1 and Chk2.   Chk2 was 
able to inhibit cell cycle progression but the disruption of the regulatory kinase domain 
abolished kinase activity (Ng et al. 2004).   
 
The mission of Chk2 is to relay signals from ATM to the cell cycle machinery.  Chk2 is 
a stable protein, expressed throughout the cell cycle in an inactive form and becomes 
activated by ATM as a result of DNA damage such double strand breaks (DSB’s) 
(Bartek and Lukas 2003).  Damage signals are then propagated by ATM 
phosphorylation of the N-terminal region of Chk2, specifically threonine 68, which 
promotes Chk2 homodimerisation (Bartek et al. 2001).  Homodimerisation of Chk2 
leads to intermolecular transphorylation of C-terminal residues Thr 383 and Thr 387 
within the auto-inhibitory loop, thus leading to the full activation of Chk2.  
Autophosphorylation of Ser 516 within the kinase domain has been described and has 
also been shown to be required for full activation of Chk2 (Wu and Chen 2003). 
 
Other checkpoint proteins thought to be involved in the dynamics of Chk2 activation 
include the DNA ends processing MRN complex, and the DSB interacting proteins 
53BP1 and MDC1 (Bartek and Lukas 2003).  The MRN (Mre11/Rad50/Nbs1) nuclease 
complex is involved in sensing DNA damage, checkpoint activation and DNA damage 
repair (Buscemi et al. 2004).  A recent report demonstrated that ATM is stimulated in 
vitro by MRN toward substrates such as p53, Chk2 and H2AX (Lee and Paull 2004).  
53BP1 binds to p53 and has been shown to be a key inducer of the DNA damage 
checkpoint signal (Wang et al. 2002).  Mdc1 was identified as a novel protein which 
works with H2AX to recruit repair proteins to sites of DNA damage and control damage 
induced checkpoint proteins such as Chk2 (Lou et al. 2003; Stewart et al. 2003).  The 
suppression of Mdc1 leads to defective S phase checkpoint and reduced apoptosis in 
response to DNA damage (Lou et al. 2003).   
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Upon activation, Chk2 signals to a number of effectors which promote cell cycle arrest 
and apoptosis.  Chk2 effector proteins include: BRCA1, a breast cancer susceptibility 
gene product; p53; and Cdc25C and Cdc25A, cell cycle phosphatases.  In the cell cycle 
an initial, short-lived response to damage in G1 phase leads to the ATM-dependent, p53-
independent activation of Chk2 (Nyberg et al. 2002). Chk2 phosphorylates Cdc25A at 
Ser 123, which in turn triggers ubiquitylation and proteasome-dependent degradation of 
Cdc25A (Bartek et al, 2001).  The loss of Cdc25A consequently regulates Cdk2 by 
maintaining its inhibitory phosphorylation and thereby preventing its association with 
cyclin E, a necessary step for progression into S phase (Nyberg et al. 2002).  A second 
stage in the G1 phase takes several hours to initiate, is p53-dependent and regulates a 
block to prevent entry into S phase. This involves the ATM/ATR and Chk2/Chk1 
activation of p53, which leads to the transcriptional activation of p21 that in turn inhibits 
the Cdk2-cyclin E complex (Nyberg et al. 2002).  This phase of G1 also involves the 
phosphorylation of Cdc25C by Chk2 at Ser 216, which inhibits the phosphatase activity 
of Cdc25C and promotes association with 14-3-3 proteins. This leads to sequestration of 
phosphorylated Cdc25C in the cytoplasm, maintaining the inhibitory phosphorylation on 
Cdk1 and thus maintaining a block at the G2/M phase of the cell cycle (Bartek et al, 
2001).   
 
BRCA1 has been identified as a substrate of Chk2 and a key regulator in the cell cycle 
(Bartek et al. 2001).  Following DNA damage, BRCA1 is phosphorylated at Ser 988 by 
Chk2, which leads to the release of BRCA1 from Chk2 and the former thus is able to 
perform repairs which are essential for cell survival (Lee et al. 2000).  The modulation 
of E2F1 by Chk2 may also regulate DNA damage-induced apoptosis.  It has been shown 
that damage leads to accumulation of E2F1, and that E2F1 null thymocytes are resistant 
to etoposide-induced apoptosis (Lin et al. 2001).  It has also been shown that Chk2 
phosphorylates E2F-1 at Serine364 as a result of DNA damage leading to regulation of 
E2F-1 stability and transcriptional activity (Stevens et al. 2003).  P53 is also a target of 
Chk2.  Following DNA damage such as IR, the activation ATM/ATR and Chk2/Chk1 
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pathways leads to the phosphorylation of p53 at sites such as Ser 15 and Ser 20, 
resulting in the transcriptional activation of p53 and a reduction of the binding of the 
negative regulator, Mdm2.  ATM can regulate p53 stability independently of Chk2, 
therefore Chk2 is not necessarily a component of ATM mediated death (Keramaris et al. 
2003).  There is, however, cooperativity in p53 activation, as ATM phosphorylates p53 
Ser15 and Chk2 phosphorylates p53 Ser 20 (Nyberg et al. 2002).  The role of p53 
phosphorylation by kinases such as Chk2 will be discussed in more details in later 
sections (see 3.1.1 to 3.1.5).     
 
Different classes of Chk2 mutation result in lack of Chk2 activity by different 
mechanisms, such as protein instability and cytoplasmic sequestration.  Somatic 
mutations of the human Chk2 gene have been identified in sporadic human malignancies 
such as carcinoma of the breast, lung, bladder, ovary and vulva as well as in 
osteosarcinomas and lymphomas (Bartek and Lukas 2003).  These mutations occur 
throughout the three functional domains of Chk2 and cause varying characteristics such 
as protein instability and kinase inactivity (Bartek and Lukas 2003).  A report by Wu 
and colleagues characterized tumour-associated Chk2 mutants.  They showed that 
frameshift mutations at the C-terminus (T366FS and R475FS) led to loss of Chk2 kinase 
activity and a mutation within the FHA domain (R145W) resulted in reduced catalytic 
activity of Chk2 (Wu et al. 2001).  This is important as the FHA domain is involved in 
protein-protein interactions and Chk2 homodimerisation, and suggests that this domain  
is essential for Chk2 activation following DNA damage (Wu et al. 2001).   
 
Several germ-line mutations of Chk2 have also been identified in patients with Li-
Fraumeni syndrome (Bell et al. 1999).  Li-Fraumeni syndrome (LFS) is a rare, highly 
penetrant familial cancer syndrome that is characterised by multiple tumours at a young 
age, which are often genetically linked to a mutation in the p53 gene (Bartek and Lucas, 
2003).  A study by Bell and colleagues (Bell et al. 1999) found germline mutations in 
the Chk2 gene (I157T, 1100delC and 1442delT) in patients with LFS which lacked a 
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mutation in TP53, suggesting that genetic alteration in Chk2 may indeed predispose to 
cancer.  This also suggested that Chk2 and p53 function in the same tumour suppression 
pathway (Bell et al. 1999).  However, it was subsequently reported that I157T and 
1100delC mutations are found at varying frequencies in normal healthy individuals, and 
therefore cannot predispose to the highly penetrant LFS (Antoni et al. 2007).   Chk2 has 
since been described as a cancer susceptibity gene, whereby mutations such as I157T 
and 1100delC confer an increased risk to cancers such as breast and prostrate, and that 
these mutations are likely to act in synergy with other factors to cause cancer (Antoni et 
al. 2007).   
 
A role for functional Chk2 as a putative target in the treatment of cancers that harbour 
the wild-type form of the kinase has been discussed.  Groups have examined both 
inhibition and activation of Chk2 in order to treat human cancers.  For example, one 
group demonstrated that siRNA to Chk2 prevented the release of the anti-apoptotic 
protein survivin from the mitochondria, which resulted in increased apoptosis following 
IR and doxorubicin treatment (Ghosh et al. 2006).  The inhibition of Chk2 may also 
have a valuable role in radioprotection, whereby targeting Chk2 with small molecule 
inhibitors, such as the selective ATP-competitive 2-arylbenzimidazole Chk2 kinase 
inhibitor, protects normal proliferating cells from the side effects of radiotherapy 
(Arienti et al. 2005).  Alternatively the activation of Chk2 may have useful therapeutic 
value to induce cell cycle arrest or apoptosis in tumour cells.  A recent report used a 
tetracycline inducible form of Chk2 in p53 null cell lines and showed that when Chk2 is 
induced, it becomes activated by phosphorylation at Thr 68 leading to decreased  
cellular proliferation, G2 arrest and increased apoptosis (Chen et al. 2005).  These 
studies combined suggest that the targeting of Chk2 either by inhibition or activation 
may have some therapeutic value.  However, it is likely that Chk1 is a superior 
therapeutic target, with one report suggesting that it is a highly relevant drug target 
(Xiao et al. 2006).    
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Figure 1.5 A schematic diagram of the DAPK family. 
A. DAPK1, B. DAPK2 (DRP-1) and C. DAPK3 (ZIPK) each showing the domains within each 
family member.  The numbers above represent the amino-acid position of each domain and the 
percentages within the kinase domain represent the degree of amino-acid homology to the 
kinase domain of DAPK1.   
 
Death-associated protein kinase 1 (DAPK1) is a Calcium-Calmodulin regulated Ser/Thr 
kinase that mediates cell death.  DAPK1 is a member of the DAPK family of three 
closely related kinases which also include DAPK2 or DRP-1 (DAPK related protein -1) 
and DAPK3 (also known as ZIPK) which share approximately 80% and 83% homology, 
respectively, to the kinase domain of DAPK1 as shown in Figure 1.5 (Gozuacik and 
Kimchi 2006).    DAP kinases were first identified as a large group of genes which 
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function as positive mediators of cell death pathways.  The identification of this group of 
genes involved the use of a technique known as ‘technical knock-out’ (TKO), which 
selects for clones that survive cytotoxic signals induced by interferon (IFN)-γ (Deiss and 
Kimchi 1991; Kimchi 1998).  The genes identified were subsequently termed death-
associated protein kinases.  DAPK1 (which we will focus on in this report) has since 
been shown to be involved in apoptotic and autophagic cell death, tumour suppression 
and metastasic suppression (Gozuacik and Kimchi 2006). 
   
The DAPK family of related CAM kinases is grouped as a subfamily due to the high 
degree of conservation within their catalytic domains, although outwith the kinase 
domain they vary greatly in their size and structure.  DAPK1 is a 160-kDa protein 
(Figure 1.5A) that consists of an N-terminal catalytic kinase domain, which is composed 
of 11 subdomains found in all Ser/Thr kinases, and contains a stretch of basic amino 
acids (residues 45 – 47) known as the basic loop (Tereshko et al. 2001).  This basic loop 
is considered a fingerprint of the DAPK family, as it is conserved among family 
members.  Because of its proximity to the substrate binding site, this basic loop may 
play an important role in substrate phosphorylation, which in turn may regulate kinase 
activity (Tereshko et al. 2001).  The Cal/CAM autoregulatory segment is found adjacent 
to the catalytic kinase domain and functions to suppress catalytic activity by binding to 
the catalytic cleft and acting as a pseudosubstrate (Shohat et al. 2001).  Inhibitory 
autophosphorylation at Ser 308 within this autoregulatory domain reduces the binding 
affinity to CAM and further stabilizes the docking within the substrate binding site 
(Shohat et al. 2001).  DAPK1 also has a large C-terminal extension that contains 
multiple functional domains: ankyrin repeats, which are necessary for localization of the 
kinase to actin stress fibres, necessary for cell death (Bialik et al. 2004); two P loops at 
residues 639-646 and 695-702, which are of unknown function; and a cytoskeletal 
interacting domain which directs the kinase to the actin cytoskeleton (Cohen et al. 1997).  
The extreme C-terminus contains two regulatory elements: a death domain followed by 
a Ser-rich tail.   It has been shown that expression of the death domain protects cells 
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from tumour necrosis factor α (TNF α) and Fas induced apoptosis (Cohen et al. 1999).  
Two proteins, extracellular signal-regulated kinase (ERK) and UNC5H2 (a death 
domain protein that induces cell death when unbound from its ligand) have been shown 
to interact with the death domain, leading to the activation of DAPK1 (Chen et al. 2005; 
Llambi et al. 2005) (will be discussed in detail below).  
 
DAPK2 (DRP-1) and ZIPK are comparatively smaller proteins (42-kDa and 52-kDa 
respectively) that differ in structure to DAPK1 outwith the kinase domain, lacking many 
of the component structures characteristic of DAPK1.  DAPK2 does contain the 
Cal/CAM autoregulatory segment (which is lacking in ZIPK), followed by a 40aa C-
terminal extension which is essential for homodimerisation of the protein.  ZIPK 
contains a C-terminal leucine zipper motif, which mediates homodimerisation and 
interactions with other leucine zipper containing proteins (Bialik and Kimchi 2006).   
 
Two important factors are proposed to activate DAPK1: firstly, the elevation of 
intracellular calcium, which is often observed in programmed cell death, and secondly, 
the dephosphorylation of DAPK1 at Ser 308 by a death-regulated phosphatase, which 
often occurs in response to cell death stimuli.  These two mechanisms operate in 
combination to allow the activation of DAPK1 in specific circumstances (Bialik and 
Kimchi 2006).  Moreover, additional phosphorylation events involving ERK and 
mitogen-activated protein kinase (MAPK) signaling pathways have been shown to 
regulate DAPK1 activity.  It has been shown that DAPK1 and ERK binding in vitro and 
in vivo is mediated by a docking sequence in the death domain of DAPK1. This 
interaction promotes the pro-apoptotic function of DAPK1 through two mechanisms 
(Chen et al. 2005): ERK phosphorylation of DAPK1 on Ser 735 leads to the stimulation 
of DAPK1 catalytic activity; and furthermore DAPK1 promotes cytoplasmic localization 
of ERK.  This leads to either the activation of cytoplamic localized DAPK1 by 
phosphorylation or impairment of ERK survival signals.  These events are thought to 
constitute a feedback loop that promotes the apoptotic effect of DAPK1 (Chen et al. 
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2005).  In addition to this study,  it was shown that a downstream effector of ERK, the 
p90 ribosomal S6 kinase (RSK), inhibited exogenous DAPK1 cellular activity by 
phosphorylation at Ser 289 within the CaM-autoregulatory binding segment (Anjum et 
al. 2005). This correlated with the suppression of apoptotic activity of DAPK1 and 
identified DAPK1 as a novel target of the p90 ribosomal S6 kinases (RSK1/2) (Anjum et 
al. 2005).     
 
It has also been shown that the Netrin-1 receptor, UNC5H2 (thought to trigger apoptosis 
in the absence of its ligand, Netrin-1), interacts with DAPK1 through their respective 
death domains.  This interaction reduces DAPK1 autophosphorylation at Ser 308, 
thereby regulating the kinase activity of DAPK1 (Llambi et al. 2005).  Netrin-1 has also 
been shown to interact with UNC5H2 to block activation of DAPK1, suggesting that 
UNC5H2 and Netrin-1 work together to control the pro-apoptotic activity of DAPK1 
(Llambi et al. 2005).   Together these studies suggest that phosphorylation of DAPK1 is 
a cellular event that controls the regulation of DAPK1 activity and therefore the 
apoptotic potential of this kinase.   
 
DAPK1 has also been shown to interact with the cytoskeleton, which is often manifested 
by the formation of membrane blebs at the cell surface, leading to loss of adherence to 
the matrix (Inbal et al. 2002).  Membrane blebbing is a common morphological feature 
of apoptosis and DAPK1 has been shown to phosphorylate the regulatory light chain of 
myosin II (MLC) on Ser 19, activating myosin contractility and subsequent formation of 
membrane blebs (Bialik et al. 2004).  DAPK1 is also necessary for the full extent of 
blebbing that accompanies caspase-dependent TNFα-induced apoptosis (Inbal et al. 
2002).  When overexpressed, DAPK1 has also been shown to be involved, under certain 
cellular and experimental contexts, in non-apoptotic cell death (also referred to as Type-
II cell death) with the accumulation of autophagic vesicles (Gozuacik and Kimchi 2006).  
The overexpression of DAPK1 leads to features characteristic of apoptotic and non-
apoptotic cell death, such as formation of autophagic vesicles, membrane blebbing and 
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extensive cell rounding in a caspase-independent cell manner (Inbal et al. 2002).  
DAPK1 has been shown to be necessary for IFNγ-induced autophagy, but not for 
starvation or rapamycin induced autophagy (Gozuacik and Kimchi 2007).  These reports 
together suggest that DAPK1 may act as a ‘molecular switch’ between apoptotic and 
autophagic cell death pathways. 
 
A common epigenetic change in human cancer is reduced gene expression as a result of 
methylation.  Many cell lines have been shown to have lost DAPK1 expression as a 
result of methylation, and not due to deletion or rearrangement of the gene (Kissil et al. 
1997).  A report described how DAPK1 expression was restored when some cell lines 
were treated with an agent (5-azadeoxycytidine) which removes the methyl groups from 
the CpG nucleotides (Kissil et al. 1997).  DAPK1 gene methylation has been observed in 
many human cancers originating from many different tissue types (Gozuacik and 
Kimchi 2006) suggesting a role for DAPK1 function in the control of biological 
properties associated with tumour progression.  There may also be a role for DAPK1 
gene methylation as a diagnostic follow-up test for different types of cancer, whereby 
downregulation of the DAPK1 gene may be used specifically to detect malignant cells 
(Gozuacik and Kimchi 2006).  
 
A role for DAPK1 as a metastasis suppressor protein has also been suggested.  One 
report examined DAPK1 expression in lung tumour growth and metastasis.  They 
showed that DAPK1 expression was absent in highly metastatic mouse lung cell cancers 
and present in low metastatic variants of the same cell line.  Following the reintroduction 
of DAPK1 there was attenuation of metastasis (Inbal et al. 1997).  They also showed that 
DAPK1 expressing clones were sensitive to TNFα treatment, but that the highly 
metastatic clones were resistant to this treatment (Inbal et al. 1997).  Other studies 
demonstrate that the loss of DAPK1 correlates with a more malignant phenotype and 
increased metastatic capacity, which is normally the result of DAPK1 hypermethylation 
(Gozuacik and Kimchi 2006).  There may therefore be a role for DAPK1 as a metastatic 
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tumour suppressor protein, where it functions to increase sensitivity of tumour cells to 
programmed cell death during metastasis.   
 
The molecular mechanisms involved in mediation of DAPK1 tumour suppression have 
suggested a role for p53.  One study showed that the coexpression of DAPK1 with 
oncogenes Myc and Ras, or E1A and Ras led to the suppression of transformation 
mediated by these pairs of oncogenes.  However, the combination of Ras and SV40 
large T-antigen, which is known to promote p53 degradation was refractory to DAPK1.  
The deletion of the p53-binding C-terminal portion of the T-antigen, thereby restoring 
p53 function, enabled the restoration of DAPK mediated tumour suppression (Raveh et 
al. 2001).  This study went on to show that DAPK1 counteracts oncogene-induced 
transformation by activating the p14ARF-Mdm2 pathway (see section 1.1.4.2), which 
leads to the stabilization of p53 by inactivating  the negative regulator Mdm2 (Raveh et 
al. 2001).   Crosstalk between DAPK interacting proteins and the p53 pathway has been 
suggested.  In addition to these studies, a report suggested that a positive feedback loop 
may operate between DAPK1 and p53.  This hypothesis was suggested due to the 
presence of p53-binding sites on the DAPK1 promoter sequence, and the fact that p53 
can induce the expression of DAPK1 (Martoriati et al. 2005).  Therefore DAPK1 and 
p53 may operate in co-ordination to regulate cell death pathways.  One such report 
suggested a connection between p53 and mammalian target of rapamycin (mTOR), a 
protein kinase central in nutrient and growth factor signalling.  It was shown that p53 
activation stimulated autophagy in an AMP-activated kinase (AMPK) and tuberous 
sclerosis complex (TSC)1/TSC2 dependent manner, both of which respond to energy 
deprevation in cells (Feng et al. 2005).  More recently it has been demonstrated that 
DAPK1 can positively regulate mTOR by forming an interaction with TSC1/2 complex 
in cells.  This interaction neutralises TSC1/2 mediated suppression of the mTOR 
translation pathway leading to stimulation of mTOR and mTOR targets: the translational 
regulators p70 S6 kinase and S6 kinase (C. Stevens et al, in press).   
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A role for DAPK1 as a novel therapeutic modality in the treatment of cancers has been 
suggested in several reports.  The inactivation of DAPK1 in many human cancers and 
the fact that reactivating or reintroducing the kinase mediates events such as apoptosis or 
autophagy suggest that DAPK1 could be a good therapeutic target.  DAPK1 has also 
been shown to play a role in pathologies of the nervous system and has been shown to 
target neuronal apoptotic regulators to block the destruction of cells after events such as 
stroke or neuronal cell death.  DAPK1 may therefore may be a useful target protein in 
otther conditions (Bialik and Kimchi 2004).  In light of the fact that DAPK1 expression 
is suppressed by methylation in many cancers, the development of demethylating agents 
may be a crucial approach for the reactivation of DAPK1 in cancers to promote cell 
death and elimination of the tumour.   
 
1.3.3.4 AMPK 
Mammalian AMP-activated protein kinase (AMPK) is another member of the CAM 
kinase superfamily, which is related to checkpoint kinases and death-associated protein 
kinases based on their catalytic kinases domains.  The protein, which was subsequently 
named AMPK, was originally identified by two independent groups who showed that 
the protein could be regulated by both phosphorylation and by AMP.  The protein 
appeared to be a physiological substrate of AMP and was therefore named AMPK 
(Hardie et al. 1998).   AMPK forms a heterotrimeric complex whose components 
include three subunits: the catalytic α subunit (63 kDa), the β subunit (38kDa) and the γ 
subunit (35kDa) (Hardie et al. 1998).  It is within the catalytic domain of the α subunit 
that AMPK becomes activated after phosphorylation at Thr 172 by an upstream kinase 
of AMPK (AMPK kinase; AMPKK) (Hawley et al. 1996).  The α subunit demonstrate 
close homology to the related S. cerevisae gene product, SFN1, and contains a typical 
protein Ser/Thr kinase domain in the N-terminus (Hardie et al. 1998).  Isoforms of the 
three subunits have been identified: α can exist as α1 or α2 isoforms; β can exist as β1 
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and β2 isoforms; and γ can exist as γ1, γ2 or γ3 isoforms (Hardie et al. 1998).  However, 
isoforms α1, β1 and γ1 are most commonly expressed in cells (Stapleton et al. 1996).  
 
AMPK acts as a metabolic sensor or ‘fuel gauge’ regulating several intracellular systems 
including the cellular uptake of glucose, the β oxidation of fatty acids, and the 
biogenesis of glucose transporter 4 (GLUT4) and the mitochondia.  Deviations within 
the ADP: ATP ratio lead to the rise in AMP, which stimulates a pathway of energy 
conservation by activating AMPK.  AMPK in turn, switches off ATP-consuming 
anabolic pathways and switches on ATP-producing catabolic pathways to conserve 
energy (Hardie et al. 1998).  AMPK is regulated in vivo by an increase in AMP and 
phosphorylation at Thr 172 by a complex of AMPKK and the tumour suppressor LKB1 
(Hawley et al. 2003; Shaw et al. 2004).  Upon activation, AMPK phosphorylates 
metabolic enzymes or alters gene expression to activate the catabolic pathways and 
inhibit the anabolic pathways (Carling 2004).  AMPK can also be activated by a 
calcium-dependent, AMP-independent process which involves phosphorylation by an 
upstream kinase, CAMKK β (Towler and Hardie 2007).   
 
AMP accumulation has also been shown to have effects on cell growth and proliferation, 
whereby treatment of cells with AMP analogs induces cell cycle arrest (Imamura et al. 
2001).  Moreover, following energy starvation, AMPK has been shown to phosphorylate 
TSC2, leading to the dephosphorylation of S6K that is required for regulation of 
translation. This also leads to the inhibition of mTOR (Inoki et al. 2003).  This report 
therefore implicated TSC2 in the coordination of cellular energy levels and cell growth 
or survival (Inoki et al. 2003).  As mentioned in section 1.1.5.4, glucose availability 
directly regulate cell proliferation, and AMPK is thought to be the mediator of this 
process (Jones et al. 2005).  When the cell is glucose deprived, AMPK is activated, 
leading phosphorylation of p53 at Ser15 and activation of p53.  Thus, implicating 
AMPK as a intrinsic regulator of the cell cycle, promoting cell cycle arrest to allow the 
cell to survive the unfavourable glucose deprived conditions (Jones et al. 2005).  A 
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recent report examined the role of a set of p53-regulated gene products including the β 
subunits of AMPK, which are shown for the first time to be regulated by the p53 protein 
as well as PTEN (phosphatase and tensin homologue), TSC2 and IGF-BP3.  Each of 
these genes is upregulated following stress and negatively regulates the IGF-1-AKT-
mTOR pathways in a p53-dependent fashion (Feng et al. 2007).  They showed that the 
genes were expressed under p53 control in a cell type and tissue-specific fashion, that 
mTOR communicates with the p53 pathway, and that AMPK β1 is a p53 regulated gene 
which is transcriptionally upregulated by a wide variety of stress signals (Feng et al. 
2007).  These results therefore suggest that p53 regulates AMPK and that AMPK is an 
essential component of the mTOR signaling pathway.    
 
Chapter 1 Introduction 
 - 55 - 
1.4 Project Aims  
In this project we will examine the role of specific members of the Calcium Calmodulin 
kinase superfamily in the modification of the p53 signaling pathway.  Phosphorylation 
of p53 at specific sites such as Ser 20 is crucial in the activation of p53 and is thought to 
involve CAM kinases such as Chk2.   Although much researched the identity of the 
main Ser 20 kinases in cells remains undefined.  To this end we will firstly set out to 
examine specific members of the CAMK superfamily and to confirm the identity of the 
main p53 Ser 20 kinase, thereby partially resolving the contraversy in the field.  
 
P53 is a tetrameric transcription factor which exhibits DNA binding activity through the 
conserved domains, Box I to V.   It is well established that the N-terminal Box-I domain 
domain of p53 provides a scaffold for binding of components of the transcriptional 
machinery.  To futher elucidate specific regions where kinases may bind and/or 
phosphorylate, we will examine the role of the Box-V domain.  Mutagenesis of p53 will 
also be performed to further define the sites of interaction and develop of understanding 
of the molecular mechanisms of the activation of p53. 
  
Cell models and gene expression studies will be used to clarify the effect of depletion of 
CAM kinases on activation of p53.  This will allow us to determine the role of kinases 
such as Chk1 and DAPK1 on activation status of p53 and allow us to determine kinase-
dependent changes in p53 target gene expression.  This may provide putative drug 
targets in which to allow manipulation of the p53 pathway. 
 
Overall the report will therefore provide insight into the role of kinases in the 
modification of the p53 signalling pathway. 
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2 MATERIALS AND METHODS 
2.1 General 
2.1.1 Reagents and Materials 
All chemicals were purchased from Sigma or BDH unless otherwise stated.  Tissue 
culture and other general use plasticware were obtained from Nunc or TPP. 
2.1.2 Buffers and Stock Solutions 
Recipes for stock solutions are listed in section 2.8.  
2.1.3 Plasmid DNA  
Plasmid DNA for use in transient transfection assays, gene reporter assays, site directed 
mutagenesis and in vivo coimmunoprecipitation assays was either sourced commercially 
or kindly donated by colleagues.  pcDNA3.1 was purchased from Invitrogen.  pcDNA3- 
p53 was a kind gift from Prof. Sir David Lane. pcDNA3 p53 ΔV was a kind gift from 
Dr. I. Dornreiter (University of Hamburg, Germany).  Other plasmids for transfection 
based assays were pDEST 3.2 Chk1 and pDEST 12.2 Chk2 which were kindly donated 
by Dr. Ashley Craig and pDEST GST-DAPK1 and DAPK3 which were a kind gift from 
Dr. Jennifer Fraser.  HA-DAPK1 was kindly donated by Adi Kimchi (Weizmann 
Institute, Israel).  FLAG Chk1 was a kind gift from KL Ball Laboratories.  Gene reporter 
assay constructs pGL3-p21WAF1-Luc and pCMV-β Gal were kind gifts from M.Oren 
(Weizmann Institute, Israel) and M.G. Luciani (University of Dundee) respectively. 
EGFP peptide constructs were constructed (D.Dornan) by ligating double-stranded 
oligonucleotides encoding Box-I, Box-V and NS into a XhoI-XbaI-digested EGFP-C3 
plasmid (Clontech).    
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2.2 Cell Culture 
2.2.1 Cell lines  
Cells were maintained in a humidified CO2 incubator (Hera) at 37oC.  
 
Table 2.1 Cell Lines  
Cell Line Source/Description Medium Growth conditions 
H1299 Human lung carcinoma, p53 null RPMI 5% CO2 
SAOS-2 Human osteosarcoma, p53 null D-Mem 5% CO2  
A375 Human malignant melanoma, p53 WT D-Mem 10% CO2 
A549 Human lung carcinoma, p53 WT D-Mem 10% CO2 
 
2.2.2 Media and Sub-culturing of Cells 
Cell stocks were maintained in medium (Invitrogen) as stated (Table 2.1) supplemented 
with 10% foetal calf serum (Invitrogen).  Media was stored at 4oC and warmed to room 
temperature before use. Cells were maintained in 10cm tissue culture dishes and were 
subcultured 2 – 3 times a week dependent on cell line.  Media was removed and cells 
were washed using sterile 1x PBS to remove any remaining media.  Cells were then 
trypsinised using 1x trypsin-EDTA solution (Invitrogen; 3ml per 10cm plate) and 
returned to incubator until cells detached.  Medium was added up to 10ml and cells were 
then split into new tissue culture dish at a seeding density of 2.2 × 106 cells per 10cm 
dish.  
 
2.2.3 Storage and Recovery of Cells 
Cells were stored in liquid nitrogen for long term storage.  To freeze cells, a confluent 
10cm dish was trypsinised as above and cells were collected by centrifugation 
(1000rpm, 5 minutes, room temperature).   The cell pellet was then resuspended in 1.5ml 
fresh medium and an equal volume of freezing medium (20% DMSO: 80% FCS).  1ml 
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cell suspension was frozen in cryogenic freezing vials within Nalgene™ Cryo 1ºC 
freezing containers before being transferred into liquid nitrogen. 
 
To recover cells, cells were thawed rapidly in a waterbath (37oC).  To remove any 
potential cytotoxic effect of DMSO, the cell suspension was added to 9ml fresh medium 
in a falcon tube and cells were collected by centrifugation (as above).  The cells were 
then resuspended in medium and transferred to a fresh tissue culture dish.  Cells were 
allowed to grow until confluency and were then subcultured as normal. 
 
2.2.4 Transient transfection of plasmid DNA 
In preparation for transfection, cells were plated out into 6 well dishes at 2 – 4 × 105 
cells per well, dependent on growth rate of the cell line.  Medium was added up to 2ml 
per well and cells were cultured for 24 hours or until 70% confluent.  Cells were 
transfected using Lipofectamine 2000™ (LF 2000; Invitrogen) according to 
manufacturer’s instructions.  Essentially, plasmid DNA was diluted in 200µl Optimem 
(Invitrogen) and total amounts were normalized using empty vector; pcDNA 3.1 
(Invitrogen).  For each transfection, 5µl of LF 2000™ was diluted in 200 µl Optimem 
and incubated for 5 minutes at room temperature.  The diluted DNA was then combined 
with the diluted LF2000 and incubated at room temperature for 20 minutes to allow 
DNA-Lipofectamine complexes to form.  The 400µl mixture was then added to cells and 
gently mixed.  Cells were then incubated for 24 hours before harvest unless otherwise 
stated.  
 
2.2.5 Transient transfection of siRNA 
siRNA to target specific genes was obtained from Dharmacon (see Table 2.2).  Prior to 
transfection, siRNA pellets were resuspended in 1 × siRNA buffer to a final 
concentration of 20µM.    The solution was then placed on an orbital shaker for 30min at 
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room temperature to ensure efficient RNA resuspension.  The 20 µM stock solution was 
aliquoted and stored at -20oC.   
 





Origin Product Catalogue 
number 
Control N/A N/A Non-targeting siRNA pool D-001206-14-20 




















TP53 NM_000546 Human siGENOME set of 4 MQ-003329-01-
0010 
 
Transfection of cells with siRNA was performed using DharmaFECT ® Buffer 4 which 
is provided at 1mg/ml.  Cells were plated out in 6 well tissue culture dishes 24 hours 
prior to transfection as described (2.2.4).  Firstly, a 1µM siRNA solution was prepared 
by adding 10µl stock solution (20µM) to 190µl Optimem. In a separate tube, 4 µl 
DharmaFECT ® Buffer 4 was added to 200 µl Optimem, mixed and incubated for 5 
minutes at room temperature.  The contents of the two tubes were then mixed and 
incubated for 20 minutes at room temperature.  The mixture was then added to the cells 
by mixing gently to give a final working concentration of 100nM siRNA.  Cells were 
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then incubated for 48 hours (unless otherwise stated) before harvesting or further 
treatment. 
2.2.6 Cell treatments  
Following transfection of cells with siRNA products and the subsequent incubation 
period, cells were either harvested (see section 2.3.1) in an undamaged state or treated 
with genotoxic agents as detailed in Table 2.3.  Following the treatment, cells were 
either harvested immediately or incubated further. 
 
Table 2.3 Cell treatments 
Treatment Dose Range Incubation time post 
treatment 
X-Ray irradiation 0.5 – 10 Gy γ  0 – 24hr 
UV (shortwave cross-linker) 10 – 80 J/m2 0 – 24hr  
 
2.2.7 MTT: Cell viability assay 
MTT is a standard colourimetric assay (an assay which measures changes in colour) 
used to determine changes in cell death under normal and cytotoxic conditions.  The 
yellow methylthiazolyldiphenyl-tetrazolium bromide (MTT) is reduced to purple 
formazan in the mitochondria of living cells.  A soluble solution such as DMSO is then 
added to dissolve the insoluble purple formazan product into a coloured solution.  The 
absorbance of this coloured solution can then be quantified by spectrophotometry.  The 
reduction reaction only takes place in living cells where the mitochondrial reductase 
enzymes are active and therefore a direct correlation can be made between the 
absorbance to the number of living cells.  
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2.2.7.1 Transient Transfection and Damage Treatment of Cells 
Firstly, cells were prepared for the cell viability assay by transient transfection with 
siRNA (see 2.2.5).  Following an incubation period of 48 hours, cells were treated with 
X-ray or UV damage as described in Table 2.3 and returned to the incubator for a further 
incubation period as described in the results section. 
2.2.7.2 MTT treatment and measurement 
A stock solution of methylthiazolyldiphenyl-tetrazolium bromide (MTT) reagent was 
prepared by dissolving 100mg MTT in 20ml sterile PBS to give a final stock 
concentration of 5mg/ml.  The solution was filtered sterilized using a 0.2µM filter and 
stored at 4oC in the dark for up to four weeks.  In preparation for use a working 
concentration of 0.25µg/ml was prepared by diluting MTT in warm medium.  The 
diluted MTT solution was added directly to the cells, leaving two wells as a blank 
(DMSO).  Cells were returned to the incubator for 4 hours at 37oC, then MTT was 
removed from the cells and DMSO (ACS spectrophotometric grade) was added to 
dissolve formazan crystals.  The absorbance was then read by spectrophotometry at 
570nm using PowerWaveXS™ Microplate Spectrophotometer (BioTek) and readings 
were collated using KC Junior package. 
 
 
2.2.8 Gene reporter assay 
2.2.8.1 Transient Transfection 
Two types of gene reporter assay systems were performed; β-Galactosidase Enzyme 
Assay System with Reporter Lysis Buffer™ (Promega) and the Dual-Luciferase® 
Reporter Assay System (Promega).   Readings were normalised to transfection 
efficiency using β-Gal (assay system) or a Renilla (Dual-Luciferase® Reporter Assay 
System).  
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2.2.8.2 Luciferase/ β-Gal assay system 
For the Luciferase/β-Gal assay system cells were transiently transfected (see section 
2.2.4) with 1µg of PGL3 luciferase reporter construct, 0.25µg pCMVβ-Gal construct and 
other constructs as required to a total plasmid concentration of 4µg.  Twenty four hours 
following transfection cells were harvested for analysis by firstly washing each well in 
2ml ice cold PBS.  70 μl of Reporter Lysis Buffer™ from the β-Galactosidase Enzyme 
Assay System (Promega) was added to each well and incubated for 10 min on ice. Cells 
were scraped into microcentrifuge tubes and debris was pelleted by centrifugation at 
13000 rpm for 2 min at 4 ºC and lysates were then transferred to fresh microcentrifuge 
tubes.   
 
For the luciferase assay, 20 μl of lysate was added to an opaque Microlite 2™ 96 well 
ELISA plate (CoStar; Corning Inc.) on ice.  50μl of luciferase substrate was then added 
and allowed to reach room temperature.  Light emission was quantified using Fluroskan 
Ascent F1™ (Labsystems) luminometer.  
 
The β-Galactosidase Assay™ (Promega) was carried out by the addition of 20 μl of 
lysate to a clear 96 well plate on ice.  20 μl β-Galactosidase 2x assay buffer was then 
added and incubated for 20 min at 37oC.  The reaction was terminated by the addition of 
50μl sodium bicarbonate and absorbance at 405nm was read using the PowerWaveXS™ 
Microplate Spectrophotometer (BioTek). 
 
The results were normalized by dividing the Luciferase readout by the β-Galactosidase 
readout to give a value of Relative Light Units.  Unless otherwise stated each data point 
is the average of two replicates, therefore confidence intervals have not been included as 
such statistical parameters are not valid. 
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2.2.8.3 Dual-Luciferase Reporter Assay System 
Dual luciferase assay system involved the transient transfection (see section 2.2.4) of 
0.14µg PGL3 luciferase reporter construct, 0.06µg Renilla luciferase reporter construct 
(pRL CMV) along with other constructs as required to a total concentration of 1.6µg.  
Twenty four hours following transfection cells were processed for analysis using the 
Dual-Luciferase® Reporter Assay System (Promega).  Cells were harvested by firstly 
washing in 2ml ice cold PBS before the addition of 100 μl 1x passive lysis buffer (PLB).  
The plate was then incubated with gentle agitation for 15 min at RT.  Cells were then 
collected into a microcentrifuge tube and debris was pelleted by centrifugation 
(13000rpm, 30 sec, 4oC).  Lysate were retained in a fresh microcentrifuge tube.  
 
The assays for firefly luciferase activity and Renilla luciferase activity were performed 
in one tube format using the Dual-Luciferase® Reporter Assay System (Promega). 
Firstly, 5 μl of lysate was added to a Microlite 2™ 96 well ELISA plate on ice.  25 μl of 
Luciferase Assay Reagent II was added to the plate and allowed to reach room 
temperature.  Light emission was quantified using the Fluroskan Ascent F1™ 
(Labsystems).  When the maximum signal of firefly luciferase activity was reached, 
Renilla luciferase activity was quantified by adding 25 μl of Stop & Glo® Reagent 
(prepared immediately before assay according to manufacturer’s instruction; Promega) 
and light emission was measured using the Fluroskan Ascent F1™. 
 
The results were normalized by dividing the maximum firefly luciferase readout by the 
maximum Renilla luciferase activity readout to give a value of Relative Light Units.  
Unless otherwise stated each data point is the average of two replicates, therefore 
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2.3 SDS-PAGE 
2.3.1 Preparation of Cell lysates  
Cells were harvested on ice by firstly removing media and washing with ice cold 1x PBS 
(see section 2.8).  Cells were then scraped into a small volume of PBS and collected in a 
microcentrifuge tube.  Cells were pelleted by centrifugation (3000rpm, 3min, 4oC) and 
the cell pellet was snap frozen in liquid nitrogen. 
 
Frozen cell pellets were lysed in 2-3 x volume urea lysis buffer (unless otherwise stated; 
see section 2.8) by pipetting up and down several times until no particles were seen.  
Lysates were then incubated on ice for 30 minutes, followed by centrifugation (13000g, 
10min, 4oC) to obtain a supernatant from which any cell debris had been removed.  The 
lysate was then snap frozen and stored at -80oC. 
 
2.3.2 Protein Quantification  
Protein was quantified using the Bradford assay.  Bradford reagent was prepared 
according to the original published recipe (Analytical Biochemistry 72, 248-254, 1976; 
see section 2.8).  Prior to use, the reagent was filtered using 0.45µM filter to remove any 
precipitate.   
 
The protein concentration of the cell lysate (see section 2.3.1) was determined by 
diluting 1µl of the lysate in 200 µl Bradford reagent (pre-warmed to room temperature) 
in a 96 well plate.  The plate was incubated for 5 minutes at room temperature and then 
read using PowerWaveXS™ Microplate Spectrophotometer (BioTek) and readings were 
collated using KC Junior software programme package. Readouts were converted to 
concentrations in mg/ml by creating a standard curve taken from the BSA standards 
values (from 0 to 8 µg).   
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2.3.3 Preparation of gels and separation of proteins by SDS-PAGE 
SDS polyacrylamide gels were prepared using 10-15% polyacrylamide as described 
(Laemmlli et al, 1970; see section 2.8) using Mini-Protean3™ (Biorad) gel casting 
modules.  Firstly, the separating gel was poured and was overlayed with water to allow 
the gel to polymerise.    Once polymerization was completed, the stacking gel was added 
along with the 10 or 15 well Teflon comb.  This again was allowed to polymerise.  The 
comb was then removed and wells were washed out with water to remove any residual 
APS.   
 
4 × SDS sample buffer was then added to lysates.  Samples were then heated for 5 
minutes at 95oC and 10-30µg samples were loaded.  5µl of Biorad protein standards 
were loaded into the first well as molecular weight markers.  Proteins were then 
separated by electrophoresis in running buffer at 180V until the Bromophenol dye front 
reached the bottom of the gel. 
 
2.3.4 Detection of fractionated proteins 
2.3.4.1 Coomassie brilliant blue staining 
SDS-PAGE (section 2.3.3) gels were fixed for coomassie staining (see section 2.8) for 5 
min and stained with Coomassie Blue Stain for 5 min to 12 h at room temperature with 
agitation.  Gels were destained until the bands were clearly visible and the background 
staining was removed. Gels were then dried by placing on Waltmann blotting paper and 
were covered with Saran Wrap and were then placed in a DryEase Gel Drying™ system 
(Invitrogen).   
 
2.3.4.2 Immunoblotting 
Transfer of separated proteins (see section 2.3.3) to Hybond-C Extra nitrocellulose 
membranes (Amersham Biosciences) was carried out electrophoretically in tanks 
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containing transfer buffer (see section 2.8) at 300mA for 60min or at 20mA overnight.  
Transferred proteins were stained with 25ml Pelikan ink (diluted 1/300 in PBS-Tween) 
for 5 minutes.  The membrane was then rinsed twice in PBS-Tween (see section 2.8) to 
remove excess stain.  Non-specific protein binding sites were blocked by incubating the 
membrane in PBS-Tween containing 5% (w/v) non-fat dried milk (Marvel), for 1 hour at 
room temperature.  For phospho-specific antibodies, non specific binding was blocked 
using TBS-Tween (see section 2.8) containing 3% BSA and 1mM β-glycerophosphate.  
The phosphatase inhibitor, β-glycerophosphate, was added to preserve phosphorylation 
of proteins.  The membranes were then incubated overnight at 4oC with primary 
antibody (see Table 2.4) diluted in blocking buffer.  The antibody was then removed and 
membranes were washed using either PBS-Tween or TBS-Tween (3 x 5 minute).  The 
binding of mouse monoclonal antibodies was detected by adding anti-mouse IgG 
secondary antibody and detection of rabbit polyclonal bound antibodies was performed 
using anti-rabbit IgG secondary antibody (both conjugated to horse radish peroxidase; 
DAKO).  Secondary antibodies were diluted 1/1000 in blocking buffer before adding to 
the membrane for incubation for 1.5 h at RT.  Following 3 x 20 minute washes, specific 
bands were detected by enhanced chemiluminescence (ECL). Membranes were overlaid 
with ECL solution 1 and 2 (mixed 1:1; see section 2.8) for 1 min, blotted dry and 
exposed to X-ray film (SLS), which was then developed (X-ray Imaging Equipment™, 
Fuji).   
 
2.3.4.3 Stripping Nitrocellulose membranes 
To reprobe a membrane, membrane bound antibodies (see section 2.3.4.2) were removed 
using stripping buffer (see section 2.8).  A fresh solution of 10ml of stripping buffer 
containing 70µl β-mercaptoethanol was added to the membrane which was then 
incubated at 50oC for 30-45 minutes with occasional agitation.  The membrane was then 
rinsed several times in ddH2O and then processed for immunoblotting as normal. 
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Table 2.4 Antibodies  
Antibody KDa Type Company Dilution 
Chk1 (G-4) 56 Mouse monoclonal Santa Cruz 1/1000 
Chk2 (A-12) 66 Mouse monoclonal Santa Cruz 1/500 
DAP Kinase 1 160 Mouse monoclonal BD 1/1000 
DAP Kinase 2 42 Rabbit polyclonal Abcam 1/500 
DAP Kinase 3 
(ZIPK)  
52 Rabbit polyclonal Abcam 1/500 
GFP 27 Rabbit polyclonal Abcam 1/2000 
IRF1 48 Mouse monoclonal BD 1/500 
IRF2 50 Rabbit polyclonal Santa Cruz 1/100 
p21WAF1 21 Mouse monoclonal Oncogene 1/1000 
PTEN 57 Mouse monoclonal Cell Signaling 1/1000 
p53 (DO1)  53 Mouse monoclonal B. Vojtesek* 1/1000 
p53 (DO12)  53 Mouse monoclonal B. Vojtesek* 1/1000 
p53– P (Ser 15) 53 Mouse monoclonal Cell Signaling 1/1000 
p53– P (Ser 15) 53 Rabbit monoclonal Cell Signaling 1/1000 
p53– P (Ser 20) 53 Rabbit monoclonal Santa Cruz 1/200 
p70-P S6 Kinase 
(Thr 389) 
70 Mouse monoclonal Cell Signaling 1/1000 
S6 Ribosomal-P 
(Ser 235/236) 
32 Rabbit polyclonal Cell Signaling 1/1000 
  * A kind gift from B. Vojtesek, Dept. of Experimental Oncology, Masaryk Memorial 
Cancer Institute, Brno, Czeck Republic. 
2.4 Microbiological Techniques  
All microbiological techniques were carried out under aseptic conditions. 
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2.4.1 Preparation of competent cells  
A starter culture of E. coli strain DH5α cells was set up in a 15ml sterile tube by 
inoculating a 2ml culture of LB with a colony of bacteria from a stock plate.  The culture 
was incubated overnight at 37oC with rotation at 225rpm.  The culture was diluted 1/100 
in 200ml of LB and incubated at 37oC with agitation at 225rpm until the OD600nm 
reached 0.3-0.5.  The cells were collected by centrifugation (10min, 8000rpm, 4oC) and 
resuspended in 80ml ice-cold TFBI (see section 2.8).  After 10 min incubation on ice the 
cells were again centrifuged (5min, 2500rpm, 4oC) and gently resuspended in 8ml of 
TFBII (see section 2.8).  The cells were incubated on ice for 15 min and 200µl aliquots 
were added to pre-chilled microcentrifuge tubes.  The aliquots were snap frozen on dry 
ice and stored at -80oC. 
 
2.4.2 Agar bacterial culture dishes 
LB agar was liquefied by heating in a microwave for 2 minutes.  The liquid agar was 
then allowed to cool to hand-warm temperature, poured into 90mm Petri dishes (Sterlin) 
which were allowed to cool at room temperature.  Antibiotic was added immediately 
prior to pouring the plates.  Agar plates were then stored at 4oC. 
 
2.4.3 Transformation of plasmid DNA by heat shock 
50μl of competent DH5α cells (see section 2.4.1) were defrosted on ice and mixed with 
1µl of plasmid DNA.  The cells were then incubated on ice for 30 min and heat-shocked 
at 42oC for 45sec.  The cells were returned to ice for 2 min before the addition of 500 µl 
LB.  The culture was then incubated at 37oC, 225rpm for 45min.  Cells were then plated 
onto LB agar bacterial culture plates containing appropriate selective antibiotic and 
incubated overnight at 37oC. 
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2.4.4 Amplification of plasmid DNA   
A starter culture was initiated by inoculating a 5ml LB culture (see section 2.8) 
containing selective antibiotic with a single bacterial colony from a stock plate (see 
section 2.4.3) or a glycerol stock (see section 2.4.5).  This was then incubated for 6-8hrs 
at 37oC (225rpm).  At this stage the 5ml culture could be processed for mini-prep 
isolation of plasmid DNA (see section 2.4.6) by centrifugation (4000rpm, 10min, 4oC).  
Alternatively, for maxi-prep isolation of plasmid DNA (see section 2.4.6) the starter 
culture was transferred to a large culture flask containing 200ml LB (with appropriate 
antibiotics) and incubated overnight under the same conditions.  The culture flask was at 
least 5x volume of culture being grown to allow for aeration.   
 
2.4.5 Glycerol stocks 
Glycerol stocks of bacterial cultures were prepared by adding 875µl starter bacterial 
culture to 125µl sterile 80% glycerol in a cryovial (Nunc).  This was then snap frozen 
and stored at -80oC.   
 
2.4.6 Purification of plasmid DNA 
Cells grown for amplification were collected by centrifugation (6000rpm, 15min, 4oC).  
Plasmid DNA was isolated using Qiagen’s HiSpeed™ Plasmid Maxi Purification Kit for 
large volume cultures or Qiagen’s QIAprep™ Spin Mini Prep Kit for small volume 
cultures according to manufacturer’s instructions. DNA was eluted into a sterile 
microcentrifuge tube in ddH2O and stored at -20oC. 
 
2.4.7 Quantification 
The concentration of plasmid DNA was determined by spectrophotometry at 260nm 
using a NanoDrop® ND-1000.  1µl of sample was pipetted onto the measurement 
pedestal and the concentration was generated using the NanoDrop® software. 
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2.4.8 Agarose Gel Electrophoresis 
Agarose (to a final concentration of 0.7%) was dissolved in 1 × TAE buffer and 
liquefied by heating in a microwave for 2 min.  The agarose solution was cooled to 
hand-warm temperature before the addition of 0.03% ethidium bromide.  Gels were cast 
and allowed to set at room temperature before being submerged in 1 × TAE buffer.  
Samples were then diluted 1:5 in DNA sample buffer, loaded alongside 1Kb or 100bp 
DNA ladders (Invitrogen) depending on plasmid size and electrophoresis was performed 
at 100V for 30 min.  Gels were visualized by UV transillumination using the 
ChemiGENIUS2 Bio Imaging System (Syngene) and the GeneSnap Imaging tool 
(Syngene).   
 
2.5 Site Directed Mutagenesis 
Site-directed mutagenesis of two genes was performed: (1) TP53 (NCBI accession 
number: NM_000546) in the mammalian expression vector pcDNA3.1 (Invitrogen) and 
(2) eGFP C3 (Clontech) containing the Box V region of p53.  
2.5.1 Primer Design 
Site directed mutagenesis primers (see Table 2.5 and Table 2.6) were designed to 
contain the desired mutation according to guidelines set by QuikChange® Site Directed 
Mutagenesis Kit (Stratagene).  Primers were designed to be 25 – 45 base pairs in length 
and have a melting temperature above 78oC.  Sequencing primers (see Table 2.7) were 
designed to anneal to specific regions of the open reading frame of the gene in order to 
verify presence of mutation.   
 
Oligonucleotide primers were purchased from Sigma-Genosys and were reconstituted in 
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Table 2.5 Site directed mutagenesis primers for p53 





Nucleotide Sequence  
Sense Primer (Nucleotides Mutated) 
Antisense Primer  




























p53 N288Y 288 bp 83 5’-CGCACAGAGGAAGAGTAT 
CTCCGCAAGAAAGGG-3’ 
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5’-CCCTTTCTTGCGGAGATACTC 
TTCCTCTGTGCG-3’ 
























Nucleotide Sequence  
Sense Primer (Nucleotides Mutated) 
Antisense Primer  
BoxV 
Ala-1 












1363bp 82.8 5’CAGCTTTGAGGTGGCTGCTTGTGCCTGTCCTG-3’ 
5’CAGGACAGGCACAAGCAGCCACCTCAAAGCTG 3’ 
BoxV 1369bp 82.0 5’GAGGTGCGTGTTGCTGCCTGTCCTGGG-3’ 
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2.5.2 Site directed mutagenesis and PCR 
All mutagenesis was carried out according to protocols as described in QuikChange® 
Site Directed Mutagenesis Kit (Stratagene).  A reaction was prepared using 10 × 
reaction buffer, 10mM oligonucleotides primers, 25mM dNTPs mix (Promega), 100ng 
template DNA and PfuTurbo DNA polymerase (Stratagene).  The plasmid was 
denatured by temperature cycling (parameters as detailed in the manufacturer’s 
instructions) which allowed the oligonucleotide primers containing the desired mutation 
to anneal. PfuTurbo DNA polymerase extended and incorporated the mutagenic primers 
to produce nicked circular strands. [Amendments to cycling parameters were made for 
annealing temperature (dependent on melting temperature of the primer) and extension 
time (1 min per Kb plasmid)].  The correct size of the product was confirmed by 
electrophoresis of 10µl of the product on a 0.7% agarose gel (see section 2.4.8).  
Successfully amplified products were digested with Dpn1 restriction enzyme 
(Invitrogen) to eliminate any remaining parental DNA template.  Bacteria were 
transformed with the product for amplification (see sections 2.4.3 and 2.4.4).  Plasmid 
DNA was then recovered from selected colonies using a Mini prep™ Kit (Qiagen) and 
DNA was sequenced (see section 2.5.3).   
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2.5.3 Sequence Analysis 
Table 2.7 Sequencing Primers 





p53 internal  
forward 1 
420bp 70oC 5’- CTGGGCTTCTTGCATTCTGG – 3’ 
p53 internal  
forward  3 
781bp 73oC 5’- GAGCCGCCTGAGGTTGGC – 3’ 
p53 internal 
reverse rev 1 
61bp 68oC 5’- GCACCAGCAGCTCCTAC – 3’  
eGFP 
forward 
1219bp 70oC 5’- GACCACTACCAGCAGAACAC – 3’ 
eGFP reverse  53oC 5’- GCTGCAATAAACAAGTTAAC – 3’ 
 
All sequence analysis was performed by the DNA sequencing service, Wellcome Trust 
Clinical Research Facility, Western General Hospital.  Primers were supplied at 1.6µM 
and plasmid DNA at 150ng/µl.  Sequencing of samples was carried out using primers as 
detailed in Table 2.7 Sequencing Primersand where appropriate standard T7 (a forward 
primer which anneals to the T7 promoter region at the 5’ end of the gene) and BGH (a 
reverse primer which anneals to the BGH polyadenylation sequence at the 3’ end of the 
gene) primers were used along side internal sequencing primers to sequence all of the 
gene.  Where possible sequencing reactions were completed and cleaned up in house 
according to ABI protocols before submitting for processing.  For each 10µl sequencing 
reaction, 2 µl Big Dye (V3.1; Applied Biosystems) was mixed with 150ng of plasmid 
DNA and 1.6pmoles primer.  PCR cycling parameters were used as detailed in the 
manufacturer’s instructions.  Samples were cleaned by ethanol/EDTA precipitation and 
submitted for sequencing.  Wild-type or mutated sequences were confirmed by 
comparison with wild-type cDNA sequence using the Clustal W online multiple 
alignment programme. 
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2.6 In vivo Co-immunoprecipitation 
2.6.1 Transient transfection of plasmid DNA  
Cells were plated out into 10cm tissue dishes at 2.2 ×106 cells per dish and allowed to 
grow until 70% confluent.  Cells were cotransfected (using 10μl lipofectamine; as 
detailed in section 2.2.4) with 1μg FLAG tagged plasmid DNA encoding the protein of 
interest such as Chk1 or DAPK1 and up to 1μg plasmid DNA encoding the putative 
binding partner, EGFP-Box V gene.  The concentration of transfected EGFP plasmid 
DNA was kept to a minimum as EGFP tag is toxic to the cell.   
2.6.2 Cell lysis and Pre-clearing  
Cells were harvested (see section 2.3.1) and lysed in 2 – 3 × volume 1% Triton X-100 
lysis buffer (see section 2.3.1) with 1 tablet Complete® Protease Inhibitor cocktail 
(Roche Diagnostics) per 10ml lysis buffer.  Following a 45 min incubation on ice, 
lysates were collected by centrifugation (13000 rpm, 10 min, 4oC).  Lysates were pre-
cleared (agarose Sepharose® CL-4B beads) to reduce non-specific binding.  20 μl 
agarose beads were washed 5 times with 500 μl lysis buffer to remove ethanol.  Lysates 
were then added to the beads and pre-cleared by incubation for 1 hour at 4oC with 
rotation.   
2.6.3 Co-immunoprecipitation of FLAG-tagged proteins 
25µl M2 (anti-FLAG) agarose beads were washed sequentially with 1ml TBS (3×), 1ml 
0.1M glycine pH 3.5 (2×), 1ml TBS (4×) and 1ml Triton-X 100 lysis buffer (5×).  The 
pre-cleared lysates (see section 2.6.2) were incubated with beads for binding of FLAG-
tagged proteins to beads M2 (anti-FLAG) agarose (overnight at 4oC with rotation).  
Unbound proteins were retained for western blot analysis and the bound proteins were 
washed in 1ml TBS (repeat 4 ×) before elution of proteins in SDS sample buffer. 
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2.6.4 Coimmunoprecipitation using antibody coupled NHS beads 
2.6.4.1 Coupling of antibodies to NHS (N-hydroxysuccinimide) activated beads 
Where FLAG-tagged proteins were not available, antibodies to the protein of interest 
were crosslinked to NHS-activated Sepharose™ 4 fast flow beads (GE Healthcare) via a 
nucleophilic substitution reaction between the primary amine of the antibody and the 
carbonyl group of the NHS moiety.   
 
Coupling: NHS activated beads were washed twice in 2 × volume ice cold 1mM HCl 
and twice in 2 × volume ice cold PBS.  5 μg of antibody was then added to 25µl beads, 
taking an aliquot of the antibody before addition.  Coupling of antibody to beads was 
carried out for 1 hour at room temperature with rotation.  An aliquot of the supernatant 
was taken following coupling and a Bradford assay (see section 2.3.2) was performed to 
determine coupling efficiency.  Where 100% coupling efficiency is achieved the protein 
concentration of the post-coupling supernatant should be reduced to almost zero. 
 
Washing was carried out to deactivate excess NHS active groups not coupled to the 
ligand and to remove any weakly bound uncoupled antibody.  The wash stages were 
alternated between high pH (Buffer A; 0.5M ethanolamine, 0.5M NaCl; pH 8.3) and low 
pH (Buffer B; 0.1M acetate, 0.5M NaCl; pH 4) buffers.  Beads were washed thrice in 2 
× volume Buffer A, and thrice in 2 × volume Buffer B. This was repeated twice more 
with an incubation of 30 min at room temperature during the second wash.  Antibody 
coupled NHS beads were pelleted and stored in PBS-NaN3 at 4oC until required.   
 
2.6.4.2 Co-immunoprecipitation of antibody bound beads 
Pre-cleared lysates (see section 2.6.2) were added to antibody bound beads (see section 
2.6.4.1) and incubated overnight at 4oC with rotation.  Unbound lysate was retained for 
western blot analysis and beads were washed in 5 × volume of PBS – T (repeated 3 
times more).  The bound proteins were eluted with SDS sample buffer for analysis.    
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2.6.5 Western Blot analysis 
Immunocomplexes (see section 2.6.3 and 2.6.4.2) were analysed by SDS-PAGE 
followed by immunoblotting (see section 2.3.4.2) with an antibody specific for the 
putative binding partner. 
 
 
2.7 Microarray Analysis 
Microarray analysis of Chk1 and DAPK1 depleted cells was performed to evaluate 
changes in gene expression profiles of the p53 signalling pathway.  Following 
incubation with siRNA (see 2.2.5), cells were either harvested immediately (see section 
2.3.1) or alternatively, cells were treated with X-ray damage (as described in section 
2.2.6), dose/incubation time as stated in results (see section 5.2.3) before harvesting.  
Microarray analysis (see section 2.7.1) was performed using the Oligo GEArray® 
System (Superarray; Bioscience Co.).  
2.7.1 Isolation of total RNA 
For preparation of total RNA, RNA was extracted from cells pellets using RNeasy® 
Mini Kit (Qiagen) according to manufacturer’s instructions.  Samples were eluted into 
30µl RNase free H2O before determining concentration and purity by spectrophotometry 
at 260nm using the NanoDrop® ND-1000.  RNA quality control was performed before 
proceeding to next step to ensure high quality RNA was obtained (according to 
manufacturer’s recommendations).  
2.7.2 cRNA Target Labeling for Oligo GEarray® Hybridisation  
The Oligo GEarray® System (SuperArray; Bioscience Co.) was used to prepare cRNA 
for Oligo GEarray Hybridisation.  The system employed a one-tube format, which firstly 
involved the synthesis of cDNA.  3µg of total RNA was used for each cDNA synthesis 
reaction which was carried out according to manufacturer’s instructions.  Subsequent 
cRNA synthesis and labeling was carried out according to manufacturer’s instructions.  
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Biotinylated-UTP (Roche) was used to label cRNA and the reaction was performed 
overnight at 37oC to ensure amplification of cRNA.  Following overnight incubation, 
cRNA purification was performed to remove any protein or large excess of 
unincorporated nucleotide.  The RNeasy® Mini Kit (Qiagen) protocol for RNA clean up 
was used and the cRNA was eluted into 50 µl 10mM Tris HCl (pH 8.0). cRNA yield 
was quantified by spectrophotometry at 260nm using the NanoDrop® ND-1000.    
 
2.7.3 Oligo GEArray® Hybridization 
Oligo GEArrray Hybridisation and detection of biotin-labeled cRNA was performed 
using the HybTube Protocol in a roller-bottle hybridization oven according to 
manufacturer’s instructions.  The array membrane was pre-hybridized in GEAhyb 
Hybridisation Solution for 2-3 hours at 60oC with slow rotation (5 to 10 rpm).  For 
hybridization of cRNA to the array membrane, 2 µg of biotin-labeled cRNA was added 
to 0.75 ml GEAhyb Hybridisation Solution and hybridized overnight at 60oC with slow 
rotation (5 to 10 rpm).   
 
The array membrane was then washed and processed for chemiluminescent detection 
using Chemiluminescent Detection Kit (Superarray; Bioscience Co.) according to 
manufacturer’s instructions.  For chemiluminescent detection, 1ml of CDP-Star 
chemiluminescent substrate was added to the hybridization tube and incubated for 5 min 
at room temperature with rotation.  Membranes were placed into a plastic sheet 
protector, blotted dry and exposed to X-ray film (SLS), which was then developed (X-
ray Imaging Equipment™, Fuji).   
2.7.4 Data analysis 
Detailed analysis of images was performed using the GEArray Expression Analysis 
Suite 2.0 (Superarray; Bioscience) software. The array image was uploaded, data 
extracted and analysis of the data was performed using the analysis tools available.  
Images are aligned to a grid either manually or automatically and the readout of signal 
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intensity was generated.  Corrections are made for background of individually defined 
areas and an average of signal intensities of the 4 four replicates on each array spot.   
Normalisation of signal intensities between samples was performed using the control 
spots, which include the house-keeping genes, present on each array. 
 
 
2.8 Buffers and solutions  
2.8.1 SDS PAGE 
2.8.1.1 Lysis Buffers: 
Urea lysis buffer:  7M Urea, 0.1M DTT, 0.05% Triton-X-100, 25mM NaCl and 20mM 
Hepes-KOH pH 7.6 
 
NP-40 lysis buffer: 0.8 % NP-40, 20mM Hepes pH 7.6, 0.32M KCl, 5mM DTT *, 
120mM okadaic acid * and 1 × complete protease inhibitor cocktail (Roche) *   
 
1% Triton-X-100 lysis buffer: 50mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 
1% (w/v) Triton-X-100 and 10% (w/v) Glycerol 
 
* Added fresh to a final concentration as stated 
 
2.8.1.2 Protein quantification 
Bradford Reagent: 100mg Coomassie Blue G-250, 50ml 95% ethanol, 100ml 85% 
phosphoric acid  (made up to 1 litre with H2O). 
2.8.1.3 Preparation of gels and separation of proteins by SDS-PAGE 
Separating Gel (10%):  0.272% Bis-acrylamide (National Diagnostics; Ultrapure 
Protogel), 0.39M Tris-HCl (pH 8.8), 0.1% SDS, 0.1% APS and 0.04% TEMED 
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Stacking Gel: 0.136% Bis-acrylamide, 0.13M Tris-HCl (pH 6.8), 0.1% SDS, 0.1% APS 
and 0.2% TEMED 
 
Running Buffer: 192mM Glycine, 25mM Tris and 0.1% (w/v) SDS 
 
4 × SDS sample buffer: 4% SDS, 25mM Tris (pH 6.8), 20% Glycerol, 10mM EDTA, 
0.06% bromophenol blue and DTT added fresh to a final concentration of O.2M 
 
2.8.1.4 Detection of fractionated protein by Coomassie Brilliant Blue 
Fix:  50% (v/v) Methanol and 10% (v/v) Acetic Acid 
Coomassie Brilliant Blue Stain: 50% (v/v) Methanol, 10% (v/v) Acetic Acid and 0.2% 
(w/v) Coomassie Blue R-250 
Destain: 10% (v/v) Methanol and 10% (v/v) Acetic Acid 
 
2.8.1.5 Immunoblotting 
Transfer Buffer: 192mM Glycine, 25mM Tris and 20% (v/v) Methanol 
 
10x PBS (phosphate buffered saline): 1.37M NaCl, 0.1M Na2HPO4 and 0.027M KCl, 
0.018M KH2PO4 (Adjusted pH to 7.4 with HCl) 
PBS – Tween: 1x PBS + 0.1% (v/v) Tween 20 
10x TBS (tris buffered saline): 1.5M NaCl and 0.5M Tris (Adjusted to pH 7.4 with 
HCl) 
TBS- Tween: 1x TBS + 0.1% (v/v) Tween 20 
 
ECL Solution 1: 100mM Tris pH 8.5, 2.5mM Luminol Stock ,0.4mM p-Coumaric Acid 
ECL Solution 2: 100mM Tris pH 8.5 and 0.02% (v/v) H202 
Both ECL solutions stored in dark 
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Stripping buffer: 62.5mM Tris (pH 6.2) and 2% SDS 
 
2.8.2 Microbiological Techniques 
2.8.2.1 Bacterial Cultures 
Luria-Bertani (LB) Broth: 1% (w/v) Tryptone, 0.5% (w/v) Yeast Extract and 1% (w/v) 
NaCl  (sterilised by autoclaving at 121oC for 20 minutes). 
 
LB Agar: 1% (w/v) Tryptone, 0.5% (w/v) Yeast Extract, 1% (w/v) NaCl and 1.5% 
(w/v) Agar, granulated (sterilised by autoclaving at 121oC for 20 minutes). 
 
Selective antibiotics used:  Ampicillin at 50µg/ml for all constructs unless otherwise 
stated. 
 
2.8.2.2 Preparation of competent cells 
Transforming Buffer 1 (TFB I): 30mM Potassium Acetate, 100mM RbCl, 10mM 
CaCl2, 50mM MnCl2 and 15% (v/v) Glycerol (adjusted to pH 5.8 with acetic acid and 
sterilized by filtration) 
Transforming Buffer 2 (TFB II): 10mM MOPS, 75mM CaCl2, 10mM RbCl2 and 15% 
Glycerol (adjusted to pH 6.5 with KOH and sterilized by filtration). 
 
2.8.2.3 Agarose Gel Electrophoresis 
50 × TAE (Tris-acetate-EDTA) Buffer: 2M Tris base, 5.71% acetic acid and 50mM 
EDTA (adjusted to pH 8.5 with KOH) 
6 × DNA Sample Buffer: 30% glycerol, 0.003 % cyanol, 0.002 % bromophenol blue 
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3 THE ROLE OF THE P53 SER 20 SITE IN 
MODULATION OF P53 TRANSCRIPTIONAL ACTIVITY 
3.1 Introduction 
3.1.1 A role for p53 Ser 20 phosphorylation in assembly of the p53 transcription 
complex 
 
Figure 3.1 P53 is a tetrameric transcription factor.   
The schematic demonstrates the four domains of p53, the location of the conserved Box-I to 
Box-V motifs and some of the common phosphorylation sites.  
 
P53 is a tetrameric transcription factor (see Figure 3.1) which exhibits sequence-specific 
DNA binding activity mediated through its core DNA-binding domain (Lane and Hupp 
2003).  The p53 core domain is characterized by four evolutionary conserved sequences 
known as Box II – Box V domains (as demonstrated in Figure 3.1) which maintain the 
structural integrity of the core domain.  The N-terminal transactivation domain of p53 
provides a scaffold for binding of components of the transcription machinery thereby 
regulating transcription from p53 target genes.  Modulation of the transcriptional activity 
of p53 depends on the docking of one of two regulatory proteins, Mdm2 or p300, which 
compete for binding of the N-terminal Box-I domain of p53.  Mdm2 is a negative 
regulator which facilitates p53 degradation via the proteasome (Oren 1999).  P300 is a 
positive regulator pathway that facilitates p53 dependent gene expression through an 
intramolecular mechanism (Goodman and Smolik 2000). Binding of p300 to p53 is 
Core DNA-bindingpolyproline C-terminal transactivation 
  Ser15     Ser20 
Thr18 
Ser315                           Ser392 
BOX I 
BOX II – BOX V 
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essential for DNA-dependent acetylation of the C-terminus of p53 which stabilizes the 
p53-p300-DNA complex (Dornan et al. 2003).  The balance between the two regulators, 
Mdm2 and p300 in competing for binding of p53 regulates the specific activity of p53.   
 
The N-terminal domain of p53 provides a scaffold for binding of components of the 
transcriptional machinery.  The assembly of the transcription complex is initiated by 
phosphorylation of p53 at Serine 392 within the C-terminal phosphorylation motif by 
kinases such as casein kinase II (CK2) (Meek et al. 1990).  The phosphorylation of this 
motif is thought to result in a conformational change in p53 leading to increased DNA-
binding and transcriptional activity (Blaydes and Hupp 1998; Appella and Anderson 
2001).  Mutation of phosphoacceptor sites within this motif has been described to 
enhance cancer incidence in transgenic mice.  An in vivo study showed that mice with a 
mutation at residue Ser389 are prone to UV-induced skin cancer (Bruins et al. 2004).  
Moreover lack of Ser389 phosphorylation has been shown to predispose mice to the 
development of 2-acetylaminofluorene-induced bladder tumours (Hoogervorst et al. 
2005).  Both studies therefore emphasise the importance of this motif in control of 
transcriptional activity of p53. 
 
A crucial event in the activation of p53 is the phosphorylation at residues Threonine 18 
and Serine 20 (Ser 20) that stabilises both the binding of the co-activator p300 (Dornan 
and Hupp 2001), reduces the binding of the inhibitory partner Mdm2 (Unger et al. 1999) 
and enhances activation of p53 target genes (Jabbur et al. 2000).  A report by Jabbur and 
Zhang demonstrates that Asp substitution (mimics phosphorylation due to the 
introduction of a negative charge within the functional group) at the two 
phosphoaccepetor sites reduces the interaction of p53 with Mdm2 and increases the 
transactivation of the p53 targets, p21WAF1/CIF1 and the apoptotic promoter, Fas (Jabbur 
and Zhang 2002).  Furthermore, mutation of the Ser 20 site in mice (Ser 23) leads to the 
formation of spontaneous B-cell lymphoma (MacPherson et al. 2004), highlighting the 
importance of this site in maintaining the appropriate balance of active and inactive p53.    
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3.1.2 Signaling pathways target p53 
 
 
Figure 3.2 The Human Kinome.   
The Calcium Calmodulin Kinase Superfamily (CAMK) form part of the phylogenetic tree known 
as the Human Kinome where members are related based on their kinase domains (Manning et 
al. 2002) 
 
Distinct stresses activate p53.  There has been a great deal of literature examining the 
role of p53 in the cellular responses to stresses such as DNA damage, oncogene 
activation and unfavourable metabolic conditions.  In response to DNA damage p53 is 
post-translationally modified at multiple sites by kinases and acetyltransferases.  DNA 
damage such as double strand breaks results in the activation of stress-induced signaling 
pathways which in turn activate cell cycle checkpoint kinases such as Chk1 and Chk2 
which are recruited to phosphorylate and stimulate p53 transcriptional activity (Nyberg 
et al. 2002).  Chk1 and Chk2 are members of the Calcium Calmodulin (CAMK) 
superfamily of kinases which forms a branch of the phylogenetic tree known as the 
Human Kinome (Figure 3.2) where members are related based on their kinase domain 
(Manning et al. 2002).  Both Chk1 and Chk2 have been shown to phosphorylate p53 at 
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multiple sites in both the N- and C-termini of p53 leading to its stabilization (Ou et al. 
2005).    Many reports have suggested Chk2 as a putative stress induced activator of p53 
(Hirao et al. 2000; Takai et al. 2002; Craig et al. 2003; Chen et al. 2005).  Therefore, a 
hypothetical model has been proposed in which CAMK superfamily members such as 
checkpoint control kinases, Chk1 and Chk2; the stress activated tumour suppressor 
protein, death-associated protein kinase (DAPK1) and the metabolic regulator, AMP-
activated protein kinase (AMPK) may all play a role in modulating p53 activity. 
 
This was supported by data in which p53 was implicated as an essential component of 
metabolic cell cycle control.  It has been demonstrated that glucose availability regulates 
cell proliferation and the metabolic sensor AMPK mediates this process.  Cells treated 
with low glucose arrest in the G1 phase of the cell cycle and it has been shown that this 
arrest is p53-dependent (Jones et al. 2005).  When the cell is glucose deprived, AMPK is 
activated leading phosphorylation of p53 at Ser15 and activation of p53.  Thus, 
activation of p53 is required to promote cell cycle arrest which will allow the cell to 
survive the unfavourable glucose deprived conditions.  Oncogenes such as c-myc also 
activate p53.  Raveh and colleagues investigated whether DAPK, a tumour suppressor 
which sensitises cells to apoptotic signals, could affect the initial steps of oncogenesis 
(Raveh et al. 2001).  They found that DAPK suppresses oncogene-induced 
transformation of primary embryonic fibroblasts by activating p53 in a p19ARF – 
dependent manner.  This led to induction of apoptosis in order to eliminate the pre-
malignant cells.  The various reports examining the role of kinases in modulating p53 
activity has led to much controversy within the field.  As such, the evaluation of stress-
activated p53 kinases is important in developing our understanding of the mechanisms 
involved in p53 activation.  This report will examine the role kinases in modulation of 
Ser 20 phosphorylation. 
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3.1.3 The modulation of p53 Ser 20 phosphorylation by Calcium Calmodulin kinase 
superfamily members has been demonstrated in vitro  
A recent report has questioned the role of Chk2 as a p53 kinase and demonstrated that 
p53 does not contain a classical Chk2 consensus site and that the p53 activation domain 
peptide fragment is not a Chk2 substrate (O'Neill et al. 2002).  In a subsequent report 
Craig and colleagues investigated the role of Chk2 as a p53 kinase, and how Chk2 could 
target a protein that does not have a Chk2 consensus site (Craig et al. 2003).    Two main 
candidate contact sites for the interaction between Chk2 and p53 were identified 
following a peptide scan of full length p53: Box-II and Box-V motifs of p53 core DNA-
binding domain (see Figure 3.1) (Craig et al. 2003).  It was shown that an N-terminal 
fragment of p53 which lacks the core domain is a poor substrate for Chk1 and Chk2.  
However, upon the addition of peptides derived from the p53 Box-II and Box-V motifs 
Chk1 and Chk2 stimulate in vitro phosphorylation of the N-terminal p53 fragment 
stimulated by an allosteric shift in Chk1 and Chk2.  This suggested that the Box-V motif 
of p53 may be essential for the binding of Chk1 and Chk2 and that binding to the core 
domain is essential for phosphorylation of N-terminus of p53 at Threonine 18 and Serine 
20 (Craig et al. 2003). 
 
Following these results, Craig and colleagues went on to examine whether other 
members of the CAMK superfamily such as such as DAPK1, Chk1, DRAK and AMPK 
which showed homology to Chk2, could be stimulated to phosphorylate N-terminal p53 
in the presence of the peptide derived from the Box-V motif of p53.  They showed that 
there was significant stimulation of Ser 20 kinase activity in the presence of the Box-V 
peptide suggesting that the kinases operate in docking-dependent manner (Craig et al. 
2007).  The ability of these kinases to operate as activators of p53 was investigated 
further in this report by Craig and colleagues.  They demonstrated that Ser 20 
phosphorylation occured in undamaged cells and therefore established the existence of 
enzymes which modify Ser 20 in cycling cells (Craig et al. 2007).  Furthermore, when 
lysates from these cells were fractionated to determine whether Ser 20 kinase activity 
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co-eluted with Chk1/Chk2 or DAPK1/DAPK3, the broad elution of Ser 20 kinase 
activity was separate from the elution of Chk1 and Chk2, however UV inducible Ser 20 
kinase activity co-purified with Chk2, suggesting that Chk2 may represent the major 
DNA damage inducible kinase (Craig et al. 2007).  They showed that DAPK1 eluted as 
a broad peak which correlated with the broad elution of Ser 20 kinase activity and that 
recombinant DAPK1 had intrinsic Ser 20 kinase activity but no Ser 15 or Thr 18 kinase 
activity (Craig et al. 2007), making it distinct from Chk1 and Chk2 which are dual site 
kinases that modify both Thr 18 and Ser 20 (Shieh et al. 2000). 
 
3.1.4  Evaluation of DAPK1, Chk1 and Chk2 as p53 activating kinases in vivo 
The identification of enzymes such as Chk1, Chk2 and DAPK1 which target Ser 20 site 
phosphorylation of p53 in a docking-dependent manner in vitro led to the investigation 
of these enzymes as p53-activating kinases in vivo.  To date the identity of the main in 
vivo p53 Ser 20 kinase remains undefined and it is likely that the activation of p53 by 
phosphorylation at Ser 20 is cell-type and damage-type dependent.  Although several 
reports examining the phosphorylation sites across the N- and C-termini of p53 have 
suggested Chk1 and Chk2 as the main p53 Ser 20 kinases in vitro (Hirao et al. 2000; 
Shieh et al. 2000; Ou et al. 2005), the role of Chk2 as a modulator of p53 has been 
questioned.  Bunz’s group examined the role of Chk2 in p53 stabilization using human 
colorectal cell lines in which Chk2 had been disrupted through gene targeting.  They 
found that disruption of Chk2 did not effect p53 stabilization, phosphorylation or 
transcriptional activation of downstream targets (Jallepalli et al. 2003).  Furthermore, 
Prives’ group demonstrated that siRNA to Chk2 resulted in reduced expression of Chk2 
but showed that p53 remained stabilized and that p53 was activated following damage 
(Ahn et al. 2003).  Therefore further evaluation of the in vivo p53 activating kinases was 
required.   
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Figure 3.3  Comparison of WT p53 and the p53 ΔV isoform.   
The p53 ΔV isoform lacks 66 internal amino acids (residues 257-322) which results in loss of a 
portion of the C-terminal end of the DNA-binding domain which includes the Box-V region 
(Prives and Manfredi 2005). 
 
The recent identification of a novel isoform of p53 (Rohaly et al. 2005) may be crucial 
to further the investigation into the Chk1:p53 interaction.  This novel p53 isoform, 
IntΔp53 (Figure 3.3; here after referred to as p53 ΔV) lacks 66 amino acids in the C-
terminus of the DNA binding domain which is the location of the conserved Box V 
domain.  It is an alternative splice variant which displays transcriptional activity in 
irradiated S phase cells only (Rohaly et al. 2005).  Previous attempts at investigating the 
role of the Box V domain by generating point mutants or short deletions within this 
region of p53 have been unsuccessful as the mutant core domains were unfolded.  
Therefore, this isoform is potentially very useful in determining specific regions of p53 
which are involved in the transcriptional activation of p53.  It will allow us to investigate 
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3.1.6 Objectives of this chapter 
The continued debate as to the identity of the main physiological p53 Ser 20 kinase(s) 
has led to controversy throughout the field of p53.  This objective of this chapter was to 
investigate and to identify the in vivo p53 Ser 20 kinase.  It is likely that different 
kinases will target this site in a cell-type specific and stress-specific manner.   The work 
presented in this chapter will also set out to develop our understanding of the mechanism 
of CAMK regulation of p53 in vivo.  
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3.2 Results  
3.2.1 Development of an in vivo p53 Ser 20 phosphorylation assay 
The identification of Chk1, Chk2 and recently DAPK as p53 Ser 20 kinases in vitro as 
well as the continued debate as to the identity of the main physiological p53 Ser 20 
kinase has provoked much controversy in the field.  To this end, the development of an 
assay in which to study the stabilization of p53 by phosphorylation was crucial in order 
to build our understanding of the signaling pathways which control p53.  A cell based 
transfection assay was developed to evaluate Ser 20 phosphorylation of exogenous p53 
protein by specific CAMK family members.  Unfortunately Ser 20 phospho-specific 
antibodies have low affinity precluding their use for studying endogenous p53 Ser 20 
signalling pathways.   Increasing amounts of p53 was transfected into H1299 cells and 
cell lysates were immunoblotted for levels of p53 protein and Ser 20 site 
phosphorylation of p53.  The results (Figure 3.4; A) clearly demonstrate that transfection 
of p53 resulted in elevated p53 protein levels and Ser 20 site phosphorylation in a dose 
dependent manner (Figure 3.4; A; lanes 2 to 7).  Therefore, these cells were useful 
models in which to study Ser 20 site phosphorylation because their endogenous Ser 20 
kinase activity (activated by transfection stress) is capable of modifying at least a 
fraction of ectopically expressed p53 protein.   
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Figure 3.4 In vivo induction of Ser 20 phosphorylation of p53 by the Calcium Calmodulin 
kinase superfamily members.  
A. Analysis of p53 phosphorylation by an endogenous Ser 20 site kinase in p53-null H1299 cells. 
Cells were transfected with increasing amounts (30ng to 1µg) of p53 expression vector (pcDNA 
3.1p53), lysed and immunoblotted for p53 (DO12) and Ser 20 site phosphorylation of p53.  B.  
Effects of kinase gene transfection on Ser 20 site phosphorylation of p53. H1299 cells were co-
transfected with 100ng of p53 expression vector and 5µg kinase expression vectors (pDEST 
12.2 Chk2, pDEST 12.2 GST DAPK1 full length, pDEST 12.2 GST DAPK1 core kinase domain 
and pDEST 3.2 Chk1), lysed and immunoblotted for p53 (DO12), Ser 20 site phosphorylation of 
p53, Chk2, DAPK1 and Chk1.  C. Effects of DAPK1 and DAPK3 kinase gene transfection on Ser 
20 site phosphorylation of p53. H1299 cells were transfected with 100ng of p53 and increasing 
amounts (1 to 5µg) of kinase expression vectors pDEST 12.2 GST DAPK1 full length or pDEST 
12.2 GST ZIPK. Lysates were immunoblotted for p53 (DO12), Ser 20 site phosphorylation of 
p53, DAPK1 and ZIPK (DAPK3). 
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3.2.2 Specific Calcium Calmodulin Superfamily members stimulate p53 Ser 20 
phosphorylation  
The p53 null cell line, H1299 was used to investigate the in vivo induction of p53 Ser 20 
phosphorylation by specific members of the Calcium Calmodulin Superfamily.  
Transfection of Chk1 and full length DAPK1 gave rise to elevated Ser 20 site 
phosphorylation (Figure 3.4; B; lanes 8 and 12).  In contrast, transfection of Chk2 
attenuated basal Ser 20 site phosphorylation (Figure 3.4; B; lanes 6) and transfection of a 
truncated form of DAPK1, DAPK1-core had little effect on basal Ser 20 site 
phosphorylation (Figure 3.4; B; lanes 10). This is associated with levels of p53 which 
appear to decrease following transfection of either Chk2 or DAPK core (Figure 3.4; B; 
lanes 6 and 10; p53 protein levels).   It is therefore likely that Ser 20 phosphorylation of 
p53 is linked to p53 protein stability.  
 
Members of the CAMK superfamily such as Chk1, Chk2 and DAPK1 had been shown 
to have phosphorylation site peptide consensus homology to the Box-I domain of p53 
and a homologue of DAPK1, DAPK3 also had peptides with a striking degree of 
homology to the Box-I domain of p53 (Craig et al. 2007).  Therefore DAPK1 and its 
homologue DAPK3 (also termed ZIPK) were compared for their ability to phosphorylate 
p53 at Ser 20 (Figure 3.4; C).  DAPK1 stimulated and DAPK3 attenuated basal Ser 20 
phosphorylation (Figure 3.4; C; comparing lanes 3 to 5 with lanes 6 to 8) in a similar 
manner to Chk2.  Therefore, DAPK1 was again demonstrated as a stimulator of Ser 20 
site phosphorylation of p53.  This supports published data which compares the ability of 
DAPK1 full length, DAPK1 core and DAPK3 to modify p53-dependent transcription 
function (Craig et al. 2007).  The transcriptional reporter assays demonstrate that full 
length DAPK1 stimulates and DAPK1 core and DAPK3 attenuate p53-dependent 
transcription function (Craig et al. 2007).  
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3.2.3 Chk1 induces a dose-dependent increase in p53-dependent transcription 
To determine whether the stimulation of transcription correlated with increased Ser 20 
site phosphorylation, a reporter assay was performed using the p21WAF1 promoter as an 
indicator of p53-dependent transcription.  A dose titration of p53 showed (i) the 
dependence of promoter activity on p53 dose and (ii) defined the range of linear 
relationship between p53 exogenous expression and p21WAF1 reporter activity.  The basal 
activity of p53 on the p21WAF1 promoter is illustrated in Figure 3.5 and demonstrates that 
following addition of p53 there is significant increase in p21WAF1 reporter activity and 
that this increase is p53 dose-dependent.  A dose of 100ng of p53 maximises the 
transcriptional activity of p21WAF1 promoter and at higher doses of p53 (200ng to 2µg) 
there is a decrease in transcriptional activity.  From this data the optimal dose of p53 for 
transcriptional activation was defined as 50ng because of the high transcriptional 
activity. 
 
To determine the effect of kinases on p53-dependent transcription the p53 gene was co-
transfected with a titration of Chk1 or Chk2.  The data (Figure 3.6) showed a dose-
dependent increase in p53-dependent transcription following transfection of Chk1 and a 
dose-dependent attenuation of p53-dependent transcription by Chk2 (as demonstrated in 
Figure 3.6).  This correlated with data in section 3.2.2 whereby only transfection of 
Chk1 but not Chk2 gave rise to elevated Ser 20 site phosphorylation.  Therefore the 
kinase dependent increase in Ser 20 phosphorylation correlates with the kinase 
dependent increase in p53 transcriptional activity and the kinase dependent decrease in 
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Figure 3.5  Determination of the optimal p53 dose in p53-dependent transcriptional 
assays.  
H1299 cells were transfected with p53 (50ng to 2µg), 1µg of PGL3 p21WAF1 luciferase reporter 
construct, 0.25µg pCMVβ-Gal construct and made up to a total of 4µg of transfected DNA with 
empty vector control.  After 24 hours the cells were lysed and luciferase and β-Galactosidase 
activity was measured.  Data shows the luciferase activity normalised to the β-Gal production 
represented as Relative Light Units (RLU).  Activity levels of the p21WAF1 reporter construct 
without p53 are represented in reporter only lane. The control lane represents the activity levels 
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Figure 3.6 Effect of the Calcium Calmodulin superfamily gene transfection on p53-
dependent reporter activity.   
H1299 cells were co-transfected with p53 (50ng), a titration of Chk1 or Chk2 (from 1 to 5 µg of 
DNA) and reporter plasmid constructs, p21WAF1 (1µg) and β-gal (0.25µg).  After 24 hours the 
cells were lysed and luciferase and β-Galactosidase activity was measured.  Data shows the 
luciferase activity normalised to the β-Gal production represented as Relative Light Units (RLU).  
Activity levels of the p21WAF1 reporter construct without p53 are represented in reporter only 
lane. The control lane represents the activity levels of untransfected (no DNA) control.   
 
  
Using two distinct transfection-based assays (p53 Ser 20 site phosphorylation and p53-
dependent transcription reporter activity), it was demonstrated that only Chk1 and 
DAPK1 could positively affect the p53 pathway, while Chk2 and DAPK3 attenuated 
p53 function.   Therefore, suggesting a link between Ser 20 phosphorylation and p53 
activity.   
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3.2.4 Identification of distinct Calcium Calmodulin Kinases as the major 
endogenous mediators of Ser 20 phosphorylation in human tumour cells 
We next set out to determine which of the three enzymes, Chk1, Chk2 or DAPK1, was 
the major mediator of ectopically expressed p53.  H1299 cells were cotransfected with 
the p53 and siRNA oligonucleotides to Chk1 or Chk2.  Cell lysates were immunoblotted 
for p53 protein, Ser 20 site phosphorylation of p53 and Chk1 protein (Figure 3.7; A).  It 
was demonstrated that Chk1 depletion gave rise to the most pronounced attenuation of 
Ser 20 site phosphorylation and reduction in p53 protein levels of ectopically expressed 
p53 (Figure 3.7; A; lane 3).  The depletion of Chk2 slightly reduced Ser 20 site 
phosphorylation but did not affect p53 protein levels (Figure 3.7; A; lane 4).   
 
We then focused on determining which of the three enzymes being studied; Chk1, Chk2 
or DAPK1 was the major endogenous mediator of Ser 20 phosphorylation in cells.  In 
order to examine this, A375 cells, which express endogenous p53 and all three Calcium 
Calmodulin superfamily members Chk1, Chk2 and DAPK1, were used.  Cell lysates 
were immunoblotted for changes in protein levels of the three kinases as well as p53 
(Figure 3.7; B).  The protein levels of each of the three kinases are significantly depleted 
using these siRNA oligonucleotides (Figure 3.7; B; comparing lane 1 with lanes 2 to 4 in 
Chk1, Chk2 and DAPK1 blots respectively).  This assay demonstrated that each of the 
kinases could be reliably silenced without affecting the levels of the other kinases and 
thus validated the specificity of the siRNA oligonucleotides.  Of the three manipulations 
only DAPK1 depletion reduced p53 protein levels (Figure 3.7; B; lane 4; p53 blot) 
suggesting that endogenous DAPK1 is the most effective stabilizer of p53 in A375 cells.   
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Figure 3.7  Determination of the major endogenous mediator of Ser 20 phosphorylation of 
ectopically expressed p53 in H1299 cells.   
A. Depletion of endogenous Chk1 in H1299 using siRNA attenuates in vivo Ser 20 site 
phosphorylation of p53.  H1299 cells were cotransfected with p53 (100ng) and 100nM siRNA 
control or 100nM siRNA to Chk1 or Chk2.  Cells were lysed and immunoblotted for changes in 
p53 protein (DO12), Ser 20 site phosphorylation of p53 and Chk1 protein.  B. Depletion of 
DAPK1 in A375 cells selectively depletes endogenous p53. A375 cells were transfected with 
100nM control or 100nM siRNA to Chk1, Chk2 or DAPK1 and immunoblotted for changes in 
Chk1, Chk2, DAPK1 and p53 protein levels (DO12). 
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The two sets of data demonstrate that Chk1 depletion in H1299 cells results in loss of 
p53 Ser 20 phosphorylation and DAPK1 depletion in A375 cells results in loss of p53 
stability.  Therefore, it can be concluded that endogenous Chk1 is required for the 
majority of Ser 20 site phosphorylation of ectopically expressed p53 in H1299 cells and 
that endogenous DAPK1 is the most effective p53 protein stabilizer in A375 cells.  This 
suggested a possible cell-specific function for the Ser 20 kinases. 
 
3.2.5 The conserved Box-V domain of p53 is required for Ser 20 site 
phosphorylation of p53 by Calcium Calmodulin kinases.  
We have shown that CAMK superfamily members regulate p53 in vivo (as described in 
sections 3.2.2 to 3.2.4).  However, the mechanism by which this occurs in unknown.  In 
vitro data suggests that the Box-V domain may be essential for the binding of CAMK 
members and the subsequent phosphorylation of p53 at Ser 20 (Craig et al. 2003).  We 
therefore set out to investigate whether this mechanism occurred in vivo.   To achieve 
this we used the naturally occurring alternative splice variant, p53 ΔV (see section 3.1.5) 
which lacks approximately 65 amino acids encompassing the Box-V docking region of 
p53.  We examined the effect of loss of the major kinase docking site on (i) Ser 20 
phosphorylation of p53 and (ii) kinase regulation of p53 activity.  The Box-V docking 
region of p53 contains the ubiquitination signal that is required for dual site stimulation 
of the E3 ubiquitin ligase function of Mdm2 (Shimizu et al. 2002; Wallace et al. 2006).  
In light of this literature we set out to validate the p53 ΔV variant and show that it 
cannot be targeted by Mdm2.  H1299 cells were co-transfected with Mdm2 and 
expression plasmids to full length p53 WT or the spliced isoform, p53 ΔV and lysates 
were immunoblotted with an anti-p53 antibody to identify the high-molecular-mass 
adducts indicative of Mdm2-mediated ubiquitination (Figure 3.8; A).   
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Figure 3.8 Deletion of the central region of p53 containing the Box-V domain blocks both 
Ser 20 site phosphorylation and ubiquitination of p53.   
A. Mdm2-mediated ubiquitination is attenuated using p53 ΔV as a substrate.  H1299 cells were 
cotransfected with 100ng p53 WT or p53 ΔV and 1µg Mdm2.  Cell lysates were immunoblotted 
with DO1 antibody to p53 to identify high-molecular-mass adducts reflective of Mdm2-mediated 
ubiquitination. B. p53 ΔV is not modified at Ser 20 after kinase transfection.  H1299 cells were 
cotransfected with 100ng p53 WT or p53 ΔV and 1µg Chk1 or DAPK1 and lysates were 
immunoblotted for p53 protein, evidence for deletion of the p53 central region using DO-12 
antibody, Ser 20 site phosphorylation of p53, Chk1 and DAPK1. C. p53 ΔV does not compete 
with WT p53 phosphorylation at Ser 20.  Using fixed p53, increasing amounts of p53 ΔV (0.1 to 
1µg) were transfected into cells, which were lysed and immunoblotted for both p53 (DO12) and 
Ser 20 phosphorylation of p53.  
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Transfection of p53 WT or p53 ΔV alone resulted in no ubiquitination (Figure 3.8; A; 
lanes 1 and 2).  However, when p53 WT is cotransfected with Mdm2 the resulting 
ubiquitination of p53 WT was clearly demonstrated (Figure 3.8; A; lane 3).  Co-
transfection of p53 ΔV expression plasmid and Mdm2 resulted in attenuation of Mdm2-
mediated ubiquitination compared to WT p53 (Figure 3.8; A; comparing lanes 3 and 4).  
Therefore, the absence of the Box-V region within the p53 ΔV isoform led to attenuation 
of Mdm2-mediated ubiquitination, which supports a requirement of the Box-V region 
for Mdm2-mediated ubiquitination of p53.  
 
To investigate the effect of loss of the Box-V region on kinase regulation, H1299 cells 
were transfected with expression plasmids to full length p53 or the spliced isoform, p53 
ΔV and the indicated Chk1 or DAPK1 kinase expression vectors (Figure 3.8 B). To 
verify the deletion of the Box-V region within p53 ΔV, the DO12 antibody which binds 
specifically to the Box-V region of WT p53 was used (Figure 3.8; B; DO12 blot; lanes 5 
and 6) and to verify the total p53 levels, the DO1 antibody was used (Figure 3.8; B; DO1 
blot; lanes 3, 4, 5 and 6).   
 
Although Ser 20 site phosphorylation of full length p53 was stimulated following 
transfection of Chk1 or DAPK1 (Figure 3.8; B; lanes 4 versus lane 3; Ser 20 blot), the 
transfected p53 ΔV exhibited no basal Ser 20 site phosphorylation (Figure 3.8; B; lane 5; 
Ser 20 blot) and cotransfection of Chk1 or DAPK1 did not induce Ser 20 site 
phosphorylation on p53 ΔV (Figure 3.8; B; lane 6 versus lane 4; Ser 20 blot).  Lack of 
DO12 staining confirms the identity of the p53 ΔV isoform (Figure 3.8; B; lanes 5 and 
6; DO12 blot).  These data demonstrate that p53 ΔV was not modified at the Ser 20 site 
and the removal of a central region of p53 containing the Box-V domain prevented both 
ubiquitination and Ser 20 site phosphorylation of p53. 
 
Furthermore, to investigate the effect of p53 WT/p53 ΔV heterotetramerisation on p53 
Ser 20 phosphorylation, fixed amounts of full length p53 and increasing amounts of p53 
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ΔV were transfected into H1299 cells.  Figure 3.8C demonstrated that transfected p53 
ΔV had no basal Ser 20 site phosphorylation (Figure 3.8; C; lane 2 versus 1) and there 
was no dose dependent decrease in Ser 20 site phosphorylation as increasing amounts of 
p53 ΔV were added (Figure 3.8; C; lanes 3 to 6).   Therefore, there is no evidence of Ser 
20 site phosphorylation by both ΔV and WT and demonstrate that p53 ΔV does not 
cooperate with wild-type p53 for phosphorylation at the Ser 20 site. 
 
3.2.6 The p53 ΔV spliced isoform is transcriptionally active 
It has been reported that the p53 ΔV isoform can induce a subset of p53 targets (p21 and 
14-3-3 σ) and that p53 ΔV exclusively associates with the p21 promoter in irradiated S-
phase cells (Rohaly et al. 2005).  In light of this report and the data which demonstrates 
that deletion of the Box-V domain prevented Ser 20 site phosphorylation of p53, a 
reporter assay was performed to investigate the transcriptional activity of the p53 ΔV 
isoform.  
 
The data showed that as demonstrated previously (see Results 3.2.3) transfection of 
Chk1 stimulated p53 WT dependent transcriptional activation (Figure 3.9).  The p53 ΔV 
protein does have intrinsic transcriptional activity suggesting that this Box-V domain 
deletion does not simply unfold and completely inactivate p53. However, p53 ΔV- 
dependent transcriptional activity was not stimulated by Chk1 transfection (Figure 3.9).  
Therefore, although it has been demonstrated that the removal of the central region of 
p53 containing the Box-V domain prevents both ubiquitination and Ser 20 site 
phosphorylation of p53, the p53 ΔV isoform shows some transcriptional activity. It is 
able to drive basal p53-dependent activity from the p21WAF1 promoter template but in 
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Figure 3.9  p53 ΔV-dependent transcriptional activity is not stimulated by transfection of 
Chk1.   
H1299 were cotransfected with Chk1-encoding gene (2 µg), p53 WT or p53 ΔV (50ng) and 
reporter plasmid constructs; p21WAF1-luc (1µg) and β-gal (0.25 µg).  After 24 hours the cells were 
lysed and luciferase and β-Galactosidase activity was measured.  Data shows the luciferase 
activity normalised to the β-Gal production represented as Relative Light Units (RLU).  Activity 
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3.2.7 The Box-V peptide attenuates p53 Ser 20 phosphorylation  
We have shown that the deletion of Box-V blocks stimulation of p53 by CAMK 
superfamily members suggesting that the p53 ΔV isoform lacks the CAMK docking site.  
In order to determine whether the CAMK members dock to Box-V in vivo we used Box-
V peptides.  It has been demonstrated using peptides derived from Box-V in in vitro 
kinase assays that the Box-V domain regulates Ser 20 phosphorylation in a docking-
dependent manner (Craig et al. 2003) and that the EGFP-Box-V fusion peptide contains 
the ubiquitination signal for Mdm2 which can inhibit Mdm2-mediated ubiquitination of 
p53 in vitro and in vivo (Wallace et al. 2006).  We therefore set out to investigate 
whether the Box-V peptide can competitively inhibit CAMK regulation of p53 Ser 20 
phosphorylation and p53-dependent transcriptional activity.   
 
H1299 cells were transfected with a titration of EGFP-control (Figure 3.10; A; lanes 2, 
4, 6 and 8) or EGFP-Box-V vectors (Figure 3.10; A; lanes 3, 5, 7 and 9).  The EGFP tag 
is toxic in the cell and increasing dose of EGFP (EGFP control or EGFP-Box-V) is 
decreasing levels of Ser 20 phosphorylation in this assay (Figure 3.10; A; Ser 20 blot; 
lanes 2 to 9).  However, the data shows that there is a clear reduction of Ser 20 site 
phosphorylation of p53 in the presence of EGFP-Box-V relative to EGFP control 
(Figure 3.10; A; Ser 20 blot; compare ‘C’ with ‘V’; lanes 2 and 3). Therefore the data 
has shows that the Box-V peptide specifically attenuates Ser 20 site phosphorylation of 
p53.  This supports the hypothesis that the Box-V peptide is a competitive inhibitor of 
Chk1 that functions by blocking the p53 binding site on Chk1, and is consistent with the 
inability of p53 ΔV to function as a Chk1 substrate in vivo.   
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Figure 3.10 The EGFP-Box-V fusion peptide attenuates Ser 20 site phosphorylation of p53 
in vivo.   
A. Transfection of EGFP-Box-V attenuates Ser 20 phosphorylation of p53 WT.  Chk1 (5µg) and 
p53 (1µg) were cotransfected into H1299 cells with increasing amounts (0.5µg to 5µg) of EGFP 
control (lanes 2, 4, 6 and 8) or 0.5µg to 5µg EGFP-Box-V (lanes 3, 5, 7 and 9). Cells were lysed 
and lysates were immunoblotted for Ser 20 site phosphorylation of p53 (DO12), p53, Chk1 and 
EGFP protein levels.  B. EGFP- Box-V fusion peptide cannot activate p53 ΔV phosphorylation in 
vivo.  1µg of vectors encoding p53 WT (lanes 1 to 3) and p53 ΔV (lanes 4 to 6) were 
cotransfected into cells with EGFP control (lanes 2 and 5) or EGFP-Box-V (lanes 3 and 6).  Cells 
were lysed and lysates were immunoblotted for p53 protein (DO1), evidence of deletion of the 
p53 central region using the DO-12 antibody, Ser 20 site phosphorylation of p53 and EGFP 
protein levels.   
Chapter 3 Results 
 - 105 - 
3.2.8 The Box-V peptide cannot restore p53 ΔV Ser 20 phosphorylation by 
endogenous Calcium Calmodulin Kinases 
Deletion of the central region of p53 containing the Box-V domain (as seen in the 
isoform, p53 ΔV) prevents Ser 20 site phosphorylation of p53 (see results 3.2.5).  It was 
therefore investigated whether the p53 ΔV protein could be reactivated for Ser 20 site 
phosphorylation in vivo using the EGFP-Box-V peptide fusion peptide.  Vectors 
encoding p53 (Figure 3.10 B; lanes 1 to 3) and p53 ΔV (Figure 3.10 B; lanes 4 to 6) 
were cotransfected with EGFP control (Figure 3.10 B; lanes 2 and 5) or EGFP-Box-V 
vector (Figure 3.10 B; lanes 3 and 6).  As previously shown the Box V peptide 
attenuated basal levels of endogenous Ser 20 site phosphorylation of full length p53 
(Figure 3.10 B; Ser 20 phosphorylation immunoblot; lane 3 versus lane 2).  There is no 
basal Ser 20 site phosphorylation of p53 ΔV (Figure 3.10 B; lane 4) as expected and 
following the addition of the Box-V fusion peptide, there was no reactivation of Ser 20 
site phosphorylation (Figure 3.10 B; lane 6).  Thus demonstrating that the EGFP-Box-V 
peptide fusion cannot activate p53 ΔV phosphorylation in vivo, under conditions where 
full-length p53 Ser 20 site phosphorylation is attenuated.  It is likely that although the 
Box-V peptide may activate endogenous kinases such as Chk1, Chk1 still fails to target 
p53 ΔV due to lack of the binding site.   
  
3.2.9 Chk1 stimulation of p53-dependent transcriptional activity is docking-
dependent and not phosphorylation-dependent 
A role for phosphorylation in p53 regulation has been suggested in reports which 
demonstrated that mutation of the Ser 20 site to Ala 20 can attenuate p53 activity in 
apoptotic and transgene-based systems (Unger et al. 1999; MacPherson et al. 2004).  
The importance of kinase docking over that of phosphorylation to stimulate p53 activity 
was previously demonstrated when a p53 Ser 20-Asp mutant marginally elevated basal 
p53-dependent transcription relative to WT, and was further stimulated by DAPK1 
(Craig et al. 2007).  In this report we have shown that the conserved Box-V domain of 
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p53 is required for Ser 20 site phosphorylation of p53 and kinase stimulation of p53-
dependent transcription (3.2.5).  It is therefore likely that Chk1 docking to the Box-V 
domain is required for Ser 20 site phosphorylation and transcriptional activation of p53 
to take place.  Docking to p53 may be a key evolutionary step and phosphorylation, may 
simply be a release mechanism. 
 
To investigate this and compare the role of phosphorylation and binding on 
transcriptional activation of p53 a transfection-based assay was performed.  Mutation of 
the Ser 20 site to alanine in full length and ΔV p53 was performed to examine the effects 
of loss of the phospho-acceptor site on basal and kinase stimulated p53-dependent 
transcription activity (Figure 3.11).  H1299 cells were cotransfected with p53 encoding 
genes (p53 full length wild-type, p53 full length S20A, p53 ΔV wild-type, or p53 ΔV 
S20A) and Chk1 or DAPK1.  The results demonstrated that for full length p53 the Ala 
20 mutation did not affect basal p53-dependent transcription reporter activity (Figure 
3.11; comparing p53 only columns).  However, the addition of either Chk1 or DAPK1 
significantly stimulated mutant but not wild-type p53-dependent transcriptional activity 
(Figure 3.11; comparing ‘p53 + Chk1’ and ‘p53 + DAPK1’ columns to ‘p53 only’ 
columns) suggesting that kinase activity may be required to stimulate p53 function.  
More strikingly, the use of the p53 ΔV wild-type and p53 ΔV S20A in this assay system 
demonstrated that kinase stimulation of p53 is dependent on binding to the Box-V 
region.  The loss of the Box-V region of either ΔV or ΔV S20A p53 resulted in low 
basal levels of p53-dependent transcriptional activity and this activity could not be 
stimulated further by addition of either Chk1 or DAPK (Figure 3.11 and as demonstrated 
previously 3.2.6).  The p53 ΔV isoform does however have lower basal transcriptional 
activity in this assay than previously demonstrated (section 3.2.6) and may suggest that 
the p53 ΔV is not consistently transcriptionally active.   
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Figure 3.11  Kinase stimulation of p53-dependent transcriptional activity is docking 
dependent and not Ser 20 phosphorylation dependent.   
H1299 cells were cotransfected with p53 encoding genes (50ng; p53 full length wild-type, p53 
full length S20A, p53 ΔV wild-type, or p53 ΔV S20A) and Chk1, DAPK1 or empty vector control 
(2µg) expression vectors along with p21WAF1-luc (1 µg) and REN-CMV (0.25 µg) reporters. After 
24 hours the cells were lysed and luciferase and Renilla activity was measured using the dual 
luciferase system.  Data shows the luciferase activity normalised to the Renilla production 
represented as Relative Light Units (RLU).  Activity levels of the p21WAF1 reporter construct 
without p53 are represented in reporter only lane.    
 
 
Together these data demonstrate the greater contribution of kinase docking to p53 via 
the Box V region over kinase phosphorylation of p53 at Ser 20 and that although Ser 20 
phosphorylation correlates with enhanced transactivation in vivo, phosphorylation is not 
required for this. 
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3.3 Discussion 
The study of specific members of the Calcium Calmodulin superfamily using 
transfection-based technologies has allowed for the determination of a candidate kinase 
as the major mediator of Ser 20 site phosphorylation of p53.  This study has also allowed 
us to delineate the mechanism of Calcium Calmodulin kinase interactions with p53 
docking sites.  The major observations and implications of this work are discussed in the 
sections below. 
 
3.3.1 Chk1 is an endogenous modifier of p53 
The identification of enzymes that phosphorylate p53 transactivation domain has been 
an important development in the ongoing mapping of signaling pathways that control 
p53-dependent transcription and consequently tumour suppression.  Phosphorylation at 
residues Threonine 18 and Serine 20 is a crucial event in the activation of p53 that 
stabilises the binding of the co-activator p300 (Dornan and Hupp 2001), reduces the 
binding of the inhibitory partner Mdm2 (Unger et al. 1999) and enhances activation of 
p53 target genes (Jabbur et al. 2000).   
 
Examination of the members of the Calcium Calmodulin superfamily of enzymes as p53 
activators in vivo followed reports which had examined, using kinase assays, the effect 
of peptides derived from the Box II and Box V domains of p53 on p53 Ser 20 
phosphorylation in vitro.  These reports identified enzymes such as Chk1, Chk2 and 
DAPK1 which may target Ser 20 site phosphorylation of p53 in a docking-dependent 
manner in vitro (Craig et al. 2003; Craig et al. 2007) and established the existence of 
enzymes which modify Ser 20 in cycling cells (Craig et al. 2007).  The development of 
the in vivo assay described in this work in which to investigate the Ser 20 site 
phosphorylation of p53 was an important tool for the research described in this study 
and led to identification of putative physiological Ser 20 kinase(s).   The study identified 
Chk1 and DAPK1 as in vivo modifiers of Ser 20 site phosphorylation of p53, supporting 
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the previously reported in vitro data (Craig et al. 2007).  Although Chk1 was identified 
as the most potent Ser 20 kinase in H1299 cells and that Chk1 transfection mediated the 
best stimulation of p53-dependent transcription reporter activity the identification of 
DAPK1 as a stimulator of in vivo Ser 20 phosphorylation of p53 was an interesting 
development.  DAPK1 has been defined as a tumour suppressor and has been shown to 
be part of the cell death pathway that mediates oncogene signaling to p53 via p19ARF 
(Raveh et al. 2001).  Although biological studies have shown that DAPK1 is involved in 
inducing myosin light chain phosphorylation (Bialik et al. 2004), autophagic vesicle 
formation (Inbal et al. 2002; Gozuacik and Kimchi 2004) and antagonizing FAK to 
activate p53-dependent apoptotic pathway (Wang et al. 2002) the physiological cell 
cycle substrate that mediates DAPK1-dependent activation of p53 remains undefined.  
The in vivo data presented in this report was interesting in light of a recent report which 
illustrated that DAPK1 could be a component of the pathway that activates p53 in 
gamma irradiated cells.  The report demonstrated that radiation-induced p53 protein 
stabilization in vivo was attenuated in kinase domain mutants of DAPK1 (Kishino et al. 
2004).  This publication along side the data presented in this report may highlight a 
potential role for DAPK1 as a component of a genetic programme to activate p53 in 
irradiated cells.   
 
The use of siRNA technology demonstrated that of the three Calcium Calmodulin 
kinases being studies Chk1 was the most potent endogenous mediator of Ser 20 site 
phosphorylation in H1299 cells and DAPK1 was identified as the most effective 
endogenous p53 protein stabilizer in A375 cells.   Therefore, suggesting that there may 
be a cell-specific function for the Ser 20 site kinases.  Calcium Calmodulin kinases are 
known to play the most dominant role in activating p53-dependent apoptosis in response 
to DNA damage in B cells and considering that mutation of the Ser 20 equivalent 
phospho-acceptor site in mice accelerates B-cell lymphoma (MacPherson et al. 2004), B 
cells may provide an useful model to study modification of p53.  The examination of B 
cells and other model cell lines in which to evaluate of how distinct CAMK superfamily 
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members activate p53 in a cell-specific manner may provide an interesting framework in 
which to identify the stress activated regulators of p53.   
 
Although the enzymes which modify p53 by phosphorylation at sites such as Ser 20 are 
beginning to be defined, the data has been controversial.  It has been shown that Chk2 
phosphorylates p53 at only Thr 18 and Ser 20 (Craig et al. 2003) whilst other in vitro 
studies have implicated both Chk1 and Chk2 in activation of p53 and have shown that 
these kinases can phosphorylate p53 at multiple sites in the N- and C-terminal domains 
leading to either stabilization or activation of p53 (Hirao et al. 2000; Shieh et al. 2000; 
Ou et al. 2005).  Furthermore it has been shown that Chk2 deletion reduces the specific 
activity of p53 in cells (Takai et al. 2002).   In this report we have demonstrated that 
Chk2 and DAPK3 are distinct from Chk1 and DAPK1 in that they lacked the ability to 
induce p53 Ser 20 site phosphorylation.  Chk2 was the original biochemically and 
genetically defined Ser 20 kinase for p53 (Shieh et al. 2000; Takai et al. 2002).  
Although the role of Chk2 as a Ser 20 kinase has been questioned (Ahn et al. 2003; 
Jallepalli et al. 2003), it did seem unusual that in this assay it lacks Ser 20 kinase 
activity, considering the vast amounts of in vitro data proposing Chk2 as the Ser 20 
kinase (Hirao et al. 2000; Shieh et al. 2000; Ou et al. 2005).  This could be the result of 
several events; either Chk2 is not active in this assay or it is mainly targeting Thr 18 and 
therefore blocking the phospho-Ser20 epitope.   
  
To date there have been little data examining the phosphorylation of p53 using this type 
of in vivo assay.  This is likely due to the low affinity of phospho-specific antibodies 
making detection of phospho-epitopes difficult in vivo.  This study was able to 
demonstrate how the use of a p53 null line, in which p53 could be expressed ectopically 
and easily detected using Ser 20 phospho-specific antibodies (which have low affinity to 
the endogenous p53 Ser 20 epitope) could be a useful tool in the evaluation members of 
the Calcium Calmodulin superfamily of kinases as putative Ser 20 site kinases.   We 
were able to identify Chk1 and DAPK1 as putative activators of p53 and showed that 
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Chk1 was likely to be the main physiological Ser 20 kinase.  It is worth noting however 
that the p53-null cell line used in these assays expresses relatively high levels of 
endogenous Chk1 compared with the other kinases examined in this assay.  This results 
in little or no variation in the expression level of Chk1 between transfected and non-
transfected lanes.  It may have been useful in these assays to use a tagged expression 
vector to Chk1 to allow the detection of transfected Chk1.  These assays have made a 
significant contribution to our understanding the mechanisms underlying p53 activation 
as a tumour suppressor and will be a foundation in which to clarify the role of Calcium 
Calmodulin kinases in the stress-activated p53 signalling pathways.  Therefore we have 
partially resolved the controversy in the field and in that provided a framework in which 
to study the kinases as stress-induced p53 activators.    
 
3.3.2 The Calcium Calmodulin kinase interaction with p53 requires the Box-V 
domain of p53 
The Box-V domain is a binding site located in the core domain of p53 that controls 
covalent modification of the p53 tetramer.  The identification of the novel but naturally 
occurring p53 isoform, p53 ΔV, (Rohaly et al. 2005) was a useful tool with which to 
investigate the specific regions of p53 which kinases may bind to and/or phosphorylate.  
The identification of this isoform, which the lacked Box-V motif, was a particularly 
interesting development as previous attempts at investigating the role of the Box-V 
domain by generating point mutants or short deletions within this region of p53 had been 
unsuccessful due to problems with unfolded mutant core domains.  Using this isoform 
we have demonstrated that deletion of the Box-V domain of p53 resulted in two events; 
(i) loss of basal and kinase-stimulated Ser 20 site phosphorylation and (ii) attenuation of 
Mdm2-mediated ubiquitination of p53.  Comparison of the p53 ΔV isoform and p53 WT 
in in vivo transfection based assays demonstrated that this isoform had no basal Ser 20 
site phosphorylation and was not modified at Ser 20 after transfection of Chk1 or 
DAPK1.  Furthermore, it was also demonstrated that p53 ΔV did not compete with WT 
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p53 for phosphorylation at Ser 20.  The attenuation of Ser 20 site phosphorylation in the 
p53 ΔV isoform correlated with previous in vitro data which demonstrated that 
modification of p53 Ser 20 by kinases occurred by a docking dependent interaction with 
the Box-V motif (Craig et al. 2003).   
 
We were also able to demonstrate using in vivo assays that Mdm2-mediated 
ubiquitination was attenuated when using the p53 ΔV isoform as a substrate.  These 
combined data suggest that the Box-V region of p53 is a multi-protein docking site for 
Calcium Calmodulin superfamily members as well as Mdm2.  The idea that the Box-V 
region may act as a multi-protein docking site correlated with literature which identified 
a novel Mdm2 interaction site in the core domain of p53.  The report identified a site 
within the S9-S10 β-sheets which is flanked by the Box IV and V motifs.  Mutation of 
this site led to increased Mdm2-dependent ubiquitination of p53 in vitro and increased 
binding of mutant p53 to RNA-Mdm2 complexes suggesting that this site may play a 
regulatory role in modulating Mdm2-mediated ubiquitination of p53 (Shimizu et al. 
2002).  The subsequent publication demonstrated that unfolding of Box-V in mutant p53 
resulted in increased ubiquitination of p53 in vivo (Shimizu et al. 2006).  Furthermore, 
Wallace and colleagues have reported a dual site docking mechanism by Mdm2 on the 
p53 tetramer which is initiated by Mdm2 occupying an allosteric pocket in the N-
terminus of p53 to induce docking to the ubiquitination signal in the Box-V domain of 
p53  (Wallace et al. 2006).  These studies along side the data which is presented in this 
report emphasise the requirement of the Box-V domain for both basal and kinase 
mediated Ser 20 site phosphorylation in vivo as well as for Mdm2-mediated 
ubiquitination of p53. 
 
The role of the Box-V domain as a multi-protein docking site and as a site which is 
crucial for the phosphorylation of p53 was verified in assays which evaluated the effect 
of an EGFP-Box-V fusion peptide on p53 phosphorylation in cells.  It had already been 
established that the EGFP-Box-V fusion peptide, which contains the ubiquitination 
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signal for Mdm2, inhibited Mdm2-mediated ubiquitination of p53 in vitro and in cells 
(Wallace et al. 2006). The data presented here demonstrated that the EGFP-Box-V 
fusion peptide attenuated basal and Chk1 mediated Ser 20 site phosphorylation of p53 
WT.  Furthermore, the EGFP-Box-V peptide fusion could not activate p53 ΔV 
phosphorylation in vivo, under conditions where full-length p53 Ser 20 site 
phosphorylation was attenuated.  It is likely that the Box-V peptide cannot overcome the 
inability of p53 ΔV isoform to phosphorylate p53 at Ser 20 due to the size of the peptide 
versus the Box-V deletion region and it is unlikely that the peptide dynamics would be 
sufficient to restore the Box-V domain activity.   The attenuation of Chk1 as an inducer 
of Ser 20 phosphorylation following the transfection of the Box-V peptide would 
suggest that the peptides are preventing phosphorylation by competitive inhibition 
resulting in the blocking of the p53 binding site on Chkl and therefore the inability of 
Chk1 to dock to the Box-V motif on the full-length p53 protein. 
 
Although it was shown that the p53 ΔV variant was not modified at Ser 20 in vivo and 
that it cannot be targeted by Mdm2 due to the lack of the docking site, the p53 ΔV 
isoform was shown to have some transcriptional activity.  It was demonstrated that the 
p53 ΔV isoform drove basal p53-dependent activity from a p21WAF1 promoter template 
but the activity could not be stimulated further by Chk1 transfection unlike that of wild-
type p53.  The fact that this p53 ΔV isoforms remains transcriptionally active is 
interesting and demonstrates that the Box-V deletion does not simply unfold and 
completely inactivate p53.  The isoform may be targeted at other phosphorylation sites 
which do not rely upon the Box-V region and resulting in its transcriptional activation.  
It has already been reported that the p53 ΔV isoform can induce a subset of p53 targets 
(p21 and 14-3-3 σ) and that p53 ΔV associates with the p21 promoter in irradiated S-
phase cells whereas full-length p53 can only do so in other cell cycle phases (Rohaly et 
al. 2005).  It may that the isoform has evolved the capacity to evade these cell cycle 
regulators during S-phase.  It has also been described that mutant p53 can act in a gain-
of-function manner in the apparent absence of wild-type p53 (Cadwell and Zambetti 
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2001).  There may be a role for mutant p53 forms to exert their gain of function 
properties on the p53 ΔV isoform and thus accounting for the transcriptional activity of 
this isoform.  Moreover, considering the recent literature describing a role for p63 and 
p73 in selectively regulating p53 transcriptional activity (Flores et al. 2002), it may be 
interesting to examine interactions between this isoform, p53 ΔV with full length p53 
and other p53 family members such as p63 and p73.    
 
The verification that Chk1 docking to the Box-V domain is required for in vivo Ser 20 
site phosphorylation of p53 to take place was an important development.  Although a 
role for phosphorylation in p53 regulation has previously been suggested (Unger et al. 
1999; MacPherson et al. 2004), we proposed that kinase docking to p53 played a more 
dominant role than phosphorylation of p53 in the CAMK-mediated p53 regulation.  
Having compared the effects of Ser20A mutation with Box-V deletion on basal and 
kinase stimulated p53-dependent transcriptional activity, I found that; (i) p53 the Ala 20 
mutation did not affect basal p53-dependent transcription reporter activity, (ii) Chk1-
stimulated transcriptional activity of the Ser20A mutant is similar to WT and (iii) the 
addition of DAPK1 significantly stimulates the Ser20A mutant but not WT p53-
dependent transcriptional activity.  These results confirm previously published data in 
which a mutation of Ser 20 to Asp 20 marginally elevated basal p53-dependent 
transcription and cotransfection of DAPK1 further stimulated the Asp 20 p53 mutant as 
well as on Ala 20 p53 mutant (Craig et al. 2007) and suggests that kinases may be 
required to stimulate p53 function although loss of this phosphorylation site by mutation 
does not affect p53-dependent transactivation.  The fact that Chk1 can stimulate 
transcriptional activity of the Ala 20 mutant to a similar level to that of wild-type (there 
is no dramatic reduction in Chk1 stimulated Ala 20 mutant transactivation activity 
compared to WT) does suggest that docking may be more important than 
phosphorylation at Ser 20 and may suggest that Chk1 could phosphorylate other sites on 
p53 leading to its activation.  However, it was the deletion of the Box-V region in the 
Ala 20 mutant in this study that provided the most striking results supporting the 
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proposed idea.  The loss of the Box-V domain resulted in complete loss of stimulation of 
p53 transactivation both under basal and kinase-stimulated conditions.  Together these 
data strongly suggest that CAMK activation of p53 is docking-dependent and indicate 
that kinase docking may be more important than phosphorylation in CAMK-dependent 
regulation of p53.  
 
Figure 3.12 The multi-protein binding sites in the Box-I and Box-V domains of p53.   
Mdm2 was the first protein to be shown to have contact sites in the Box-V domain and it is now 
known that the ubiquitination signal within the Box-V motif drives the dual-site binding of Mdm2 
to both the Box-I and the Box-V domains to mediate C-terminal ubiquitination of p53. In this 
report we have shown that Calcium Calmodulin kinases (Cal-CAMK) have evolved a docking-
dependent interaction with the Box-V domain which mediates phosphorylation of Ser 20 in the 
Box-I motif at the N-terminal of p53.   
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In conclusion these assays have allowed us to clarify the role of Calcium Calmodulin 
kinases in activation of p53 and have provided a framework in which to study the 
kinases as stress-induced p53 activators.   We have also demonstrated (as summarized in 
Figure 3.12) that the Box-V region of p53 can function as a docking site for Calcium 
Calmodulin superfamily members as well as an Mdm2 ubiquitination signal and that 
protein interactions with this site controls p53 activation.  These assays have made a 
significant contribution to elucidate the mechanisms underlying p53 tumour suppressor 
function.  
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4 THE CONSERVED P53 BOX V DOMAIN IS A 
CALCIUM CALMODULIN KINASE BINDING SITE 
4.1 Introduction 
4.1.1 Defining key domains required for p53 interactions  
 
Figure 4.1 The Box peptides are adjacent in the tertiary structure of p53.   
The minimal adjacent locations of the Box-II, Box-IV and Box-V peptides (in the S2 and H2 
motifs) within the core domain are highlighted (Craig et al. 2003). 
 
The identification of a Chk2 docking site in the Box-V motif of p53 (Craig et al. 2003) 
and as established in this report, the Box-V region of p53 is a multi-protein docking site 
required to activate p53 phosphorylation and ubiquitination (see section 3.2.5) has 
provided a basis for the continued research into kinase and p53 interactions.  Figure 4.1 
highlights the locations of the Box-II, Box-IV and Box-V peptides which are non-
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contiguous in linear sequence but are adjacent in the tertiary structure  (Craig et al. 
2003).   
 
Protein kinases such as Ser/Thr kinases and Tyr kinases play a major role in signal 
transduction pathways leading to the modification of protein function by 
phosphorylation.   Protein kinases are structurally similar but differ in terms of charge 
and hydrophobicity of surface residues (Ubersax and Ferrell 2007).  Structural 
characteristics of the kinase active site such as the catalytic cleft and consensus 
sequences determine the first level of substrate specificity.  Consensus sequences are 
defined as amino acids situated either side of the phosphorylation site which play a 
significant role in kinase-substrate recognition (Kennelly and Krebs 1991).  In most 
cases the active site of a kinase interacts with four amino acids either side of the 
phosphorylation site (Ubersax and Ferrell 2007).   Consensus site have been determined 
for several kinases such as protein-kinase A (PKA), cyclin-dependent kinase (CDK) and 
casein-kinase 1 (CK1).    
 
In addition to this, distal docking sites increase the affinity of a kinase for a substrate and 
are separate from the kinase active site, usually 50 -100 residues away from the 
phosphorylation site (Ubersax and Ferrell 2007).  The importance of protein-kinase 
docking sites in the specificity of kinase interaction was highlighted in a report by 
Biondi and Nebreda (2003).  Their studies on three families of Ser/Thr kinases 
demonstrated that some kinases rely upon direct docking interactions with substrates to 
sites distinct from the phospho-acceptor sequences (Biondi and Nebreda 2003).   
 
The work described here sets out to determine the interaction of kinases to the Box-V 
domain.  Binding assays were performed to investigate the in vivo interaction of kinases 
and Mdm2 with the Box-V domain of p53 which drive the modification of p53.   
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4.1.2 Examining the role of ‘Gain of function’ mutation on kinase modulation of 
p53 activity  
 
 
Figure 4.2  Relative mutation frequency in human cancer.  
A representation of the domain structure of p53 with columns indicating the relative frequency of 
cancer-associated mutations for each residue according to the TP53 mutation database of the 
International Agency for Research on Cancer (Joerger and Fersht 2007). 
 
P53 is a key tumour suppressor gene which characteristically protects the cell from 
potentially damaging cellular stress by promoting growth arrest, apoptosis and cellular 
senescence.  The p53 tumour suppressor gene operates as one of the major barriers 
against cancer development.  The p53 pathway is frequently impaired in human cancer 
and in almost 50% of all human cancers the p53 gene is mutated.  Of these mutants 74% 
are missense point mutations that target the DNA binding core domain which result in 
expression of the mutant p53 protein which is DNA contact defective and 
conformationally impaired (Prives and Hall 1999). This therefore prevents p53-
dependent transcription and tumour suppression.  P53 mutations can arise sporadically 
or are inherited as a germline mutation in Li-Fraumeni syndrome.  In many cases 
tumour-derived p53 mutants accumulate at a much higher level in cancer cells than wild-
type p53 due to their failure to be targeted by Mdm2 for degradation (Haupt et al. 1997; 
Midgley and Lane 1997).  As demonstrated by the diagram (Figure 4.2) which shows the 
relative mutation frequency in human cancer, areas where mutations occur at a markedly 
higher frequency than the others are known as mutation “hot-spots”.  For example, 
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mutation at codons 175, 248, 249 and 273 account for 25% of missense mutations 
identified in human cancers (Hainaut and Hollstein 2000).   The mechanism by which 
p53 promotes pro-oncogenic activities has been examined in numerous reports, some 
suggesting that tumour derived p53 mutants have acquired novel functions which 
promote cancer cell growth.   
 
The clarification of the role of p53 in carcinogenesis has been and continues to be a 
complex process.  Following the initial discovery of p53 in 1979 as an SV40-binding 
protein  (Lane and Crawford 1979; Linzer and Levine 1979) there has been significant 
development in the clarification of the role of p53 in carcinogenesis.  It was 
subsequently classified as a proto-oncogene due to the apparent upregulation of p53 
expression in proliferating cells (Milner and Milner 1981; Milner 1984; Reich and 
Levine 1984).  The molecular cloning of the TP53 gene (Zakut-Houri et al. 1983; Zakut-
Houri et al. 1985) and discovery of the sequence of the mouse wild-type TP53 gene led 
to the revelation that previous experiments had employed mutant p53 variants (Eliyahu 
et al. 1988; Finlay et al. 1988) and that wild-type p53 actually suppressed oncogene-
mediated transformation (Eliyahu et al. 1989; Finlay et al. 1989).  This established p53 
as a bona fide tumour suppressor.  These developments have provided a basis for 
elucidation of the various roles of p53 in carcinogenesis and have established distinct 
roles in which one of three events can occur; firstly, p53 loss of function, where the p53 
gene mutates or there is complete loss of the gene; secondly, mutant p53 dominant-
negative function, where there is promotion of tumourigenesis due to the mutant p53 
inactivating WT p53 in cells by heteraoligomerisation; and finally, mutant p53 gain of 
function, where expression of mutant p53 in cells lacking WT p53 enhances their 
tumourigenic potential.     
 
There is has been a steady increase in number of reports examining the idea of mutant 
gain of function and its implications as a determinant in human tumour development.  In 
this report we will examine the molecular mechanisms of the oncogenic gain of function 
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nature of mutant p53 as well as the effect of this type of mutation of p53 on the 
interaction potential with kinases.  A major molecular role of gain of function mutants is 
modulating the transcriptome of p53.  Mutant p53 interactions with chromatin and DNA 
is central to transcriptome activities and in a review by Kim and Deppert (2004) it was 
suggested that the interaction of mutant p53 with DNA is determined by DNA structure 
and not specific motifs as required by WT p53.  They described how mutant p53 binds 
to high affinity MAR elements (regulatory DNA sequences important for higher order 
chromatin reorganization and propagation of chromatin modification) and that binding 
to MAR was independent of consensus motif but increasing dependent on length of 
DNA (Kim and Deppert 2004).  The complex interactions of mutant p53 with DNA and 
the mechanisms of transcriptional regulation are described by Menendez and colleagues.  
They describe how transcriptional regulation by mutant p53 is a consequence of the 
sequence-specific DNA-binding activity of WT p53 and how changes in target response 
elements which provide for p53 regulation of target genes can affect the expression of 
genes and thus the biological outcomes.  They emphasise the importance of clarifying 
the relationship between WT or mutant p53 and target response elements to develop our 
understanding of the p53 master regulatory network (Menendez et al. 2007).   
 
Models for the gain of function activity mutant p53 have been suggested.  Firstly, 
mutant p53 has been shown to interact with other p53 family members, p63 and p73 
resulting in the inhibition of the proapoptotic function of these related family members.  
Li and Prives described how some mutants interact with and downregulate the 
transcriptionally active forms of p63 and p73 which resulted in reduced apoptotic 
response and radioresistance in tumour cells (Li and Prives 2007).  Two separate reports 
demonstrated that inhibition of p73 by mutant p53 abrogated apoptosis and cytotoxicity 
induced by anti-cancer drugs (Bergamaschi et al. 2003; Irwin et al. 2003) and that 
downregulation of mutant p53 enhanced chemosensitivity (Irwin et al. 2003). New in 
vivo models using knock-in mice with p53 ‘hot-spot’ mutation at codons 172 and 270 
(murine equivalent of human R175H and R273H hot-spot mutations) were made to 
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resemble mutation of p53 in Li-Fraumeni syndrome (Lang et al. 2004; Olive et al. 2004).  
They found that mutant p53 associated with p63 and p73 in tumour cells of mice (Lang 
et al. 2004; Olive et al. 2004) and that silencing mutant p53 resulted in increased the 
activity of p53 family target genes such as p21 which was likely to be a result of the 
increased activity of endogenous p63 and p73 in the absence of mutant p53 (Lang et al. 
2004).  Thus mutant p53 may promote tumourigenesis through downregulation of its 
family members.       
 
Moreover, it has been described how mutant p53 targets DNA indirectly by the 
interaction with other transcription factors such as NF-Y (Di Agostino et al. 2006).  
Under damaging conditions mutant p53 interacts with NF-Y via DNA-binding 
consensus sequences known as CCAAT sites (these sites are present in the regulatory 
regions of many key genes involved in the regulation of cell cycle).  This results in the 
abnormal upregulation of expression of NF-Y cell cycle target genes and recruitment of 
p300 leading to histone acetylation (Di Agostino et al. 2006). 
 
In addition a more direct pro-oncogenic gain of function role of mutant p53 in which 
mutant p53 regulates the expression of a specific set of genes has been suggested.  
Mutation of p53 can result in a null phenotype for the regulation of p53 target genes.  
However, in many cases mutation of p53 results in the gain of function phenotype as a 
result of the transactivation of genes which are not normally regulated by p53.  For 
example, the multi-drug resistance (MDR-1) gene, was one of the first genes to be 
identified as upregulated by mutant p53 (Chin et al. 1992; Dittmer et al. 1993). Other 
studies have demonstrated that p53 mutants are involved in the upregulation of 
expression of numerous genes involved in cellular processes implicated in cancer 
progression.  For example, p53 mutants such as 143A, 175H, 248W, 273H and 281G 
were shown to elevate the expression of EGFR (Ludes-Meyers et al. 1996) and NFKB2 
was upregulated by 281G (Deb et al. 2002).  Furthermore the 175H mutant can 
negatively regulate genes and has been shown to repress the transcription of genes such 
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as the CD95/Fas/Apo1 gene, which encodes a death receptor implicated in a variety of 
apoptotic response (Zalcenstein et al. 2003; Weisz et al. 2007).   
 
Variation in the transactivation of p53 target genes is a characteristic of most p53 
mutants which retain this gain of function activity (Rowan et al. 1996; Ryan and 
Vousden 1998).  Recently groups have examined the consequences of missense 
mutations on the potential for p53 to transactivate genes through sequence-related 
response elements using model systems based on yeast Saccharomyces cerevisiae (Inga 
et al. 2001; Resnick and Inga 2003) and more recently in human cells (Menendez et al. 
2006).  A paper by the Ishioka group (Kakudo et al. 2005) constructed a yeast-based 
functional assay to demonstrate the variable ability of p53 gain of function mutants to 
transactivate specific target genes and induce apoptosis.  They evaluated a group of 
more than 2000 p53 mutants representing all possible amino acid substitutions caused by 
a point mutation throughout the protein (5.9 substitutions per residue).  Of these mutants 
635 were shown to have increased or decreased activity for target genes compared with 
wild-type p53 and these were defined as “diverse” mutant p53s because of their diverse 
transcriptional activity for distinct p53 target genes.  They hypothesised that if cellular 
responses such as cell cycle arrest and apoptosis are dependent on the group of p53 
target genes transactivated, the ability of p53 to induce apoptosis should differ among 
the mutant p53s and therefore should correlate with the transactivation profile of the 
specific p53 target genes (Kakudo et al. 2005).  To examine the hypothesis they 
randomly selected 30% of these mutants and evaluated their transcriptional activities and 
their ability to induce apoptosis.  The study identified gain of function mutants which 
displayed apoptotic activity above WT as well as mutants with increased transcriptional 
activity from one or more p53 promoters.  There was no significant correlation between 
ability to induce apoptosis and the transcriptional activity on any target gene examined 
indicating that it is either a pool of transactivated p53 target genes that determines the 
cellular response or a target gene not examined in the study (Kakudo et al. 2005).  
 
Chapter 4 Results 
 - 124 - 
4.1.3 Objectives of chapter  
The objective of this chapter was to extend our knowledge of WT and mutant p53 
interactions with kinases and Mdm2.  Coimmunoprecipitation assays were used to 
examine kinase binding to the Box-V region of p53, and to further identify sites of 
interaction, mutagenesis of the Box-V region was performed.  Mutation of p53 occurs in 
approximately half of all human tumours.  In order to develop our understanding of the 
molecular mechanisms of the oncogenic gain of function phenotype and the molecular 
interactions of mutant p53 we examined the basal and kinase-stimulated transcriptional 
activities of specific p53 mutants.  With reference to recent reports (Kakudo et al. 2005) 
several mutants were selected based on their increased transcriptional activity from p53 
promoters and their reported frequency in human cancers.  These tumour-derived p53 
mutants are thought to display gain of function properties toward target genes.  
Mutagenesis of p53 allowed the creation of a set of mutants which could be used to 
investigate the effect of kinases and Mdm2 on modulation of mutant p53 activity.  Using 
transcriptional based assays allowed us to evaluate whether the activity of these mutants 
can be modulated by kinases and/or Mdm2 and further identify sites of interaction 
between p53 and its regulatory proteins.  Developing an understanding of the gain of 
function properties of mutant p53 and its interaction with kinases and Mdm2 is 
important for the development of strategies to evade this gain of function of mutant p53 
and to optimise approaches aimed at p53 reactivation. 
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4.2 Results 
4.2.1 Examination of kinase and Mdm2 binding to p53 core domain 
The ability of the EGFP Box-V fusion peptide to attenuate basal and Chk1-stimulated 
phosphorylation of p53 at Ser 20 (see section 3.2.7) suggests that the peptide may bind 
to Chk1 and therefore competitively inhibiting the action of Chk1 in phosphorylating 
p53 at Ser 20.  Furthermore the examination of Chk1 stimulated p53-dependent 
transcriptional activity (see section 3.2.9) demonstrated a greater contribution of kinase 
docking to p53 over kinase phosphorylation of p53 at Ser 20.  We therefore set out to 
examine whether kinases and/or Mdm2 bind to the Box-V region of p53 and, if yes, to 
determine specific regions important for binding and to characterize the regions of 
interaction.   
 
4.2.1.1 The Calcium Calmodulin Kinases bind stably to the EGFP-Box-V fusion 
peptide in cells   
An in-vivo coimmunoprecipitation assay was performed to investigate whether Chk1 
and EGFP-Box-V peptide form an interaction in vivo.  FLAG-Chk1 and EGFP variants 
(EGFP control, EGFP-Box I or EGFP-Box V) were expressed and samples after the 
FLAG pull-down were immunoblotted with an anti-EGFP IgG for the respective binding 
fractions including control (a), empty vector (b), EGFP (c), EGFP-Box-I (d) and EGFP-
Box-V (e).  When EGFP-Box-V peptide was coexpressed with FLAG-Chk1, Chk1 
formed a complex with the EGFP-Box-V peptide, as demonstrated by the presence of a 
positive band in the bound fraction (Figure 4.3; A; Blot e; lane 4).  However, when 
EGFP-Box-I or EGFP control peptide was coexpressed with FLAG-Chk1, there was no 
formation of a bound complex (Figure 4.3; A; Blots c and d; lane 4).  The ability of the 
EGFP-Box-V fusion peptide to form a stable immune complex with Chk1 in cell lysates 
suggests that the attenuation of p53 phosphorylation by the EGFP-Box-V fusion peptide 
might be attributable to its ability to bind to and inhibit Chk1. 
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Figure 4.3 Chk1 binds stably to the EGFP-Box-V fusion peptide in cells.  
A. H1299 cells were cotransfected with vectors encoding FLAG-Chk1 (1µg) and EGFP variants 
(0.5µg; EGFP control, EGFP-Box I and EGFP-Box V).  24 hours following transfection cells were 
lysed (lane 1) and lysates were precleared (lane 2) and FLAG-Chk1 was immunoprecipitated 
with anti-FLAG agarose beads.  EGFP variants were quantified both in the unbound fraction 
(lane 3) and the bound fraction (lane 4).  Samples after the FLAG pull-down were immunoblotted 
with an anti-EGFP IgG for the respective binding fractions including control (a), empty vector (b), 
EGFP (c), EGFP-Box-I (d) and EGFP-Box-V (e).  B. H1299 cells were cotransfected with FLAG-
Chk1 (1µg) and a titration of EGFP-Box-V (0.1 to 1µg).  As a control, 1µg FLAG-Chk1 was 
transfected into cells. 24 hours following transfection cell were lysed, cell lysates were 
precleared and FLAG-Chk1 was subjected to immunoprecipitation with anti-FLAG agarose 
beads.  Quantification of the EGFP-Box-V in the unbound (U; lanes 3, 5, 7, 9 and 11) or bound 
(B; lanes 4, 6, 8, 10 and 12) fractions after FLAG pull-down was performed by immunoblot using 
an anti-EGFP IgG.  Protein levels of Chk1 were quantified by immunoblot under non-reducing 
conditions. C. Expression of transfected Chk1.  FLAG-Chk1 was transfected into cells (0, 0.1, 
0.2, 0.5, 1.0 and 2.0µg).  Cells were lysed and lysates were immunoblotted for Chk1 (lower band 
is endogenous Chk1 and upper band is FLAG-tagged Chk1) and FLAG-tagged Chk1.  
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To further investigate and confirm the interaction between Chk1 and Box-V peptide, a 
coimmunoprecipitation assay was performed.  The vector encoding FLAG-Chk1 was 
coexpressed with a titration of EGFP-Box-V into H1299 cells.  Cell lysates were 
subjected to immunoprecipitation with anti-FLAG agarose beads followed by 
quantification of the EGFP-Box-V in the unbound (Figure 4.3 B; unbound; lanes 3, 5, 7, 
9 and 11) or bound (Figure 4.3 B; bound; lanes 4, 6, 8, 10 and 12) fractions.  Samples 
after FLAG pull-down were immunoblotted with an anti-EGFP IgG.  Protein levels of 
Chk1 were quantified by immunoblot under non-reducing conditions to allow for 
separation of Chk1 from heavy and light chain products.  The immunoblot clearly 
demonstrates a dose-dependent increase of EGFP-positive bands in the bound fraction 
(Figure 4.3 B; comparing bound fraction ‘B’; lanes 4, 6, 8, 10 and 12; EGFP blot).  
Therefore, indicating that the Box-V fusion peptide is binding to FLAG-Chk1.  
However, it is evident that the majority of EGFP-Box-V peptide remains in the unbound 
fraction (Figure 4.3 B; comparing unbound fraction ‘U’; lanes 3, 5, 7, 9 and 11; EGFP 
blot) and that the majority of Chk1 protein is present in the bound fraction (Figure 4.3 B; 
comparing bound fraction ‘B’; lanes 4, 6, 8, 10 and 12; Chk1 blot).  This could be a 
result of the finite binding capacity of the beads.  It is likely that the majority of FLAG-
Chk1 is binding to the anti-FLAG beads resulting in a reduced capacity for the FLAG-
Chk1: EGFP-Box-V complexes to bind to the anti-FLAG beads.   
 
To demonstrate the expression levels of untagged Chk1 and FLAG-tagged Chk1, H1299 
cells were transfected with a titration (0, 0.1, 0.2, 0.5, 1.0 and 2.0µg) of FLAG-Chk1.  
Cells were lysed and lysates were immunoblotted for Chk1 and FLAG-tagged Chk1 (C; 
lanes 1 to 6).  The lower band of the Chk1 blot represents endogenous Chk1 and upper 
band is FLAG-tagged Chk1. The level of endogenous Chk1 is demonstrated (Figure 4.3 
C; lane 1) and following the addition of FLAG-Chk1 there is a dose-dependent increase 
in protein levels of transfected Chk1 (Figure 4.3 C; lanes 2 to 5; Chk1 and FLAG 
immunoblot).  Therefore these results demonstrate that addition of tagged Chk1 resulted 
in the increasing levels of Chk1 protein in the cell. 
Chapter 4 Results 
 - 128 - 
In order to further investigate the role of other kinases such as DAPK1 in binding to the 
Box-V domain coimmunoprecipitation assays were performed.  Vectors encoding HA-
DAPK1 (the HA-DAPK vector also contains the FLAG epitope) and EGFP variants 
(EGFP control, EGFP-Box I or EGFP-Box V) were coexpressed in H1299 cells.  Cells 
lysates were subjected to immunoprecipitation with anti-FLAG agarose beads.    
Quantification of the EGFP variant in the unbound (Figure 4.4 A; unbound (U); lanes 3, 
5, 7 and 9) or bound (Figure 4.4 A; bound (B); lanes 4, 6, 8 and 10) fractions after 
FLAG pull-down was performed by immunoblot using an anti-EGFP IgG.  The data 
demonstrated that when EGFP-Box-V was cotransfected with HA-DAPK1, DAPK1 
formed a complex with the EGFP-Box-V peptide, as demonstrated by the presence of a 
positive band in the bound fraction (Figure 4.4 A; lane 10; EGFP blot).  The ability of 
the EGFP-Box-V fusion peptide to form a stable immune complex with DAPK1 as well 
as Chk1 in cell lysates is a further example of a kinase interacting with the Box-V fusion 
peptide and therefore supports the data that the attenuation of p53 phosphorylation 
following the addition of the EGFP-Box-V fusion peptide (see section 3.2.7) might be 
attributable to its ability to bind to and inhibit kinases.   
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Figure 4.4 DAPK1 binds stably to EGFP-Box-V fusion peptide in cells.   
A. H1299 cells were cotransfected with vectors encoding HA-DAPK1 (1µg) and EGFP variants 
(0.5µg; EGFP control, EGFP-Box I and EGFP-Box V).  Cells were lysed, lysates were 
precleared and HA-DAPK1 was immunoprecipitated with anti-FLAG agarose beads. 
Quantification of the EGFP variant in the unbound (U; lanes 3, 5, 7 and 9) or bound (B; lanes 4, 
6, 8 and 10) fractions after FLAG pull-down was performed by immunoblot using an anti-EGFP 
IgG. B. H1299 cells were cotransfected with the vector encoding HA-DAPK1 (1µg) and a titration 
of EGFP-Box-V (0 to 1µg).  24 hours following transfection cell were lysed, cell lysates were 
precleared and HA-DAPK1 was subjected to immunoprecipitation with anti-FLAG agarose beads 
followed by quantification of the EGFP-Box-V in the unbound (U; lanes 3, 5, 7, 9 and 11) or 
bound (B; lanes 4, 6, 8, 10 and 12) fractions by immunoblot using an anti-EGFP IgG. DAPK1 
levels were quantified by immunoblot.  
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To further support this data and confirm the interaction between DAPK1 and Box-V 
peptide, the vector encoding HA-DAPK1 was coexpressed with a titration of EGFP-
Box-V in H1299 cells.  Cell lysates were subjected to immunoprecipitation with anti-
FLAG agarose beads followed by quantification of the EGFP-Box-V in the unbound 
(Figure 4.4 B; unbound (U); lanes 3, 5, 7, 9 and 11) or bound (Figure 4.4 B; bound (B); 
lanes 4, 6, 8, 10 and 12) fractions.  The data generally demonstrates a dose dependent 
increase of EGFP-positive bands in the bound fraction (Figure 4.4; B; comparing bound 
fraction ‘B’; lanes 4, 6, 8, 10 and 12; EGFP blot).  The reduction in EGFP-Box-V levels 
in lane 10 is likely to be a loading error.  As demonstrated previously in FLAG-Chk1 
coimmunoprecipitation assays the majority of EGFP-Box-V peptide remains in the 
unbound fraction (Figure 4.4; B; comparing unbound fraction ‘U’; lanes 3, 5, 7, 9 and 
11) and that the majority of DAPK1 protein is present in the bound fraction (Figure 4.4 
B; comparing bound fraction ‘B’; lanes 4, 6, 8, 10 and 12).  Again this is likely be a 
result of the finite binding capacity of the beads in that the majority of HA-DAPK1 is 
binding to the beads meaning that there is a reduced capacity to allow HA-DAPK1: 
EGFP-Box-V complexes to bind to the anti-FLAG beads.  Alternatively it could be that 
there is only a small proportion of EGFP expressed which binds to DAPK1 or Chk1 due 
to a number of factors including localization, conformation or post translational 
modification of DAPK1 or Chk1.  However, this small proportion of binding is very 
significant as it confirms in vivo binding of Chk1/DAPK1 to the Box-V fusion peptide 
does occur. 
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Figure 4.5 The binding of Mdm2 stabilizes the Box-V fusion peptide.   
A. The vector encoding Mdm2 (1µg) was cotransfected with EGFP variants (0.5µg; EGFP 
control, EGFP-Box I and EGFP-Box V) into H1299 cells.  24 hours following transfection cell 
were lysed (lane 1), cell lysates were precleared (lane 2) and Mdm2 was subjected to 
immunoprecipitation using NHS-activated sepharose beads to which the anti-Mdm2 antibody, 
2A10, had been previously coupled.  EGFP variants were quantified both in the unbound fraction 
(lane 3) and the bound fraction (lane 4) by immunoblot with an anti-EGFP IgG. Mdm2 levels 
were shown by immunoblot.  B. H1299 cells were cotransfected with a titration of the vector 
encoding Mdm2 (0, 1 or 2µg) and EGFP variant (0.5µg; EGFP control, EGFP-Box I or EGFP-
Box V). 24 hours following transfection cells were lysed, cell lysates were precleared and Mdm2 
was subjected to immunoprecipitation using 2A10 coupled NHS-activated sepharose beads. 
EGFP variants were quantified both in the unbound fraction (odd numbered lanes 1to17) and the 
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bound fraction (even numbered lanes 2 to 18) by immunoblot with an anti-EGFP IgG.  Mdm2 
levels were shown by immunoblot.  
 
4.2.1.2 Binding of Mdm2 stabilizes the EGFP Box-V fusion peptide 
Mdm2 negatively regulates p53 by ubiquitination and it is the Box-V docking region of 
p53 which contains the ubiquitination signal that is required for the dual site stimulation 
of the E3 ubiquitin ligase function of Mdm2 (Wallace et al. 2006).  Therefore in light of 
the data which demonstrates the binding of kinases Chk1 and DAPK1 to the EGFP-Box-
V fusion peptide in cells, Mdm2 was examined to determine whether it too formed a 
complex with the EGFP-Box-V fusion peptide in cells.   
 
The vector encoding Mdm2 was coexpressed with EGFP variants (EGFP control, EGFP-
Box I or EGFP-Box V) in H1299 cells.  Mdm2 was subjected to immunoprecipitation 
using NHS-activated sepharose beads coupled with the anti-Mdm2 antibody, 2A10.  
EGFP variants were quantified both in the unbound fraction (lane 3) and the bound 
fraction (lane 4) by immunoblot with an anti-EGFP IgG.  The results demonstrate that 
when EGFP-Box-V was cotransfected with Mdm2, similar to Chk1 and DAPK1, Mdm2 
formed a complex with the EGFP-Box-V peptide, as demonstrated by the presence of a 
positive band in the bound fraction (Figure 4.5; A; ‘Mdm2 + GFP Box-V’ lane 4; EGFP 
blot).  
 
To further investigate the interaction between Mdm2 and the Box-V peptide a 
coimmunoprecipitation assay was performed to examine the levels of stabilization of the 
Box-V peptide.  A titration of the vector encoding Mdm2 was cotransfected with EGFP 
variant (EGFP control, EGFP-Box I or EGFP-Box V) into H1299 cells.  EGFP variants 
were quantified both in the unbound fraction (Figure 4.5 B; lanes 1, 3, 5, 7, 9, 11, 13, 15 
and 17) and the bound fraction (Figure 4.5 B; lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18) by 
immunoblot with an anti-EGFP IgG.  The results confirm that Mdm2 and the EGFP-
Box-V peptide form a complex in vivo (Figure 4.5 B; comparing lanes 14, 16 and 18 
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with 2, 4, 6, 8, 10 and 12; EGFP blot) and demonstrate that the Box-V peptide is 
stabilized by transfection of increasing levels of Mdm2 (Figure 4.5 B; comparing lanes 
14, 16 and 18; EGFP blot).  It is likely that the binding of Mdm2 to the Box-V peptide is 
blocking the EGFP-Box-V degradation and leading in its stabilization.  
 
 
4.2.2 Creation of p53 ‘Gain of function’ mutants to examine kinase - p53 interaction 
To develop our understanding of the sites important for p53-kinase interactions, several 
mutants were selected (as shown in Table 4.1) which have been reported in human 
cancers and have increased transcriptional activity from p53 promoters.  These mutants 
had previously been demonstrated to have gain of function properties which included 
increased apoptotic activity above wild type p53 as well as increased transcriptional 
activity from one or more p53 promoters (Kakudo et al. 2005).  The mutants were used 
in reporter assays to determine whether the activity of these mutants could be modulated 
by kinases and Mdm2 and to further define the key domains on p53 required for p53-
kinase interaction.  
 
As demonstrated by Figure 4.6 p53 ‘Gain of function’ mutations (D208N, D207H, 
D207E, R209I and H214Q) were located in the 240 epitope, an exposed loop in p53 
which is unfolded in mutant p53.  Mutations located in the box V domain (A276V) were 
also been chosen to further examine the importance of the Box V domain in Chk1 
docking. Other mutations were located in the extreme C-terminus of the DNA-binding 
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Table 4.1 A summary of the selected p53 mutants: transcriptional and apoptotic activity  






compared to WT 
1 D208N + 5 Equal or Decreased 
2 D207H + 1 Equal or Decreased 
3 D207E + 3 Equal or Decreased 
4 R209I + 1 Equal or Decreased 
5 H214Q + 4 Increased  
6 N288Y +/- 4 Equal or Decreased 
7 K291E +/- 1 Increased 
8 A276V +/- 6 Equal or Decreased 
9 N288T + 2 Equal or Decreased 
10 K292I + 2 Increased 
11 K292N + 2 Equal or Decreased 
 
Table 4.1 Data summarised from publication (Kakudo et al. 2005) represents mutant p53 with 
increased (+) or mutant p53 with both decreased and increased (+/-) transcriptional activities for 
one or more of the eight p53 binding sequences. The TP53 mutation database (http://p53. 
curie.fr/) was used for mutation frequency and numbers represent the recorded frequency in 
human cancers.  Evaluation of the ability to induce apoptosis was calculated in the subG1 
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Figure 4.6 A diagram of p53 showing the location of the mutations (Craig et al. 2003).   
The red dash boxes show the location of the chosen mutants which are in the:  240 epitope, an 
exposed loop in p53 which is unfolded in mutant p53; the extreme C-terminus of the DNA-
binding domain; and the Box-V domain (chosen to further examine the importance of the Box-V 
domain in Chk1 docking). The Box-V peptide sequence (as well as the Box-II) are shown in red.  
  
4.2.2.1 The p53 His175 mutant is transcriptionally activated by Chk1 
It has been demonstrated that in many tumour-derived mutants a point mutation within 
the core domain of p53 can inactivate p53 function (Gannon et al. 1990; Kern et al. 
1992).  Mutation at codon 175 in p53, one of the hot-spots for mutation in human 
cancer, can lead to inactivation of p53 as this residue plays an important role in 
maintaining the structure of the DNA binding domain (Cho et al. 1994).  Before 
examining the selected p53 ‘gain of function’ mutants, the common tumour-derived 
mutant, p53 His175, was examined for its basal and kinase stimulated p53-dependent 
transcriptional activity (Figure 4.7).    
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Figure 4.7 The p53His 175 isoform is transcriptionally activated by Chk1.  
H1299 cells were cotransfected with Chk1-encoding gene (2 µg), p53 WT or p53 His 175 (50ng) 
and reporter plasmid constructs; p21WAF1-luc and β-gal.  After 24 hours the cells were lysed and 
luciferase and β-Galactosidase activity was measured.  Data shows the luciferase activity 
normalised to the β-Gal production represented as Relative Light Units (RLU).  Activity levels of 
the p21WAF1 reporter construct without p53 are represented in reporter only lane. 
 
The results demonstrate that the mutant encoded by the HIS175 allele induced no basal 
transcriptional activity from the p21WAF1 reporter (Figure 4.7; blue column; His175 
only).  However, ectopic expression of Chk1 increased transcriptional activity of the 
transfected p53His175 (Figure 4.7; blue column; His175 + Chk1).  This data examining 
a common tumour derived p53 mutant is potentially very interesting as it has already 
been demonstrated that this mutation enhances p53 ubiquitination both in vitro and in 
vivo (Shimizu et al. 2006).  This Chk1-dependent transcriptional reactivation of the p53 
HIS175 mutant suggests that Chk1, similar to Mdm2, may play an important role in 
modulation of p53 activity.   Furthermore the data provided an interesting foundation on 
which to expand and develop our knowledge of the potential of kinase activation to 
increase or restore the activity of some p53 mutants.  
Chapter 4 Results 
 - 137 - 
4.2.2.2 Transfected of Calcium Calmodulin kinases have little effect on Ser 20 
phosphorylation of ectopically expressed p53 mutants 
Evaluation of kinases such as Chk1 and DAPK1 using assays such as in vivo Ser 20 
phosphorylation and reporter based assays has identified Chk1 as a major genetic 
modifier of wild-type p53 (see section 3.2.4).  To evaluate the basal and kinase-
stimulated levels of Ser 20 phosphorylation of ectopically expressed mutant p53 
compared to wild-type p53 an in vivo phosphorylation assay was performed.  To this 
end, Chk1 and DAPK1 were used in the Ser 20 phosphorylation assay to investigate in 
vivo induction of mutant p53 Ser 20 phosphorylation.  H1299 cells were co-transfected 
with wild-type or mutant p53 and Chk1 or DAPK1 expression vectors.  Lysates were 
immunoblotted for p53 protein levels, Ser 20 site phosphorylation of p53 as well as for 
protein levels of Chk1 (Figure 4.8 A) and DAPK1 (Figure 4.8 B).   
   
The western blot demonstrates that the expression levels of p53 mutants are similar to 
that of wild-type p53 (Figure 4.8 A and B; p53 blot).  The results (Figure 4.8; A and B) 
indicate that although Chk1 stimulates wild-type p53 Ser 20 phosphorylation (Figure 4.8 
A; comparing lanes 23 and 24). Chk1 is unable to stimulate the p53 Ser 20 activity of 
most of the eleven mutants (Figure 4.8 A; comparing odd numbered lanes with even 
numbered lanes). However, p53 mutant 8 (A276V), mutant 10 (K292I) and mutant 11 
(K292N) do show some evidence of increased Ser 20 phosphorylation following the 
addition of Chk1 (Figure 4.8 A; Mut 8 comparing lanes 15 and 16; Mut 10 comparing 
lanes 19 and 20; Mut 11 comparing lanes 21 and 22; Ser 20 blot).  These mutants are 
potentially interesting due to their location in or adjacent to the Box-V domain and were 
further investigated for their transcriptional activity.  Following the addition of DAPK1, 
there was however no evidence of stimulation of either wild-type or mutant p53 Ser 20 
phosphorylation (Figure 4.8 B; Ser 20 blot).  The lack of stimulation of wild-type p53 
Ser 20 phosphorylation following the addition of DAPK1 in this assay is likely to be the 
result of high level of basal p53 Ser 20 phosphorylation whereby upon addition of 
DAPK1 the stimulation of p53 Ser 20 phosphorylation is masked.  This high basal p53 
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Ser 20 phosphorylation could be activated by transfection stress.   These results suggest 
that the mutation of p53 in general results in the loss of the ability of kinases to activate 
Ser 20 phosphorylation of p53 and that there may be a role for kinases to phosphorylate 






Figure 4.8 p53 mutants are not phosphorylated at Ser 20.   
A and B. H1299 cells were co-transfected with 1µg of WT or mutant p53 (see Table 4.1 for 
details of mutants) and 1µg expression vectors to Chk1 (A) or DAPK1 (B).  24 hours following 
transfection cells were lysed and lysates were immunoblotted for p53 protein levels (DO12), Ser 
20 site phosphorylation of p53 as well as for protein levels of Chk1 and DAPK1.   
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4.2.2.3 Basal transcriptional activity of the p53 mutants is promoter dependent 
A preliminary gene reporter assay was performed to examine the basal and kinase 
stimulated transcriptional activity of the p53 mutants.  H1299 cells were cotransfected 
with p53 expression construct and Chk1.  The p53 target, p21, was used as a promoter 
indicator of basal and kinase stimulated p53-dependent transcription.  The results 
demonstrated that of the p53 mutants examined in this preliminary gene reporter assay 
only specific mutants showed gain of function transcriptional activity above that of WT 
p53 and that in the main there was no significant kinase stimulated transcriptional 
activity towards the p21WAF1 promoter (Figure 4.9).  Mutants 1 to 5 with mutations 
located in the exposed 240 epitope demonstrated basal p53-dependent transcriptional 
activity similar to that of WT p53 whereas mutants 6 to 11 with mutations located in or 
adjacent to the Box-V region displayed basal p53-dependent transcriptional activity 
above that of WT p53 (Figure 4.9).  This was potentially interesting due to the location 
of these mutants, adjacent to the Box-V region and suggested that some unfolding of the 
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Figure 4.9  p53 mutants display some kinase stimulated p53-dependent transcriptional 
activity.   
H1299 cells were cotransfected with 50ng of WT or mutant p53 expression construct, 2µg Chk1 
and reporter plasmid constructs; p21WAF1-luc (1µg) and REN-CMV (0.25µg).  After 24 hours the 
cells were lysed and luciferase and Renilla activity was measured.  Data shows the luciferase 
activity normalised to the Renilla production represented as Relative Light Units (RLU).  Activity 
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Mutants which retain their ability to transactivate p53 target genes often show variability 
in the specific target genes which they are able to transactivate.  For example mutants 
have been shown to transactivate p21WAF1 but not BAX promoter (Rowan et al. 1996).  
In light of this data gene reporter assays were performed to compare and contrast the 
basal transcriptional activity of the p53 ‘Gain of function’ mutants using the two 
common p53 target genes, p21WAF1 (cell cycle effector) and BAX (apoptotic effector).  
H1299 cells were cotransfected with a titration of p53 expression construct and reporter 
plasmid constructs; p21WAF1-luc or BAX-luc and REN-CMV.   
 
The results demonstrate the contrasting transactivation potential of the p53 mutants on 
p21WAF1 and BAX and show that the comparative transcriptional activity of these 
promoters in these gene reporter assays is quite dramatic (Figure 4.10 A and B).  The 
normalised result as represented by the Relative Light Units (RLU) is in general 10 fold 
lower for the BAX promoter (Figure 4.10 B) compared to the p21WAF1 promoter (Figure 
4.10 A).  Examination of mutant p53-dependent transcriptional activity from the 
p21WAF1 promoter demonstrates a general trend; as the transactivation activity of the 
mutants towards the p21WAF1 promoter (Figure 4.10 A) decreases as p53 levels are 
increased (from 50ng to 500ng) suggesting that the system is more sensitive at lower 
levels of p53.  The exceptionally high relative readings for Mutant 4 (100ng p53) and 
Mutant 9 (50ng p53) are due to low firefly and renilla readings which is likely the result 
of sample loading error and therefore not reliable and cannot be considered  for analysis 
(Figure 4.10 A; Mutant 4, 100ng and Mutant 9, 50ng).   Mutants derived from the 
exposed loop of p53 have similar transactivation activity toward p21WAF1 to WT p53 
(Figure 4.10 A; Mutants 1 to 5) whereas mutants 6, 7 and 8, which are located in or 
adjacent to the Box-V domain, show increased transactivation potential compared to WT 
(Figure 4.10 A).  The other C-terminal mutants demonstrate a decreased transactivation 
potential compared to WT (Figure 4.10 A; Mutants 9, 10 and 11).   
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Figure 4.10 Basal transcriptional activity of p53 mutants is promoter dependent.   
A & B. H1299 cells were cotransfected with a titration of WT or mutant p53 expression construct 
(50, 100, 200 or 500ng) and reporter plasmid constructs; p21WAF1-luc (A; 0.14µg) or BAX-luc (B; 
0.14µg) and REN-CMV (0.06µg).  After 24 hours the cells were lysed and cell lysates were 
analyzed for their luciferase and Renilla activity.  Data shows the luciferase activity normalised to 
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the Renilla production represented as Relative Light Units (RLU).  Activity levels of the p21 
reporter construct without p53 are represented in reporter only lane.  
 
In contrast examination of mutant p53-dependent transcriptional activity from the BAX 
promoter demonstrates a general trend of increasing transactivation potential towards the 
BAX promoter (Figure 4.10 B) as levels of p53 are increased (from 50ng to 500ng).   It 
may either be that this promoter operates more effectively at higher levels of p53, or 
alternatively that other cofactors may be required to stimulate the transcriptional 
activation of mutant p53 toward this promoter.   In the main the transactivation activity 
of the p53 mutants on the BAX promoter remains at similar levels to WT p53 (Figure 
4.10 B; comparing Mutants 1 to 6 to WT).  However, it is the activity of the p53 mutants 
with mutations located in or adjacent to the Box-V domain which produces the most 
interesting result (Figure 4.10 B; comparing Mutants 6 to 11 to WT) as these mutants 
demonstrate a decreased transactivation potential compared to WT p53.  This contrasted 
dramatically with the increased transactivation potential of mutants 6, 7 and 8 on the 
p21WAF1 promoter.  In particular mutant 7 (K292I) and mutant 8 (A276V) exhibited the 
most dramatic contrast in transactivation activities (Figure 4.10; comparing figures A 
and B; Mutants 7 and 8) and would therefore will be examined further.  Overall, from 
these results we can conclude the p53-dependent transcriptional activity of these mutants 
is promoter dependent.  That is, more mutants demonstrate gain of function potential 
towards the p21WAF1 promoter whereas the transactivation potential of p53 mutants 
towards the BAX promoter is in most cases similar to WT p53.   This data was 
consistent with data from the Ishioka group in which these mutants (K292I and A276V) 
showed contrasting activities on the p21WAF1 and BAX promoters whereas other mutants 
such as those examined in these assays do not demonstrate such contrasting activities 
(Kakudo et al. 2005).   
 
Chapter 4 Results 
 - 144 - 














p53 Mut 7 (K292I)
p53 Mut 8 (A276V)
A.
 

















p53 Mut 7 (K292I)
p53 Mut 8 (A276V)
B.
 
Figure 4.11  Basal transactivation activity of p53 mutants is promoter dependent.   
H1299 cells were cotransfected with a titration of WT or mutant p53 expression construct (25, 
50, 100, 200 or 500ng) and reporter plasmid constructs; p21WAF1-luc or BAX-luc (0.14µg) and 
REN-CMV (0.06µg).  After 24 hours the cells were lysed and cell lysates were analysed for their 
luciferase and Renilla activity.  Data shows the luciferase activity normalised to the Renilla 
Chapter 4 Results 
 - 145 - 
production represented as Relative Light Units (RLU).  Activity levels of the p21WAF1 reporter 
construct without p53 are represented in reporter only lane.   
 
In light of the dramatically contrasting activities of p53 mutant 7 (K292I) and mutant 8 
(A276V) towards the two examined promoters (p21WAF1 and BAX), these mutants were 
examined further using the gene reporter assay.  To confirm previous results (Figure 
4.10), we extending the titration range of the mutant p53 and firstly examined the mutant 
basal p53-dependent transcriptional activity on the two promoters (Figure 4.11 A and 
B).   
 
Examination of specific mutants (7; K292I and 8; A276V) basal transcriptional activity 
from the p21WAF1 and BAX promoters demonstrates as previously that gain of function 
transactivation potential is promoter dependent (Figure 4.11; comparing A and B).  
Mutant p53 transcriptional activity towards the p21WAF1 promoter increases as p53 levels 
are increased (Figure 4.11; A; Mut 7 and Mut 8; comparing columns 25 to 1000ng p53) 
whereas WT p53 transcriptional activity from the p21WAF1 promoter decreases as levels 
of p53 increase (Figure 4.11; A; WT p53; comparing columns 25 to 1000ng p53).  This 
pattern of activity results in the p53 mutants demonstrating gain of function 
transcriptional activity as levels of p53 are increased.  In contrast, mutant p53 
transcriptional activity on the BAX promoter remains lower than WT p53 transcriptional 
activity at all levels of p53 but in general as p53 levels are increased, the transcriptional 
activity of all p53s toward the BAX promoter increases (Figure 4.11; B; comparing 
columns 25 to 1000ng p53).  The exceptionally high relative readings for p53 WT 
(25ng) is due to low firefly and renilla readings which is likely the result of sample 
loading error and therefore not reliable and cannot be considered  for analysis (Figure 
4.11; B; p53 WT; 25ng).  This data therefore supports previously demonstrated data 
whereby these p53 mutants, 7 and 8 demonstrated promoter specific gain of function 
characteristics.   
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4.2.2.4 P53 Mutants are not stimulated transcriptionally by addition of kinases or 
Mdm2 
To develop and verify basal transcriptional data, the kinase and Mdm2 stimulated p53-
dependent transcriptional activity was examined.  Chk1 and DAPK1 were used in these 
gene reporter assays to examine the effect of kinases on p53 mutant transcriptional 
activity from both the p21WAF1 and BAX promoters.  H1299 cells were cotransfected 
with a fixed amount of p53 expression construct, a titration of Chk1 or DAPK1 and 
reporter plasmid constructs; p21WAF1-luc or BAX-luc and REN-CMV.  
 
The data represented in Figure 4.12 compares Chk1 and DAPK1 stimulation of p53 
mutant activity from the p21WAF1 promoter (Figure 4.12; A and B respectively) and 
Chk1 and DAPK1 stimulation of p53 mutant activity from the BAX promoter (Figure 
4.12; C and D respectively).  The data demonstrates that addition of kinases results in no 
stimulation of gain of function transcriptional activity of the p53 mutants on either 
promoter (Figure 4.12; A, B, C and D; comparing columns 0ng kinase with 50, 100, 250, 
500 or 1000ng kinase).  On the p21WAF1 promoter, Mutant 7 demonstrates basal activity 
similar to WT p53 (Figure 4.12; A and B; comparing p53 Mut 7 to p53 WT) whereas 
Mutant 8 has increased basal transcriptional activity compared to WT (Figure 4.12; A 
and B; comparing p53 Mut 8 to p53 WT).  On the BAX promoter, mutant 7 and 8 
demonstrate no transcriptional activity above that of WT (Figure 4.12; C and D; 
comparing p53 Mut 7 and p53 Mut 8 to p53 WT) which is consistent with the data 
demonstrated previously Figure 4.11 B).  The data point representing the effect of 100ng 
Chk1 on p53 Mut 7 has been removed as the relative reading is exceptionally high and 
lies outwith the scale of the graph (Figure 4.12; C; p53 Mut 7; 100ng Chk1).  This is the 
result of low firefly and renilla readings which is likely the result of sample loading 
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Figure 4.12 Kinases do not stimulate transactivation activity of the p53 mutants.  
A and B: Effect of Chk1 (A) and DAPK1 (B) on p53 mutant activity on the p21WAF1 promoter. 
H1299 cells were cotransfected with WT or mutant p53 expression construct (100ng), a titration 
of Chk1 or DAPK1 (50, 100, 200, 500 or 1000ng) and reporter plasmid constructs; p21WAF1-luc 
(140ng) and REN-CMV (60ng).  C and D: Effect of Chk1 (C) and DAPK1 (D) on p53 mutant 
activity on the BAX promoter (as above with 140ng BAX-luc).  After 24 hours cell lysates were 
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analysed for their luciferase and Renilla activity (normalised data shown Relative Light Units 
(RLU)).   
 
Overall, although there is no stimulation of transcriptional activity by addition of kinases 
it is interesting that Mutant 8 (A276V) consistently demonstrates basal transcriptional 
activity toward the p21WAF1 promoter above WT.  This is the only p53 mutant with a 
mutation actually located in the Box-V domain and it was hypothesized that this 
mutation may play an important role in the interaction of Mdm2 with the Box-V domain. 
 
To address this hypothesis the assay was repeated to examine the effect of Mdm2 on p53 
mutant transcriptional activity on the p21WAF1 promoter.  The results demonstrate that 
similar to Chk1 and DAPK1, Mdm2 does not stimulate p53-dependent transcriptional 
activity from the p21WAF1 promoter (Figure 4.13).    The results show that in general in 
this assay the transcriptional activity of both mutants remain above that of wild-type p53 
(Figure 4.13; comparing Mutant 7 and Mutant 8 with WT p53).  However, the addition 
of increasing levels of Mdm2 decreases the transactivation potential of Mutant 7 (Figure 
4.13; p53 Mut 7; comparing 0ng with 50, 100, 250, 500 or 1000ng Mdm2) and may 
suggest that this mutant is hyper-sensitive to Mdm2 (Figure 4.13; p53 Mut 7; 1000ng 
Mdm2).  In contrast to this result, p53 Mutant 8 (A276V) appears to be resistant to 
Mdm2-mediated inhibition of p53 transcriptional activity (Figure 4.13; p53 Mut 8; 
1000ng Mdm2).  This mutant (A276V) is located in the conserved Box-V domain, the 
location of the ubiquitination signal for Mdm2. The observed resistance of this mutant to 
Mdm2-mediated inhibition of p53 transcriptional activity may be consistent with the loss 
of the Mdm2 binding site. 
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Figure 4.13 Mdm2 does not stimulate transactivation activity of the p53 mutants on 
p21WAF1 promoter.   
H1299 cells were cotransfected with a fixed amount p53 expression construct (100ng), a titration 
of Mdm2 (50, 100, 200, 500 or 1000ng) and reporter plasmid constructs; p21WAF1-luc or BAX-luc 
(0.14µg) and REN-CMV (0.06µg).  After 24 hours the cells were lysed and cell lysates were 
analysed for their luciferase and Renilla activity.  Data shows the luciferase activity normalised to 
the Renilla production represented as Relative Light Units (RLU).  Activity levels of the p21WAF1 
reporter construct without p53 are represented in reporter only lane. 
 
Although neither kinases nor Mdm2 stimulated the transcriptional activity of the p53 
mutants, Mutant 7 (K292I) and 8 (A276V) demonstrated increased basal transcriptional 
activity from the p21WAF1 promoter.  The fact that these mutants contain mutations that 
are located in or adjacent to the Box-V region of p53 could prove particularly 
interesting.  Therefore an approach which examined mutagenesis of the Box-V region 
was employed to investigate the kinase – p53 interaction in more detail.  
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4.2.3 Examination of specific sites of interation of kinases on p53 Box-V domain 
To expand upon Box-V in vivo interaction data, mutagenesis of the Box-V region was 
also performed.  The Box-V peptide was previously identified as the most potent Chk1 
and Chk2 activator in vitro (Craig et al. 2003).  This report examined the effects of 
individual amino acid mutations on Box-V peptide activation of Chk2 and identified 
mutation of amino acids to alanine at specific sites (270, 272, 273, 274 and 277) in the 
S10 β-sheet attenuated Chk2 activation by the Box-V peptide (Craig et al. 2003).  This 
suggested that specific sites in the Box-V domain were important in the interaction with 
Chk2 and therefore should be investigated for interaction with other kinases.   
 
 
Figure 4.14  Creation of double alanine mutants to examine kinase-p53 interaction.   
A. The schematic diagram shows the sequence of the EGFP-Box-V fusion peptide, the 
corresponding amino-acid residues, and the double alanine-mutated EGFP-Box-V derivatives 
(underlined).  B. Expression levels of the EGFP mutants compared to WT.  H1299 cells were 
transfected with 1µg EGFP mutant variant.  After 24 hours cells were lysed and lysates were 
immunoblotted for levels of EGFP using the anti-EGFP IgG.   
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In order to investigate specific kinase binding regions within the Box-V domain, a set of 
double alanine mutants spanning the sequence of the Box-V peptide were prepared by 
site directed mutagenesis of EGFP-Box-V WT (Figure 4.14; A).  This enabled us to 
investigate which regions of the Box-V domain kinases preferentially bind to. 
 
4.2.3.1 DAPK1 and Chk1 have distinct but overlapping binding requirements on p53 
Box-V 
It has been demonstrated that the Box-V fusion peptide binds to both Chk1 and DAPK1 
in cells (Figure 4.3 and Figure 4.4 respectively).  In order to investigate the specific 
regions of the Box-V peptide which kinases may have a preferential binding capacity 
for, coimmunoprecipitation assays were performed using the Box-V alanine mutants. 
EGFP mutant and variants were quantified both in the unbound fraction (Figure 4.15 A; 
unbound (U); lanes 1 to 21; odd numbers) and the bound fraction (Figure 4.15 A; bound 
(B); lanes 2 to 22; even numbers) by immunoblot with an anti-EGFP IgG.  The results 
demonstrate as shown previously that Chk1 forms a complex with Box-V-WT (Figure 
4.15 A; lane 18; bound fraction).  There were varying levels of binding of the Box-V 
alanine mutants to Chk1 with increased stabilization of the Box-V mutants 4, 5a and 6 
(Figure 4.15 A; comparing lanes 8, 10 and 14 with lane 18; bound fraction) and reduced 
stabilization of the Box-V alanine mutants 1, 2, 3, 5b and 7 (Figure 4.15 A; comparing 
lanes 2, 4, 6 and 16 with lane 18; bound fraction).   Thus, suggesting that the first six 
(residues 267 – 274) and last two (residues 280 and 281) amino acids of the Box-V 
peptide may play an important role in the binding potential of Chk1.  This data is 
consistent with in vitro data which showed that amino acids residues 270, 272, 273 and 
274 were important for Chk2 activation of p53 (Craig et al. 2003).   
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Figure 4.15 Examination of kinase binding to Box-V mutants demonstrates that binding 
occurs at specific sites.   
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(Fig 4.15)  A. H1299 cells were cotransfected with vectors encoding Chk1 (1µg) and EGFP-Box-
V mutants (0.5µg; EGFP-Box-V/ 1 to 7; see Figure 4.14 for details) or EGFP variants (0.5µg; 
EGFP-Box I and EGFP-Box V).  24 hours following transfection cells were lysed, lysates were 
precleared and Chk1 was subjected to immunoprecipitation using NHS-activated sepharose 
beads to which the anti-Chk1 antibody had been previously coupled to.  EGFP mutants and 
variants were quantified both in the unbound fraction (U; lanes 1 to 21; odd numbers) and the 
bound fraction (B; lanes 2 to 22; even numbers) by immunoblot with an anti-EGFP IgG. Chk1 
levels were quantified by immunoblot B. H1299 cells were cotransfected with vectors encoding 
HA-DAPK1 (1µg) and EGFP-Box-V mutants (0.5µg; EGFP-Box-V/ 1 to 7) or EGFP variants 
(0.5µg; EGFP-Box-I and EGFP-Box-V).  Cells were lysed, lysates were precleared and HA-
DAPK1 was immunoprecipitated with anti-FLAG agarose beads.  Quantification of the EGFP 
mutant or variant in the unbound (U; lanes 1 to 21; odd numbers) or bound (B; lanes 2 to 22; 
even numbers) fractions after FLAG pull-down was performed by immunoblot using an anti-
EGFP IgG. DAPK1 levels were quantified by immunoblot. 
 
To examine the level of binding of Box-V mutants by DAPK1, H1299 cells were 
cotransfected with vectors encoding HA-DAPK1 and EGFP Box-V mutants (EGFP-
Box-V/ 1 to 7) or EGFP variants (EGFP-Box I-WT and EGFP-Box V-WT) as controls.  
Cells were lysed, lysates were precleared and HA-DAPK1 was immunoprecipitated with 
anti-FLAG agarose beads.  Quantification of the EGFP mutants and variants in the 
unbound (U; lanes 1 to 21; odd numbers) or bound (B; lanes 2 to 22; even numbers) 
fractions after FLAG pull-down was performed by immunoblot using an anti-EGFP IgG.  
The results demonstrate as shown previously that DAPK1 forms a complex with Box-V-
WT (Figure 4.15; B; lane 18; bound fraction).  There were varying levels of binding of 
the Box-V mutants by DAPK1.  There was increased stabilization of the Box-V mutants 
2, 3, 4 and 5a (Figure 4.15; B; comparing lanes 4, 6, 8 and 10 with lane 18; bound 
fraction) and reduced stabilization of the mutants 1, 5b, 6 and 7 when compared to Box-
V-WT (Figure 4.15; B; comparing lanes 2, 12, 14 and 16 with lane 18; bound fraction).  
DAPK1 may therefore bind preferentially to the first two (residues 267 and 268) and last 
six (residues 275 - 281) amino acids as their mutation to alanine decreases the binding of 
DAPK1 to Box-V.  The data demonstrated that the central amino acids of Box-V peptide 
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have a reduced binding affinity for DAPK1 suggesting that these sites are not 
necessarily required for binding.  
4.2.3.2 The EGFP-Box-V fusion peptide binds preferentially to Mdm2 
In has previously been shown that mutation of single amino acids Ser 3 and Phe 4 
(residues 269 and 270 of p53 Box-V) resulted in reduced binding activity to the acid 
domain of Mdm2 suggesting that these sites were important in contributing to the 
activity of the peptide.  In contrast mutation of sites Val 8, Cys 9 and Cys 11 (residues 
274, 275 and 277) both increased the activity of peptides as E3-ligase inhibitors and 
increased binding affinity for Mdm2 suggesting that these mutations was less crucial for 
binding and for the resulting Mdm2 catalysed ubiquitination to take place (Wallace et al. 
2006).  To further investigate levels of stabilization of the Box-V peptide by Mdm2 the 
vector encoding Mdm2 was cotransfected with EGFP mutants (EGFP-Box-V/ 1 to 7) or 
EGFP variants (EGFP-Box I and EGFP-Box V) into H1299 cells.  EGFP mutants and 
variants were quantified both in the unbound (Figure 4.16; unbound (U); lanes 1 to 21; 
odd numbers) or bound (Figure 4.16; bound (B); lanes 2 to 22; even numbers) fractions 
after FLAG pull-down was performed by immunoblot using an anti-EGFP IgG.   
 
As previously demonstrated (Figure 4.5) the binding of Mdm2 stabilises the Box-V 
fusion peptide.  There is increased level of stabilization when Mdm2 is 
coimmunoprecipitated with the Box-V alanine mutants 4, 5a, 5b and 6 (Figure 4.16; 
comparing lanes 8, 10, 12 and 14 with lane 18; bound fraction) and reduced levels of 
stabilization when Mdm2 is coimmunoprecipitated with Box-V alanine mutants 1, 2, 3 
and 7 compared to Box-V WT (Figure 4.16; comparing lanes 2, 4, 6 and 16 with lane 
18; bound fraction).  The pattern of binding correlated with a report which used a Box-V 
alanine substituted library to examine the features of the Box-V region required for the 
inhibitory activity of Mdm2 (Wallace et al. 2006).  The pattern of stabilization by Mdm2 
across the Box-V peptide is also similar to that observed in the Chk1 
coimmunoprecipitation assay (Figure 4.15 A), where both Mdm2 and Chk1 appear to 
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have reduced stabilization and thus binding affinity to mutants 1, 2, 3 and 7.  Therefore, 
suggesting that the first six and last two amino acids of the WT Box-V peptide may play 
an important role in the binding potential of both Chk1 and Mdm2 and may suggest 
competition between Chk1 and Mdm2 for binding to the Box-V domain in vivo.   
 
Figure 4.16 The EGFP-Box-V peptide binds preferentially to Mdm2.   
The vector encoding Mdm2 (1µg) was cotransfected with EGFP-Box-V mutants (0.5µg; EGFP-
Box-V/ 1 to 7) or EGFP variants (0.5µg; EGFP-Box I and EGFP-Box V) into H1299 cells.  24 
hours following transfection cell were lysed and cell lysates were precleared.  Mdm2 was 
subjected to immunoprecipitation using NHS-activated sepharose beads to which the anti-Mdm2 
antibody, 2A10, had been previously coupled to.  EGFP mutants and variants were quantified 
both in the unbound (U; lanes 1 to 21; odd numbers) or bound (B; lanes 2 to 22; even numbers) 
fractions after pull-down was performed by immunoblot using an anti-EGFP IgG. Mdm2 levels 
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Table 4.2 Levels of stabilization of double alanine Box-V mutants compared to Box-V-WT 
Box-V Mutant Residues Chk1  DAPK1 Mdm2 
Box-V/1 267, 268 ↔ ↓ ↓ 
Box-V/2 269, 270 ↔ ↑↑ ↔ 
Box-V/3 271, 272 ↔ ↑↑ ↓ 
Box-V/4 273, 274 ↑↑ ↔ ↑ 
Box-V/5a 275, 276 ↑ ↑ ↑ 
Box-V/5b 276, 277 ↓ ↔ ↑ 
Box-V/6 278, 279 ↑↑ ↔ ↑↑ 
Box-V/7 280, 281 ↓ ↓ ↓ 
(↔ similar to WT; ↑ increased stabilization; and ↓ decreased stabilization above WT)  
 
Therefore, examination of binding capacity of kinases and Mdm2 to the Box-V peptide 
using mutants derived from the Box-V peptide has confirmed previously described data 
in which Calcium Calmodulin kinases and Mdm2 bind to the Box-V peptide.  The 
coimmunoprecipitation assays have given some insight into specific regions where 
kinases or Mdm2 may bind.  By comparing the stabilization levels of the EGFP-Box-V 
mutant fusion peptide to that of EGFP-Box-V WT we have been able to define sites 
which may be important in contributing to the activity of the peptide. Table 4.2 
summarises this data and as highlighted the sites that show decreased stabilization after 
mutation are the sites of interest.  This may be of importance in defining the areas of 
interaction between p53 and kinases or Mdm2 and therefore contribute to the initiation 
of signals which control p53 activity.   
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4.3 Discussion 
The objective of this chapter was to examine and extend our knowledge of interactions 
between kinases and p53.  This involved using coimmunoprecipitation assays to 
examine kinase binding to the Box-V region of p53 and to characterise sites of 
interaction, double alanine mutants spanning the Box-V motif were made.  To further 
define the domains required for p53: kinase interactions, a selected group of p53 ‘gain of 
function’ mutants were examined for their basal and kinase stimulated transcriptional 
activity to different p53 targets.  This allowed us to develop our understanding of the 
molecular mechanisms behind oncogenic gain of function, as well as expand our 
knowledge of the interactions of p53 mutants and whether these interactions could be 
modulated by kinases.  This will go some way to revealing the biochemical pathways 
and putative targets for the treatment of cancers that display mutant p53. 
 
4.3.1 Chk1 and Mdm2 have overlapping binding requirements on p53 Box-V 
We have established that the Box-V region is a multi-protein binding site required to 
activate p53 phosphorylation and ubiquitination (Wallace et al. 2006; Craig et al. 2007).  
To further investigate this interaction between kinases and/or Mdm2 and the Box-V 
motif of p53 binding assays were performed in vivo.  Using EGFP non-specific and 
EGFP-Box-I as controls we were able to demonstrate that both kinases of interest, Chk1 
and DAPK1, bound specifically and stably to Box-V in cells.   This result was validated 
by cotransfection of a titration of the Box-V fusion peptide and kinase of interest; which 
demonstrated a dose-dependent relationship between levels of transfected Box-V and the 
formation of FLAG-Chk1: EGFP-Box-V immune-complexes.  This observation 
supported previous data in which the addition of the Box-V fusion peptide attenuated 
phosphorylation of p53 at Ser 20 (see section 3.2.7) and that this attenuation of 
phosphorylation may be attributable to the binding of the Box-V fusion peptide to 
kinases and thereby preventing the phosphorylation of p53.  We have demonstrated here 
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that kinases do indeed bind to the Box-V fusion peptide in cells and that the Box-V 
domain of p53 forms a docking site for the Calcium Calmodulin kinase superfamily.     
 
Mdm2 was the first Box-V domain binding protein to be identified (Shimizu et al. 2002) 
and more recently it has been shown that the Box-V region provides the ubiquitination 
signal for Mdm2 which is required for the dual-site docking mechanism of Mdm2 on the 
p53 tetramer (Wallace et al. 2006).  In this report coimmunoprecipitation assays were 
performed as previously using EGFP non-specific and EGFP-Box-I as controls and we 
were able to demonstrate that Mdm2 formed a complex specifically with the Box-V 
peptide and not with the Box-I peptide in cells.  In addition, we showed that the Box-V 
peptide was stabilized by transfection of increasing levels of Mdm2.  The stable binding 
of Mdm2 is thought to prevent the degradation of the peptide and thereby stabilizing it.  
The fact that EGFP-Box-I did not bind to Mdm2 is this and the previous assay is 
surprising as it had been demonstrated in vitro using a peptide from the Box-I activation 
domain of p53 that Mdm2 was fully competent for binding to the Box-I domain of p53 
(Wallace et al. 2006).  It may be the case the Box-I alone is not sufficient to form the 
binding site and that the alternative binding site in the Box-V region may also be 
required.  However, the ability of the EGFP-Box-V fusion peptide to form a stable 
immune complex with Mdm2 in cell lysates is expected and correlates with previously 
described data in which the Box-V domain of p53 forms part of a binding surface for 
Mdm2 that is involved in signaling p53 ubiquitination (see section 3.2.5) 
 
Mutation of Box-V domain has been previously performed to investigate the role of 
specific residues of this docking interface on Box-V peptide activation of Chk2 (Craig et 
al. 2003). This report by Craig and colleagues examined the effects of individual amino 
acid mutations and identified mutation of amino acids to alanine at specific sites (270, 
272, 273, 274 and 277) in the S10 β-sheet attenuated Chk2 activation by the Box-V 
peptide (Craig et al. 2003).  To further investigate the interaction between the 
kinases/Mdm2 and Box-V region of p53 double alanine mutants spanning the Box-V 
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peptide region were created to determine specific sites of interaction.  These results 
demonstrated that both Chk1 and Mdm2 showed reduced stabilization and binding 
affinity to mutants 1, 2, 3 and 7 and DAPK1 showed reduced stabilization and binding 
affinity to mutants 1, 5b, 6 and 7.    Therefore, suggesting that the first six and last two 
amino acids of the WT Box-V peptide may play an important role in the binding 
potential of both Chk1 and Mdm2 and that the first two and last six amino acids of the 
WT Box-V peptide may play an important role in the binding potential of both DAPK1. 
The patterns of binding correlated with a report which used a Box-V alanine substituted 
library to examine the features of the Box-V region required for the inhibitory activity of 
Mdm2 (Wallace et al. 2006).  Wallace and colleagues showed that mutation of single 
amino acids Ser 3 and Phe 4 resulted in reduced binding activity to the acid domain of 
Mdm2 suggesting that these sites were important in contributing to the activity of the 
peptide.  In contrast mutation of sites (Val 8, Cys 9 and Cys 11) both increased the 
activity of peptides as E3-ligase inhibitors and increased binding affinity for Mdm2 
suggesting that these mutations was less crucial for binding and for the resulting Mdm2 
catalysed ubiquitination to take place (Wallace et al. 2006).    
 
It is worth noting that in the assays examining the Box-V mutants, there is no evidence 
of the control Box-I forming a complex with Mdm2.  As described above, this result is 
unexpected.  It may have been useful to use more than one antibody to Mdm2 to allow 
detection of binding at different regions on Mdm2, although in these assays the limited 
availability of lysates restricted the number of analyses undertaken on one sample.  As 
an improvement to the overall presentation of the coimmunoprecipitation data and to 
allow the reader to examine detail of each important band with ease, the immunoblots 
could have been presented in a larger format but due to the number of samples, this too 
has its limitations.  
 
However, the fact that both Mdm2 and the Calcium Calmodulin kinases bind and 
stabilize the Box-V region, and that Chk1 and Mdm2 demonstrate similar patterns of 
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interaction with the Box-V peptide is potentially very interesting.  This and previous 
published data (Shimizu et al. 2002; Wallace et al. 2006) suggest that the Box-V motif is 
a conformationally flexible multiprotein binding domain that controls covalent 
modification of the p53 tetramer.  Recent studies which used nuclear magnetic 
resonance revealed that the acid domain of Mdm2 can bind directly to the core domain 
of p53 and that on binding to p53 this acid domain fragment of Mdm2 induced 
significant chemical shifts throughout the core domain especially within the Box-V 
motif  (Yu et al. 2006).  These data may suggest that different proteins compete with 
each other for binding to this specific region of p53 and that the outcome of this 
competition may be a factor in the regulation of p53.   Considering the results from this 
report it is possible that the Calcium Calmodulin kinases, Chk1/DAPK1 and Mdm2 
could antagonize each other through competition for the same multi-protein docking 
site.  Results have demonstrated that the p53 mutant, p53 HIS175 can be stimulated 
transcriptionally by transfection of Chk1 (see section 4.2.2.1).  Although it has been 
established that the p53 HIS175 protein is hyperubiquitinated in vivo due to the 
unfolding of the protein and thus the exposure of the Box-V motif (Shimizu et al. 2006), 
this transcriptional reactivation of the p53 HIS175 mutant from the p21WAF1 reporter by 
Chk1 suggests that Chk1 may overcome Mdm2-mediated ubiquitination by competition 
for binding to the Box-V interface and drive p53 into a transactivation-competent rather 
than a ubiquitinated state.   
 
Therefore, the data presented here along side previous reports highlight the potential for 
the Box-V domain of p53 to function both as a Calcium Calmodulin kinase docking site 
and an Mdm2 ubiquitination signal, which would allow cells to control p53 modulation 
in response to various stresses which it may encounter.    
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4.3.2 The role of p53 ‘Gain of Function’ mutants  
We have shown here that mutation of key contact sites on p53, specifically the Box-V 
domain can lead to loss of kinase binding to p53 which will likely negatively effect the 
activation of p53.   Mutation of p53 is one of the most common events in cancer.  One of 
three events normally occur which contribute to the progression of the cancer: p53 loss 
of function; mutant p53 dominant-negative function; or mutant p53 gain of function, 
where expression of mutant p53 in cells lacking WT p53 enhances their tumourigenic 
potential.  This report has examined the role of the gain of function nature of mutant p53 
in order to develop our understanding of the molecular mechanisms of the oncogenic 
gain of function phenotype and the molecular interactions of mutant p53.  With 
reference to recent reports (Kakudo et al. 2005) a set of mutants was created to evaluate 
whether the activity of these mutants could be modulated by kinases and/or Mdm2 and 
thereby simultaneously further identify sites important for the interaction of p53 with 
kinases/Mdm2.   
Comparison of two common p53 target genes, p21 and BAX demonstrated that basal 
activity of the p53 mutants was promoter dependent and that p53 mutants were not 
stimulated transcriptionally by the addition of kinases or Mdm2.  The report did 
however identify two potentially interesting mutations, A276V and K2921, which are 
found within or adjacent to the Box-V region.  The p53 proteins containing these 
mutations demonstrate the most dramatic contrast in transactivation activities from the 
p21WAF1 and BAX promoters.  A more detailed examination of these specific mutants 
(K292I and A276V) demonstrated that gain of function transactivation potential was 
promoter-dependent and that these p53 mutants demonstrated p21WAF1 promoter specific 
gain of function characteristics.  It is likely that these mutants bind to the high affinity 
binding sites of the p21WAF1 promoter but not to the low affinity binding sites on the 
BAX promoter.  However, the data demonstrated that neither kinases nor Mdm2 further 
stimulated the transcriptional activity of these two p53 gain of function mutants on either 
promoter.  It was interesting, however, that Mutant 8 (A276V), consistently 
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demonstrated basal transcriptional activity toward the p21WAF1 promoter above that of 
WT p53 and appeared to be resistant to Mdm2-mediated inhibition of p53 transcriptional 
activity (Figure 4.13).  This was the only p53 mutant examined that exhibited a mutation 
within the Box-V domain, the location of the ubiquitination signal for Mdm2.  The 
observed resistance of this mutant to Mdm2-mediated inhibition of p53 transcriptional 
activity may be consistent with the loss of the Mdm2 binding site.  Although in these 
assays this Box-V mutant p53 was not stimulated transcriptionally by kinases or Mdm2, 
it may nevertheless play an important role in kinase or Mdm2 interaction with the Box-
V domain in a similar manner to the common tumour-derived mutant p53 His175.  
Indeed it is possible to imagine that mutant 8 may favour the binding of kinases rather 
than Mdm2, thus driving p53 into a transactivation competent state.     
The recent reports demonstrating the role of the p53 core domain in binding to Mdm2 
suggest that p53 mutants show alterations in their sensitivity to Mdm2 (Shimizu et al. 
2006).  A recent paper by the Vousden group examined the ubiquitination and 
degradation of mutant p53.  They demonstrated that p53 mutants are ubiquitinated in 
vivo independently of Mdm2 and suggest that the chaperone-associated ubiquitin ligase 
(CHIP) and other E3 ligases may play more of an important role in the ubiquitination 
and degradation of mutant p53 (Lukashchuk and Vousden 2007).   It may be that mutant 
8 is activated transcriptionally towards other p53 targets which may be more sensitive to 
kinase stimulation of transcriptional activity or to events such as ubiquitination.  A more 
diverse approach utilizing a range of p53 targets to examine the basal and kinase 
stimulated transcriptional activity of both mutant and wild-type p53 needs to be 
employed if we are to address these gaps of information. 
Selection of the mutants for this study was based on a recent publication by the Ishioka 
group (Kakudo et al. 2005).  They employed a yeast-based functional assay to evaluate 
the activity of a diverse selection of p53 mutants.  Others studies have also employed 
yeast-based functional assays in which to investigate transcriptional activation and 
altered promoter selectivity of mutant p53 (Inga et al. 2001; Resnick and Inga 2003).  
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Most recently Menendez and colleagues investigated the relationship between changes 
in the p53 master regulatory network and biological outcomes using human cells as a 
model.  They demonstrated that p53 mutations in human cells resulted in a wide range of 
biological outcomes because of the ability of the mutants to change the spectra of genes 
targeted by p53 (Menendez et al. 2006).  Therefore the use of human cells will 
considerably contribute to the continued progression of the research examining 
transcriptional activation and altered promoter selectivity of mutant p53 and provide an 
interesting insight into p53 mutagenesis in cancer. 
The affinity of p53 mutants for various p53 target sequences as well as their protein-
protein interactions can be determined by the structure and energetic response of the 
mutant.  The stability of full-length p53 is dictated by its core domain which at 
temperatures only slightly above body temperature will melt (Ang et al. 2006).  The 
folding state of the mutant can be affected by mutations which reduce the 
thermostability of the protein.  Studies have examined the folding states of mutants at 
low temperatures and have demonstrated that mutants can be grouped into distinct 
classes which correlate with the location of the mutations in the p53 structure (Bullock 
et al. 2000).  For example, the structural hotspot mutations in the DNA-binding surface 
are destabilized to varying degrees and show different patterns of DNA-binding activity 
in their folded state (Bullock et al. 2000).  Therefore, the activity of gain of function 
mutants may be defined by their thermodynamic stability.  For example the mutants 
examined in detail in this study (A276V and K292I) demonstrated contrasting 
transcriptional activities towards the p53 target genes p21 and BAX.   The location of 
these mutations in the DNA binding domain may suggest that these mutants demonstrate 
varying degrees of stability which may therefore affect their ability to activate 
downstream targets.  Examination of the thermostability of these mutants is a potentially 
interesting follow-up study in which to clarify the activity of these mutants, their 
interactions with other proteins and thus the control of p53 activity.   
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Knock-in mouse models provide another approach to investigating the role of p53 
mutants in cancer progression.  For example, development of murine model with 
mutation at p53 amino acid site 172 which corresponds to the R175H hot-spot mutation 
in human cancers to simulate Li-Fraumeni-like mutant p53, demonstrated that the 
mutant p53 associated with p63 and p73 in tumour cells of mice (Lang et al. 2004).  
They also showed that silencing mutant p53 resulted in increased the activity of p53 
family target genes such as p21WAF1 which was likely to be a result of the increased 
activity of endogenous p63 and p73 in the absence of mutant p53 (Lang et al. 2004).  
These studies proposed a means by which mutant p53 may promote tumourigenesis 
through downregulation of its p53 family members.  With respect to continuing the 
investigation of the mutants examined in this study, the use of knock-in mouse models 
could be a potentially interesting way to clarify how interactions with other proteins may 
control the modulation of p53 activity.   
These and other approaches have provided a basis on which to build our understanding 
of the activity of p53 mutants and the resulting biological outcomes.  The way in which 
we approach the design of individual therapeutic strategies is likely to depend on 
individual mutation phenotypes and will therefore be complex but crucial in the 
treatment of many cancers.  The results presented in this chapter of this report has 
highlighted the importance of the Box-V domain of p53 to function as a Calcium 
Calmodulin kinase docking site and an Mdm2 ubiquitination signal as well as 
highlighting the effect of specific mutations within p53 on kinase activation of p53.  The 
role of kinases such as Chk1 and DAPK1 on activation of p53 should therefore be 
investigated further to determine kinase-dependent changes in p53 target gene 
expression. 
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5 IDENTIFICATION OF KINASE DRUG TARGETS FOR 
REACTIVATION OF THE P53 RESPONSE 
5.1 Introduction 
5.1.1 siRNA technology 
RNA interference (RNAi) is a naturally occurring cellular defense mechanism against 
viral infections and transposons which utilize double stranded RNA (dsRNA) for self-
propagation (Fuchs and Borkhardt 2007; Iorns et al. 2007).  RNAi is a useful tool for 
selective transient or stable repression of gene expression and is considered a much more 
efficient method for gene silencing than the time consuming gene knockout in animal 
model systems (Fuchs and Borkhardt 2007).  RNAi as a method to manipulate gene 
expression was first performed in Caenorhabditis elegans (Fire et al. 1998) and soon 
after performed in cultured mammalian cells to suppress the expression of endogenous 
and heterologous genes (Elbashir et al. 2001).  The use of dsRNA in mammalian cells 
can however lead to the induction of interferon response and global shutdown of protein 
synthesis (Iorns et al. 2007).   To overcome this problem short interfering RNA (siRNA) 
are used to silence gene expression (Iorns et al. 2007).   
 
siRNAs are short annealing duplexes of approximately 21 nucleotides in length and are 
generally synthetic in origin (Martin and Caplen 2007).  They can be directly added to 
the cell by transfection and function by binding to their complementary mRNA which 
leads to the degradation of the mRNA and therefore the attenuation of gene expression 
(Fuchs and Borkhardt 2007).  Alternatively the siRNA duplexes can be generated within 
the cell by introducing plasmids that express short-hairpin RNA (shRNA).  shRNA are 
precursors of siRNA which are processed within the cell by the DICER enzyme into 
siRNA which promote the transcript degradation by binding to their complementary 
mRNA (Iorns et al. 2007).   Investigations utilizing both of these techniques have 
defined the roles for genes such as the AURORA B kinase in RAS transformation (Kanda 
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et al. 2005) and have identified PAI1 as a critical downstream target of p53 after the 
induction of replicative stress (Kortlever et al. 2006).  
 
Alternatively, RNAi libraries can be used to target multiple genes simultaneously.  
RNAi libraries are made up of reagents which target every single gene in the genome 
and are useful in elucidating phenotypes associated with loss-of-function of many 
individual genes simultaneously (Iorns et al. 2007).  There are two types of RNA library: 
collections of vector based shRNA expression vectors; or libraries of siRNA (Iorns et al. 
2007).  Large scale screens are used in cancer research for the identification of new 
components in cancer relevant signaling pathways such as p53 (Fuchs and Borkhardt 
2007).  RNAi can also be used therapeutically to treat viral infections such as the 
respiratory syncytical infection, ocular and neurogenerative disease (Kim and Rossi 
2007). 
 
For the purpose of this study we will focus on using siRNA duplexes (specifically 
Dharmacon RNAi reagents) to study the effect of kinase depletion on activation of p53.   
 
5.1.2 Microarray technology  
The advent of microarray technology has transformed molecular biology.  Previously 
there had been many different techniques used for the analysis of gene expression at 
mRNA level.  These have included northern blotting, differential display, serial analysis 
of gene expression, and dot-blot analysis (van Hal et al. 2000).  However, these 
techniques are in general quite limited due to low sensitivity and small sample number 
capability.  The development of DNA microarrays which assess variation of genes in the 
genome and RNA microarrays which compare changes in expression of all RNA 
transcripts in the transcriptome has allowed the study of the entire genome and the 
transcriptome (Plomin and Schalkwyk 2007).  Microarray technology allows the 
investigation of changes in transcription rates of nearly all genes of the genome in a 
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particular tissue or cell, as a result of different disease states, the stage of development 
and in response to intentional experimental perturbations (Stoughton 2005).  Types of 
microarray include class comparison, which compares expression profiles of different 
tissue types; class prediction which compares normal tissues to tumour tissues; and class 
discovery, which aims to discover new taxonomies, groupings or clusters within a 
collection of samples (Manning et al. 2007).  
 
Microarrays can be categorized as either (i) cDNA arrays in which probes are 
constructed with PCR products of up to a few thousand base pairs or (ii) 
oligonucleotides arrays which use either short (20 – 30 mer) or long (60 – 70mer) 
oligonucleotides (Draghici et al. 2006).  The technology is based on the hybridization of 
mRNA to a high density array of immobilized target sequences each corresponding to a 
specific gene (van Hal et al. 2000).  Each array contains several thousand DNA 
sequences which act as gene specific probes and are immobilized on a solid support such 
as nylon, glass or silicone (Manning et al. 2007).  The process involves the reverse 
transcription of mRNA samples to cDNA, the incorporation of fluorescent, radioactive 
or chemiluminescent labeled nucleotides and the binding (hybridisation) of cDNA to the 
array membrane (van Hal et al. 2000; Manning et al. 2007).  The emission signal of each 
spot on each array is a quantitative measurement which corresponds to the expression 
level of each gene (van Hal et al. 2000).  The resulting output reading provides a ‘snap-
shot’ of the profile of gene expression throughout the genome allowing the comparison 
of different groups, different time points and different tissues (Plomin and Schalkwyk 
2007). 
 
Microarrays have contributed to clarification of disease mechanisms, identified novel 
genes, assigned function to previously unannotated genes and enabled the grouping of 
genes into functional pathways (Stoughton 2005).  As well as gene expression analysis, 
DNA microarrays have facilitated biochemical and functional genomic studies of DNA 
binding proteins.  These technologies include ChIP-chip (or genome wide location 
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analysis), which utilizes chromatin immunoprecipitation of a protein followed by the 
microarray based detection of enriched DNA fragments to identify the in vivo 
transcription factor binding sites; Dam technology, which examines the DNA-binding 
site protein fused to DNA adenine methyltransferase (Dam) for identification of in vivo 
binding sites across the genome; and lastly PBM (protein-binding microarray) 
technology which allows high throughput characterization of DNA-binding proteins by 
assaying their binding to double stranded DNA microarrays (Bulyk 2006). For the 
purpose of this study we will focus on the use of microarrays for gene expression 
profiling.   
 
Microarrays are commonly used to examine differences in expression of specific genes 
across samples (Manning et al. 2007).  The use of microarrays to study such differences 
has many advantages over that of other gene expression technologies because of their 
relatively small size, their greater sensitivity, their requirement for a much smaller 
amount of starting material and the arrays have the potential for much larger sample 
screening (van Hal et al. 2000).  The development of microarray technology has allowed 
for the detailed profiling of tumours where previous studies have examined only 
individual genes as potential targets (Nagasaki and Miki 2006).  For example, breast 
cancers were classified based on profiles of gene expression (Perou et al. 1999) and from 
that the classification of cancer subtypes and prediction of therapeutic outcomes was 
established (Perou et al. 2000).  Examination and comparison of gene expression 
profiles of primary carcinomas, liver metastases and carcinomatoses to normal samples 
identified genetic patterns associated with different stages of liver tumourigenesis 
(Kleivi et al. 2007).  Microarray analysis was used to study effect of damage such as 
ionizing radiation (IR) on changes in gene expression profiles was examined in a paper 
by Snyder and Morgan.  They used microarray analysis to confirm that genes such as 
GADD45 and CDKN1A are consistently upregulated in response to IR and that there is 
also a substantial p53-independent component to the transcriptional profile following IR 
damage (Snyder and Morgan 2004).  It is hoped that the development of gene expression 
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profiling along with analysis of protein expression and interactions will lead to the 
development of drugs targeted to specific molecules (Nagasaki and Miki 2006).  
Furthermore, by examining the clinical response to radiotherapy, it should be possible to 
identify genes linked to radiosensitivity (Snyder and Morgan 2004) .   
 
There are however several concerns and issues associated with microarray analysis of 
gene expression.  Although changes in the mRNA level of genes gives an insight into 
which genes are transcriptionally active, microarray results do not automatically 
translate into changes in protein expression or phenotype (Manning et al. 2007).  Indeed, 
protein function is also controlled at the translational and post-translational levels.  The 
transcriptional profiling of RNA has many issues.  RNA is labile, is often prone to 
producing artifacts and in many examples RNA is too far removed from the actual 
cellular effectors (Hoheisel 2006).    Issues such as sensitivity, accuracy, specificity and 
reproducibility must be carefully considered (Draghici et al. 2006).  Variation in results 
can be influenced by several factors such as the biological samples, human variation and 
limitations to data analysis (Hoheisel 2006).  With regard to this, results should always 
be viewed cautiously and should ideally always be validated using techniques such as 
RT-PCR.   
 
The screening of human cancers using microarray technology has emerged as a powerful 
new tool in developing novel diagnostic, prognostic and therapeutic targets for cancers 
(Manning et al. 2007).   The use of primary analytical methods such as hierarchical 
clustering and statistical analysis based on differential expression to examine cancer 
transcriptome data has allowed the clarification of several issues (Rhodes and 
Chinnaiyan 2005).  For example, cancer can be distinguished from normal tissue using 
gene expression profiles; cancer subtypes often have distinct gene expression profiles; 
gene expression profiles of signature tumours can often predict disease recurrence and 
treatment response; and lastly heterogeneous cancers which can be subclassified into 
molecular subtypes of cancer often have distinct gene expression profiles (Rhodes and 
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Chinnaiyan 2005).   However, other more advanced methods of analysis have uncovered 
important biological profiles not apparent in standard analysis methods.  Methods such 
as ‘meta-analysis’, which analyses multiple sets of data to extract common gene 
expression patterns from independent cancer signatures and ‘protein interaction 
networks’ which elucidate the gene expression in context of the complex molecular 
networks using protein-protein interaction (interactome) maps have advanced the study 
of gene expression in cancer (Rhodes and Chinnaiyan 2005). 
 
The role of p53 as a tumour suppressor is mainly due to its activity as a transcription 
factor that activates the transcription of many genes in response to cell stresses leading 
to growth arrest and/or apoptosis (Levine 1997).   Microarray analysis has been used in 
several studies to address the issue of p53-dependent gene expression (Zhao et al. 2000; 
Kannan et al. 2001).  Zhao and colleagues used the human carcinoma cell line, EB-1, 
containing stably transfected p53 to examine the levels of genes regulated following 
DNA damaging treatments such as γ radiation and UV.  Cluster analysis revealed that 
genes could be grouped into distinct subsets and the expression of some genes was 
altered in a similar manner after all treatments (Zhao et al. 2000).  DNA microarrays 
were used to identify the primary and secondary targets of p53 (Kannan et al. 2001).  
This group compared a human cancer cell line which expresses temperature sensitive 
murine p53 (H1299-ts-p53Val135) to the p53 null cell line, H1299 and used 
cycloheximide treatment (inhibits protein synthesis) to distinguish between primary and 
secondary p53 target genes.  They showed that without cycloheximide there were 259 
upregulated and 125 downregulated genes and upon cycloheximide treatment less than 
20% of the above genes were up or down regulated.  These genes were considered as 
primary targets (Kannan et al. 2001).  Both studies go some way to clarifying the p53 
targets in various cellular contexts and to clarify both the early and late response genes.   
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5.1.3 Objectives and Experimental Approach  
The identification of Chk1 and DAPK1 as p53 activators has led to investigation of the 
effects of loss of these kinases on p53 signaling as well as the p53 response following IR 
damage.   In this chapter we set out to clarify the effect of kinase depletion on the 
activation of p53 using siRNA technology.   We then went on to combine siRNA 
technology and oligonucleotide microarrays which are low density gene arrays, to 
profile the gene expression of 113 genes involved in the human p53 signalling pathway 
(Superarray).  This would allow us to examine the effect of kinase depletion on 
activation status of p53 target genes.    
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5.2 Results 
5.2.1 Development of cell models to study the effect of loss of kinases on p53 
signaling  
We have previously identified, using in vivo assays such as transcription based reporter 
and siRNA putative kinases which may activate p53 by phosphorylation (see sections 
3.2.1 to 3.2.4).  Furthermore, we have found using coimmunoprecipitation assays that 
kinases and Mdm2 form an interaction with the Box-V motif of p53.   In light of the 
identification of Chk1 and DAPK1 as p53 activators it was necessary to go on to 
determine the effects of loss of these kinases on p53 signaling utilizing siRNA and 
microarray technology. 
 
5.2.1.1 Optimisation of siRNA technology  
A preliminary transient transfection assay was set up to compare and contrast the siRNA 
transfection delivery reagents, DharmaFECT® (Dharmacon) with the nucleic acid 
transfection reagent, Lipofectamine™ 2000 (Invitrogen) on the depletion of endogenous 
kinases and the effect on p53 expression.   Two tumour cell lines, A375 and A549 which 
express both p53 and the Calcium Calmodulin kinases (Chk1, Chk2 and DAPK1) were 
used to optimize the assay.   A375 or A549 cells were transfected with 100nM 
siCONTROL or 100nM siRNA oligonucleotides to one of each of the three kinases 
(Chk1, Chk2 and DAPK1) using either DharmaFECT® Buffers 1 to 4 or 
Lipofectamine™ 2000 transfection delivery agents.  48 hours following transfection 
cells were lysed and cell lysates were immunoblotted for changes in protein levels of the 
three kinases as well as p53 (Figure 5.1 A; A375 and Figure 5.1 B; A549).   
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Figure 5.1 Comparison of DharmaFECT and Lipofectamine transfection delivery reagents. 
A375 (A) or A549 (B) cells were transfected with 100nM control or 100nM siRNA to Chk1, Chk2 
or DAPK1 using 4µl DharmaFECT® Buffers 1 to 4 or Lipofectamine™ 2000 transfection delivery 
agents.  48 hours following transfection cells were lysed and cell lysates were immunoblotted for 
changes in Chk1, Chk2, DAPK1 and p53 protein levels (DO12). 
 
Firstly, using A375 cells, the results demonstrated that the protein levels of Chk1 are 
significantly depleted using these siRNA oligonucleotides with either DharmaFECT or 
Lipofectamine 2000 (Figure 5.1 A; comparing odd numbered lanes (siControl) with 
even numbered lanes (siKinase); Chk1 blot).  The only exception was when using 
DharmFECT Buffer 3 with siRNA to Chk1 there is less of a reduction in protein levels 
(Figure 5.1 A; comparing lanes 5 and 6 and lanes 11 and 12; Chk1 blot).  These data 
demonstrate that following depletion of Chk1 there is stabilization of p53 protein to 
varying levels dependent on transfection delivery buffer (Figure 5.1 A; siChk1; 
Chapter 5 Results 
 - 175 - 
comparing odd numbered lanes with even numbered lanes; p53 blot (i)).  This is also 
demonstrated following depletion of DAPK1, although the stabilization is less marked 
(Figure 5.1 A; siDAPK1; comparing odd numbered lanes with even numbered lanes; 
p53 blot (iii)).  Stabilisation of p53 following depletion of Chk2 is not evident is this 
assay (Figure 5.1 A; siChk2; comparing odd numbered lanes with even numbered lanes; 
p53 blot (ii)).  This was a particularly interesting result and suggested that the depletion 
of kinases, Chk1 and DAPK1 led to the stabilization of p53 levels in these tumour cells.   
 
A375 cells characteristically express low levels of endogenous Chk2 and DAPK1 which 
makes the detection of protein levels by western blot increasing difficult (Figure 5.1 A; 
Chk2 and DAPK1 blot).  Therefore, A549 cells which characteristically express higher 
levels of endogenous DAPK1 as well as Chk1 and Chk2 were used to support the data 
demonstrated in A375 cells.   The results demonstrated that the three kinases can be 
successfully depleted in A549 cells using the siRNA oligonucleotides with the 
DharmaFECT buffers 1, 2 and 4 and not Buffer 3 or Lipofectamine 2000 (Figure 5.1 B; 
comparing odd numbered lanes (siControl) with even numbered lanes (siKinase); Chk1, 
Chk2 or DAPK1 blots respectively).   The results reflect A375 cell data in which there is 
stabilization of p53 following depletion of Chk1 and DAPK1 but not Chk2 (Figure 5.1 
B; siChk1 and siDAPK1; comparing odd numbered lanes with even numbered lanes; 
p53 blot (i) and (iii) respectively).   
 
Using the two cell lines to examine changes in protein levels of both kinases and p53 
following treatment with siRNA oligonucleotides demonstrated that kinases could be 
successfully depleted and that depletion of Chk1 and DAPK1 led to the stabilization of 
p53.  However, the aim of this preliminary assay was to determine the best transfection 
delivery buffer to use in future assays.   Taking the two sets of data together it was 
decided the best transfection delivery buffer was DharmaFECT Buffer 4, based on levels 
of kinase depletion and p53 stabilisation.   
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We then went on to determine optimal incubation time for depletion of kinases.  A375 
cells were transfected with 100nM siControl or 100nM siRNA oligonucleotides to (i) 
Chk1, (ii) Chk2 and (iii) DAPK1 for either 24, 48 or 72 hours.  Cells were lysed and 
lysates were immunoblotted for changes in protein levels of Chk1, Chk2 or DAPK1 and 
p53.     
 
Figure 5.2  Optimisation of siRNA to determine the optimal siRNA incubation time.  
A375 cells were transfected with 100nM siControl or 100nM siRNA oligonucleotides to (i) Chk1, 
(ii) Chk2 and (iii) DAPK1 for either 24, 48 or 72 hours.  Cells were lysed and lysates were 
immunoblotted for changes in protein levels of the Chk1, Chk2 or DAPK1 and p53. 
 
The results demonstrate that 24 hours following transfection of siRNA oligonucleotides 
there is approximately 50% depletion of kinases (Figure 5.2; comparing lanes 1 and 4; 
Chk1, Chk2 and DAPK1 blots).  However, by 48 hours there is maximal depletion of 
protein levels of each of the kinases (Figure 5.2; comparing lanes 2 and 5; Chk1, Chk2 
and DAPK1 blots).  P53 is stabilized after Chk1 depletion (Figure 5.2; comparing lanes 
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1, 2 and 3 with lanes 4, 5 and 6; p53 blot).  Based on these results it was determined that 
the protein levels of the kinases were significantly depleted from the 48hours timepoint 
onwards. 
 
5.2.1.2 P53 is stabilized following damage 
There has been a significant volume of literature examining the role of Calcium 
Calmodulin kinases in modulation of p53 activity and many reports have suggested 
Chk2 as a putative stress activator of p53 (Hirao et al. 2000; Takai et al. 2002; Craig et 
al. 2003; Chen et al. 2005).  However, the role of Chk2 as a p53 kinase has been 
questioned in several reports (Ahn et al. 2003; Craig et al. 2003; Jallepalli et al. 2003) 
and in this report we have identified Chk1 and DAPK1 as putative p53 activators in 
cycling cells (see section 3.2.4).  In this chapter of this report we have demonstrated that 
p53 is stabilized following depletion of Chk1 or DAPK1 but not Chk2 (Figure 5.1).  
However, whether p53 is active or inactive in these assays is unknown.  To determine 
the effect of damage such as X-ray and UV on p53 stabilisation following depletion of 
Chk1 or DAPK1, siRNA assays were performed in conjunction with IR or UV treatment 
in A375 cells.   
 
A375 cells were transfected with 100nM siControl or 100nM siRNA to Chk1 or DAPK1 
for 48 hours.  Cells were then treated with either X-ray (5Gy) or UV (25J/m2) and 
incubated for 4 or 6 hours, respectively before harvesting.  Firstly examining X-ray data, 
the results demonstrated that p53 is stabilized following depletion of Chk1 or DAPK1 
(Figure 5.3 A; siChk1; comparing lanes 1 and 3; p53 blot and B; siDAPK1; comparing 
lanes 5 and 7; p53 blot) and that p53 is further stabilized following X-ray damage 
treatment (Figure 5.3 A; siChk1; comparing lane 4 with lane 2; p53 blot and B; 
siDAPK1; comparing lane 8 with lane 6; p53 blot).   
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Figure 5.3  Comparison of effect damage treatments following kinase depletion on p53 
stabilisation in A375 cells.   
A and B. Cells were transfected with 100nM siControl or 100nM siRNA to Chk1 (A) or DAPK1 
(B) for 48 hours.  Cells were then treated with X-ray (5Gy) and incubated for 4 hours before 
harvesting.  Cells were lysed and lysates were immunoblotted for changes in protein levels of 
p53, Chk1 or DAPK1, phospho-p53 Ser 15 and phosho S6.  C and D. Cells were transfected 
with 100nM siControl or 100nM siRNA to Chk1 (C) or DAPK1 (D) for 48 hours.  Cells were then 
treated with UV (25J/m2) and incubated for 6 hours before harvesting.  Cells were lysed and 
lysates were immunoblotted for changes in protein levels of p53, Chk1 or DAPK1, phospho-p53 
Ser 15, phosho-S6 ribosomal protein (Ser235/236, 2F9) and phospho-p70 S6 kinase (Thr389, 
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The stabilization of p53 following damage is not dependent on Ser 15 phosphorylation 
in these cells (Figure 5.3 A; siChk1; comparing lanes 3 and 4; p-p53 Ser 15 blot and B; 
siDAPK1; comparing lanes 7 and 8; p-p53 Ser 15 blot).  UV damage also stabilized p53 
and depletion of kinases further stabilized p53 (Figure 5.3 C; siChk1 comparing lanes 11 
and 12; p53 blot and D; siDAPK1 comparing lanes 15 and 16; p53 blot).  Similar to X-
ray this UV damage induced stabilization of p53 is not dependent on Ser 15 
phosphorylation of p53 (Figure 5.3 C; siChk1 comparing lanes 11 and 12; p-p53 Ser 15 
blot and D; siDAPK1 comparing lanes 15 and 16; p-p53 Ser 15 blot) but may be 
dependent on phosphorylation at other sites on p53.   
 
Recently it has been demonstrated that DAPK1 can positively regulate mTOR 
(mammalian target of rapamycin) by forming an interaction with tuberous sclerosis 
(TSC)1/TSC2 complex in cells.  This interaction neutralises TSC1/2 mediated 
suppression of the mTOR translation pathway leading to stimulation of mTOR as 
determined by changes in activity of the translational regulator, p70 S6 kinases (C. 
Stevens et al, in press).  The kinases which are responsible for phosphorylation of 
ribosomal protein S6 (rpS6), S6K1 and S6K2, are direct targets of mTOR which 
activates these kinases through phosphorylation at specific S/T residues. 
Phosphorylation of T389 correlates most closely with S6K activity in vivo (Proud 2007).  
Moreover a recent report has suggested a crosstalk between p53 and mTOR signaling 
pathways leading to the coordinate regulation of cell growth, proliferation and death 
(Feng et al. 2005).  Here we show here that following depletion of Chk1 or DAPK1 
there is no change in S6 kinase phosphorylation (Figure 5.3 A; Chk1; comparing lanes 1 
and 3; p-S6 blot and B; DAPK1; comparing lanes 5 and 7; p-S6 blot) and X-ray damage 
does not induce phosphorylation of S6 kinase (Figure 5.3 A; Chk1; comparing lanes 3 
and 4; p-S6 blot and B; DAPK1; comparing lanes 7 and 8; p-S6 blot).  Following UV 
damage there is increased S6 kinase phosphorylation (Figure 5.3 C; siChk1 comparing 
lanes 9 and 10; p-S6 blot and D; si DAPK1; comparing lanes 13 and 14; p-S6 blot) but 
this phosphorylation is not further increased following depletion of kinases (Figure 5.3 
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C; siChk1 comparing lanes 10 and 12; p-S6 blot and D; si DAPK1; comparing lanes 14 
and 16; p-S6 blot). Interestingly, following UV damage there is also increased 
phosphorylation of the translational regulator p70 S6 kinase (Figure 5.3 C; siChk1 
comparing lanes 9 and 10; p-p70 S6 kinase blot and D; siDAPK1; comparing lanes 13 
and 14; p-p70 S6 kinase blot) and this p70 S6 kinase activity is increased further 
following depletion of kinases (Figure 5.3 C; siChk1 comparing lanes 9 and 10 with 
lanes 11 and 12; p-p70 S6 kinase blot and D; si DAPK1; comparing lanes 13 and 14 
with lanes 15 and 16; p-p70 S6 kinase blot).  Therefore although p53 stabilisation 
following depletion of kinases is not dependent on Ser 15 phosphorylation is these cells, 
there could be a role for the translational regulators, S6K1 and S6K2.  As described, 
activated DAPK1 neutralises TSC mediated suppression of mTOR translation pathway 
(C. Stevens, in press).  Thus following depletion of DAPK1 we would expect a decrease 
mTOR activity.  However we have shown here that the depletion of DAPK1 leads to the 
increased activity of p70 S6 kinase as well as increased stabilization of p53 which may 
therefore suggest a crosstalk between p53 and mTOR signaling pathways.   
 
5.2.1.3 Comparison of lysis buffers 
To further investigate the mechanism of p53 stabilisation by kinase downregulation, 
assays were performed to compare levels of p53 stabilisation following lysis of cells 
using two lysis buffers, urea and NP-40.  In all previous assays cells were lysed with the 
denaturing urea lysis buffer which is used to ensure the preservation of phospho-
epitopes.  NP-40 is a detergent lysis buffer which contains phosphatase inhibitors which 
preserve the phospho-epitopes.  Firstly, to determine the effect of lysis buffer on both 
undamaged and damaged A375 cells, cells were treated with 25J/m2 UV irradiation and 
harvested 6 hours following treatment.  Cells were lysed with either urea or NP-40 lysis 
buffer and lysates were immunoblotted for changes in protein levels of Chk1, Chk2, 
DAPK1, p53, IRF1, S6 ribosomal protein or p70 S6 kinase. 
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Figure 5.4 Effect of lysis buffer on p53 stabilisation.   
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(Figure 5.4) A. A375 cells were either undamaged or treated with 25J/m2 UV irradiation and 
cells were harvested 6 hours following treatment.  Cells were lysed with either urea or NP-40 
lysis buffer and lysates were immunoblotted for changes in protein levels of Chk1, Chk2, 
DAPK1, p53, IRF1 or the translational regulators S6 ribosomal protein and p70 S6 kinase.  B 
and C. A375 cells were transfected with either 100nm siControl or 100nM siRNA to Chk1 or 
DAPK1 for 48hours.  Following incubation with siRNA cells were either undamaged or treated 
with 5Gy X-ray irradiation (B) or 25J/m2 UV (C), incubated then harvested 4 or 6 hours later, 
respectively.  Cells were then lysed with either Urea (a) or NP-40 (b) lysis buffer and cell lysates 
were immunoblotted for protein levels of Chk1, DAPK1, p53, IRF-1, PTEN and p21WAF1. 
 
In support of previous data (Figure 5.3), following UV damage Chk1 and Chk2 protein 
levels are reduced suggesting that these kinases are not stabilized following UV damage 
and this is not dependent on lysis buffer (Figure 5.4 A; comparing lanes 1 and 2; urea 
lysis and lanes 3 and 4; NP40 lysis; Chk1 and Chk2 blots).  The protein levels of 
DAPK1 are unchanged following UV damage (Figure 5.4 A; comparing lanes 1 and 2; 
urea lysis and lanes 3 and 4; NP40 lysis; DAPK1 blot).  P53 protein levels increase 
following damage suggesting the protein is stabilized although this stabilization of p53 
is not dependent on lysis buffer (Figure 5.4 A; comparing lanes 1 and 2; urea lysis and 
lanes 3 and 4; NP40 lysis; p53 blot).  IRF-1 (interferon regulatory factor -1), a 
transcriptional activator of genes involved in interferon response, is decreased following 
UV damage (Figure 5.4 A; comparing lanes 1 and 2; urea lysis and lanes 3 and 4; NP40 
lysis; IRF1 blot).  IRF-1 has been shown to modulate the expression of the cell cycle 
control gene, p21WAF1, by synergising with p53 resulting in the recruitment of p300 to 
and subsequent acetylation of promoter bound p53 which in turn leads to increased p53-
dependent p21WAF1 promoter activity (Dornan et al. 2004).  We are able to demonstrate 
following UV damage that the activity of the translational regulators p70 S6 kinase and 
S6 kinase are increased (Figure 5.4 A; comparing lanes 1 and 2; urea lysis and lanes 3 
and 4; NP40 lysis; p-p70 S6 kinase and S6 kinase blots). 
 
To compare and contrast the effect of the two lysis buffers on p53 stabilisation following 
kinase depletion and subsequent damage treatments, A375 cells were transfected with 
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either 100nM siControl or 100nM siRNA to Chk1 or DAPK1 for 48hours.  The results 
demonstrate that following either IR (Figure 5.4 B; lanes 1 to 12) or UV (Figure 5.4 C; 
lanes 13 to 24) damage, p53 is stabilized as demonstrated by the p53 DO12 blots (Figure 
5.4 B; IR; comparing lanes 1 and 2 with lanes 3 and 4 or UV; comparing lanes 13 and 14 
with lanes 15 and 16; DO12 blot).  However, p53 is not stabilized further upon Chk1 
depletion and damage (Figure 5.4 B; IR; comparing lanes 7 and 8 with lanes 3 and 4; or 
Figure 5.4 C; UV; comparing lanes 19 and 20 with lanes 15 and 16; DO12 blot).  This is 
also the case for DAPK1 depletion and IR damage (Figure 5.4 B; IR; lanes 11 and 12 
with lanes 3 and 4) although the results are less clear for UV damage.  The results also 
demonstrate that changing lysis buffer has no effect on p53 stabilisation (Figure 5.4 B; 
IR or UV; comparing odd numbered lanes with even numbered lanes; DO12 blot).  
Interesting the phospho-p53 Ser 15 levels increase slightly following UV (Figure 5.4 C; 
UV; comparing lanes 15 and 16 with lanes 13 and 14; p-p53 Ser 15 blot) and this seems 
to increase further following kinase depletion (Figure 5.4 C; UV; siChk1 lanes 19 and 20 
and siDAPK1 lanes 23 and 24; p-p53 Ser 15 blot).  This damage induced 
phosphorylation is less obvious following IR damage and kinase depletion (Figure 5.4 
B; IR; comparing lanes 3 and 4 with lanes 7 and 8; p-p53 Ser 15 blot). 
 
Using the DO1 antibody, which is specific to the N-terminal Box-I domain we are able 
to demonstrate and confirm that p53 is stabilized following damage (Figure 5.4 B; IR; 
comparing lanes 1 and 2 with lanes 3 and 4 or UV; comparing lanes 13 and 14 with 
lanes 15 and 16; DO1 blot) but this stabilization is slightly increased following depletion 
of Chk1 (Figure 5.4 B; IR; lanes 7 and 8 or UV; lanes 19 and 20; DO1 blot) and to a 
lesser extent DAPK1 (Figure 5.4 B; IR; lanes 11 and 12 or UV; lanes 23 and 24; DO1 
blot).  The binding of the DO1 antibody to p53 is blocked by the phosphorylation of p53 
at Ser 20 (Craig et al. 1999) and these data shown here therefore suggest that there is no 
phosphorylation of Ser 20 following depletion of these kinases and damage. 
 
Chapter 5 Results 
 - 184 - 
We are also able to demonstrate that there is stabilization of IRF-1 following depletion 
of Chk1 and damage (Figure 5.4 B; IR; comparing lanes 7 and 8 with lanes 5 and 6 or C; 
UV; lanes 19 and 20 with lanes 17 and 18; IRF-1 blot) or depletion of DAPK1 and UV 
damage (Figure 5.4 C; UV; comparing lanes 23 and 24 with lanes 21 and 22; IRF-1 
blot).     Furthermore the stabilization of IRF-1 appears to be increased on lysis of cells 
using NP-40 lysis buffer (Figure 5.4 B; IR or UV; comparing odd numbered lanes with 
even numbered lanes; IRF-1 blot) suggesting that stabilization of IRF-1 may be lysis 
buffer dependent.  The stabilization of IRF-1 may correlate with the increased 
expression of p21.  p53 and IRF-1 have been shown to converge to regulate p21WAF1 
gene expression (Dornan et al. 2004).  Following IR and Chk1 depletion there is 
increased p21 expression (Figure 5.4 B; IR; comparing lanes 7 and 8 with lanes 5 and 6; 
p21 blot) but for UV damage the data is unconvincing (Figure 5.4 C; UV; p21).   
 
The tumour suppressor PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) activates p53 in tumours which leads to the induction of senescence (Li 
and Ross 2007).  We show here that PTEN is not activated following damage (Figure 
5.4 B; IR; comparing lanes 3 and 4 with lanes 1 and 2 or C; UV; comparing lanes 15 and 
15 with lanes 13 and 14; PTEN blot) or depletion of kinases (Figure 5.4 B and C; 
comparing siCON with siChk1 or siDAPK1; PTEN blot) and therefore is not involved in 
the stabilization of p53 is this pathway.  However, PTEN, like IRF-1 is affected by the 
lysis buffer suggesting that the expression of this protein is dependent on the type of 
denaturing buffer. 
 
Overall, we are able to demonstrate that p53 is stabilized following kinase depletion, it is 
further stabilized following damage such as X-ray or UV and that this stabilization is not 
dependent on lysis buffer used.  There may be a role for IRF-1 which may coordinate 
with p53 to control cell cycle progression.  The activity translational regulator S6 may 
suggest a crosstalk between p53 and mTOR signaling pathways leading to the 
coordinate regulation of cell growth, proliferation and death (Feng et al. 2005).  
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5.2.2 A cell viability assay demonstrates that depletion of kinases and subsequent 
damage does not result in any additional cell death 
We have shown that depletion of kinases results in stabilization of p53 and that damage 
leads to increased stabilization of p53.  To investigate the consequence of this 
stabilization of p53 a cell viability assay was performed.  This would allow the 
evaluation of levels of cell proliferation and therefore allow us to determine whether 
depletion of kinases and subsequent damage insult was causing cell death resulting from 
activation of p53 pathway.  The standard colourimetric assay, MTT assay, was used to 
measure changes in cell number and therefore determine the potential cytotoxic effects 
of kinase depletion and damage.  A375 cells were untransfected (cells only), mock 
transfected (mock) or transfected with 100nM siControl or 100nM siRNA to Chk1, 
Chk2 and DAPK1 for 48 hours.  Cells were then treated with either X-ray (5Gy) or UV 
(25J/m2) and incubated for 4 or 6 hours, respectively before addition of MTT solution 
for 4 hours.  Following incubation, DMSO was added to dissolve formazan crystals and 
absorbance was read at 570nm by spectrophotometry against a DMSO control.  
 
The results are shown in the two bar graphs (Figure 5.5), the first examining the effect of 
kinase depletion and IR damage on cell viability (Figure 5.5 A) and the second 
examining the effect of kinase depletion and UV damage on cell viability (Figure 5.5 B).  
The results show that transfection is resulting in no reduction in cell viability (Figure 
5.5; A or B; comparing mock and cells only controls) and that depletion of kinases has 
little or no effect on cell viability in undamaged cells (Figure 5.5; A or B; comparing 
siCON with siChk1, siChk1 or siDAPK1; blue bar; without IR/UV).   
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Figure 5.5  An MTT assay demonstrates that depletion of kinases and damage has no 
effect on cell viability.   
A375 cells were transfected with 100nM siControl or 100nM siRNA to Chk1, Chk2 or DAPK1 for 
48 hours.  Cells were then treated with either 5Gy X-ray (A) or 25J/m2 UV (B) and incubated for 
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4 or 6 hours, respectively before addition of MTT solution for 4 hours.  Following incubation, 
DMSO was added to dissolve formazan crystals and absorbance was read at 570nm. Data was 
normalised using DMSO as a blank and is represented as optical density at 570nm.   Each data 
point is the average of four replicates with error bars showing standard deviation. 
 
The results also demonstrate that IR (5Gy X-ray) damage does not result in a reduction 
in cell viability in kinase depleted cells (Figure 5.5 A and B; comparing without IR, blue 
bars with plus IR, red bars; siChk1, siChk1 and siDAPK1) and that following UV 
damage in kinase depleted cells there is little effect on cell viability (Figure 5.5 C; 
comparing without UV, blue bars with plus UV, red bars; siChk1 and siChk1).   We can 
conclude in the main that neither kinase depletion nor damage is affecting the viability 
and therefore the proliferation potential of these cells.  Therefore the stabilization of p53 
in these cells following kinase depletion does not result in increased cell death in this 
assay and that there may be other factors involved. 
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5.2.3 A microarray study demonstrates that silencing of kinases leads to increased 
activation of p53 target genes 
The previous assays have demonstrated that depletion of Chk1 and DAPK1 leads to 
stabilization of p53.  It was therefore necessary to examine the effect of blocking these 
kinases on the activation of the p53 signaling pathway.  Microarray analysis of Chk1 and 
DAPK1 depleted cells was performed to evaluate the changes in gene expression 
profiles of 113 genes involved in the human p53 signalling pathway using the Oligo 
GEArray® System (Superarray; Bioscience Co.). 
 
5.2.3.1 Microarray analysis of Chk1 or DAPK1 depleted (undamaged) cells 
Firstly, oligonucleotide microarrays were used to assess the global effect of loss of Chk1 
and DAPK1 in undamaged conditions.  A375 cells were transfected with 100nM 
siControl or 100nM siRNA to Chk1 or DAPK1 for 48 hours.  Labelled cRNA from 
kinase depleted A375 cells was assessed for changes in gene expression profile of the 
genes involved in the p53 signalling pathway.   
 
The results are demonstrated in Figure 5.6 which shows the raw images of each 
microarray and gives an overview of the effect of depletion of Chk1 or DAPK1 kinases 
on upregulation of p53 signalling genes.  It is apparent that there is a basal level of genes 
upregulated as demonstrated by the siRNA non-targetting control (Figure 5.6 A; si Con).  
On depletion of Chk1 there was significant upregulation of genes, indeed compared to 
control there are almost 4 fold more genes upregulated (Figure 5.6 B; siChk1; 70 genes 
upregulated) and DAPK1 depletion up to 3 fold more genes upregulated (Figure 5.6 C; 
siDAPK1; 56 genes upregulated).  The details of each of the genes upregulated are also 
represented in Table 5.1 where genes have been categorized based on their function.  It 
can be concluded from this table and the raw images that depletion of either Chk1 or 
DAPK1 leads to an upregulation of p53 signalling genes, some of which are upregulated 
at a basal level (siCon) and are present following depletion of kinases and others are 
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upregulated only following depletion of either Chk1 or DAPK1.  This activation of the 





Figure 5.6 A microarray analysis of effect of kinase depletion on p53 signalling pathway. 
A375 cells were transfected with 100nM siControl (A) or 100nM siRNA to Chk1 (B) or DAPK1 
(C) for 48 hours.  Total RNA was isolated from the cells, which was then reverse transcribed into 
cRNA, labeled with biotin and hybridized to the Oligo GEArray® DNA Microarray, Human p53 
Signaling Pathway (Superarray; Bioscience Co.).  The control, house-keeping genes are 
indicated by arrows and the specific house-keeping genes chosen for normalization of data are 
indicated by the broader red arrows.   
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Table 5.1 Genes expressed in A375 cells following depletion of kinases  
 Gene 
Symbol 
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Table 1.1 Genes expressed in A375 cells following depletion of Chk1 or DAPK1.  Genes are 
categorized based on their function.  ‘X’ represents a gene upregulated by visual assessment 
and a highlighted gene symbols represent genes which are upregulated (by visual assessment) 
under all three conditions.  
.  
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A more detailed analysis was performed using the GEArray Expression Analysis Suite 
(Superarray) software which allows the user to upload the array image, extract data from 
the uploaded image and perform analysis of the data using the various analysis tools 
which are available.  Images are aligned to a grid either manually or automatically and 
from this a readout of signal intensity is generated and corrections are made for 
background of individually defined areas and an average of signal intensities of the 4 
four replicates on each array.   Normalisation of signal intensities between samples can 
be performed using the control spots, which include the house-keeping genes, present on 
each array.  House keeping genes are normally expressed consistently under most 
conditions and are therefore a useful normalization method to control for discrepancies 
between levels signal intensities due to variation in hybridisation of mRNA to the 
membrane.   As shown in Figure 5.6, I have selected RPS27A and ACTB to use for 
normalization as these housekeeping genes are represented consistently across each of 
the samples.  Each value shown in Table 5.2 represents the level of mRNA expression 
following background correction and normalization and is represented as relative units.   
 
Table 5.2 demonstrates the ratio of gene intensities between the test (e.g. siChk1) and 
the reference (e.g. siCON) samples, which are represented as fold changes.  The 
significance of each individual fold change is defined by applying a cut-off value where 
a fold change of 1.5 between reference and test sample is deemed a significant 
repression or induction.   Upregulation of genes are shown as positive values and 
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Table 5.2 Ratio of gene expression between samples (represented as fold changes)   





































































































































































Chapter 5 Results 






































































































































Table 1.2 Ratio of gene expression between samples (represented as fold changes). Values 
highlighted in grey represent genes which are upregulated in siControl; ● represents a gene 
which is considered absent in siChk1; ■ represents a gene which is considered absent in 
siDAPK1; ▲ represents a gene which is upregulated more in siDAPK1 than siChk1; and * 
represents a spot which is considered as bleeding, therefore value for that gene may be 
underestimated.   
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In general the fold induction of gene expression is highest following Chk1 depletion 
(Table 5.2, siChk1 Vs siCON).  Following depletion of DAPK1 there is a similar pattern 
of genes induced as when Chk1 is depleted but in general the fold induction is lower 
than that following Chk1 depletion (Table 5.2, siDAPK1 Vs siCON).  We are able to 
demonstrate this clearly by directly comparing the levels of fold change following 
DAPK1 depletion versus Chk1 depletion where the downregulation is represented as a 
negative inverse value (Table 5.2; siDAPK1 vs siChk1).  This has highlighted two genes 
which are upregulated to a greater extent (more than 1.5 fold) following DAPK1 
depletion, the apoptotic gene, BAX (BCL2-associated X protein) and the cell cycle gene, 
CDKN1A (cyclin-dependent kinase inhibitor 1A; p21).  However the latter is likely to be 
an anomaly due to ‘bleeding’ whereby the spot signal intensity is considered to be 
greater than the average value of all spots, therefore underestimating the actual signal 
intensity (annotated in Table 5.2 by an asterix *). 
 
Many genes are considered to be absent in all groups (control and following kinase 
depletion) and cannot therefore be included in calculations for fold change.  These have 
been represented in Table 5.2 as considered absent following Chk1 depletion (● siChk1 
vs siCON) or considered absent following DAPK1 depletion (■ siDAPK1 vs siCON).  
Some genes are upregulated at a basal level (as demonstrated in Table 5.1; siCON) and 
following depletion of kinases, these genes are upregulated further (Table 5.2; fold 
induction comparisons; siChk1 Vs siCON and siDAPK1 Vs siCON; highlighted in 
grey).  These 14 genes have also been represented in Figure 5.7 which demonstrates the 
basal transcript levels of each gene as well as following depletion of kinases 
(represented as relative units; RU).  This has highlighted several genes which show 
significant upregulation following depletion of one or both kinases (as calculated by fold 
induction; see Table 5.2).  Genes include BIRC5, KLF6 and SFN.  The other genes do 
not demonstrate a upregulation as their fold induction is less than or equal to 1.5 (see 
fold induction in Table 5.2).      
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Figure 5.7  Comparison of basal and kinase stimulated transcript levels of genes.   
The 14 genes which are considered to be upregulated in the control (siCON) group are shown in 
this graph which demonstrates the basal and kinase stimulated transcript level of each gene 
(represented as relative units, RU).  Several genes are considered to have ‘bleeding’ of signal 
intensity in one or more groups and this has resulted in under represented transcript levels 
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Another 22 genes are considered to be absent in control (siCON) but present following 
depletion of kinases (siChk1 or siDAPK1).  These upregulated genes have been 
represented in Table 5.2 as values of fold induction.  Although considered to be absent 
in the control group (siCON) they do have values greater than or equal to 0.01, therefore 
an increase in the value following depletion of kinase has been included in this table to 
represent the fold change. 
 
It is apparent that the depletion of kinases results in significant upregulation but no 
downregulation of p53 signalling pathway genes.   To demonstrate the genes with the 
highest fold induction and compare the fold induction following either Chk1 or DAPK1 
depletion, a figure was generated showing the upper 50% of gene fold induction (Figure 
5.8 A).  This demonstrates that genes such as NFKB1, HK2, ATR and E2F1 are 
upregulated to a higher extent following depletion of kinases and are therefore likely to 
play a significant role following depletion of kinases.  However as most of them are 
upregulated to a greater extent in siChk1 group they are more likely to play a role 
following in Chk1 depletion.  At the other end of the scale the lower 50% of gene fold 
induction is represented in a similar figure (Figure 5.8 B) and demonstrate the genes 
which are upregulated to a lesser extent following depletion of kinases.  At this end of 
the scale the comparative fold change between siChk1 and siDAPK1 is very similar 
suggesting that this low level induction of genes is occurring to a similar extent 
following depletion of either Chk1 or DAPK1. 
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Comparison of fold induction levels following kinase depletion 

























































si Chk1 Vs siCON 
siDAPK1 Vs siCON 
A.
 
Comparison of fold induction levels following kinase depletion 

























































si Chk1 Vs siCON 
siDAPK1 Vs siCON 
B.
 
Figure 5.8  Comparison of fold induction levels following kinase depletion.  
Graphs showing the upper 50% (A)  and lower 50% of genes upregulated (B).  
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To provide an overall view of the effect of depletion of kinases on activation of p53 
target genes, the Clustergram analysis tool (GEArray Expression Analysis Suite) was 
used to create a cluster diagram to demonstrate the microarray data.  Clustergram 
analysis demonstrates the hierarchical clustering of genes, where genes that are more 
similar in terms of their expression patterns (i.e. not clustered in terms of gene function) 
are joined at lower heights in the dendogram and those that are less similar are joined at 
higher heights.     
 
The data presented in the clustergram is based upon the colour coding of genes based on 
results from the entire dataset, where colours are assigned based on values in the whole 
dataset (Figure 5.9).  This allows the expression levels of all genes to be compared 
across the whole dataset.  Although this method is less sensitive in that genes expressed 
at lower levels are under represented, it allows the comparison of upregulation of the 
genes within a sample as well as the comparison of upregulation of the genes across the 
three sample groups.  The clustergram therefore provides an overall picture of the effect 
of depletion of kinases on upregulation of p53 target genes.  It demonstrates that the 
genes that are upregulated in siCON are also upregulated in the other samples.  It also 
demonstrates that siChk1 has upregulated genes which are unique to this group and that 
genes that are upregulated in siDAPK1 are also mostly upregulated in siChk1.   
 
Overall we have been able to demonstrate using microarray technology that depletion of 
either Chk1 or DAPK1 leads to significant upregulation of p53 target genes.  Thus 
providing an insight into the pathways involved in upregulation of p53 target genes in 
undamaged conditions.   
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Figure 5.9 Gene expression profile following depletion of kinases demonstrates that Chk1 
and DAPK1 depletion leads to upregulation of p53 target gene expression.  
Clustergram analysis is used to demonstrate the correlation of genes, where genes that are 
more similar are joined at lower heights in the dendogram and those that are less similar are 
joined at higher heights.  Genes are colour coded based on the entire dataset thereby allowing 
the comparison of genes within a sample as well as across the three groups.  The colour 
represents the magnitude of gene expression whereby green represents low gene expression 
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5.2.3.2 Microarray analysis of kinase depleted, X-Ray treated cells 
In light of the data which demonstrated that p53 was stabilized on depletion of kinases 
and was further stabilized following X-ray damage (see section 5.2.1.2) and that the 
depletion of kinases led to upregulation of p53 target genes (see section 5.2.3.1), we set 
out to examine the effect of X-ray treatment on activation of p53 target genes using the 
same microarray technology.  A375 cells were transfected with 100nM siControl or 
100nM siRNA to Chk1 or DAPK1 for 48 hours.  Cells were then treated with 5Gy X-ray 
and incubated for a further 4 hours.  Labelled cRNA from kinase depleted, X-ray treated 
cells was then assessed for changes in gene expression profile to examine early 
responses of the genes involved in the p53 signalling pathway.   
 
The results are demonstrated in Figure 5.10 which shows the raw images of each 
microarray and gives an overview of the effect of depletion of Chk1 or DAPK1 kinases 
and IR damage on upregulation of p53 signalling genes.  The numbers of genes 
upregulated by visual assessment have been indicated in Figure 5.10 in brackets.  It is 
apparent that there is a basal level of p53 target genes upregulated as demonstrated by 
the siRNA non-targeting control and following IR damage there is a significant 
upregulation of p53 target genes in the siControl (Figure 5.10 A; siCON; 18 genes 
upregulated vs B; siCON + IR; 75 genes upregulated).  On depletion of either Chk1 or 
DAPK1 there is a significant upregulation of genes (Figure 5.10 B; siChk1; 84 genes 
and C; siDAPK1; 67 genes) confirming previous data as demonstrated in section 5.2.3.1.  
However following IR damage there is no upregulation of genes in DAPK1 depleted 
cells (Figure 5.10 E; siDAPK1; 67 genes versus F; siDAPK1 + IR; 67 genes) and in the 
case of Chk1 depleted cells there may even be some down regulation of genes following 
IR damage (Figure 5.10 C; siChk1; 84 genes versus F; siChk1 + IR; 75 genes).  The 
details of each of the genes upregulated are also represented in Table 5.3 where genes 
have been categorized based on their function.  This table highlighted some additional 
genes which are upregulated on kinase depletion and which were not seen previously 
(see Table 5.1).  Overall the examination of the effect of kinase depletion and damage on 
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the regulation of p53 target genes by visual assessment has suggested that although there 
is upregulation of p53 target genes following IR damage in control, this damage insult 
does not result in further upregulation of p53 target genes following depletion of 
kinases.  The results therefore suggest that the depletion of either kinase may play more 
of a role in the activation of p53 in undamaged conditions.   
 
 
Figure 5.10 A microarray analysis of effect of X-ray damage on kinase depleted cells. 
A375 cells were transfected with 100nM siControl or 100nM siRNA to Chk1 or DAPK1 for 48 
hours.  Cells were then treated with 5Gy X-ray and incubated for a further 4 hours.  Total RNA 
was isolated from the cells, which was then reverse transcribed into cRNA, labeled with biotin 
and hybridized to the Oligo GEArray® DNA Microarray, Human p53 Signaling Pathway (OHS-
027; Superarray; Bioscience Co.). The control, house-keeping genes are indicated by arrows 
and the specific house-keeping genes chosen for normalization of data are indicated by the 
broader red arrows.  The numbers of genes upregulated by visual assessment is indicated in 
brackets.  
Chapter 5 Results 
 - 204 - 
Table 5.3 Genes expression in A375 cells following kinase depletion and IR damage 
 Gene 
Symbol 
siCON siCON + 
IR 
siChk1 siChk1 + 
IR 
siDAPK siDAPK
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Table 1.3 Gene expression in A375 cells following kinase depletion and IR damage.  Genes are 
categorized based on their function.  ‘X’ represents a gene upregulated by visual assessment 
and a highlighted gene symbols represent genes which are upregulated (by visual assessment) 
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A more detailed analysis was performed using the GEArray Expression Analysis Suite 
(Superarray) software as described in section 5.2.3.1.   As shown in Figure 5.10, I have 
selected RPS27A and ACTB to use for normalization as these housekeeping genes are 
represented consistently across each of the samples.  Each value shown in Table 5.4 
represents the level of mRNA expression following background correction and 
normalization and is represented as relative units.  Table 5.4 demonstrates the ratio of 
gene intensities between the test (e.g. siCON + IR) and the reference (e.g. siCON basal) 
samples, which are represented as fold changes.  The significance of each individual fold 
change is defined by applying a cut-off value where a fold change of 1.5 between 
reference and test sample is deemed a significant repression or induction.   Genes which 
are considered absent in both the test and reference samples are indicated (Table 5.4; ● 
symbol), and genes which are considered absent across all three sample comparison 
groups, have been removed.  Upregulation of genes are shown as positive values and 
repression of genes as negative inverse values. 
 
We have already shown that the depletion of kinases leads to significant upregulation of 
p53 target genes (see 5.2.3.1).  This microarray assay was used to demonstrate the effect 
of X-ray damage in kinase depleted cells on expression of p53 target genes.  The results 
demonstrate that the highest upregulation of p53 target genes following damage occurs 
in the non-targeting siRNA control group (Table 5.4; siCON+IR vs siCON), suggesting 
that this type of damage in these cells causes significant upregulation of p53 target genes 
without kinase depletion.  The most upregulated of these genes have been presented in 
Figure 5.11 which demonstrates the fold induction following damage of the upper 50% 
of genes upregulated.  Some of the genes represented in this figure (Figure 5.11; e.g. 
NFKB1, HK2, E2F1 and PMP22) have been previously shown to be significantly 
upregulated following depletion of Chk1 (see Figure 5.8 A) although the fold induction 
was lower in the latter case.  Thus suggesting that IR damage in these cells induces the 
expression of similar genes to kinase depletion but the level of upregulation is higher 
following IR damage than kinase depletion.  
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Table 5.4 Ratio of gene expression between samples (represented as fold changes) 
 Gene 
Symbol 
siCON + IR Vs. 
siCON 
siChk1 + IR Vs. 
siChk1  
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Table 1.4 Ratio of gene expression between samples (represented as fold change). Gene 
symbols highlighted in grey represent genes which are upregulated at a basal level in 
siCONTROL; ● represents genes considered absent in both the reference and test samples;  
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siCON + IR Vs. siCON
 
Figure 5.11 Genes upregulated following damage.   
A graph representing the fold induction levels of the upper 50% of genes upregulated in non-
targetting siRNA control treated cells following IR damage. An asterix (*) represents spots which 
are considered as bleeding, therefore value for that gene may be underestimated 
 
Upon damage to Chk1 depleted cells, there is no significant fold change in upregulation 
of the majority of genes and as indicated by the negative values there is some 
downregulation of p53 target genes following the damage insult (Table 5.4; siChk1+IR 
vs siChk1).  This is also true of DAPK1 depleted cells whereby for the majority of genes 
there is no significant fold change in upregulation of genes and many genes are found be 
downregulated upon damage (Table 5.4; siDAPK1+IR vs siDAPK1).  In light of the fact 
that IR damage causes no further upregulation of p53 target genes in kinase depleted 
cells, analysis of fold induction between irradiated groups was not shown as there is no 
significant change in level of gene upregulation between groups (siControl + IR 
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compared to siChk1 + IR or siDAPK1 + IR).  This result is also reflected in the 
clustergram (Figure 5.12) where these groups have been represented as most similar.  
 
To provide an overall view of the effect of depletion of kinases on activation of p53 
target genes, the Clustergram analysis tool (GEArray Expression Analysis Suite) was 
used to create a cluster diagram to demonstrate the microarray data as described 
previously (see section 5.2.3.1).   The data presented in the clustergram is based upon 
the colour coding of genes based on results in each sample, where colours are assigned 
based on values of a certain sample (Figure 5.12).  This allows the comparison of 
expression levels of all genes across all six profiles and thereby providing an overall 
picture of the effect of IR damage and/or kinase depletion on upregulation of p53 target 
genes.  It demonstrates that there is a low basal level of genes upregulated in siCON 
treated cells and that following kinase depletion there is significant upregulation of p53 
target genes.  Following IR damage there is significant upregulation of genes in siCON 
treated cells, but kinase depleted cells are not significantly upregulated further following 
IR damage (Figure 5.12).  As eluded to above, the way in which clustergram has 
grouped the samples is interesting.  For instance, siCON +IR, siChk1 + IR and siDAPK1 
+ IR are represented as most similar; si Chk1 and siDAPK1 form a second group; and 
siCON is different.  This would support the data whereby kinase (either Chk1 or 
DAPK1) depletion alone results in the most significant upregulation of genes.   
 
Overall these data suggest that although there is upregulation of p53 target genes 
following IR damage in control, this damage insult on these cells following depletion of 
kinases does not result in further upregulation of p53 target genes.  Therefore, 
suggesting that the depletion of either kinase may play a significant role in the activation 
of p53 but this damage in these cells does not lead to upregulation of any additional p53 
target genes.  It may be more appropriate in future studies to examine a different 
timepoint following IR damage to examine cell response over time. 
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Figure 5.12 Gene expression profile demonstrates that IR damage leads to upregulation 
of p53 target gene expression in control group only.  
Clustergram analysis is used to demonstrate the correlation of genes, where genes that are 
more similar are joined at lower heights in the dendogram and those that are less similar are 
joined at higher heights.  The colour coding of genes is based on results in each sample, where 
colours are assigned based on values of a certain sample allowing the comparison of expression 
levels of all genes across all six profiles.  The colour represents the magnitude of gene 
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5.2.3.3 Microarray analysis following the combined depletion of p53 and DAPK1 
In light of the data which demonstrated that kinase depletion resulted in significant 
upregulation of p53 target genes (see sections 5.2.3.1 and 5.2.3.2) further investigation 
was carried out to clarify the effect of combined depletion of DAPK1 and p53 and to 
elucidate the pathways which result in the activation of the p53 target genes.    
 
Before evaluating the effect of the combined depletion of p53 and kinases on activation 
of p53 target genes using microarray technology western blotting was performed to 
confirm that RNAi was effective.   A375 and A549 cells were transfected with 100nM 
siControl; or cotransfected with either a combination of 50nM sip53 and 50nM siRNA 
oligonucleotides to Chk1, Chk2 or DAPK1 to give combined total of 100nM siRNA 
oligonucleotides, for 48hrs.  Protein levels were confirmed by immunoblotting for p53 
and kinases in A375 and A549 cells.   
 
The immunoblots confirm that siRNA oligonucleotides to p53 can deplete p53 protein 
levels in both A375 (Figure 5.13 B; lanes 1 to 4; p53 blot) and A549 (Figure 5.13 C; 
lanes 1 to 4; p53 blot) cell lines.  Chk1, Chk2 and DAPK1 protein levels are also 
significantly depleted using the siRNA oligonucleotides in both cells (Figure 5.13 B and 
C; lanes 2, 5 and 6 Chk1 blot; lanes 3, 5 and 7 Chk2 blot and lanes 4, 6 and 7 DAPK1 
blot respectively).  In both cell lines the combined depletion of both Chk1 and DAPK1 
results in the most significant stabilization of p53 (Figure 5.13 B and C; comparing lane 
6 with lanes 5, 7 and 8; p53 blot).  This reflects previous data in which Chk1 and 
DAPK1 are demonstrated to be the main p53 kinases in these cells (see section 3.2.2).  
In A375 cells there is evidence that the depletion of p53 alone causes a reduction in 
protein levels of Chk2 and DAPK1 (Figure 5.13 B; lane 1; Chk2 and DAPK1 blots) 
suggesting that the expression of these kinases may dependent on p53.  This does not 
occur in A549 cells, suggesting that this may a cell specific event or is merely a 
transfection anomaly.  The results do however confirm that combining siRNA to Chk1 
and DAPK1 does result in stabilization of p53. 
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Figure 5.13 Immunoblots confirm depletion of protein levels following the comined 
depletion of p53 and kinases.   
A and B. Evaluation of protein levels following the combined depletion of p53 and kinases.  A375 
(A) and A549 (B) cells were transfected with 100nM siControl; or cotransfected with either a 
combination of 50nM sip53 and 50nM siRNA oligonucleotides to Chk1, Chk2 or DAPK to give 
combined total of 100nM siRNA oligonucleotides; or a combination of 50nM siRNA 
oligonucleotides to Chk1, Chk2 or DAPK1 to give combined total of 100nM siRNA 
oligonucleotides (for 48hrs).  Protein levels were confirmed by immunoblotting for p53 and 
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Microarray analysis of A375 cells cotransfected with RNAi to DAPK1 and p53 was then 
performed.  Labelled cRNA from kinase and p53 depleted cells was then assessed for 
changes in gene expression profile of p53 signalling pathway genes.  The combined 
effect of depletion of DAPK1 and p53 are demonstrated in Figure 5.14 which shows the 
raw images of each microarray and gives an overview of the effect of the combined 
depletion on upregulation of p53 signalling genes.  
 
Figure 5.14  Microarray analysis of combined depletion of p53 and DAPK1 in A375 cells. 
A375 were transfected with 100nM siDAPK1 or cotransfected with a combination of 50nm sip53 
+ 50nM siCON or 50nM sip53 + 50nM siDAPK to give a combined total of 100nM siRNA 
oligonucleotides.  Total RNA was isolated from the cells, which was then reverse transcribed into 
cRNA, labeled with biotin and hybridized to the Oligo GEArray® DNA Microarray, Human p53 
Signaling Pathway (OHS-027; Superarray; Bioscience Co.). The control, house-keeping genes 
are indicated by arrows and the specific house-keeping genes chosen for normalization of data 
are indicated by the broader red arrows.  The numbers of genes upregulated by visual 
assessment is indicated in brackets. 
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We have previously shown that non-targetting siRNA control transfected cells 
characteristically demonstrate low basal upregulation of p53 target genes and that 
depletion of DAPK1 leads significant upregulation of p53 target genes (see section 
5.2.3.1).  In this assay we have used siRNA to DAPK1 as a control in which to compare 
the effect of depletion of p53 and the combined depletion of p53 and DAPK1 on 
regulation of p53 target genes. The results demonstrated in Figure 5.14 show the total 
number of genes upregulated (shown in brackets), estimated by visual assessment.   The 
number of upregulated genes following depletion of DAPK1 (Figure 5.14 A; 65 genes 
upregulated) confirms previous microarray data in which depletion of DAPK1 led to 
upregulation of 57 or 67 p53 target genes (Figure 5.6 C and Figure 5.10 E, respectively).  
Upon depletion of p53 there is a similar number of target genes upregulated, as seen 
following DAPK1 depletion (Figure 5.14 B; 66 genes upregulated).  However, following 
the combined depletion of both DAPK1 and p53 there is a dramatic reduction in the 
number of genes upregulated (Figure 5.14 C; 16 genes upregulated).  This low level of 
upregulation of p53 target genes has until now only been observed is the control group 
(Figure 5.6 A and Figure 5.10A; both show 18 genes upregulated) and suggests that the 
combined depletion of DAPK1 and p53 is returning the activation of p53 target genes to 
a basal level.  The details of each of the genes upregulated are also represented in (Table 
5.5) where genes have been categorized based on their function.  It can be concluded 
from this table and the raw images that the actual genes upregulated following either 
DAPK1 or p53 depletion are similar and that the combined depletion of DAPK1 and p53 
is resulting in the return of the number of upregulated genes to a basal level, similar to 
that observed following the treatment of cells with a non-targeting siRNA control.  It 
would therefore suggest that the upregulation of genes following DAPK1 depletion is 
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Table 5.5 Genes expressed following the combined depletion of DAPK1 and p53 
 Gene 
Symbol 
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Table 1.5 Genes expressed in A375 cells following the combined depletion of DAPK1 and p53.  
‘X’ represents a gene upregulated by visual assessment and a highlighted gene symbols 
represent genes which are upregulated (by visual assessment) under all three conditions.  
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A more detailed analysis was performed using the GEArray Expression Analysis Suite 
(Superarray) software as described in section 5.2.3.1.   As shown in Figure 5.14, I have 
selected RPS27A and ACTB to use for normalization as these housekeeping genes are 
represented consistently across each of the samples.  Each value shown in Table 5.6 
represents the level of mRNA expression following background correction and 
normalization and is represented as relative units.  Table 5.6 demonstrates the ratio of 
gene intensities between the test (e.g. siDAPK1 and sip53 combined) and the reference 
(e.g. siDAPK1) samples, which are represented as fold changes.  The significance of 
each individual fold change is defined by applying a cut-off value where a fold change 
of 1.5 between reference and test sample is deemed a significant repression or induction.   
Genes which are considered absent in both the test and reference samples are indicated 
(Table 5.6; ● symbol).  A value of fold difference has been applied where the gene is 
considered present in the reference group (i.e. siDAPK1 or sip53) but considered absent 
in the test group (i.e siDAPK1 + sip53).  Although considered absent, in general genes 
in the latter group have a value of greater than or equal to 0.01, therefore a value of fold 
difference has been applied (Table 5.6).  Upregulation of genes are shown as positive 
values and repression of genes as negative inverse values. 
 
The results demonstrate that the combined depletion of DAPK1 and p53 results in a 
significant downregulation of p53 target genes compared to the single depletion of 
DAPK1 or p53 (Table 5.6; column 1, siDAPK1 + sip53 Vs. siDAPK1 and column 2, 
siDAPK1 + sip53 Vs. sip53; downregulated genes represented as negative inverse 
values).  Genes that are downregulated in siDAPK1 + sip53 compared to both individual 
si depletions are highlighted in grey (Table 5.6; 25 genes).  This level of gene regulation 
following the combined depletion of DAPK1 and p53 reflects the level of gene 
regulation previously demonstrated in the non-targeting siRNA control (Figure 5.6 A 
and Figure 5.10A; both show 18 genes upregulated) and suggests that the combined loss 
of DAPK1 and p53 results in the loss of the cell’s ability to upregulate p53 target genes 
to a greater extent than RNAi control.   
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Table 5.6 Ratio of genes expressed between samples (represented as fold changes) 
 Gene 
Symbol 
siDAPK1 + sip53 
Vs. siDAPK1 
siDAPK1 + sip53 
Vs.  sip53  
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Table 1.6 Ratio of genes expressed between samples (represented as fold changes). 
Highlighted in grey represent genes downregulated following the combined depletion of DAPK1 
and p53; ● represents a gene considered absent in both the reference and test samples; ■ 
represents a gene considered absent in either reference groups, siDAPK1 or sip53; N/A 
represents a fold difference value cannot be applied due to considered absence of gene in both 
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groups; * represents spots are considered ‘bleeding’, therefore gene value may be 
underestimated.  
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The fact that the depletion of p53 leads to the significant upregulation of p53 target 
genes is of interest.  We would expect that following depletion of p53 that there would 
be a downregulation of some p53 target genes and upregulation of other genes as p53 
acts to repress the transcription of some genes as well as activate the transcription of 
other genes.  However, the actual genes upregulated and the level gene upregulation are 
similar to that seen following DAPK1 depletion (Figure 5.14 and Table 5.5).  This is 
also demonstrated in Table 5.6 which demonstrates the fold change in the level of genes 
expressed between DAPK1 and p53 depleted cells (Table 5.6; column 3; sip53 vs. 
siDAPK1).  This data shows that although the level of gene expression following p53 
depletion is lower than that following DAPK1 depletion (Table 5.6; column 3; sip53 vs. 
siDAPK1; downregulated genes represented as negative inverse values), the fold change 
is in general not too large.  These data suggest that although p53 is depleted, the 
upregulation of target genes may occur as a result of other factors causing stress within 
the cell.   
 
Figure 5.15 compares the transcript levels of the 25 genes which are considered to be 
upregulated following the combined depletion of DAPK1 and p53 to the transcript levels 
following DAPK1 or p53 depletion (represented as relative units, RU).  This figure 
demonstrates that of these 25 genes upregulated in each of the three groups, transcript 
levels are highest following DAPK1 depletion (Figure 5.15; siDAPK1; blue column).  
The only exception to this pattern is the SMARCB1 gene, which demonstrates increased 
transcript levels following p53 depletion but this is likely to be the result of ‘bleeding’ of 
signal intensity which reduces the value of the transcript level (Figure 5.15; sip53; red 
column; SMARCB1).  In general the transcript levels following p53 depletion are less 
than two fold lower than the transcript levels following DAPK1 depletion (Figure 5.15; 
sip53; red column; also shown in Table 5.6).  Genes such as CDKN1A and RB1, both 
cell cycle regulators, show similar levels of upregulation following either DAPK1 or p53 
depletion suggesting that these genes may have similar roles as target genes upregulated 
following depletion of DAPK1 or p53.  Following the combined depletion of DAPK1 
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and p53 transcript levels of the 25 genes are significantly reduced suggesting that there 
is almost complete loss in the cell’s ability to induce the p53 target genes.   
 
 























































































Figure 5.15  Comparison of transcript levels of genes upregulated following either single 
gene or combined gene depletion.   
The transcript levels of the 25 genes which are considered to be upregulated following the 
combined depletion of DAPK1 and p53 are shown along side the transcript levels following 
DAPK1 or p53 depletion (represented as relative units, RU). Several genes are considered to 
have ‘bleeding’ of signal intensity in one or more groups and this has resulted in under 
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To provide an overall view of the effect of depletion of kinases on activation of p53 
target genes, the Clustergram analysis tool (GEArray Expression Analysis Suite) was 
used to create a cluster diagram to visualise the microarray data as described previously 
(see section 5.2.3.1).  The data presented in the clustergram is based upon the colour 
coding of genes based on results from the entire dataset, where colours are assigned 
based on values in the whole dataset (Figure 5.16).  This allows the expression levels of 
all genes to be compared across the whole dataset.  Although this method is less 
sensitive in that genes expressed at lower levels are under represented, it allows the 
comparison of upregulation of the genes within a sample as well as the comparison of 
upregulation of the genes across the three sample groups and thereby provides an overall 
picture of the effect of the combined depletion of DAPK1 and p53 on p53 target gene 
expression.  It demonstrates that depletion of DAPK1 or p53 leads to similar pattern of 
significant gene upregulation and a similar high level of gene expression (Figure 5.16; 
siDAPK1 or sip53; mixture of green, black and red gene expression).  However, 
following the combined depletion of both DAPK1 and p53 there are very few genes 
upregulated and the level of expression is low (Figure 5.16; siDAPK1 + siP53 
combined; mainly green representing low gene expression). 
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Figure 5.16 The combined depletion of DAPK1 and p53 leads to downregulation of p53 
target gene expression.   
Clustergram analysis is used to demonstrate the correlation of genes, where genes that are 
more similar are joined at lower heights in the dendogram and those that are less similar are 
joined at higher heights.  Genes are colour coded based on the entire dataset thereby allowing 
the comparison of genes within a sample as well as across the three groups.  The colour 
represents the magnitude of gene expression whereby green represents low gene expression 
and red represents high gene expression. 
 
 
Overall these data demonstrate that the combined depletion of DAPK1 and p53 results in 
loss of upregulation of p53 target genes.  The fact that DAPK1 depletion results in the 
significant upregulation of p53 target genes and that the combined depletion with p53 
causes a return to levels of gene expression previously only observed in the non-
targeting control is interesting.  p53 depletion alone also results in the upregulation of 
the same set of target p53 target genes as DAPK1 depletion suggesting that the presence 
of neither p53 nor DAPK1 is essential for the upregulation of these target genes.   
However, the presence of at least one of DAPK1 or p53 is required for upregulation of 
these p53 target genes, as when both p53 and DAPK1 are depleted there is significant 
reduction in the p53 target gene upregulation.  These results suggest that the 
upregulation of genes following DAPK1 depletion is p53 dependent and therefore may 
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5.3 Discussion 
In this chapter we set out to clarify the effect of kinase depletion on the activation status 
of p53 using gene knockdown technology.  We were able to show that p53 is stabilized 
following kinase depletion under both damaged and undamaged conditions.  We went on 
to combine siRNA and microarray technology to profile the effect of kinase depletion on 
the expression of 113 genes of the human p53 signalling pathway.  Using 
oligonucleotides microarrays we were able to demonstrate that the depletion of Chk1 
and DAPK1 led to significant upregulation of p53 target genes and that IR damage did 
not further upregulate these genes.  Microarray analysis of the effect of the combined 
depletion of p53 and DAPK1 demonstrated that the silencing of both genes dramatically 
reduced the levels of genes upregulated by either DAPK1 or p53 depletion alone.  The 
implications of these findings will be discussed in the two sections below. 
 
5.3.1 A role for kinases a negative regulators of p53 
Initially in this study we set out to identify kinases which may activate p53.  
Hypothetical models were proposed in which Calcium Calmodulin kinases such as 
Chk1, Chk2, DAPK1 and AMPK may play a role in modulating p53 activity. Indeed 
DAPK1 had been shown to suppress oncogene-induced transformation of primary 
embryonic fibroblasts by activating p53 in a p19ARF – dependent manner leading to 
induction of apoptosis to eliminate the pre-malignant cells (Raveh et al. 2001) and Chk1 
and Chk2 were shown to phosphorylate p53 at multiple sites on p53 leading to its 
stabilization and activation (Ou et al. 2005).   The subsequent examination of Calcium 
Calmodulin kinases led to the identification of Chk1 and DAPK1 as putative kinases 
which stimulate the Ser 20 phosphorylation of p53 (see section 3.2.2).   
 
In this chapter we used siRNA technology to investigate the effect of depletion of these 
kinases on the activation status of p53.  We showed that silencing Chk1 and DAPK1 
resulted in the stabilization of p53 at the protein level and that this stabilization was 
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further enhanced following damage insult (either IR or UV) in kinase depleted cells.  As 
A375 cells characteristically express low levels of endogenous Chk2 and DAPK, the 
detection of protein levels by western blot proved difficult, and led to variation in the 
clarity of some immunoblots.  To overcome this issue, A549 cells which 
characteristically express higher levels of endogenous DAPK1 as well as Chk1 and 
Chk2, were used to support the initial data demonstrated in A375 cells.  The 
investigation of the cause of the stabilization of p53 following depletion of kinases 
demonstrated that it was not dependent on Ser 15 phosphorylation in these cells, 
although there could be a role for phosphorylation of p53 at other sites.  In light of 
recent literature we went on to examine the role of kinases and p53 in the signal 
transduction pathways that lead to mTOR activation.   DAPK1 has been shown to be 
part of the ribosomal S6 kinase-mediated pathway that attenuates DAPK1 function 
(Anjum et al. 2005). Recently, it has been demonstrated that DAPK1 can positively 
regulate mTOR (mammalian target of rapamycin) by forming an interaction with TSC2 
complex in cells.  This interaction neutralises TSC1/2 mediated suppression of the 
mTOR translation pathway, leading to stimulation of mTOR as determined by changes 
in activity of mTOR targets: the translational regulators p70 S6 kinase and S6 kinase (C. 
Stevens et al, in press).  We showed that following UV damage there was increased S6 
phosphorylation but this phosphorylation was not further increased following depletion 
of kinases. Interestingly, following UV damage there was also increased 
phosphorylation of the translational regulator p70 S6 kinase and this p70 S6 kinase 
activity was increased further following depletion of either Chk1 or DAPK1.  In light of 
the recent literature (C. Stevens et al, in press), we would have expected to have seen a 
decrease in mTOR activity following depletion of DAPK1.  However we have described 
here that the depletion of DAPK1 led to the increased activity of p70 S6 kinase as well 
as increased stabilization of p53. Recent reports have suggested a crosstalk mechanism 
between p53 and mTOR signaling pathways leading to the coordinate regulation of cell 
growth, proliferation and death (Feng et al. 2005).  The stabilization of p53 following 
kinase depletion reported here may therefore suggest crosstalk between p53 and mTOR 
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signaling pathways, whereby the expected activation of the mTOR pathway following 
DAPK1 depletion may be inhibited by the upregulation of p53 signal transduction 
pathways.   
 
A cell viability assay suggested that the depletion of Chk1 or DAPK1 and the resulting 
activation of p53 were not leading to significant cell death or activation of cell death 
pathways.  In light of the fact that there was no evidence of cell death, it may have been 
useful to follow up this issue of activation of p53 by examining for evidence of cell 
cycle arrest and apoptosis.  The use of a technique such as flow cytometry in which data 
can be quantified would have been a useful method in provided information on cellular 
outcome following activation of p53.   However, at this stage a detailed examination of 
the signalling pathways affected by the activation of p53 was undertaken.  
 
We went on to examine the effect of blocking Chk1 and DAPK1 on the activation of 
113 genes regulated by the p53 signaling pathway by microarray analysis.  We were able 
to show that following depletion of Chk1 and DAPK1 there was significant upregulation 
of p53 target genes.  This highlighted a mixture of genes such as ATR (involved in cell 
cycle arrest), E2F1 (promotes cell proliferation), and NFκB1 (promotes inflammation) 
which are upregulated to a higher extent following depletion of kinases.  As these genes 
are induced in a wide range of cell functions they are likely to play a role in maintaining 
a balance between cell proliferation, cell cycle arrest and apoptosis similar to that 
achieved in normal cells as kinase depleted cells showed no changes in overall cell 
viability.     
 
Interestingly following kinase depletion and subsequent IR damage there was not much 
change in the expression of p53 target genes compared to kinase depletion alone 
suggesting that this type of damage in these cells did not induce further upregulation of 
genes.  Only in the non-targeting control arrays was the effect of IR damage apparent 
where there was significant upregulation of p53 target genes.  As there is such a high 
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level of upregulation of genes following kinase depletion, it could be that the activation 
of genes following the damage insult is being masked and no additional genes are being 
activated.  Additionally, the results would therefore suggest that the depletion of kinases 
produces a similar response to IR damage in these cells in terms of the expression 
profiles of p53 target genes and would suggest that kinase depletion or IR damage 
induces the expression of a variety of genes involved in different cellular processes in 
order to achieve the desired outcome: presumably continued cell proliferation with a 
minimal amount of cell cycle arrest and/or apoptosis as overall cell viability was 
unchanged. 
  
The significant upregulation of p53 protein and of p53 target genes following the 
silencing of kinases compared to a non-targeting control suggested that the presence of 
these kinases may have a role in the suppression of p53 and therefore may act as 
negative regulators of p53.  The role of Chk1 as a negative regulator of p53 was 
suggested in a report by the Nakanishi group.  They demonstrated using Chk1 null ES 
cells that the loss of Chk1 resulted in the activation of Chk2-p53-dependent DNA 
damage checkpoint (Niida et al. 2007).  Furthermore, a report demonstrated that Chk1 
depleted U2-OS (wild-type p53 status) exhibited activated Chk2 and increased p53 
stabilisation.  Although this activation was further enhanced upon replication block 
(hydroxyurea treatment; HU) and subsequent release, the enhanced activation was 
demonstrated to be independent of Chk2 or p53 status of the cells (Cho et al. 2005).   
However, the activation of Chk2 and p53 in Chkl depleted cells without treatment could 
support previously described data (Niida et al. 2007) and the microarray data which has 
been presented in this report.   This could suggest a role for Chk2 in the activation of 
p53 following the loss of Chk1, whereby a feedback loop results in the activation of 
Chk2 following depletion of Chk1 to promote the activation of p53 and subsequent 
apoptotic or cell cycle pathways.  In support of this hypothesis, Chk2 was upregulated at 
the gene level following Chk1 depletion in both sets of microarray data presented here.  
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Similarly, it may be possible that DAPK2 and DAPK3 are upregulated following 
DAPK1 depletion. 
 
Although DAPK1 and Chk1 depletion led to significant upregulation of p53 targets, we 
have previously shown DAPK1 as well as Chk1 to stimulate phosphorylation of p53 (see 
section 3.2.2).  These results may suggest a dual function role for kinases with Chk1 and 
DAPK1 acting either as survival factors or as inducers of cell cycle arrest and apoptosis.  
The former role as a survival factor in suppressing p53 activation would support recent 
literature whereby DAPK1 was shown to form a multi-protein survival complex with 
cathepsin B and this complex negatively regulated TNFR-1 dependent cell death 
pathways (Lin et al. 2007).  Furthermore, DAPK1 has been shown to form a complex 
with TSC2 in cells leading to the stimulation of growth-promoting mTOR translational 
pathways (C. Stevens et al, in press).   The latter role of DAPK1 in phosphorylation and 
activation of p53 is consistent with the original studies on the involvement of DAPK1 in 
apoptotic pathways.  Indeed, DAPK1 has been shown to be part of the cell death 
pathway that mediates oncogene signaling to p53 via p19ARF (Raveh et al. 2001), 
inducing myosin light chain phosphorylation and membrane blebbing associated with 
cytoplasmic changes during apoptosis (Bialik et al. 2004), stress induced autophagic 
vesicle formation (Inbal et al. 2002; Gozuacik and Kimchi 2004) and antagonizing FAK 
to activate p53-dependent apoptotic pathway (Wang et al. 2002). 
 
The suggestion that DAPK1 may act as a survival factor led us to examine the effect of 
the combined depletion of DAPK1 and p53 in A375 cells.  Interestingly following the 
single depletion of p53, virtually the same p53 target genes were upregulated as 
following DAPK1 depletion suggesting that p53 may play a similar role in the activation 
of target genes as DAPK1.  We were also able to show that the combined depletion of 
p53 and DAPK1 resulted in the blocking of upregulation of p53 target genes.  The level 
of gene upregulation following combined depletion was similar to that seen in the non-
targetting control group.  This suggests that the presence of both p53 and DAPK1 in this 
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cell system suppresses the activation of p53 target genes.  Therefore, upon targeted 
depletion of either p53 or DAPK1 there is significant stimulation of p53 target genes but 
the combined depletion blocks this stimulation suggesting that the loss of both is 
detrimental to reactivation of the p53 response.  The role of kinases such as DAPK1 and 
Chk1 as putative drug targets for reactivation of the p53 response will be discussed in 
the following section (5.3.2).   
 
The study of gene expression using microarray technology is a useful way in which to 
determine the activation status of signaling pathways and putative target genes.  In this 
study we have been able to use microarray technology to investigate the effect of kinase 
depletion on activation of p53 which has led to the identification of putative kinase drug 
targets, namely Chk1 and DAPK1, for reactivation of the p53 response. However, we 
must consider the implications of these results and future investigations.  It is always 
necessary to validate microarray data by way of techniques such as reverse transcribed 
PCR (RT-PCR).  Oligonucleotide microarrays are often less sensitive at detecting the 
range of transcript abundance.  A report by Draghici and colleagues discusses the issues 
of accuracy (or sensitivity), the precision (or reproducibility) and specificity (ability to 
bind to specific sequence) of microarray technology and suggests that the expression and 
magnitude of gene expression is often less sensitive in oligonucleotides microarrays than 
RT-PCR (Draghici et al. 2006).  As discussed in the introduction (section 5.1.2), there 
have been several studies examining p53-dependent gene expression by microarray 
analysis (Zhao et al. 2000; Kannan et al. 2001).   However, as the function of protein 
coding genes is carried out by the protein product it is important to study the expression 
of genes at protein level.  A recent report used 2D gel electrophoresis to examine p53-
dependent expression at the protein level and to identify novel proteins.  They were able 
to separate approximately 5800 protein spots, of which 115 showed substantial 
expression changes upon p53 activation and 55 spots were identified by mass 
spectrometry.  Many of the proteins identified by mass spectrometry had no previous 
connection to p53 and were shown to have different functions such as mRNA 
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processing, translation, redox regulation and apoptosis (Rahman-Roblick et al. 2007).  
Therefore further work is required to validate the data presented here by using 
techniques such as RT-PCR and furthermore examine the expression of genes at protein 
level by using techniques such as 2D gel electrophoresis.  As a first step in this 
validation approach, we have shown that the levels of p53 protein are increased 
following depletion of Chk1 and/or DAPK1.   
 
5.3.2 Kinase drug targets for reactivation of the p53 response 
Microarrays have been successfully applied to the identification of drug targets, drug 
development and treatment validation (Manning et al. 2007).  A report described how 
the cellular effects of potent inhibitor compounds of human cyclin-dependent kinase 2 
(CDK2) were characterized in yeast on a genome wide scale by monitoring changes in 
mRNA levels in treated cells with the use of oligonucleotide probe arrays (Gray et al. 
1998).   Furthermore, gene expression analysis can be used as a method for drug 
validation and identification of secondary drug targets.  A report used gene expression 
analysis to identify pathways that were altered by a immunosuppressant drug (FK506) in 
use in the clinic and demonstrated that the drug had off-target effects (Marton et al. 
1998).   Around half of all tumours carry mutation in p53 which results in loss of ability 
to activate p53-induced cell cycle arrest and apoptosis.  In this report we have 
demonstrated that the depletion of kinases such as Chk1 and DAPK1 led to the 
upregulation of p53 target genes.  Upon validation, the implication of this data could be 
signigicant and could provide a platform on which to develop specific kinase inhibitors 
to Chk1 and DAPK1 to allow reactivation of the p53 response and therefore the 
induction of cell cycle arrest and apoptosis to prevent progression of tumours that 
contain mutations in p53.  Several reports have examined different methods in which to 
reactivate p53.  Small molecules such as PRIMA-1 (proline-rich membrane anchor-1), 
which suppresses growth of cells expressing mutant p53, have been identified. These 
can restore wild-type function to mutant p53 and may be forerunners in the development 
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of anti-cancer drugs (Bykov et al. 2003).   Others studies have examined the in vivo 
activation of p53 by small molecule inhibitors (Nutlin-3) of the negative regulator of 
p53, Mdm2 (Vassilev et al. 2004).  More recently, a report has suggested how the 
combined use of Mdm2 and Mdm4 antagonists in cancer cells expressing WT-p53 may 
allow the increased activation of p53 (Toledo and Wahl 2007).  
 
Several reports have examined the roles of kinases such as Chk1 as therapeutic targets 
for cancer treatment.  Cell cycle checkpoint abrogation has been proposed as a method 
to sensitise cancer cells to DNA damaging agents (Dixon and Norbury 2002; Zhou and 
Bartek 2004).  In normal cells DNA damage leads to p53 dependent cell cycle arrest in 
G1 whereas tumour cells, deficient in p53, rely on checkpoints to mediate arrest in S or 
G2 phase. Therefore targeting cell cycle checkpoints would only abrogate cell cycle 
blocks in tumour cells, as normal cells would still arrest in G1, and promote mitotic 
catastrophe and apoptosis of tumour cells (Dixon and Norbury 2002; Zhou and Bartek 
2004).  A report by Xiao and colleagues compared three kinases involved in cell cycle 
checkpoint control to determine the main kinase(s) responsible for cell cycle arrest of 
mammalian cells.  They showed that downregulation of Chk1, but not Chk2 or MK2, 
abrogated stress induced G2 arrest, which led to mitotic catastrophe or apoptosis. The 
double inhibition of Chk1 and Chk2 was no better than Chk1 inhibition alone,  therefore 
suggesting that Chk1 was the only relevant checkpoint kinase as a target for cancer 
treatments (Xiao et al. 2006).  More recently a report described how the inhibition of 
Chk1 was used to activate p53 to promote the elimination of tumour cells.  The 
depletion of Chk1 preferentially killed tetraploid colon cancer cells in their normal 
model, abolished spindle assembly checkpoint and caused premature and abnormal 
mitosis leading to the activation of p53 and p53-regulated transcripts, Puma and BBC-3 
(Vitale et al. 2007).  Therefore, several reports have investigated the role of small 
molecule inhibitors designed to known negative regulators of p53 (Mdm2) as well as to 
kinases as putative anti-cancer therapies which abrogate cell cycle blocks specifically in 
tumour cells and promote the reactivation of p53 which leads to increased apoptosis and 
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mitotic catastrophe.  The data presented in this report supports the recent literature with 
regard to the targeting of Chk1 to reactivate the p53 pathway (Xiao et al. 2006; Vitale et 
al. 2007).  In addition to this data we propose another member of the Calcium 
Calmodulin superfamily of kinases, DAPK1 as a putative drug target for reactivation of 
the p53 pathway.   Although DAPK1 was originally shown to be implicated in cell death 
pathways, it is now becoming apparent that DAPK1 may act as a survival factor (Lin et 
al. 2007).  This data presented here would also support a role for DAPK1 as a survival 
factor and a potential target for design of therapies to treat human cancers. 
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6 SUMMARY, CONCLUSIONS AND FUTURE 
DIRECTIONS 
6.1 Defining the role of Calcium Calmodulin Kinases in modulation of 
p53 activity 
Protein phosphorylation is the most widespread type of post-translational modification 
which occurs in signal transduction (Ubersax and Ferrell 2007).  Protein kinases are key 
signaling enzymes which play a major role in the regulation of multiple cellular 
responses.  Therefore the clarification of the role of p53 phosphorylation by protein 
kinases is essential to the development of our understanding of the signaling pathways 
crucial to the activation of p53. 
 
A crucial event in the activation of p53 is the phosphorylation at residues Threonine 18 
and Serine 20 (Ser 20) that both stabilises the binding of the co-activator p300 and 
reduces the binding of the inhibitory partner Mdm2.  These phosphorylation events 
therefore enhance activation of p53 target genes.  The identification of enzymes that 
phosphorylate the p53 transactivation domain at residues such as Thr 18 or Ser 20 has 
been an important development in the ongoing mapping of signaling pathways that 
control p53-dependent transcription and consequently tumour suppression.   
 
In this report we examined specific members of the Calcium Calmodulin kinase 
(CAMK) superfamily and their role in modulation of p53 activity.  Using transcription-
based assays and a newly developed in vivo Ser 20 phosphorylation assay we showed 
that Chk1 and DAPK1 but not Chk2 phosphorylated p53 at Ser 20, which led to 
transcriptional activation of p53.  Verification of these results using siRNA technology 
demonstrated that Chk1 was the most potent endogenous mediator of Ser 20 site 
phosphorylation in H1299 cells, and DAPK1 was identified as the most effective 
endogenous p53 protein stabilizer in A375 cells, thus suggesting a cell-specific function 
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for these kinases.  These results have contributed significantly to the clarification of the 
role of Calcium Calmodulin kinases in the stress-activated p53 signalling pathways, 
partially resolving the controversy in the field as to the identity of the main p53 Ser 20 
kinases in vivo (Ahn et al. 2003; Jallepalli et al. 2003).  Indeed, our work suggests that 
Chk1 and DAPK1, rather than Chk2 were the main Ser 20 kinases.  However, in order to 
investigate the role of other members of the CAMK superfamily it would be necessary 
to employ a wide scale screening approach.  The use of a p53 null line, in which p53 can 
be expressed ectopically and easily detected using Ser 20 phospho-specific antibodies 
would be a useful tool to continue the evaluation members of the Calcium Calmodulin 
superfamily of kinases as putative Ser 20 site kinases.  It has been shown that mutation 
of the Ser 20 equivalent phospho-acceptor site in mice accelerates B-cell lymphoma 
(MacPherson et al. 2004) therefore B cells may provide a useful model in which to study 
modification of p53.  Cell models could be developed in order to evaluate how distinct 
CAMK superfamily members activate p53 in a cell-specific manner and may provide an 
interesting framework in which to identify the stress activated regulators of p53.   
 
Moreover, a recent report described a technique for detecting the specific activity of 
Ser/Thr kinases in cells through the introduction of expression vectors encoding 
modified substrate kinase fusion proteins (Suda et al. 2008).  They fused p53 with 
individual kinase domains of Chk1, Cdk5 and DYRK3 and showed that phosphorylation 
of p53 Ser 15 and Ser 20 sites could be significantly induced by the catalytic activity of 
kinases such as Chk1 contained within fusion proteins.   To verify the data they used a 
kinase-inactive mutant and showed that the mutation blocked phosphorylation of p53, 
thereby showing that the Ser15/Ser20 activity was dependent on the catalytic activity of 
the fused target kinase (Suda et al. 2008).  This type of system may be useful in the 
elucidation of the sites within p53 which specific kinases such as Chk1 phosphorylate.  
It also could be used as a screening method in which to examine the role of other related 
CAM kinases as well as kinases from other families such as CK1 (casein kinase 1) and 
TK (tyrosine kinases) in modulation of p53 activity.   
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6.2 Calcium Calmodulin kinases & Mdm2 have overlapping binding 
requirements on p53 Box-V 
Our studies examining the interaction of kinases with p53 demonstrated the requirement 
of the Box-V domain of p53 for kinase-docking and subsequent kinase-mediated 
phosphorylation of the Box-I domain.  The previously identified naturally occurring p53 
isoform, p53 ΔV, (Rohaly et al. 2005) was a useful tool with which to investigate the 
specific regions of p53 which kinases may bind to and/or phosphorylate.  Using this 
isoform we were able to demonstrate that deletion of the Box-V domain of p53 resulted 
in two events; (i) loss of basal and kinase-stimulated Ser 20 site phosphorylation and (ii) 
attenuation of Mdm2-mediated ubiquitination of p53.  These combined data suggest that 
the Box-V region of p53 is a multi-protein docking site for Calcium Calmodulin 
superfamily members as well as Mdm2.  The idea that the Box-V region may act as a 
multi-protein docking site correlated with literature which identified a novel Mdm2 
interaction site in the core domain of p53 (Shimizu et al. 2002) and that this interaction 
site was necessary for a dual site docking mechanism of Mdm2 on the p53 tetramer 
(Wallace et al. 2006).   
 
The clarification that the Box-V region is a multi-protein binding site required to 
activate p53 phosphorylation and ubiquitination led to further investigation examining 
the interaction between kinases and/or Mdm2 and the Box-V motif of p53.  Binding 
assays performed in vivo demonstrated that Chk1, DAPK1 and Mdm2 form an 
interaction with the Box-V domain and that this interaction required distinct residues in 
the Box-V protein.  We showed that Chk1 and Mdm2 appeared to have overlapping 
requirements for binding to the Box-V domain. This suggested that the Calcium 
Calmodulin kinases, Chk1/DAPK1 and Mdm2 may antagonize each other through 
competition for the same multi-protein docking site.   Supporting this idea was the result 
which demonstrated that the p53 mutant, p53 HIS175 could be stimulated 
transcriptionally by transfection of Chk1.  Although it has been established that the p53 
HIS175 protein is hyperubiquitinated in vivo due to the unfolding of the protein and thus 
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the exposure of the Box-V motif (Shimizu et al. 2006), this transcriptional reactivation 
of the p53 HIS175 mutant from the p21WAF1 reporter by Chk1 suggests that Chk1 may 
overcome Mdm2-mediated ubiquitination by competition for binding to the Box-V 
interface and drive p53 into a transactivation-competent rather than a ubiquitinated state. 
The idea that different proteins compete with each other for binding to this specific 
region of p53 resulting in the regulation of p53 reflected recent data which used nuclear 
magnetic resonance to show that on binding to p53 the acid domain fragment of Mdm2 
induced significant chemical shifts throughout the core domain of p53 especially within 
the Box-V motif  (Yu et al. 2006).  A technique such as this which uses immobilized 
peptide arrays could be employed to examine the binding of other CAM kinases to p53 
and identify specific binding sites in the p53 Box-V domain.  It would also be useful to 
verify the binding results using immunofluorescence whereby colocalisation of the 
protein and Box-V domain could be examined in cells.   
 
The clarification of the protein interactions with the Box-V site and the resulting control 
of p53 activation have made a significant contribution to this field.  However, we should 
continue to investigate which other proteins interact with this site to further elucidate the 
mechanisms underlying p53 tumour suppressor function. 
 
6.3 The role of ‘Gain of function’ mutation on kinase modulation of 
p53 activity 
Mutation of key contact sites on p53 such as the Box-V domain can have a detrimental 
effect on the activation of p53 (Craig et al. 2003; Wallace et al. 2006).   However, some 
mutations can result in a gain of function phenotype and interactions of proteins with 
these p53 mutants can positively stimulate p53 (Kim and Deppert 2004; Li and Prives 
2007; Menendez et al. 2007).  In this report we examined the gain of function nature of 
mutant p53 in order to develop our understanding of the molecular mechanisms of the 
oncogenic gain of function phenotype and the molecular interactions of mutant p53.  
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Based upon results from a recent paper (Kakudo et al. 2005), a set of mutants was 
created to evaluate whether the activity of these mutants could be modulated by kinases 
and/or Mdm2 and thereby simultaneously further identify sites important for the 
interaction of p53 with kinases/Mdm2.  We identified two potentially interesting 
mutations, A276V and K2921, which are found within or adjacent to the Box-V region.  
A detailed examination of these mutants (K292I and A276V) demonstrated that gain of 
function transactivation potential was p21WAF1 promoter-dependent but that kinases did 
not further stimulate the transcriptional activity on either the p21WAF1 or BAX promoters 
suggesting that these sites play an important role in kinase docking. Interestingly the 
A276V mutant appeared to be resistant to Mdm2-mediated inhibition of p53 
transcriptional activity.  This mutation lies within the Box-V domain, the location of the 
ubiquitination signal for Mdm2.  The observed resistance of this mutant to Mdm2-
mediated inhibition of p53 transcriptional activity may be consistent with the loss of the 
Mdm2 binding site and would suggest that mutation of this site may play an important 
role in Mdm2 interaction with the Box-V domain.  It may be possible that the A276V 
mutant favours the binding of kinases rather than Mdm2, thus driving p53 into a 
transactivation competent state.   
 
Although this transcriptional data provides insight into interactions of the p53 mutants, it 
would have been useful to perform these assays in triplicate to allow for formal 
statistical analysis to be applied.  This would allow for validation of the data and clarify 
any doubt surrounding reproducibility. 
 
To further investigate the role of these mutants in the potential stimulation of p53 
activity, we could employ techniques such as yeast-based functional assays.  These 
simple assays can be used to predict the transcriptional behaviour of mutant p53 in 
higher eukaryotes.  For example, Campomenosi and colleagues employed a yeast based 
assay in which they examined a selection of mutants and investigated the promoter 
specific transactivation potential of each mutant, thus allowing the categorization of 
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mutants based on their transcriptional behaviour (Campomenosi et al. 2001).   In light of 
the data which shows that p21 can protect against cell killing by chemotherapeutic drugs 
in some settings (Waldman et al. 1997), this type of assay would allow the proper 
classification of mutants which may have valuable clinical applications in the treatment 
of cancers.  Indeed, tumours containing p53 mutants with gain of function p21 
transactivation potential may display resistance to chemotherapeutic agents.  It would 
therefore be of clinical value to identify such tumours and either select an appropriate 
treatment regime to minimise drug resistance or combine chemotherapeutics with a p21-
targeting agent.  
 
Further investigation could also focus on the development of mouse models in which to 
clarify the role of mutant p53 in cancer progression.  For example, a report described the 
development of a murine model with mutation at p53 amino acid site 172 (corresponds 
to the human R175H hot-spot mutation) to simulate Li-Fraumeni-like mutant p53 and 
demonstrated that the mutant p53 associated with p63 and p73 in tumour cells of mice 
(Lang et al. 2004).  They also showed that silencing mutant p53 resulted in increased  
activity of p53 target genes such as p21WAF1 which was likely to be a result of the 
increased activity of endogenous p53 family members p63 and p73 (Lang et al. 2004).  
These studies proposed a means by which mutant p53 may promote tumourigenesis 
through downregulation of its family members.  With respect to continuing the 
investigation of the mutants examined in this study, the use of knock-in mouse models 
could be a potentially interesting and a highly informative way to clarify how 
interactions with other proteins such as CAM kinases may control the modulation of p53 
activity. 
The experimental approaches outlined above could provide a basis on which to build our 
understanding of the activity of p53 mutants and the resulting biological outcomes.  The 
way in which we approach the design of individual therapeutic strategies is likely to 
depend on individual mutation phenotypes and will therefore be complex but crucial in 
the treatment of many cancers.   
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6.4 The identification of kinase drug targets for reactivation of the 
p53 response 
In the final results chapter of this report set we set out to clarify the effect of kinase 
depletion on activation of p53.  Using gene knockdown technology we demonstrated 
that p53 is stabilized at the protein level following Chk1 and DAPK1 depletion under 
both damaged and undamaged conditions.  Moreover, using gene expression 
microarrays which profile gene expression of the p53 signalling pathway we were able 
to demonstrate that the depletion of Chk1 and DAPK1 led to significant upregulation of 
p53 target genes.  Further microarray analysis of the effect of the combined depletion of 
p53 and DAPK1 demonstrated that the silencing of both genes dramatically reduced the 
level of p53 target genes upregulated.  This suggests that the upregulation of genes 
following DAPK1 depletion was p53-dependent.   These results could have significant 
implications, some of which are discussed in the following sections. 
 
6.4.1 A role for kinases as negative regulators of p53 
The significant upregulation of p53 target genes following the silencing of Chk1 and 
DAPK1 compared to a non-targeting control suggested that the presence of these kinases 
may have a role in the suppression of p53 and therefore may act as negative regulators 
of p53.  The role of Chk1 as a negative regulator was supported by recent literature 
which showed that Chk1 depletion led to activation of p53 and Chk2 (Cho et al. 2005; 
Niida et al. 2007).  Together these results could suggest a role for Chk2 in the activation 
of p53 following the loss of Chk1, whereby a feedback loop results in the activation of 
Chk2 following Chk1 depletion to promote the activation of p53.  This proposed 
pathway of interaction is shown in Figure 6.1.  It would be interesting to test this 
hypothesis by studying the activation status of proteins such as other members CAMK 
superfamily which may be involved in the signaling pathways which activate p53 
following loss of kinases.  It may be that several kinases are able to compensate for the 
loss of each other whereby loss of Chk1 for example may activate many additional 
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kinases which in turn activate p53.  Mammalian cell culture models in which kinases 
such as Chk1 are depleted by siRNA and cells are selected to generate a stable inducible 
kinase knockdown cell line would be a useful system to study the interactions between 




Figure 6.1 A proposed mechanism for the activation of p53 following Chk1 depletion. 
Upon damage the activation of checkpoint kinases occurs through ATM and ATR which lead to 
the activation of p53.  Upon depletion of Chk1, there may be a crosstalk between pathways 
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In addition to the potential role of Chk1 and DAPK1 as negative regulators of p53, we 
have also shown DAPK1 as well as Chk1 to stimulate phosphorylation of p53 leading to 
its transcriptional activation (see sections 3.2.2 and 3.2.3). These results, although 
contradictory, agree with the current controversy in the field and may suggest an overall 
role for kinases such as DAPK1 as survival factors which supports recent literature (Lin 
et al. 2007).  This role in which kinases such as DAPK1 both activate and repress p53 to 
promote survival could have several implications.  DAPK1 may be able to ‘sense’ the 
varying cellular conditions conditions or cellular environment and promote either 
activation or repression of p53, as appropriate, by phosphorylation at different residues 
to ensure the survival of the cell.  For example, DAPK1 normally represses p53 when 
there is no damage to ensure that the cell can go on dividing as normal.  However, upon 
damage DAPK1 phosphorylates p53 which ensures that the damaged cells are either 
eliminated or arrested until the damage is repaired.  This prevents the propagation of 
mutated cells and ensures the survival of the tissue as a whole.     
 
6.4.2 Development of drug targets 
The disruption of normal signal transduction pathways is a key feature in the 
development and progression of cancer. Kinases are therefore therapeutically important 
drug targets. Upon targeted depletion of either Chk1 or DAPK1 there was significant 
stimulation of p53 target genes, which suggests that kinases such as DAPK1 and Chk1 
could be exploited as putative drug targets for reactivation of the p53 response.    Upon 
validation, using techniques such as flow cytometry, the implication of this data could be 
significant and could provide a platform on which to develop specific kinase inhibitors 
to allow reactivation of the p53 response and therefore the induction of cell cycle arrest 
and apoptosis to prevent progression of tumours.  Several reports have examined the 
roles of kinases such as Chk1 as therapeutic targets for cancer treatment (Xiao et al. 
2006; Vitale et al. 2007).  In light of these reports, as well as the data we have presented 
here, further investigation should focus on the development of kinases inhibitors which 
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promote the reactivation of p53 to advance the elimination of the tumour.  Several 
reports, such as the use of the Mdm2 inhibitor Nutlin-3 to activate the p53 pathway 
(Vassilev et al. 2004), have shown the valuable role of small molecule inhibitors.  
Development of small molecule inhibitors to kinases has already been successful in 
some cases such as the tyrosine kinase inhibitor gleevec (or imatinib) which has been 
used in the clinic to treat certain types of cancer.  Several other kinase inhibitors are 
currently being developed as anti-cancer agents (Zhou and Bartek 2004).   The data 
presented here suggests that there would be therapeutic value in developing small 
molecule inhibitors to kinases (such as Chk1 and DAPK1) involved in the p53 signalling 
pathway.   
 
6.5 Conclusion 
The activation of p53 is crucial step in the pathway which controls tumour progression.  
It is therefore unsurprising that the p53 pathway is compromised in most human cancers.  
The identification of Chk1 and DAPK1 as key modifiers of the p53 signalling pathway 
in vivo has been a crucial development in field.  Investigations have allowed the 
elucidation of the role of specific regions within p53 for the complex docking-dependent 
interactions of kinases and/or Mdm2 with p53.  The identification of Chk1 and DAPK1 
as suppressors of p53 was a surprising but significant development in the study of p53. 
This finding may result in the development of anti-cancer drugs targeted to Chk1 or 
DAPK, with the aim of reactivating the p53 pathway, and thereby inhibiting tumour 
progression.    
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